Clinical trial NCT03215277
Conditions: Ankylosing Spondylitis
Keywords: Ankylosing Spondylitis Bimekizumab AS Certolizumab Pegol Cimzia
Sponsor: UCB Biopharma SRL
Start date: 2017-10-04; Completion date: 2020-05-25
Enrollment: 76 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared to certolizumab pegol in the treatment of subjects with active ankylosing spondylitis (AS).

Detailed description:

Arms: arm 1: Subjects will receive several bimekizumab administrations on pre-defined time points. Placebo will be provided in this arm to mask the certolizumab pegol loading dose. arm 2: Subjects will receive several certolizumab pegol administrations on pre-defined time points.
Interventions: intervention 1: Bimekizumab intervention 2: Certolizumab pegol intervention 3: Placebo
Intervention descriptions: intervention 1: One bimekizumab dose will be administered. intervention 2: Two certolizumab pegol doses will be administered. One of these doses is a loading dose. intervention 3: Placebo will be provided to maintain the blinding.

Protocol documents:
Prot_000.pdf: 
UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 1 of 136
PROTOCOL AS0013 AMENDMENT 3
A MULTICENTER, PHASE 2A, RANDOMIZED, 
INVESTIGATOR-BLIND, SUBJECT-BLIND, PARALLEL-GROUP 
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF 
BIMEKIZUMAB AND CERTOLIZUMAB PEGOL IN SUBJECTS 
WITH ACTIVE ANKYLOSING SPONDYLITIS
PHASE 2A
EudraCT Number: 2017-000957-37
IND Number: 128708
Sponsor:
UCB Biopharma SPRL
Allée de la Recherche 60
1070 Brussels
BELGIUM
Protocol/Amendment number
Date
Type of amendment
Final protocol
19 Apr 2017
Not applicable
Protocol amendment 1
30 May 2017
Nonsubstantial
Protocol amendment 1.1 (CZ)
07 Sep 2017
Substantial
Protocol amendment 1.1 (DE)
09 Oct 2017
Nonsubstantial
Protocol amendment 1.1 (NL)
18 Sep 2017
Substantial
Protocol amendment 2
05 Mar 2018
Substantial
Protocol amendment 2.1 (CZ)
07 Mar 2018
Substantial
Protocol amendment 2.2 (DE)
07 Mar 2018
Substantial
Protocol amendment 2.3 (NL)
27 Apr 2018
Substantial
Protocol amendment 2.4 (CZ)
03 Jul 2018
Substantial
Protocol amendment 3
27 Feb 2019
Substantial
Confidential Material
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.
PUBLIC COPY 
r:
P
r:
harma S
OP
harma S
e la Rec
CO
e la Rec
1070 
LIC 
1070 
PU
P
not be used to support any marketing authorization 
CTS 
oriz
CTS 
PRL
rt a
PRL
erche 60
por
erche 60
russels
upp
russels
ELGIUM
su
ELGIUM
d t
ed
ed
ed
ed
se
u
be
NL)
no
NL)
t
t canno
no
t 2.1 (CZ)
can
t 2.1 (CZ)
nn
ment 2.2 (D
t ca
ment 2.2 (D
ca
ent c
ndment 2.3
ent 
ndment 2.3
ment c
amendment
men
amendment
en
ume
ol amendm
um
ol amendm
This docume
um
s 
nd any extensions or variations thereof.
M
i
M
Dat
n
Dat
ns
19 A
te
19 A
te
3
x
3
ex
y e
ny
ny
ny
ny
ny
a
ion and
nd
an
DE)
io
DE)
n
atio
3 (NL)
atio
3 (NL)
icatio
t 2.4 (CZ)
ica
t 2.4 (CZ)
at
plic
ment 3
plic
ment 3
applic
pl


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 2 of 136
STUDY CONTACT INFORMATION
Sponsor
UCB Biopharma SPRL
Allée de la Recherche 60
1070 Brussels
BELGIUM
Sponsor Study Physician
Name:
Address:
UCB Celltech, 208 Bath Rd, Slough, Berkshire, SL1 3WE, UK
Phone:
Fax:
Exploratory Project Manager
Name:
Address:
Alfred-Nobel-Str 10, 40789 Monheim, Germany
Phone:
Fax:
Clinical Trial Biostatistician
Name:
Address:
UCB Celltech, 208 Bath Rd, Slough, Berkshire, SL1 3WE, UK
Phone:
Fax:
Clinical Monitoring Contract Research Organization
Name:
PAREXEL International (IRL) Limited
Address:
One Kilmainham Square, Inchicore Road, Kilmainham, Dublin 8, Ireland
Phone:
+353 1 473 9500
Fax:
+353 1 473 9501
PUBLIC COPY 
OP
0, 40789
IC C
0, 40789
C
LIC
B
PU
PUB
PUB
ot be used to support any marketing authorization 
a
3WE, UK
ketin
3WE, UK
ting
ke
a
y m
t a
Monheim
ppo
Monheim
po
upp
s
d t
us
B Celltech
t be
B Celltech
be
ot
This document canno
nn
ca
ca
ca
ca
Monitor
ent 
Monitor
:
e
ddress:
ocu
ddress:
um
Phone
do
Phone
oc
s
Fa
s
Fa
s d
s
be
not
an
an
and any extensions or variations thereof.
of
K
th
K
ere
th
ns
tio
va
m, German
s or
m, German
or
s
io
ns
ex
h, 208 Bat
any
h, 208 Bat
ny
d a
and
application 
n
ring Co
atio
ring Co
PA
ca
PA
ca
ic
pl
ap
n a


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 3 of 136
SERIOUS ADVERSE EVENT REPORTING
Serious adverse event reporting (24h)
Fax
Europe and Rest of the World: +32 2 386 24 21
US and Canada: +1 800 880 6949 or +1 866 890 3175
Email
Global: DS_ICT@ucb.com 
PUBLIC COPY 
uthorization 
za
ori
This document cannot be used to support any marketing aut
uth
application and any extensions or variations thereof.


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 4 of 136
TABLE OF CONTENTS
LIST OF ABBREVIATIONS..................................................................................................10
1
SUMMARY.....................................................................................................................15
2
INTRODUCTION ...........................................................................................................16
2.1 Axial spondyloarthritis.....................................................................................................16
2.2 Bimekizumab ...................................................................................................................17
2.2.1
Clinical experience with bimekizumab................................................................18
2.2.2
Nonclinical studies with bimekizumab................................................................19
2.3 Certolizumab pegol..........................................................................................................19
2.3.1
Clinical experience with CZP..............................................................................20
2.4 Study rationale .................................................................................................................20
3
STUDY OBJECTIVE(S).................................................................................................21
3.1 Primary objective.............................................................................................................21
3.2 Secondary objective.........................................................................................................21
3.3 Other exploratory objectives............................................................................................21
4
STUDY VARIABLES.....................................................................................................21
4.1 Efficacy variables.............................................................................................................21
4.1.1
Primary efficacy variable.....................................................................................21
4.1.2
Secondary efficacy variables ...............................................................................21
4.1.3
Other efficacy variables.......................................................................................22
4.2 Safety variables................................................................................................................22
4.2.1
Primary safety variables ......................................................................................22
4.2.2
Other safety variables ..........................................................................................22
4.3 Other PK and PD variables..............................................................................................22
4.3.1
Other PK variables...............................................................................................22
4.3.2
Other PD variables...............................................................................................22
4.4 Other immunological variable(s) .....................................................................................23
4.5 Other nonhereditary pharmacogenomic variables ...........................................................23
4.6 Other pharmacogenetic variables.....................................................................................23
5
STUDY DESIGN.............................................................................................................23
5.1 Study description .............................................................................................................23
5.1.1
Screening Period (minimum of 2 and up to 4 weeks)..........................................24
5.1.2
Treatment Period (Week 0 to Week 12)..............................................................24
5.1.3
Treatment Extension Period (Week 12 to Week 48)...........................................24
5.1.4
Safety Follow-up Period (Week 48 to Week 64).................................................25
5.2 Safety monitoring strategy...............................................................................................25
5.3 Imaging evaluation...........................................................................................................25
5.4 Study duration per subject................................................................................................25
PUBLIC COPY 
.
PY
.........
PY
........
..........
OP
..........
..........
CO
..........
.........
C C
.........
bles
LI
bles .....
LIC
.....
es
UB
es.......
UB
.......
..........
PU
..........
able
P
able
This document cannot be used to support any marketing authorization 
7
..
h
..18
hor
18
........
uth
........19
h
19
....
a
............
a
........
.....
ng
............
ng
.......
........
tin
............
in
....
...........
ke
...........
............
ar
............
............
m
...........
............
ny
............
............
a
............
...........
ort
...........
...........
po
............
o
.
............
up
............
............
s
............
............
to
...........
...........
ed
...........
es
u
es ..........
us
..........
es
e
es........
e
........
ables
t be
ables....
b
....
variables
ot 
variables
ological va
nno
ological va
hereditary
can
hereditary
harmacog
nt c
harmacog
UDY DES
en
UDY DES
Study des
ume
Study des
5.1.1
cu
5.1.1
5.1.2
doc
5.1.2
5
d
5
application and any extensions or variations thereof.
19
f
19
.....
e
.....20
eof
20
...........
her
...........20
e
20
............
th
............
.........
ns
............
s
...
............
tio
............
.....
iat
............
at
.......
..............
ar
..........
............
v
............
............
o
............
.........
ns
............
s
...
......
io
............
o
......
............
ns
............
............
te
............
............
ex
............
............
y
............
............
an
............
............
d
............
variable(s)
and
variable(s)
y pharmac
n a
y pharmac
genetic va
tion
genetic va
SIGN
cat
SIGN....
a
....
scription
plic
scription
Screeni
app
Screeni
Trea
ap
Trea


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 5 of 136
5.5 Planned number of subjects and site(s)............................................................................25
5.6 Anticipated regions and countries....................................................................................25
5.7 Schedule of assessments ..................................................................................................26
5.8 Schematic diagram...........................................................................................................31
5.9 Rationale for study design and selection of dose.............................................................32
6
SELECTION AND WITHDRAWAL OF SUBJECTS...................................................33
6.1 Inclusion criteria ..............................................................................................................33
6.2 Exclusion criteria .............................................................................................................35
6.3 Withdrawal criteria ..........................................................................................................38
6.3.1
Potential drug-induced liver injury IMP discontinuation criteria........................40
6.4 Study stopping rules.........................................................................................................41
6.5 Retesting/rescreening.......................................................................................................41
7
STUDY TREATMENT(S) ..............................................................................................42
7.1 Description of investigational medicinal product(s)........................................................42
7.2 Treatment(s) to be administered ......................................................................................42
7.3 Packaging.........................................................................................................................43
7.4 Labeling ...........................................................................................................................43
7.5 Handling and storage requirements..................................................................................43
7.6 Drug accountability..........................................................................................................44
7.7 Procedures for monitoring subject compliance................................................................44
7.8 Concomitant medication(s)/treatment(s)..........................................................................44
7.8.1
Permitted concomitant treatments (medications and therapies) ..........................45
7.8.2
Prohibited concomitant treatments (medications and therapies).........................45
7.8.3
Rescue medication...............................................................................................47
7.9 Blinding............................................................................................................................47
7.9.1
Procedures for maintaining and breaking the treatment blind.............................47
7.9.1.1
Maintenance of study treatment blind.......................................................48
7.9.1.2
Breaking the treatment blind in an emergency situation...........................48
7.10 Randomization and numbering of subjects......................................................................48
8
STUDY PROCEDURES BY VISIT ...............................................................................49
8.1 Screening Visit (Visit 1) ..................................................................................................49
8.2 Baseline (Visit 2, Week 0)...............................................................................................51
8.3 Week 2 (Visit 3)...............................................................................................................52
8.4 Week 4 (Visit 4)...............................................................................................................52
8.5 Week 6 (Visit 5)...............................................................................................................53
8.6 Week 8 (Visit 6)...............................................................................................................53
8.7 Week 10 (Visit 7).............................................................................................................54
8.8 Week 12 (Visit 8).............................................................................................................54
C COPY 
......
Y
......
........
PY
.........
Y
.
..........
CO
..........
PUBLIC C
.........
C C
.........
........
LIC
..........
C
..
ect com
BLI
ect com
/treatme
PUB
/treatme
itant tr
PU
itant tr
port any marketing authorization 
.33
or
33
......
th
......35
ho
35
..
a
............
au
..........3
...........
g
...........
............
ting
............
............
ke
............
....
a
............
ar
........
............
m
............
...........
y
...........
............
an
............
............
rt
............
t be used to suppo
............
po
............
............
upp
............
pliance
sup
pliance..
u
..
nt(s)
to
nt(s).......
to
.......
eatments (
ed t
eatments (
nt treatme
sed
nt treatme
...........
u
...........
.........
be
...........
e
..
This document cannot 
for maint
ot b
for maint
Maintenan
nno
Maintenan
Breakin
can
Breakin
ization an
t ca
ization an
DY PROC
ent
DY PROC
creening V
me
creening V
Baselin
cum
Baselin
8.3
do
8.3 Wee
oc
Wee
8.4
s d
8.4 W
8
s
8
or variations thereof.
8
f
8
...
e
...40
eof
40
.........
ere
.........41
e
41
........
th
............
h
....
............
s
............
..
o
............
on
..........
.........
ati
.............
............
ari
............
............
va
............
any extensions or
............
or
............
............
s
............
...........
on
...........
............
si
............
(medicati
tens
(medicati
ents (med
exte
ents (med
............
y e
............
...........
ny
...........
application and a
t
d
taining an
d a
aining an
nce of stud
and
nce of stud
ng the tre
n an
ng the tre
nd numbe
tion
nd numbe
CEDURE
atio
CEDURE
Visit (Vi
lica
Visit (Vi
ne (Visit 2
ppl
ne (Visit 2
a
k
a
k 2 (Vis
ap
2 (Vis
(


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 6 of 136
8.9 Week 16 (Visit 9), Week 20 (Visit 10), Week 28 (Visit 12), Week 32 (Visit 13), Week 
40 (Visit 15), and Week 44 (Visit 16)..............................................................................55
8.10 Week 24 (Visit 11) and Week 36 (Visit 14) ....................................................................56
8.11 Week 48 (Visit 17)/Early Withdrawal Visit ....................................................................57
8.12 Safety Follow-Up Visit (Week 64, Visit 18, 20 weeks after the final dose of IMP).......58
8.13 Early Withdrawal Visit ....................................................................................................58
8.14 Unscheduled Visit............................................................................................................58
9
ASSESSMENT OF EFFICACY......................................................................................59
9.1 ASDAS ............................................................................................................................59
9.2 ASAS20, ASAS40, and ASAS partial remission ............................................................60
9.3 BASDAI...........................................................................................................................60
9.4 Inflammation – BASDAI (mean of Questions 5 and 6) ..................................................61
9.5 Function – BASFI............................................................................................................61
9.6 Patient global assessment (PGADA) ...............................................................................61
9.7 PhGADA..........................................................................................................................61
9.8 Total and nocturnal spinal pain........................................................................................62
9.9 hs-CRP .............................................................................................................................62
9.10 Hospital Anxiety and Depression Scale...........................................................................62
9.11 PET-MRI or PET-CT scan...............................................................................................62
10
ASSESSMENT OF PHARMACOKINETIC/ 
PHARMACODYNAMIC/PHARMACOGENOMIC/ PHARMACOGENETIC 
VARIABLE(S) ................................................................................................................62
10.1 Pharmacokinetic variables ...............................................................................................62
10.2 Pharmacodynamic variables ............................................................................................63
10.3 Nonhereditary pharmacogenomic variables.....................................................................63
10.4 Pharmacogenetic variables...............................................................................................63
11
ASSESSMENT OF IMMUNOLOGICAL VARIABLE(S) ............................................63
12
ASSESSMENT OF SAFETY..........................................................................................64
12.1 Adverse events.................................................................................................................64
12.1.1
Definitions ...........................................................................................................64
12.1.1.1
Adverse event............................................................................................64
12.1.1.2
Serious adverse event ................................................................................64
12.1.1.3
Adverse events of special interest .............................................................66
12.1.1.4
Adverse events for special monitoring......................................................67
12.1.2
Procedures for reporting and recording adverse events.......................................67
12.1.2.1
Description of adverse events....................................................................67
12.1.2.2
Rule for repetition of an adverse event......................................................68
12.1.2.3
Additional procedures for reporting serious adverse events .....................68
12.1.3
Follow up of adverse events ................................................................................68
PUBLIC COPY 
.
Y
....
Y
...
........
PY
.........
Y
.
.........
CO
..........
O
.
C
.........
C
.........
..........
IC
..........
COKINE
BLI
COKINE
HAR
UB
HARMA
UBL
MA
..........
PU
..........
This document cannot be used to support any marketing authorization 
58
or
58
.....
th
.....59
ho
59
...........
au
...........59
h
59
...........
g a
...........
............
ing
............
..........
ket
............
t
..
............
ark
............
............
ma
............
...........
y
...........
............
any
............
............
rt
............
............
po
............
....
p
............
pp
........
TIC/ 
su
TIC/ 
COGENO
o s
COGENO
..
d
............
d to
..........
............
ed
............
...........
us
...........
ogenomic 
be u
ogenomic 
riables
t be
riables...
b
...
OF IMMU
not 
OF IMMU
T OF SA
nn
T OF SA
vents
ca
vents....
a
....
Definitio
nt c
Definitio
.1.1.1
men
.1.1.1
12.1.1.2
um
12.1.1.2
12.1
cu
12.1
1
1
d
1
application and any extensions or variations thereof.
9
f
9
....60
of
60
........
re
........60
eo
60
............
the
............
.......
s t
............
t
.....
..........
on
..............
....
ati
...........
atio
.......
............
ria
............
............
va
............
....
or
............
or
........
............
s o
............
OMIC/ PH
sion
OMIC/ PH
............
ns
............
..........
te
..............
............
ex
............
c variables
ny e
c variables
............
an
............
UNO
d
UNOLOG
d a
LOG
AFETY
an
AFETY.
............
n 
............
ons
ti
ons ......
tio
......
Advers
cat
Advers
2
Seri
ic
Seri
.1.3
ap
.1.3
A
p
A
.1.4
ap
.1.4


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 7 of 136
12.2 Pregnancy.........................................................................................................................69
12.3 Suspected transmission of an infectious agent.................................................................70
12.4 Overdose of investigational medicinal product ...............................................................70
12.5 Safety signal detection .....................................................................................................70
12.6 Laboratory measurements................................................................................................70
12.6.1
Evaluation of PDILI ............................................................................................72
12.6.1.1
Consultation with Medical Monitor and local hepatologist ......................77
12.6.1.2
Immediate action: Determination of IMP discontinuation........................77
12.6.1.3
Testing: Identification/exclusion of alternative etiology...........................77
12.6.1.4
Follow-up evaluation.................................................................................79
12.7 Other safety measurements..............................................................................................79
12.7.1
Vital signs ............................................................................................................79
12.7.2
Body weight and height.......................................................................................80
12.7.3
Physical examination...........................................................................................80
12.7.4
12-lead electrocardiogram ...................................................................................80
12.7.5
Tuberculosis and TB risk factor assessment and management ...........................80
12.7.5.1
Tuberculosis assessment by IGRA............................................................82
12.7.5.2
Chest X-ray for tuberculosis......................................................................82
12.7.5.3
Tuberculosis questionnaire........................................................................83
12.7.5.4
Tuberculosis management.........................................................................83
12.7.6
Pregnancy testing.................................................................................................84
12.7.7
Assessment of suicidal ideation and behavior.....................................................84
13
OTHER STUDY MEASUREMENTS ............................................................................84
13.1 Demographic and Baseline characteristics ......................................................................84
13.2 Medical history ................................................................................................................84
13.3 Ankylosing spondylitis history ........................................................................................84
13.4 Prior and concomitant medications..................................................................................84
14
STUDY MANAGEMENT AND ADMINISTRATION.................................................85
14.1 Adherence to protocol......................................................................................................85
14.2 Monitoring .......................................................................................................................85
14.2.1
Definition of source data .....................................................................................85
14.2.2
Source data verification .......................................................................................86
14.3 Data handling...................................................................................................................86
14.3.1
Case Report Form completion.............................................................................86
14.3.2
Database entry and reconciliation........................................................................86
14.3.3
Subject Screening and Enrollment log/Subject Identification Code list..............86
14.4 Termination of the study..................................................................................................87
14.5 Archiving and data retention............................................................................................87
LIC COPY 
......
Y
......
sment a
OPY
sment a
y IGRA
COP
y IGRA
losis
C C
losis...
C
...
onnaire
LIC
onnaire
PUB
nagemen
BLI
nagemen
.........
PU
.........
cidal i
PU
cidal i
support any marketing authorization 
.77
or
77
......
th
......77
ho
77
............
au
............7
...........
g
...........
............
ting
............
............
ke
............
...........
ar
............
............
m
............
...........
y
...........
nd manage
any
nd manage
............
rt
............
............
po
............
............
upp
............
not be used to su
...........
su
...........
............
to
............
eation an
d t
eation an
M
s
MENTS
sed
ENTS
e characte
e us
e characte
...........
be
...........
ylitis histo
ot b
ylitis histo
This document cann
mitant m
no
mitant m
ANAGEM
an
ANAGEM
ce to prot
t ca
ce to prot
itoring
ent
itoring .
.1
m
.1
Def
e
Def
4.2.2
cum
4.2.2
14.3
doc
14.3 Dat
oc
Dat
14
d
14
ons or variations thereof.
7
f
7
...
e
...79
eof
79
.........
ere
.........79
e
79
...
th
............
th
.........
............
s
............
............
on
............
...........
ati
...........
ement
aria
ement ....
............
va
............
..........
or
..............
............
s
............
d any extension
...........
on
...........
............
si
............
d behavio
ens
d behavio
............
xt
............
teristics
y ex
teristics
.......
ny
...........
ny
....
ory
d
ory .......
d a
.......
plication an
edication
nd
edication
MENT AN
n an
MENT AN
tocol
tion
tocol....
on
....
...........
at
...........
finition o
lica
finition o
app
Source d
ppl
Source d
handlin
ap
handlin
C


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 8 of 136
14.6 Audit and inspection ........................................................................................................87
14.7 Good Clinical Practice .....................................................................................................88
15
STATISTICS ...................................................................................................................88
15.1 Definition of analysis sets................................................................................................88
15.2 General statistical considerations.....................................................................................88
15.3 Subject disposition...........................................................................................................89
15.4 Subject characteristics......................................................................................................89
15.5 Planned efficacy analyses ................................................................................................89
15.5.1
Analysis of the primary efficacy variable............................................................89
15.5.2
Supportive analysis of the primary efficacy variable ..........................................90
15.5.3
Analysis of the secondary efficacy variables.......................................................90
15.5.4
Analysis of the other efficacy variables...............................................................90
15.6 Pharmacokinetic analyses ................................................................................................90
15.7 Immunological analyses...................................................................................................91
15.8 Planned safety and other analyses....................................................................................91
15.8.1
Safety analyses.....................................................................................................91
15.9 Handling of protocol deviations.......................................................................................91
15.10
Handling of dropouts or missing data....................................................................91
15.11
Planned interim analysis and data monitoring.......................................................91
15.12
Determination of sample size.................................................................................92
16
ETHICS AND REGULATORY REQUIREMENTS......................................................92
16.1 Informed consent .............................................................................................................92
16.2 Subject identification cards..............................................................................................93
16.3 Institutional Review Boards and Independent Ethics Committees..................................93
16.4 Subject privacy.................................................................................................................94
16.5 Protocol amendments.......................................................................................................94
17
FINANCE, INSURANCE, AND PUBLICATION.........................................................94
18
REFERENCES ................................................................................................................94
19
APPENDICES .................................................................................................................99
19.1 Modified New York (mNY) Classification Criteria for AS ............................................99
19.2 Markedly abnormal laboratory values ...........................................................................100
19.3 Protocol Amendment 1 ..................................................................................................101
19.4 Protocol Amendment 2 ..................................................................................................107
19.5 Protocol Amendment 3 ..................................................................................................117
20
DECLARATION AND SIGNATURE OF INVESTIGATOR .....................................135
21
SPONSOR DECLARATION ........................................................................................136
PUBLIC COPY 
......
Y
......
.........
PY
.........
..........
CO
..........
g data
C CO
g data.
C
.
d data m
LIC 
d data m
size
BL
size...
BL
...
OR
PU
ORY RE
PUB
Y RE
.....
P
.....
This document cannot be used to support any marketing authorization 
.89
or
89
......
th
......89
ho
89
............
au
............8
.......
g
...........
g
....
............
ting
............
............
ke
............
..
a
............
ar
..........
.....
m
............
m
.......
...........
y
...........
............
an
............
..............
rt
..........
............
po
............
onitoring
upp
onitoring
...........
su
...........
QUIREM
to s
QUIREM
........
d
............
d
....
............
se
............
ds and Ind
e us
ds and Ind
...........
be
...........
nts
ot
nts........
ot
........
SURANC
nno
SURANC
CES
a
CES ......
an
......
DICES
t ca
DICES .
ified New
ent
ified New
Markedly a
me
Markedly a
3
c
3 Protoco
cum
Protoco
19.4
doc
19.4 Prot
oc
Prot
19.5
s d
19.5 P
20
s
20
application and any extensions or variations thereof.
9
f
9
...
e
...90
eof
90
.........
ere
.........90
e
90
............
th
............
............
s
............
............
on
............
...........
ati
...........
............
ari
............
............
va
............
............
or
............
............
s
............
..........
on
...........
MENTS
nsio
MENTS.
............
en
............
............
xt
............
ndependen
y ex
ndependen
......
ny
...........
ny
.....
............
d a
............
CE, AND 
and
CE, AND 
............
n a
............
............
ion
............
w York (m
atio
w York (m
abnormal
lica
abnormal
ol Amend
ppl
ol Amend
ocol Am
ap
col Am
l


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 9 of 136
LIST OF TABLES
Table 5‒1:
Schedule of assessments ..................................................................................26
Table 5‒2:
Exposure to bimekizumab by dose ..................................................................33
Table 7‒1:
Treatments administered..................................................................................43
Table 7‒2:
Prohibited or restricted medications and required wash-out periods prior 
to Baseline........................................................................................................45
Table 12‒1:
Anticipated serious adverse events for the population of subjects with AS....65
Table 12‒2:
Laboratory measurements................................................................................71
Table 12‒3:
Required investigations and follow-up for PDILI ...........................................74
Table 12‒4:
PDILI laboratory measurements......................................................................77
Table 12‒5:
PDILI information to be collected ...................................................................79
Table 19‒1:
Modified New York (mNY) Classification Criteria for AS ............................99
Table 19‒2:
Definitions of markedly abnormal hematology values..................................100
Table 19‒3:
Definitions of markedly abnormal biochemistry values................................100
LIST OF FIGURES
Figure 5‒1:
Schematic diagram...........................................................................................31
C COPY 
matolo
Y
matolo
biochem
OPY
biochem
PUBLIC
T OF F
IC C
T OF F
.........
BL
.........
rketing authorization 
45
r
45
S
t
S....
th
....65
ho
65
...........
au
........... 7
........
ng
............
g
....
............
eti
............
port any mark
...........
rk
...........
for AS
ma
for AS .
a
.
values
ny m
values....
mistry valu
t any
mistry valu
This document cannot be used to supp
FIGURE
ppo
FIGURE
............
su
............
s thereof.
71
f
71
.....
e
.....74
eof
74
......
he
............
e
......7
ons or variations t
...........
s t
...........
............
on
............
............
at
............
ues
a
ues.......
ar
.......
application and any extension
ES
s
ES
............
on
............


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 10 of 136
LIST OF ABBREVIATIONS
AE
adverse event
AESI
adverse event of special interest
AESM
adverse event for special monitoring
ALP
alkaline phosphatase
ALT
alanine aminotransferase
ANCOVA
analysis of covariance
AS
ankylosing spondylitis
ASAS
Assessment of SpondyloArthritis International Society
ASAS20, 40, 5/6
Assessment in SpondyloArthritis International Society 20%, 40%, 5 out of 6 
response criteria
ASDAS
Ankylosing Spondylitis Disease Activity Score
ASDAS-ID
Ankylosing Spondylitis Disease Activity Score inactive disease
ASDAS-MI
Ankylosing Spondylitis Disease Activity Score major improvement
AST
aspartate aminotransferase
axSpA
axial spondyloarthritis
BA
bioavailability
BASDAI
Bath Ankylosing Spondylitis Disease Activity Index
BASFI
Bath Ankylosing Spondylitis Functional Index
BCG
Bacille Calmette-Guérin
BMI
body mass index
BP
blood pressure
BSA
body surface area
CD
cluster of differentiation
CDC 
Centers for Disease Control 
CDMS
clinical data management system
CHO
Chinese Hamster Ovarian
CI
confidence interval
COX-2 inhibitor
cyclooxygenase 2 inhibitor
CPM
Clinical Project Manager
CPMP
Committee for Proprietary Medicinal Products
CRO
contract research organization
CRP
C-reactive protein
CSR
clinical study report
PUBLIC COPY
e Activ
PY 
e Activ
ng Spon
BLI
ng Spon
ylosing S
PUB
ylosing S
Calme
PU
Calme
ot be used to support any marketing authorization 
0%, 40%, 
eting
0%, 40%, 
re inactive
ma
re inactive
Score maj
ny 
Score maj
ylitis Dise
sup
ylitis Dise
pondylitis 
to s
pondylitis 
e-
d
-Guérin
d t
Guérin
index
use
index
pressure
be u
pressure
dy surface
t be
dy surface
This document cannot
cluster o
not
cluster o
Cen
nn
Cen
X
c
X-
c
-2 inhib
cum
2 inhib
CPM
doc
CPM
CPM
s d
CPM
d any extensions or variations thereof.
5
h
5 out of 6
here
out of 6
e disease
tion
e disease
ajor improv
iati
ajor improv
ease Activ
ons
ease Activ
Functiona
sio
Functiona
e area
an
e area
application and
f differen
nd 
f differen
ters for D
an
ters for D
clinical d
on 
clinical d
Chine
atio
Chine
c
a
c
bitor
pp
bitor


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 11 of 136
C-SSRS
Columbia-Suicide Severity Rating Scale
CT
computed tomography
CZP
certolizumab pegol
DMARD
disease-modifying antirheumatic drug
DMC
Data Monitoring Committee
DVU
disco-vertebral unit
ECG
electrocardiogram
eCRF
electronic Case Report Form
EDC
electronic data capture
EPM
Exploratory Project Manager
ES
Enrolled Set
FAS
Full Analysis Set
FDA
Food and Drug Administration
FSH
follicle-stimulation hormone
GCP
Good Clinical Practice
GFR
glomerular filtration rate
GI
gastrointestinal
GMP
Good Manufacturing Practice
HADS
Hospital Anxiety and Depression Scale
HADS-A
Hospital Anxiety and Depression Scale—Anxiety 
HADS-D
Hospital Anxiety and Depression Scale—Depression 
HbcAg
hepatitis B core antibody
HbsAg
hepatitis B surface antigen
HBV
hepatitis B virus
HCV
hepatitis C virus
HIV
human immunodeficiency virus
HLA
human leukocyte antigen
hs-CRP
high sensitivity C-reactive protein
hPDSC
human periosteum-derived stem cell
IB
Investigator’s Brochure
IBD
inflammatory bowel disease
ICH
International Council for Harmonisation
ICF
Informed Consent form
IEC
Independent Ethics Committee
PUBLIC COPY 
ate
C C
ate
acturing P
BLI
acturing P
Anxiety a
PUB
Anxiety a
Anxi
P
Anxi
This document cannot be used to support any marketing authorization 
ractice
su
ractice
nd Depres
to 
nd Depres
ety and De
ed 
ety and De
Anxiety and
use
Anxiety and
tis B core 
be u
tis B core 
patitis B s
t be
patitis B s
hepatitis
not
hepatitis
hep
nn
hep
P
DSC
cu
DSC
IB
do
IB
IBD
s d
IBD
application and any extensions or variations thereof.
ssion Scale
nsio
ssion Scale
epression S
ten
epression S
d Depressi
ext
d Depressi
antibody
ny e
antibody
surface ant
any
surface ant
s B virus
nd 
s B virus
patitis C vi
an
patitis C vi
human im
ion 
human im
huma
atio
huma
h
a
h


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 12 of 136
IGRA
Interferon-Gamma Release Assay
IIV
interindividual variability
IL
interleukin
im
intramuscular
IMP
investigational medicinal product
IRB
Institutional Review Board
IUD
intrauterine device
IUS
intrauterine hormone-releasing system
im
intramuscular
iv
intravenous
IRT
interactive response technology
LTB
latent tuberculosis
LTBI
latent tuberculosis infection 
MAR
missing at random
MCID
minimal clinically important difference
MCP-Mod
multiple comparison procedure – modeling
MCS
mental component summary
MedDRA®
Medical Dictionary for Regulatory Activities
MI
multiple imputation
MMP
matrix metalloproteinase
mNY
Modified New York (criteria)
MOS
Medical Outcomes Study
MRI
magnetic resonance imaging
MTB
mycobacterium tuberculosis 
MTX
methotrexate
nr-axSpA
nonradiographic-axial spondyloarthritis
NRI
nonresponder imputation
NRS
numeric rating scale
NSAID
nonsteroidal anti-inflammatory drug
NTMB
nontuberculous mycobacteria
NYHA
New York Heart Association
OPV
oral polio vaccine
PCS
physical component summary
PD
pharmacodynamics
PUBLIC COPY 
ant differ
OP
ant differ
procedure
C CO
procedure
t summa
LIC 
t summa
onary fo
BLI
onary fo
mputatio
PUB
mputatio
etallo
P
etallo
used to support any marketing authorization 
nce
rt
nce
– modelin
port
modelin
y
u
y
Regulator
sup
Regulator
proteinase
ed 
proteinase
New York 
use
New York 
document cannot be
al Outcom
be u
al Outcom
agnetic res
t be
agnetic res
mycoba
not
mycoba
met
nn
met
This do
AID
cu
AID
NTMB
doc
NTMB
NYH
s d
NYH
y extensions or variations thereof.
ng
o
ng
ry 
o
ry Activiti
ons
Activiti
k (criteria)
ext
k (criteria)
application and any
mes Study
ny e
mes Study
sonance im
any
sonance im
acterium tu
nd 
acterium tu
hotrexate
an
hotrexate
nonradiog
ion 
nonradiog
nonre
atio
nonre
a


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 13 of 136
PDILI
potential drug-induced liver injury
PD-PPS
Pharmacodynamics Per-Protocol Set
PET
positron-emission tomography
PET-CT
positron-emission tomography – computed tomography
PET-MRI
positron-emission tomography – magnetic resonance imaging
PFS
pre-filled syringe
PGADA
Patient’s Global Assessment of Disease Activity
PhGADA
Physician’s Global Assessment of Disease Activity
PK
pharmacokinetics
PK-PPS
Pharmacokinetics Per-Protocol Set
PPS
Per-Protocol Set
PS
Patient Safety
PsA
psoriatic arthritis
PSO
psoriasis
Q2W
every 2 weeks
Q4W
every 4 weeks (monthly)
QTcF
QT interval corrected for heart rate using Fridericia’s formula 
RA
rheumatoid arthritis
RCTC
Rheumatology Common Toxicity Criteria
RIF
mycobacterium tuberculosis rifampin
RNA
ribonucleic acid
RS
Randomized Set
RUV
residual unexplained variability
SAE
serious adverse event
SAP
Statistical Analysis Plan
sc
subcutaneous(ly)
SD
standard deviation
SFU
Safety Follow-up
SI
sacroiliac
SpA
spondyloarthritis
SOP
standard operating procedure
SS
Safety Set
SSZ
sulfasalazine
STIR
short-tau-inversion recovery
PUBLIC COPY 
ly)
C C
ly)
cted for h
LIC 
cted for h
thritis
BLI
thritis
ology Co
PUB
ology Co
teriu
P
teriu
This document cannot be used to support any marketing authorization 
eart rate us
upp
eart rate us
mmon Tox
to 
mmon Tox
m tuberculo
ed 
m tuberculo
acid
use
acid
mized Set
e u
mized Set
sidual une
t be
sidual une
serious a
not
serious a
Stat
nn
Stat
SpA
doc
SpA
SOP
s d
SOP
application and any extensions or variations thereof.
sing Frider
s o
sing Frider
xicity Crite
nsio
xicity Crite
osis
te
osis rifamp
ten
rifamp
explained v
any
explained v
adverse ev
nd 
adverse ev
tistical An
an
tistical An
subcutane
ion 
subcutane
stand
atio
stand
S
a
S


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 14 of 136
SUVAUC
standardized uptake value by area under the curve
t½
half-life
TB
tuberculosis
TEAE
treatment-emergent adverse event
TNF
tumor necrosis factor
TNFα
tumor necrosis factor alpha
ULN
upper limit of normal
VAS
visual analog scale
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 15 of 136
1
SUMMARY
This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, parallel-group, 
study to investigate the efficacy and safety of bimekizumab (also known as UCB4940) and 
certolizumab pegol ([CZP]; Cimzia®) in adult subjects with active ankylosing spondylitis (AS).
Eligible subjects will have active AS, determined by documented radiologic evidence (X-ray) 
fulfilling the Modified New York criteria for AS (van der Linden et al, 1984), including 
symptoms for ≥3 months and age of onset <45 years. Furthermore, subjects will have moderate 
to severe active disease at Screening (Bath Ankylosing Spondylitis Disease Activity Index 
[BASDAI] ≥4 and spinal pain ≥4 [BASDAI Question 2]). 
The primary objective of the study is to evaluate the efficacy of bimekizumab administered 
subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
subjects with active AS. The primary efficacy variable is the change from Baseline in 
Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12. The secondary objective 
of the study is to assess the safety and tolerability of bimekizumab. The secondary efficacy 
variables include the determination of ASDAS inactive disease (ASDAS-ID) and ASDAS major 
improvement (ASDAS-MI) at Week 12. Primary safety variables include the incidence of 
adverse events (AEs), serious adverse events (SAEs), and AEs leading to withdrawal from 
investigational medicinal product (IMP).
Other exploratory objectives of the study are to evaluate the effect of bimekizumab or CZP on 
changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
bimekizumab, to obtain additional biomarkers and clinical and imaging data as applicable, and to 
assess the efficacy and safety of bimekizumab or CZP during the Treatment Period and the 
Treatment Extension Period.
Multiple sites in North America, Europe, and the Asian-Pacific (APAC) region will randomize at 
least 60 subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
The study consists of a Screening Period (2 to 4 weeks), Treatment Period (12 weeks), Treatment 
Extension Period (36 weeks), and a Safety Follow-up (SFU) Period (20 weeks after the final 
dose of the IMP). Therefore, the maximum duration of the study is 68 weeks. 
Screening Period
The Screening Period will last for a minimum of 2 weeks and up to 4 weeks. During the 
Screening Period, the Investigator will assess the eligibility of subjects according to the inclusion 
and exclusion criteria. The Screening Period will also enable washout of any medications not 
permitted for use during the study. 
PUBLIC COPY
y v
Y
y v
s), and A
PY 
s), and A
 to
C
 to evalu
CO
evalu
pharmac
C C
pharmac
markers 
LIC
markers 
mekizum
BL
mekizum
a, Eur
PU
a, Eur
annot be used to support any marketing authorization 
erate
ori
erate
ex
th
ex
ministered
g au
ministered
he treatm
ing 
he treatm
Baseline in
eting
Baseline in
The second
ket
The second
he second
ark
he second
SDAS
ma
SDAS-
a
-ID
a
ID
es include
y m
es include
Es leading
any 
Es leading
ate the eff
ort
ate the eff
kinetics (
ppo
kinetics (
and clinica
upp
and clinica
ab or CZP
sup
ab or CZP
ope, and th
ed t
ope, and th
ceive eith
sed
ceive eith
ing Period
e us
ing Period
s), and a S
be 
s), and a S
fore, the m
ot b
fore, the m
ent ca
eriod will
can
eriod will
riod, the I
t ca
riod, the I
ion criter
ent 
ion criter
This docume
ed for use
men
ed for use
and any extensions or variations thereof.
ed 
ed 
ment of 
reo
ment of 
in 
h
in 
ndary obje
the
ndary obje
dary effic
ns t
dary effic
D) and AS
ons
D) and AS
e the incid
atio
e the incid
g to withd
riat
g to withd
fect of bi
r v
fect of bi
(PK) and 
or
(PK) and 
cal and im
ns o
cal and im
P during th
ions
P during th
the Asian
ten
the Asian
her bimek
xte
her bimek
d (2
y
d (2 to
y e
to 4 w
e
4 w
Safety Fo
any
Safety Fo
maximum
d an
maximum
ation 
ll last for 
n a
ll last for 
Investigat
tion
Investigat
ria. The S
atio
ria. The S
applic
e during th
lica
e during th


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 16 of 136
Treatment Period
At Baseline/Day 1, subjects will be randomized in a 2:1 ratio to receive the following blinded 
study treatments during the Treatment Period:

Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 

Certolizumab pegol 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 
200mg sc Q2W in Weeks 6 to 10.
The IMP will be administered sc in the clinic by trained site personnel. 
Treatment Extension Period
After completing the 12-week Treatment Period, subjects will enter a 36-week Treatment 
Extension Period and will receive the following treatments:

Subjects randomized to bimekizumab during the Treatment Period will receive bimekizumab 
320mg sc every 4 weeks (Q4W) from Week 12 to Week 44. 

Subjects randomized to CZP during the Treatment Period will receive CZP 400mg Q4W 
from Week 12 to Week 44. 
Subjects not responding to treatment will be withdrawn from the study as per Investigator’s 
discretion.
Safety Follow-Up Period
All subjects who complete the study or who discontinue early, including those withdrawn from 
study treatment, will have a SFU Visit at 20 weeks after their final dose of IMP. 
2
INTRODUCTION
2.1
Axial spondyloarthritis
Spondyloarthritis (SpA) is an umbrella term applied to a family of rheumatic diseases (including 
axial spondyloarthritis [axSpA], psoriatic arthritis [PsA], reactive arthritis, the arthritis of 
inflammatory bowel disease [IBD], and undifferentiated spondyloarthritis) that have features in 
common with each other and distinct from other inflammatory arthritides, particularly 
rheumatoid arthritis (RA). 
Axial SpA is a chronic inflammatory disease that impacts a substantial proportion of the 
population. Limited evidence exists regarding the exact prevalence of axSpA; however, recent 
data suggest that the prevalence is similar to that of RA in the US (axSpA: 0.7% to 1.4%; RA: 
0.5% to 1.0%) (Reveille et al, 2012; Myasoedova et al, 2010; Helmick et al, 2008). 
The Assessment of SpondyloArthritis International Society (ASAS) working group established 
classification criteria to distinguish 2 broad categories of SpA: peripheral SpA and axSpA 
(Rudwaleit et al, 2011; Rudwaleit, 2010; Rudwaleit et al, 2009b). This division is based on the 
body part predominantly involved in the inflammatory process. Therefore, peripheral SpA 
includes diseases affecting mainly peripheral joints, such as reactive arthritis and PsA, whereas 
axSpA comprises those diseases with mainly axial involvement (sacroiliac [SI] joints and spine), 
including AS diagnosed with radiographic involvement and nonradiographic axSpA (nr-axSpA). 
PUBLIC COPY
ent Peri
PY 
ent Peri
 withdra
CO
 withdra
udy or w
PUB
udy or w
U Visi
PU
U Visi
nnot be used to support any marketing authorization 
CZP 
ho
CZP 
eek Trea
etin
eek Trea
iod will re
mar
iod will re
d will rec
any
d will rec
wn from t
port
wn from t
ho discon
to s
ho discon
at 20 wee
d to
at 20 wee
ON
s
ON
dyloarth
be u
dyloarth
s an umbr
t be
s an umbr
[axSpA],
not 
[axSpA],
l disease 
nno
l disease 
This document ca
ch other a
an
ch other a
thritis (RA
t ca
thritis (RA
A is a chro
ent
A is a chro
tion. Lim
me
tion. Lim
a suggest t
cum
a suggest t
0.5% to 1.
ocu
0.5% to 1.
The
do
The A
o
A
clas
s 
clas
(
tion and any extensions or variations thereof.
tment 
her
tment 
receive bi
ons
receive bi
ceive CZP
riat
ceive CZP
the study 
or v
the study 
ntinue ear
sio
ntinue ear
eks after t
ens
eks after t
hritis
ny e
hritis
rella term
any
rella term
, psoriatic
d a
, psoriatic
[IBD], an
and
[IBD], an
applica
and
n
and distin
n a
distin
RA).
io
RA).
onic infla
catio
onic infla
mited evid
lica
mited evid
that the p
pplic
that the p
.0%) (Rev
app
0%) (Rev
men
a
men


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 17 of 136
Patients with axSpA have inflammatory back pain. The disease typically originates in the 
sacroiliac joints, then progresses to the spine. In the sacroiliac joints and the spine, active 
inflammation results in erosions, sclerosis, and fatty lesions seen on an magnetic resonance 
imaging (MRI). However, the most characteristic feature is new bone formation leading to 
ankylosis of the SI joints and syndesmophytes attached to the vertebral bodies. As a result of 
extended syndesmophyte formation, over time the spine may become fused. Objective signs of 
inflammation (such as enthesitis, dactylitis, peripheral arthritis, or uveitis), genetic features (such 
as the presence of human leukocyte antigen [HLA] B27), and laboratory parameters (such as 
elevated C-reactive protein [CRP]) may also be present (Braun, 2012; Rudwaleit et al, 2009a; 
Braun and Sieper, 2007). Disability in axSpA is related to both the degree of inflammatory 
activity, causing pain, stiffness, fatigue, and poor quality of sleep, and to the degree of bony 
ankylosis, causing loss of spinal mobility. Patients with AS show radiographic progression of 
disease with X-ray identified sacroiliitis, while "Bamboo spine" may develop when the outer 
fibers of the fibrous ring of the intervertebral discs ossify, which results in the formation of 
marginal syndesmophytes between adjoining vertebrae.
Nonsteroidal anti-inflammatory drugs are often rapidly effective for the symptoms (pain and 
stiffness) of axSpA (Poddubnyy, 2013; Poddubnyy et al, 2012), but many patients lose or never 
have clinically meaningful response and structural damage often progresses despite their use. 
Conventional disease-modifying antirheumatic drugs (DMARDs, eg, methotrexate [MTX] and 
sulfasalazine [SSZ]) have no proven efficacy in axial disease, but may benefit patients with 
peripheral joint disease (Haibel et al, 2007; Braun et al, 2006; Haibel et al, 2005). Therefore, 
DMARDs are recommended only in patients with predominantly peripheral manifestations 
(Braun et al, 2011). Patients who are intolerant of or have inadequately responded to nonsteroidal 
anti-inflammatory drugs (NSAIDs), or those in whom NSAIDs are contraindicated, have 
approved treatment options such as tumor necrosis factor (TNF) inhibitors.
Recently, the interleukin (IL)-17 cytokine family has been identified as a therapeutic target in 
axSpA and secukinumab, an IL-17A monoclonal antibody, has recently been approved as a 
treatment option in active AS. 
Treatment with tumor necrosis factor alpha (TNFα)-antagonists has demonstrated marked 
improvement in almost all features of AS, a subset of the axSpA population. For AS, many of the 
processes which lead to inflammation and subsequent damage, as in RA, are driven by 
dysregulated TNFα production, including extracellular matrix degradation due to matrix 
metalloproteinase (MMP) production (Davis and Mease, 2008).
2.2
Bimekizumab
Bimekizumab (UCB4940) is an engineered, humanized full length monoclonal antibody of 
immunoglobulin (Ig)G1 subclass of approximately 150,000 Dalton, which is expressed in a 
genetically engineered Chinese Hamster Ovarian (CHO) cell line. Bimekizumab has high affinity 
for human IL-17A and human IL-17F and selectively and potently inhibits the activity of both 
isoforms in vitro. Interleukin-17A and IL-17F are key proinflammatory cytokines believed to 
play important roles in autoimmune and inflammatory diseases. Therefore, bimekizumab permits 
an evaluation of the potential for additional efficacy, which may be conferred by dual inhibition 
of both cytokines, in patients suffering from diseases in which both cytokines are active. 
Bimekizumab is being developed for the treatment of patients with inflammatory diseases such 
as PsA, psoriasis (PSO), and axSpA. 
PUBLIC COPY
al, 
Y
al, 
damage
PY 
damage
rugs (DM
OPY
rugs (DM
in axial 
CO
in axial 
 Braun e
C C
 Braun e
ients wi
LIC 
ients wi
intoleran
BLIC
intoleran
s), or tho
UBL
s), or tho
h as tum
PU
h as tum
cy
P
cy
not be used to support any marketing authorization 
uch
iz
uch
as
o
as
009a;
tho
009a;
matory 
uth
matory 
ee of bony
au
ee of bony
progressio
ng a
progressio
p when
ting
p when th
g
th
n the form
keti
n the form
or the sym
ma
or the sym
 but many
y m
 but many
ften progr
any 
ften progr
MARDs, e
t an
MARDs, e
disease, bu
ort a
disease, bu
t al, 2006
por
t al, 2006
h predo
upp
h predom
p
m
nt of or ha
sup
nt of or ha
se in whom
o s
se in whom
or necrosi
d to
or necrosi
tokine fam
sed
tokine fam
17A mono
use
17A mono
rosis fact
t be
rosis fact
t all featur
ot 
t all featur
This document cann
d to inflam
nno
d to inflam
Fα produc
ann
Fα produc
nase (MM
t ca
nase (MM
Bim
nt 
Bim
kizumab (
me
kizumab (
muno
cum
munoglob
um
glob
geneticall
doc
geneticall
for hum
do
for hum
isof
s d
isof
s
nd any extensions or variations thereof.
y 
o
y 
on of 
eof
on of 
he outer 
ere
he outer 
mation of 
the
mation of 
mptoms (p
ons
mptoms (p
ny patients
atio
ny patients
gresses de
riat
gresses de
eg, metho
aria
eg, metho
ut may be
r va
ut may be
6; Haibel e
or v
6; Haibel e
minantly p
s o
minantly p
ave inadeq
ons
ave inadeq
om NSAID
sion
om NSAID
is factor (
nsi
is factor (
mily has b
xten
mily has b
oclonal an
ext
oclonal an
tor alpha (
any
tor alpha (
ures of AS
d a
ures of AS
application an
mmation 
and
mmation 
ction, inc
n an
ction, inc
MP) produ
on 
MP) produ
mekizum
atio
mekizum
(UCB494
plica
(UCB494
bulin (Ig)
ppl
bulin (Ig)
y engine
app
y engine
IL
a
IL-1


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 18 of 136
2.2.1
Clinical experience with bimekizumab
Four clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque psoriasis, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, 
and UP0031 in 12 healthy volunteers. 

UP0008 was a Phase 1, First-in-Human (FIH) randomized, subject-blind, investigator-blind, 
placebo-controlled, single-dose, dose-escalating study in 39 subjects with mild-to-moderate 
plaque PSO. In this study bimekizumab was administered by intravenous (iv) infusion of 
single ascending doses and was well tolerated at doses of up to 640mg. The maximum 
tolerated dose was not reached, and no safety issues were identified. Dose-proportional PK 
was displayed between bimekizumab 8mg and 640mg. The median t½ ranged between 
17.00 days and 25.55 days across the treatment groups. Dose-dependent improvements in the 
psoriatic lesion of interest were observed after bimekizumab administration for all features of 
plaque PSO in the study. 

RA0124 was an open-label, parallel-group, single-dose study to evaluate the absolute 
bioavailability (BA), dose proportionality, and safety and tolerability of 2 dose levels of 
bimekizumab given by sc injection versus bimekizumab given by iv infusion in 30 healthy 
subjects. Similar BA was observed for the 2 doses tested (0.656 and 0.631 for the 
bimekizumab 80mg and bimekizumab 160mg doses, respectively). No new safety issues 
were observed versus previous studies when bimekizumab was administered sc as a single 
dose of 80mg or 160mg, or iv at a dose of 160mg.

PA0007 was a randomized, subject-blind, investigator-blind, placebo-controlled, 
multiple-dose administration study to evaluate the safety, PK, and pharmacodynamic (PD) 
profiles of bimekizumab administered iv to subjects with active PsA who had an inadequate 
response to at least 1 nonbiologic disease-modifying antirheumatic drug (DMARD) and/or 
1 approved biologic DMARD. Bimekizumab was administered to 4 cohorts of subjects as a 
loading dose of 240mg, 80mg, 160mg, or 560mg followed by 2 maintenance doses at 
3-weekly intervals of 160mg, 40mg, 80mg, or 320mg, respectively. There were no 
unexpected clinically relevant safety findings and all doses were well tolerated.

UP0031, evaluated the relative bioavailability, safety and tolerability of 2 bimekizumab 
formulations (a histidine-based formulation 2x80mg and an acetate-based formulation 
1x160mg) administered by sc injection to healthy volunteers. Results showed similar 
geometric means for AUC between the 2 bimekizumab formulations 
(2x80mg=653.8day*μg/mL; 1x160mg=628.3day*μg/mL) and the relative BA for the 
bimekizumab 1x160mg versus 2x80mg formulations was calculated as 96.1% with a 95% 
confidence interval (CI): 72.7,127.0. The wide 95% CI was expected due to the small sample 
size in UP0031.
Additional studies of bimekizumab are ongoing. RA0123 is a Phase 2a, double-blind, 
randomized, placebo-controlled, multiple dose study to evaluate the safety, PK, PD, and efficacy 
of multiple doses of bimekizumab administered as add-on therapy to stable CZP therapy in 
subjects with moderate to severe RA. UC0011 is a Phase 2a study, which will evaluate the 
efficacy, safety, tolerability, and PK of an iv loading dose and 2 sc maintenance doses of 
bimekizumab in subjects with moderate to severe active ulcerative colitis. PS0010, PS0011, 
PS0016, and PS0018 are Phase 2 studies, which will evaluate the PD, PK, safety, and/or efficacy 
PUBLIC COPY
um
Y
um
es teste
PY 
es teste
g doses, 
OPY
g doses, 
en bimek
CO
en bimek
of 160m
C CO
of 160m
L
blind, i
LIC
blind, i
udy to ev
BL
udy to ev
ministered
PUB
ministered
P
ologic d
PU
ologic d
D
P
D
d to support any marketing authorization 
e
of 
o
of 
m 
th
m 
tional PK
uth
tional PK
between
au
between
provemen
g a
provemen
on for all
ting
on for all
valu
ark
valuate th
ark
ate th
ability of 
ma
ability of 
en by iv i
y m
en by iv i
(0
n
(0.656 an
ny 
.656 an
respective
t an
respective
izumab w
ort a
izumab w
g.
p
g.
nvestigato
upp
nvestigato
aluate the 
sup
aluate the 
iv to subj
to s
iv to subj
nnot be use
isease
d to
isease-
t
-mo
to
mo
Bimekizum
sed
Bimekizum
g, 160mg,
use
g, 160mg,
mg, 40mg
e u
mg, 40mg
elevant sa
be 
elevant sa
the relati
ot 
the relati
histid
nno
histidine
no
ine b
ocument ca
ministere
an
ministere
means fo
t ca
means fo
mg=653.8d
nt c
mg=653.8d
ekizumab 
men
ekizumab 
onfidence
ume
onfidence
size in U
cum
size in U
This do
Additio
doc
Additio
rando
s d
rando
of
s
of
nsions or variations thereof.
nts in the
eof
nts in the
l features 
ere
l features 
he absolut
s t
he absolut
f 2 dose le
ons
f 2 dose le
infusion i
tion
infusion i
nd 0.631 f
iat
nd 0.631 f
ely). No n
aria
ely). No n
was admin
va
was admin
or
n
or-blind, p
ns o
blind, p
e safety, P
ions
e safety, P
bjects with
sio
bjects with
and any exten
odifying 
ens
odifying 
mab was 
xten
mab was 
, or 560m
ext
, or 560m
g, 80mg, o
y e
g, 80mg, o
afety findi
any
afety findi
ive bioava
d a
ive bioava
based for
and
based for
application a
ed by sc in
n an
ed by sc in
or AUC be
on 
or AUC be
day*μg/m
atio
day*μg/m
b 1x160mg
icat
b 1x160mg
e interval 
plic
e interval 
UP0031.
ppl
UP0031.
a
l studie
ap
l studie


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 19 of 136
of bimekizumab administered sc to subjects with PSO. PA0008 and AS0008 are Phase 2b 
double-blind, randomized, placebo-controlled, multiple-dose studies to evaluate the efficacy and 
safety of bimekizumab in subjects with active PsA or AS, respectively.
Additional information on the clinical data for bimekizumab is available in the current version of 
the Investigator’s Brochure (IB).
2.2.2
Nonclinical studies with bimekizumab
Parallel inhibition of IL-17A and IL-17F has shown potent effects in a variety of animal models 
of inflammatory disease. Intravenously administered bimekizumab was well tolerated in repeat 
dose toxicology studies in Cynomolgus monkeys with a no adverse effect level of 
200mg/kg/week. The findings of note in toxicity studies were diarrhea related to infectious 
enteritis (observed in the single dose study) and asymptomatic mild colonic ulceration in a 
proportion of animals (in the repeat dose study); this latter finding was not associated with 
hematology abnormalities. Data suggest that bimekizumab has induced primary lesions to the 
mucosa associated lymphoid tissue via a pharmacologically-related mechanism. In a second 
repeat-dose study, none of the minor apoptosis/necrosis findings observed in gut associated 
lymph nodes were seen. In animals given the highest dose of bimekizumab in the study 
(20mg/kg/week), a slightly higher number of protozoa (Balantidium coli) was observed in the 
cecum and colon as compared to the control animals and low dose animals. Therefore, the gut 
associated lymph node lesions observed in the first study are considered to be accidental and/or 
linked to exaggerated pharmacology and proliferation of Balantidium coli and are considered to 
be the result of a change in local mucosal immunity. 
Additional information on the nonclinical data for bimekizumab is available in the current 
version of the IB.
2.3
Certolizumab pegol
Treatment with TNFα-antagonists has demonstrated marked improvement in almost all features 
of AS, a subset of the axSpA population. For AS, many of the processes which lead to 
inflammation and subsequent damage, as in RA, are driven by dysregulated TNFα production, 
including extracellular matrix degradation due to matrix metalloproteinase (MMP) production 
(Davis and Mease, 2008). 
The RAPID-axSpA study enrolled subjects with active axSpA with objective signs of 
inflammation, and the results indicated that baseline disease burden was similar between the AS 
and nr-axSpA subpopulations (Landewe et al, 2014; Sieper et al, 2013b). In the RAPID-axSpA 
study it was shown that CZP rapidly reduced the signs and symptoms of axSpA over 24 weeks of 
double-blind treatment in the broad axSpA population, including in the AS and the nr-axSpA 
subpopulations, and that the responses to the treatment were similar in both subpopulations 
(Landewe et al, 2014; Sieper et al, 2013b) and maintained up to Week 96 (Mease et al, 2014; 
Sieper et al, 2014).
Certolizumab pegol has a high affinity for human TNFα and binds with a dissociation constant 
(KD) of 90pM. Tumor necrosis factor alpha (TNFα) is a key pro-inflammatory cytokine with a 
central role in inflammatory processes. 
Certolizumab pegol does not contain a fragment crystallizable (Fc) region, which is normally 
present in a complete antibody, and therefore does not fix complement or cause 
PUBLIC COPY
os
Y
os
oa (
PY
oa (Ba
Y 
Ba
mals and 
OPY
mals and 
first stu
COP
first stu
oliferati
C CO
oliferati
al immun
IC C
al immun
nical da
BLI
nical da
b peg
PU
b peg
used to support any marketing authorization 
models
horiz
models
n repeat 
tho
n repeat 
infectious
g au
infectious
ceration in
ng 
ceration in
associated
eting
associated
primary le
ket
primary le
echanism
arke
echanism
bserved in
mar
bserved in
mekizuma
y m
mekizuma
ntidium co
ny 
ntidium co
ow dose a
t any
ow dose a
dy are con
ort a
dy are con
on of 
po
on of Bala
por
Bala
ity. 
p
ity. 
a for bim
sup
a for bim
ol
ed
ol
s has dem
use
s has dem
ument cannot be u
opulation
e us
opulation
nt damage
be 
nt damage
atrix degr
ot b
atrix degr
08).
no
08).
A study e
ann
A study e
and the re
ca
and the re
A subpop
nt c
A subpop
was shown
ent
was shown
-blind tre
me
blind tre
This docu
populatio
cum
populatio
(Landewe
docu
(Landewe
Sie
do
Sieper 
do
per 
Ce
s 
Ce
extensions or variations thereof.
s
in a 
re
in a 
d with
here
d with
esions to t
the
esions to t
m. In a sec
s th
m. In a sec
n gut asso
ons
n gut asso
ab in the 
tion
ab in the 
oli
ia
oli) was o
iati
) was o
animals. T
aria
animals. T
nsidered t
va
nsidered t
antidium c
or v
antidium c
ekizumab
ons
ekizumab
monstrated
exte
monstrated
plication and any 
n. For AS
y ex
n. For AS
e, as in R
ny 
e, as in R
gradation d
d an
gradation d
enrolled s
an
enrolled s
esults ind
on a
esults ind
pulations 
tion
pulations 
n that CZ
cati
n that CZ
eatment
lica
eatment
app
in
a
in
ons, and t
ppli
ons, and t
 et al, 20
app
et al, 20
, 201
a
, 201


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 20 of 136
antibody-dependent cell-mediated cytotoxicity in vitro. It does not induce apoptosis in vitro in 
human peripheral blood-derived monocytes or lymphocytes, or neutrophil degranulation.
2.3.1
Clinical experience with CZP
Certolizumab pegol is indicated for the treatment of adult patients with active AS in multiple 
countries around the world.
After the loading dose, the recommended maintenance dose of CZP for adult subjects with AS is 
CZP 200mg Q2W or CZP 400mg Q4W.
Additional information on the clinical data for CZP is available in the current version of the IB 
and the product information available in each country.
2.4
Study rationale
The first TNF blockers used for the treatment of patients with active AS showed great promise. 
(Brandt et al, 2000). However, despite good effects on signs and symptoms, C-reactive protein 
and inflammation as detected by MRI, the TNFα inhibitors did not appear to prevent new bone 
formation in the spine (van der Heijde et al, 2008). A 12-year longitudinal study shows that the 
higher the disease activity, the more the structural damage in the spine, and thus concluding that 
inflammation and new bone formation are related (Ramiro et al, 2014). Understanding the role of 
different cytokines in driving new bone formation allows for improved treatments for AS 
patients. There is a growing association, and interest, for the involvement of IL-17 signaling in 
bone pathology during spondyloarthritis disease progression. The role of IL-17A in driving bone 
loss and destruction is well documented (Chabaud et al, 2001). More recently, in vitro studies 
demonstrated that mesenchymal cells incubated in the presence of IL 17A and bone 
differentiation medium leads to the formation of extracellular calcified bone matrix with an 
increase in alkaline phosphatase activation (Osta et al, 2014), suggesting that IL-17A may have a 
role not only in bone destruction, but under the right conditions in driving new bone formation. 
Wein et al, demonstrated in in vivo mouse models that in the absence of Schnurri3, a key gene in 
osteoblast differentiation, leads to increased bone mass; a response enhanced in the presence of 
IL-17A (Wein et al, 2012). The presence of Schnurri3 and osteoclasts activation at a site of bone 
inflammation leads to bone destruction, however in the absence of these, the same inflammation 
will induce new bone formation. In the AS patient at the syndesmophytes when mesenchymal 
cells from vertebral ligaments are inflamed in the physical absence of osteoclasts, this will 
induce new bone formation (Miossec, 2017). Recently, IL 17-producing γδ-T cells have been 
associated with periosteal bone formation for fracture repair (Ono et al, 2016); the periosteum is 
also implicated in pathologic bone formation in SpA (Lories et al, 2009). Using a biomimetic 
human periosteum-derived stem cell (hPDSC) model of osteogenic differentiation demonstrated 
that either/both IL-17A or/and IL-17F are able to drive pathologic bone formation (Shah et al, 
2017). Inhibiting both IL-17A and IL-17F has the potential to impact the pathophysiology of 
new bone formation in AS patients.
AS0013, the current subject-blind and investigator-blind study has been designed to evaluate the 
efficacy and safety of bimekizumab in a clinical setting in subjects with AS. The features of bone 
lesions are both erosive and neo-appositive and it is not clear if the inflammatory and erosive 
process precedes the new formation of bone. 18F-fluoride positron-emission tomography –
computed tomography (PET-CT) or 18F-fluoride positron-emission tomography – magnetic 
resonance imaging (PET-MRI) will be used to investigate the effects of bimekizumab on the 
PUBLIC COPY
mage
Y
mage
Ramiro
PY 
Ramiro
on allow
OP
on allow
interest, 
CO
interest, 
isease pr
C C
isease pr
d (Chaba
LIC 
d (Chaba
s incuba
BLI
s incuba
e forma
UB
e forma
e activa
PU
e activa
n, bu
P
n, bu
used to support any marketing authorization 
S is
riz
S is
of the IB 
utho
of the IB 
howed gre
etin
howed gre
oms, C
rke
oms, C-
e
-re
e
re
ppear to p
ark
ppear to p
gitudinal s
ma
gitudinal s
he spine, a
y m
he spine, a
et al, 2014
any
et al, 2014
for impro
t an
for impro
for the inv
ort 
for the inv
ogression
ppo
ogression
ud et al, 2
upp
ud et al, 2
ed in the
sup
ed in the
on of ext
to s
on of ext
ion (Osta 
d to
ion (Osta 
t under th
ed 
t under th
vo mouse 
use
vo mouse 
ment cannot be u
s to increa
e us
s to increa
The prese
be 
The prese
ne destruc
ot b
ne destruc
formation
not
formation
l ligament
nno
l ligament
e formatio
can
e formatio
th periost
t ca
th periost
cated in p
ent 
cated in p
periosteum
men
periosteum
This docum
either/bot
um
either/bot
017). Inhi
ocu
017). Inhi
new bon
doc
new bon
AS0
s d
AS0
e
s
e
extensions or variations thereof.
eat promi
her
eat promi
eactive pr
the
eactive pr
prevent ne
ns t
prevent ne
study sho
ions
study sho
and thus c
atio
and thus c
4). Under
riat
4). Under
roved trea
vari
roved trea
volvemen
r va
volvemen
n. The role
or 
n. The role
2001). Mo
ns o
2001). Mo
presence 
ons
presence 
tracellula
sio
tracellula
a et al, 201
ens
a et al, 201
he right co
xten
he right co
models th
exte
models th
pplication and any 
ased bone
y ex
ased bone
ence of Sc
ny 
ence of Sc
uction, how
d an
uction, how
n. In the A
nd a
n. In the A
nts are infl
and
nts are infl
on (Mioss
n a
on (Mioss
teal bone 
tion
teal bone 
pathologic
atio
pathologic
um
lic
um-
c
-derive
ica
derive
ap
th IL
pli
th IL-
pli
-17A
ic
17A
ibiting bo
app
ibiting bo
format
ap
format


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 21 of 136
process of osteoproliferation as determined by the inhibition of osteoblast activity. Based on data 
showing that TNFα blockers have limited effect on osteoblast metabolism, the current study uses 
a TNFα inhibitor to show a potential differential inhibition of osteoblast activity between 
bimekizumab and CZP. 
3
STUDY OBJECTIVE(S)
This is a Phase 2a, multicenter, randomized, subject-blind and investigator-blind, parallel-group 
study to evaluate the efficacy and safety of bimekizumab compared to CZP in subjects with 
active AS. The effect of study treatments on the process of osteoproliferation will be evaluated in 
a subgroup of subjects at selected sites.
3.1
Primary objective
The primary objective of the study is to evaluate the efficacy of bimekizumab administered sc 
Q2W for 12 weeks compared to CZP in the treatment of subjects with active AS.
3.2
Secondary objective
The secondary objective of the study is as follows:

To assess the safety and tolerability of bimekizumab
3.3
Other exploratory objectives
The other exploratory objectives of the study are as follows:

To evaluate the effect of bimekizumab or CZP on changes in bone formation 

To assess the PK and immunogenicity of bimekizumab

To assess additional biomarker, clinical, and imaging data as available

To assess the efficacy and safety of bimekizumab or CZP during the Treatment Extension 
Period
4
STUDY VARIABLES
4.1
Efficacy variables
4.1.1
Primary efficacy variable
The primary efficacy variable for this study is as follows:

Change from Baseline in ASDAS at Week 12
4.1.2
Secondary efficacy variables
The secondary efficacy variables for this study are as follows:

ASDAS-ID at Week 12

ASDAS-MI at Week 12
PUBLIC COPY 
mab
PY
mab
ves
COP
ves
dy are as
C CO
dy are as
mab or C
LIC
mab or C
genicity 
UBL
genicity 
rker, cli
PU
rker, cli
not be used to support any marketing authorization 
up
iz
up
h
o
h
aluated in
tho
aluated in
b adminis
ting
b adminis
ive AS.
keti
ive AS.
follows:
por
follows:
ZP on cha
upp
ZP on cha
f bimekiz
o su
f bimekiz
nical, and 
d to
nical, and 
y of bime
sed
y of bime
ARIABL
be 
ARIABL
cy varia
ot b
cy varia
This document can
mary effi
nno
mary effi
fficacy var
ca
fficacy var
e from Ba
ent 
e from Ba
The secon
ocu
The secon

d

AS
o
AS

s

nd any extensions or variations thereof.
stered sc
ere
stered sc
anges in b
ns o
anges in b
zumab
ion
zumab
imaging 
ens
imaging 
ekizumab
xte
ekizumab
LES
ny
LES
ables
d a
ables
application a
ficacy va
and
ficacy va
ariable for
on a
ariable for
aseline in
atio
aseline in
Second
plic
Second
ndary effic
app
dary effic
ID
a
ID


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 22 of 136
4.1.3
Other efficacy variables 
Assessment time points for the other efficacy variables are specified in Table 5‒1. The following 
efficacy variables are exploratory and are assessed over the Treatment Period and Treatment 
Extension Period, as applicable:

Change from Baseline in ASDAS

ASAS20 response

ASAS40 response

Time to ASAS20 response

Time to ASAS40 response

ASAS partial remission

Change from Baseline in BASDAI

Changes in bone formation as measured by standardized uptake value by area under the 
curve (SUVAUC) and derived from PET-MRI or PET-CT at Baseline, Week 12, and Week 48 
4.2
Safety variables
4.2.1
Primary safety variables
The primary safety variables for this study are as follows:

Incidence of AEs and SAEs

Adverse events leading to withdrawal from IMP
4.2.2
Other safety variables
The other safety variables for this study are as follows:

Change from Baseline in vital signs (blood pressure, temperature, pulse rate) and body 
weight

Change from Baseline in physical examination

Change from Baseline in standard 12-lead electrocardiogram (ECG) intervals (RR, PR, QRS, 
QT, and QT intervals corrected for heart rate using Fridericia’s formula [QTcF]) 

Change from Baseline in clinical laboratory values (hematology, biochemistry, and 
urinalysis)
4.3
Other PK and PD variables
4.3.1
Other PK variables
The PK variables are plasma concentrations of bimekizumab and CZP.
4.3.2
Other PD variables
The PD variables assessed at time points specified in Table 5‒1 are the blood or blood derivative 
(eg, plasma) concentrations of cytokines and chemokines of relevance to IL-17A/F signaling 
PUBLIC COPY 
y are as 
C C
y are as 
thdrawa
PUB
thdrawa
aria
P
aria
This document cannot be used to support any marketing authorization 
e value by
mar
e value by
Baselin
y m
Baseline, 
m
e, 
follows:
ppo
follows:
from IMP
to s
from IMP
bles
sed
bles
s study a
us
s study a
n vital sig
be 
n vital sig
seline in p
nno
seline in p
m Baseline
can
m Baseline
QT interva
t ca
QT interva
ge from B
en
ge from B
inalysis)
me
inalysis)
4.3
o
4.3
4.3.1
s do
4.3.1
T
s
T
application and any extensions or variations thereof.
y area und
ons
y area und
Week 12
tion
Week 12
MP
n
MP
are as foll
ex
are as foll
gns (blood
any 
gns (blood
physical e
and
physical e
e in stand
n a
e in stand
vals correc
tion
vals correc
Baseline i
cati
Baseline i
Oth
pp
Oth


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 23 of 136
pathway, TNF signaling pathway, AS biology, and bone metabolism. Additional variables may 
include, but will not be limited to, serum complement concentrations and mononuclear cell 
subtypes.
4.4
Other immunological variable(s)
Immunological variables will allow evaluation of immunogenicity as well as immunological 
biomarkers. Anti-bimekizumab antibody and anti-CZP antibody detection prior to and following 
study treatment will be evaluated.
4.5
Other nonhereditary pharmacogenomic variables
Where local regulations permit, blood and urine will be collected at specific time points specified 
in Table 5‒1 and stored for up to 20 years to allow for potential exploratory analyses of 
ribonucleic acid (RNA), proteins, and metabolite biomarkers relevant to AS, bone metabolism. 
and the inflammatory and immune response processes. The nature and format of these tentative 
analyses will be determined at a later stage. 
4.6
Other pharmacogenetic variables 
Additional blood samples will be collected from subjects who consent to participate in the 
pharmacogenetic substudy at specific time points specified in Table 5‒1 and stored at -80°C for 
up to 20 years. Pharmacogenetic biomarkers may be measured to evaluate the relationship to 
response to treatment with bimekizumab, AS disease biology, bone metabolism, and 
inflammatory and immune response processes. The nature and format of these tentative 
sub-study analyses will be determined when the results of the main study are made available.
5
STUDY DESIGN
5.1
Study description
AS0013 is a multicenter, randomized, subject-blind and investigator-blind, parallel-group study 
to evaluate the efficacy and safety of bimekizumab compared to CZP in adult subjects with 
active adult-onset AS. 
To be eligible to participate, subjects must meet the following key inclusion criteria: 

Subjects will have active adult-onset AS, meeting Modified New York criteria for AS with: 

BASDAI score ≥4

Spinal pain score ≥4 (from BASDAI Question 2). 

hs-CRP levels should be above the upper limit of normal (ULN) at the Screening Visit. One 
re-test of hs-CRP is permitted during the Screening Period upon discretion of the 
Investigator.

Subject must have had an inadequate response to, have a contraindication to, or has been 
intolerant to at least 2 NSAIDs (inadequate response to an NSAID is defined as lack of 
response to at least 14 days of continuous NSAID therapy at the highest tolerated dose of the 
administered NSAID.) If taking NSAIDs at study entry, subjects must be on a stable dose for 
2 weeks prior to Baseline. 
PUBLIC COPY
ects w
Y
ects w
pecified
PY 
pecified
ay be me
OP
ay be me
S disease
CO
S disease
esses. Th
C C
esses. Th
when th
LIC
when th
N
UB
N
ption
PU
ption
This document cannot be used to support any marketing authorization 
ng
iz
ng
points spec
au
points spec
lyses of 
g a
lyses of 
bone met
ting
bone met
mat of the
ketin
mat of the
consent to
ny m
consent to
in
a
in Table
any
Table 5
y
5
asured to e
rt a
asured to e
biology, b
ort 
biology, b
e nature an
ppo
e nature an
results of
upp
results of
zed, subjec
sed
zed, subjec
ety of bim
us
ety of bim
ate, subje
ot b
ate, subje
ve active a
nno
ve active a
I score
can
I score ≥
n
≥4
nal pain sc
nt c
nal pain sc
CRP level
men
CRP level
e-
u
-test of h
um
test of h
Investig
ocu
Investig

d

Sub
o
Sub
application and any extensions or variations thereof.
ecified
of.
ecified
tabolism.
ereo
tabolism.
hese tentat
ther
hese tentat
to particip
atio
to particip
5‒
ri
‒1
ri
1 and s
riat
and s
evaluat
var
evaluate
r
e
bone met
r va
bone met
and forma
or 
and forma
of the main
ns o
of the main
ect
ex
ect-
x
-blind a
exte
blind a
mekizumab
ex
mekizumab
ects must 
d an
ects must 
adult
and
adult-
nd
-ons
d
ons
4
core
tio
core ≥
io
≥4 (f
on
4 (f
ls should 
lica
ls should 
hs
p
hs-
pl
-CRP is
plic
CRP is
gator.
app
gator.
mus
a
mus


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 24 of 136

In addition, the subject may not have been exposed to more than 1 TNF antagonist prior to 
the Baseline Visit and may not be a primary failure to any TNF antagonist therapy (defined 
as no response within the first 12 weeks of treatment with the TNF antagonist.
At least 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will receive 
either bimekizumab or CZP up to Week 44 (final dose of IMP). 
AS0013 will include a Screening Period of 2 to 4 weeks, a 12-week Treatment Period, a 36-week 
Treatment Extension Period, and a 20-week Safety Follow-up Period (after the final dose of 
IMP). 
In approximately 25 subjects at selected sites, a PET-MRI or PET-CT scan will be performed at 
Screening and during the study at Week 12 and Week 48/Early Withdrawal Visit if PET-positive 
lesions were observed in the previous scan.
5.1.1
Screening Period (minimum of 2 and up to 4 weeks)
Assessments of eligibility as described in Section 6 will be initiated during the 2- to 4-week 
Screening Period. The informed consent will be obtained as described in Section 8.1. The 
Screening Period will also enable the washout of medications not permitted for use during the 
study.
The assessments at the Screening Visit are presented in Table 5‒1.
5.1.2
Treatment Period (Week 0 to Week 12)
Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
treatments: 

Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
order to maintain the blind vs the CZP loading dose at these visits. 

CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W in 
Weeks 6 to 10.
Study treatments will be prepared and administered by appropriately trained unblinded site 
personnel. 
5.1.3
Treatment Extension Period (Week 12 to Week 48)
After completing the 12-week Treatment Period, subjects will enter a 36-week Treatment 
Extension Period and will receive the following treatments:

Subjects randomized to bimekizumab during the Treatment Period will receive bimekizumab 
320mg sc Q4W from Week 12 to Week 44. 

Subjects randomized to CZP during the Treatment Period will receive CZP 400mg Q4W 
from Week 12 to Week 44. 
Subjects not responding to treatment during the Treatment Period will be withdrawn from the 
study as per Investigator’s discretion and will not enter the Treatment Extension Period.
The assessments during the Treatment Extension Period are presented in Table 5‒1.
COPY 
Y
nted in 
OPY
nted in 
Y
PUBLIC C
0 to We
CO
0 to We
a 2:1 rat
LIC 
a 2:1 rat
W 
PU
W from W
PUB
from W
at Base
PU
at Base
th
P
th
port any marketing authorization 
eek 
z
eek 
f 
o
f 
performed
auth
performed
if PET
g au
if PET-po
u
po
s)
ke
s)
uring the 2
arke
uring the 2
bed in
ma
bed in Sec
ar
Sec
ot permitte
y m
ot permitte
able
t a
able 5
an
5‒
a
‒1
n
1
nt cannot be used to suppo
eek 12)
port
eek 12)
o to receiv
upp
o to receiv
Week 0 thr
to s
Week 0 thr
line (Visi
d to
line (Visi
e CZP loa
sed
e CZP loa
eks 0, 2, a
us
eks 0, 2, a
prepared
ot b
prepared
reatment
ann
reatment
ting the 1
t ca
ting the 1
This documen
Period an
ent 
Period an
ubjects ran
me
ubjects ran
320mg s
cum
320mg s

d

Subj
oc
Subj
frfr
S
s
S
or variations thereof.
d at
f
d at
positive
of.
positive
2
s
2-
s
- to 4
s th
to 4-
t
-w
h
w
ction
ns
ction 8.1
ns
8.1
ted for use
tion
ted for use
tion and any extensions 
ive the fol
s o
ive the fol
rough We
nsio
rough We
it 2), Wee
ens
it 2), Wee
ading dos
xte
ading dos
and 4
y ex
and 4 (loa
ex
(loa
d and adm
d an
d and adm
t Extens
n an
t Extens
12
ti
12-
o
-
applicat
week T
ion
week T
nd will re
atio
nd will re
ndomized
plica
ndomized
sc Q4W fr
ppl
sc Q4W fr
cts rand
ap
cts rand
k


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 25 of 136
5.1.4
Safety Follow-up Period (Week 48 to Week 64)
All subjects who complete the study or who discontinue from the study early, including those 
withdrawn from the IMP treatment, will have a SFU Visit at 20 weeks after their final dose of 
IMP. The assessments at the SFU Visit are presented in Table 5‒1.
5.2
Safety monitoring strategy
An independent Data Monitoring Committee (DMC) will review study safety data on an ongoing 
basis. Details will be available in the DMC charter. Cardiovascular and Neuropsychiatric 
Adjudication Committees will review and monitor cardiovascular and neuropsychiatric events. 
Further details are provided in Section 12.5.
5.3
Imaging evaluation
In a subpopulation of AS0013, a PET-MRI or PET-CT scan of the entire spine will be performed 
at selected sites in approximately 25 subjects at Screening, and during the study at Week 12 and 
Week 48/Early Withdrawal Visit if PET-positive lesions were observed in the previous scan. 
The PET-MRI or PET-CT scan should be performed after confirmation of eligibility for the 
study based on screening assessments. All subjects at selected sites are eligible provided that a 
separate Informed Consent form (ICF) for the imaging evaluation has been signed.
5.4
Study duration per subject
For each subject, the study will last a maximum of up to 68 weeks, as follows:

Screening Period: minimum of 2 weeks and up to 4 weeks

Treatment Period: 12 weeks

Treatment Extension Period: 36 weeks

Safety Follow-up Period: 20 weeks after the final dose of IMP for subjects completing the 
study or discontinuing from the study early, including those withdrawn from study treatment.
The end of the study is defined as the date of the last visit of the last subject in the study.
5.5
Planned number of subjects and site(s)
It is anticipated that approximately 120 subjects will be screened in order to enroll at least 
60 subjects in the main study and at least 25 subjects in the PET-CT or PET-MRI substudy at 
multiple sites.
5.6
Anticipated regions and countries
The study sites will be located in North America, Europe, and APAC countries with possible 
extension to other regions.
PUBLIC COPY
sele
Y
sele
ging eva
PY 
ging eva
ect
CO
ect
imum of
C C
imum of
weeks an
BLIC
weeks an
d: 36 w
PU
d: 36 w
ed to support any marketing authorization 
oing 
riz
oing 
events.
tho
events.
ine will b
eting
ine will b
e study at
ket
e study at
ed in the p
arke
ed in the p
mation of 
ma
mation of 
sites are e
y m
sites are e
uation has
any
uation has
up to 68 w
ppo
up to 68 w
d up to 4 w
supp
d up to 4 w
eeks
d t
eeks
ment cannot be us
weeks afte
use
weeks afte
m the study
e us
m the study
ined as th
be
ined as th
ed num
not 
ed num
at approxi
ann
at approxi
he main st
can
he main st
s.
n
s.
cu
An
n
An
study site
um
study site
This doc
xtension t
ocu
xtension t
xtensions or variations thereof.
be perform
here
be perform
t Week 12
the
t Week 12
previous 
s th
previous 
eligibility
ions
eligibility
eligible p
atio
eligible p
as been sig
riat
as been sig
weeks, as
or 
weeks, as
weeks
ns
weeks
ation and any ex
er the fina
exte
er the fina
dy early, in
y ex
dy early, in
he date of 
any
he date of 
mber of s
nd a
mber of s
ximately 1
an
ximately 1
study and 
on a
study and 
pplica
nticipat
icat
nticipat
tes w
ppli
tes will be
plic
ill be
ap
to other r
app
to other r


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 26 of 136
5.7
Schedule of assessments
Table 5‒1:
Schedule of assessments
Study Period
SCr
Treatment Period
Treatment Extension Period
SFUa
Visitb/Week 
(Visit window ±3 days)
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
Procedures
SV
BL 
W0
W2
W4
W6
W8
W10
W12
W16
W20
W24
W28
W32
W36
W40
W44
W48
/WD
W64
Written informed 
consentc
X
Demographic data
X
AS history
X
Inclusion/exclusion 
criteria 
X
Xd
Significant past medical 
history and concomitant 
diseases
X
Xe
Prior and concomitant 
medicationsf
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Adverse events
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
C-SSRS
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
HADS
X
X
X
X
X
X
X
X
X
X
X
X
X
X
BASDAI
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
BASFI
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
PGADA
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
PhGADA
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Total and nocturnal 
spinal pain (NRS)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
PUBLIC COPY 
Y
PY
OP
OP
OPY
OP
CO
C
O
IC
PUB
C
X
P
X
PU
P
be used to support any marketing authorization 
27 
n 
27
at
nsion Peri
au
nsion Peri
ut
V13
ng
V13
V
a
t g a
W28
ke
W28
W3
et
W3
et
et
eti
a
et
ar
y ma
y
ny
an
rt
n
rtrtrt
p ort
pp
to up
X
d t
X
to
to
to
se
to
X
us
X
se
se
se
e
nt cannot be use
X
b
X
X
 
X
e u
be
b
ot b
X
nn
X
X
ot
ot
ot
n o
X
c
X
X
n
X
nn
an
X
t c
X
This document ca
l
T
l
ca
nt a
X
e
X
X
nt
nt
nt
m nt
X
u
X
X
m
X
me
ocum
y extensions or variations thereof.
od
f
od
14
e
14
V15
eo
V15
of
re
32
t
32
W36
the
W36
he
th
s 
o
ati
ri
ari
ari
ari
ari
va
or
s
n on
X
te
X
X
ns
e en
X
X
x
X
ex
tion and any e
X
ny
X
y
a
X
d
X
an
a
X
a
X
X
nd
X
d
an
X
n a
X
an
an
an
n an
X
tio
X
application
X
n
X
n
on
X
c
X
X
at
X
tio
ca
X
plic
X
ica
ca
ca
app
pp
pp
pp ca


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 27 of 136
Table 5‒1:
Schedule of assessments
Study Period
SCr
Treatment Period
Treatment Extension Period
SFUa
Visitb/Week 
(Visit window ±3 days)
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
Procedures
SV
BL 
W0
W2
W4
W6
W8
W10
W12
W16
W20
W24
W28
W32
W36
W40
W44
W48
/WD
W64
Physical examination 
(incl. height and 
weight)g
X
X
X
X
X
Vital signs (BP, pulse, 
temperature)h
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
12-lead ECG (local)
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Tuberculosis 
questionnaire
X
X
X
X
X
X
IGRA TB testi
X
X
Pregnancy testj
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Hematology/
biochemistry/urinalysisk
X
X
X
X
X
X
X
X
X
X
X
X
Serology (HIV, 
Hepatitis B and C, 
HLA-B27)k, l
X
Blood samples for 
cytokines, complement, 
and biomarker analysisk
X
X
X
X
X
X
X
Blood sampling for 
bimekizumab and CZP 
plasma concentrationsk
X
X
X
X
X
X
X
Bimekizumab and CZP 
antibody detectionk
X
X
X
X
X
X
X
PUBLIC COPY 
X
Y
X
OPY
X
CO
X
X
P
X
OP
OP
OP
OP
X
C
X
CO
C
O
LIC
B
C
X
U
X
BL
PUB
X
PU
X
PU
P
be used to support any marketing authorization 
27 
n 
27
at
Period
tho
Period
ho
V14
au
V14
uth
th
th
g a t
W32
ting
W32
W
g
W
g
et g
ke
ma
e
X
y m
X
m
ny m
X
t a
X
an
ort
ort
ort
ort
p ort
up
up
upp
up
X
o s
X
s
to
X
d t
X
to
to
to
se
to
This document cannot be use
l
T
l
se
se
se
t be
se
X
t b
an ot b
X
an
an
nt an
X
me
X
e
cum
u
any extensions or variations thereof.
V15
f
V15
e
W36
ere
W36
W4
e
W4
eo
th re
X
h
X
th
th
the
o
th
X
ati
X
tio
ari
o
X
va
X
ar
ar
ar
ar
X
v
X
v
or
s
on
X
sio
X
ion
on
on
n on
X
e
X
ns
on and any exten
xt
a
e
an
an
a
a
cation
X
o
X
applicatio
ca on a
X
a
X
ca
ca
ca
pp
pp
pp
pp ca


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 28 of 136
Table 5‒1:
Schedule of assessments
Study Period
SCr
Treatment Period
Treatment Extension Period
SFUa
Visitb/Week 
(Visit window ±3 days)
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
Procedures
SV
BL 
W0
W2
W4
W6
W8
W10
W12
W16
W20
W24
W28
W32
W36
W40
W44
W48
/WD
W64
Blood sample for 
hs-CRPk
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Blood samples for 
pharmacogenetic 
variables
X
X
X
Blood samples for 
nonhereditary 
pharmacogenomic 
variables
X
X
X
X
X
Urine samples for 
biomarker research
X
X
X
X
Chest X-ray or CT scan 
of chest m
X
X
Sacroiliac joint X-rayn
X
PET-MRI or PET-CT 
scan as a substudy at 
selected siteso
X
X
X
Contact the IRT
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
IMP administrationp
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
AS=ankylosing spondylitis; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASFI=Bath Ankylosing Spondylitis Functional Index; 
BL=Baseline; BP=blood pressure; CT=computed tomography; C-SSRS=Columbia Suicide Severity Rating Scale; CZP=certolizumab pegol; 
ECG=electrocardiogram; HADS=Hospital Anxiety and Depression Scale; HCV=hepatitis C virus; HIV=human immunodeficiency virus; HLA-B27=human 
leukocyten antigen B27; hs-CRP=high sensitivity C-reactive protein; IGRA=Interferon-Gamma Release Assay; IMP=investigational medicinal product; 
IRT=interactive response technology; NRS=numeric rating scale; PET-CT=positron-emission tomography-computer tomography; PET-MRI=positron-emission 
tomography – magnetic resonance imaging; PGADA=Patient’s Global Assessment of Disease Activity; PhGADA=Physician’s Global Assessment of Disease 
Activity; Q2W=every 2 weeks; Q4W=every 4 weeks; SCr=Screening; SFU=Safety Follow-Up; SV=Screening Visit; TB=tuberculosis; V=Visit; W=Week; 
PUBLIC COPY 
OPY
X
CO
X
OP
OP
OP
C
OP
LIC
UB
PU
PU
cannot be used to support any marketing authorization 
27 
n 
27
at
Period
tho
Period
ho
V14
au
V14
uth
th
th
g a t
W32
ting
W32
W
g
W
g
et g
X
rk
X
ke
ma
e
ma
ma
ma
ny ma
an
up ort
X
s
X
up
up
up
to up
to
to
to
se
to
se
se
se
se
u
ot be
X
nn
X
X
ot
ot
ot
n o
X
c
X
X
n
X
This document 
l
T
l
nn
an
=Bath Anky
t c
=Bath Anky
; CT=comp
ent 
; CT=comp
DS=Hospita
men
DS=Hospita
CRP=high
me
CRP=high
 technolog
cum
 technolog
ic resonanc
ocu
ic resonanc
ery 2 weeks
doc
ery 2 weeks
ca
n and any extensions or variations thereof.
V15
f
V15
e
W36
ere
W36
W4
e
W4
eo
th re
X
s
X
X
h
X
th
th
the
th
n
ari
o
ar
ar
ar
n or ar
ns
on
s
en
xt
e
y e
a
e
X
a
X
X
nd
X
d
an
application a
X
n a
X
an
an
an
n an
ylosing Spo
tion
ylosing Spo
puted tomo
atio
puted tomo
al Anxiety a
cat
al Anxiety a
h sensitivity
plica
h sensitivity
gy; NRS=nu
ppli
gy; NRS=nu
ce imaging;
app
e imaging;
Q4W=ev
ap
Q4W=ev
n


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 29 of 136
Table 5‒1:
Schedule of assessments
Study Period
SCr
Treatment Period
Treatment Extension Period
SFUa
Visitb/Week 
(Visit window ±3 days)
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
Procedures
SV
BL 
W0
W2
W4
W6
W8
W10
W12
W16
W20
W24
W28
W32
W36
W40
W44
W48
/WD
W64
WD=Early Withdrawal Visit; WHO=World Health Organization
a Safety Follow-Up Visit occurs 20 weeks after the final dose for all subjects who complete the study or who discontinue early, including those withdrawn from 
study treatment. 
b Visit windows of ±3 days from the first dose at all visits through Week 48. The SFU Visit window is -3 and +7 days from the final dose.
c A separate Informed Consent Form is required for subjects participating in the 2 sub-studies: 1) with biomarker, pharmacogenetic and nonhereditary 
pharmacogenomic blood-samples and 2) PET-MRI or PET-CT scans.
d Ensure there are no significant changes in medical history that would exclude the subject based on the exclusion criteria.
e Ensure that there are no significant changes in the medical history.
f Prior and concomitant medication at Screening and Baseline; concomitant medication only at all other visits.
g The physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, height (Screening only) and weight (Screening, 
Week 12 and Week 48/WD only).
h Vital signs (blood pressure, pulse rate, and temperature) are to be measured prior to drug administration at all visits and at 30 minutes and 1 hour after dosing at 
Baseline/Day 1.
i QuantiFERON TB test or another WHO-validated IGRA test such as Elispot test, if QuantiFERON TB test is not locally available. 
j Pregnancy testing will performed on serum at Screening and on urine at all other visits. Pregnancy test results must be negative prior to administering IMP. 
k At dosing visits, all blood samples are taken prior to dosing. Blood samples for IMP and anti-IMP antibody detection will be processed as per instructions in the 
laboratory manual. After Screening, until Week 12, hs-CRP data will not be sent to the Investigator to protect the blinded nature of the treatment assignments.
l Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface antigen (HBsAg+); 2) positive 
for anti-hepatitis B core antibody (HBcAb+) are excluded; a positive test for HCV is defined as: 1) positive for hepatitis C antibody (anti-HCV Ab), and 2) 
positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also excluded.
m If a subject has had a recent radiograph or CT scan of the chest within 3 months prior to the Screening Visit, it may be used as the Screening chest X-ray. The 
chest X-ray/CT scan of the chest at Week 48/WD is to be done if medically indicated only (eg, positive TB-test).
n If subjects have a previous X-ray documenting AS meeting eligibility criteria, they are eligible for study entry after reconfirming their eligibility by central 
reading. If no X-ray is available one must be performed at Screening. If the previous X-ray is more than 1 year old, and central read criteria for randomization 
are not met, another X-ray may be performed if permitted by local guidelines.
o A PET-MRI or PET-CT scan should be done up to 2 weeks before Baseline and within 2 weeks after the W12 and W48/WD Visit if PET-positive lesions are 
observed in the previous scan. If a subject withdraws from the study early, the PET-MRI or PET-CT scan must be repeated at the WD visit only, if the prior 
examination was done more than 12 weeks prior to the WD visit and the previous PET-scan showed positive lesions.
p CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W in Weeks 6 to 10 and 400mg Q4W from Week 12 to Week 44. 
Bimekizumab will be administered at a dose of 160mg sc Q2W from Week 0 through Week 10 and 320mg sc Q4W from Week 12 to Week 44. The IMP will be 
administered at the end of the visit after all assessments have been completed. Subjects randomized to bimekizumab will receive 1 placebo injection at Baseline 
PUBLIC COPY 
studie
PY
studie
the subjec
OP
the subjec
nt medica
C C
nt medica
oms of act
IC C
oms of act
e measur
BL
e measur
est such a
PU
est such a
nd on u
P
nd on u
This document cannot be used to support any marketing authorization 
27 
n 
27
at
l
T
l
Period
tho
Period
ho
V14
au
V14
uth
th
th
g a t
W32
ting
W32
W
g
W
g
et g
ke
who discon
ark
who discon
w is
w is -
m
-3 and 
y m
3 and 
) with biom
ny 
) with biom
based on th
t a
based on th
on only at 
por
on only at 
ve TB, risk
ppo
ve TB, risk
d prior to dr
sup
d prior to dr
Elispot tes
d to
Elispot tes
rine at all o
ed t
rine at all o
ood sample
sed
ood sample
data will n
use
data will n
is B by any
e us
is B by any
ded; a posit
be 
ded; a posit
ple, HCV p
t be
ple, HCV p
an of the ch
ot 
an of the ch
WD is to be
no
WD is to be
ti
a
ting AS me
ann
ng AS me
st be perfor
can
st be perfor
rformed if 
t ca
rformed if 
ld be done 
nt c
ld be done 
f a subject 
en
f a subject 
than 12 we
me
than 12 we
Weeks 0, 2, a
um
Weeks 0, 2, a
administere
ocu
administere
end of the v
doc
end of the v
application and any extensions or variations thereof.
V15
f
V15
e
W36
ere
W36
W4
e
W4
eo
th re
th
th
the
ntinue early
ns t
ntinue early
+7 days fro
tion
+7 days fro
marker, pha
iatio
marker, pha
he exclusio
var
he exclusio
all other vi
or v
all other vi
k for exposu
s o
k for exposu
rug admini
ons
rug admini
st,
n
st, if Quant
nsi
if Quant
ther visits. 
ten
ther visits. 
es for IMP 
xte
es for IMP 
ot be sent t
ext
ot be sent t
y of the foll
y e
y of the foll
tive 
n
tive test for
ny 
test for
olymerase 
any
olymerase 
he
d
hest within 
d a
st within 
e done if m
nd 
e done if m
eeting eligi
an
eeting eligi
rmed at Scr
n a
rmed at Scr
permitted b
ion
permitted b
up to 2 we
atio
up to 2 we
withdraws
cat
withdraws
eeks prior to
lica
eeks prior to
and 4 (load
plic
and 4 (load
ed at a dose
app
ed at a dose
sit after a
ap
it after a


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 30 of 136
Table 5‒1:
Schedule of assessments
Study Period
SCr
Treatment Period
Treatment Extension Period
SFUa
Visitb/Week 
(Visit window ±3 days)
V1
V2
V3
V4
V5
V6
V7
V8
V9
V10
V11
V12
V13
V14
V15
V16
V17
V18
Procedures
SV
BL 
W0
W2
W4
W6
W8
W10
W12
W16
W20
W24
W28
W32
W36
W40
W44
W48
/WD
W64
(Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4). 
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
27 
n 
27
at
l
T
l
Period
tho
Period
ho
V14
au
V14
uth
th
th
g a t
W32
ting
W32
W
g
W
g
et g
ke
application and any extensions or variations thereof.
V15
f
V15
e
W36
ere
W36
W4
e
W4
eo
th re
th
th
the


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 31 of 136
5.8
Schematic diagram
Figure 5‒1: Schematic diagram
CZP=certolizumab pegol; N=number of subjects; Q2W=every two weeks; Q4W=every 4 weeks; sc=subcutaneous(ly); SFU=Safety Follow-up, W=week
a Subjects not responding to treatment during the Treatment Period will be withdrawn from the study as per Investigator’s discretion and will not enter the 
Treatment Extension Period.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
27 
n 
27
at
l
T
l
mber of sub
men
mber of sub
reatment du
me
reatment du
od.
u
od.
nt cannot be used to support any marketing aut
applicatio
bjects; Q2W
cat
bjects; Q2W
uring the T
lica
uring the T
tion and any extensions or variations thereof.


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 32 of 136
5.9
Rationale for study design and selection of dose
AS0013 is a Phase 2a, multicenter, randomized, subject-blind and investigator-blind study to 
evaluate the efficacy and safety of bimekizumab and CZP in adult subjects with active AS. 
AS0013 includes a 12–week Treatment Period, a 36-week Treatment Extension Period, and a 
20-week SFU Period. Rationales for the study design, selected population, and bimekizumab 
doses are provided below.
Study design
AS0013 was designed to evaluate the efficacy, safety and the process of osteoproliferation using 
PET imaging techniques at Screening and after 12 and 48 weeks of treatment. The scientific 
rationale suggesting a role for IL-17A treatment in bone formation as compared to TNFα 
treatment is provided in detail in Section 2.4.
While the primary evaluation will be conducted after 12 weeks, a 36-week Treatment Extension 
Period has been added in order to maintain the treatment blind after subjects have reached 
Week 12 (ie, the evaluation of the primary efficacy variable) and to allow continued access to 
IMP for subjects responding to treatment. This extension also allows further evaluation of the 
inhibition of the osteoproliferative effect of bimekizumab and CZP at Week 48 and to compare 
this to Baseline and Week 12.
Population
AS0013 was designed to evaluate the potential benefit of bimekizumab to prevent bone 
formation in subjects at risk of new bone formation (disease progression) and comparing the 
outcome to treatment with CZP. Inclusion criteria will ensure that all subjects have active AS. 
Some exclusion criteria are intended to eliminate subjects who may present an unacceptable 
safety risk were they to participate in this investigational study program. Active AS is defined by 
a BASDAI score ≥4 and a spinal pain score ≥4 (from BASDAI Question 2). The full list of 
inclusion and exclusion criteria is provided in Section 6.
Dose selection
The following dose regimens of bimekizumab and CZP will be evaluated during the Treatment 
Period:

Bimekizumab 160mg sc Q2W from Week 0 through Week 10 

CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W in 
Weeks 6 to 10.
Exposure levels up to 8-fold greater than 160mg Q2W have been previously studied in the 
development of bimekizumab. In the single ascending dose study UP0008, a single dose of 
bimekizumab 640mg was tested. In the multiple dose study PA0007, a bimekizumab 560mg 
loading dose followed by 2 subsequent 320mg doses every 3 weeks was tested. At exposure 
levels achieved at these doses, the compound had no significant safety concerns. Additionally, in 
the above clinical studies (UP0008 and PA0007), bimekizumab was administered iv and the 
current study proposes to administer the compound sc. The exposure of the drug is expected to 
be lower than after iv administration due to lower bioavailability following sc administration 
and, therefore, the dose regimens are expected to be safe. No safety concerns have been reported 
in ongoing clinical studies evaluating cumulative monthly doses of bimekizumab 320mg in other 
PUBLIC COPY 
mab 
Y
mab 
ntial ben
C C
ntial ben
ne forma
LIC 
ne forma
lusion cr
BLI
lusion cr
ded to el
UB
ded to el
pate in th
PU
pate in th
l pa
P
l pa
ment cannot be used to support any marketing authorization 
tion using
tho
tion using
cientific
auth
cientific
o TNFα
g au
o TNFα
Treatme
etin
Treatme
bjects hav
rke
bjects hav
allow con
mark
allow con
ows furthe
ma
ows furthe
CZP at W
ny m
CZP at W
efit of bim
ppo
efit of bim
ion (disea
upp
ion (disea
teria will 
sup
teria will 
minate su
to s
minate su
is inves
d to
is investig
o
tig
n score ≥4
ed 
n score ≥4
provided
use
provided
mens of bim
t be
mens of bim
160mg sc
ann
160mg sc
mg sc Q2W
t ca
mg sc Q2W
6 to
nt
to 10.
nt 
10.
ure levels 
me
ure levels 
This docu
elopment 
cum
elopment 
bimekizum
ocu
bimekizum
loading
do
loading
level
s d
level
th
s
th
plication and any extensions or variations thereof.
nt Extens
her
nt Extens
ve reached
s th
ve reached
ntinued ac
ns 
ntinued ac
er evaluat
ion
er evaluat
Week 48 a
atio
Week 48 a
mekizuma
or 
mekizuma
ase progre
ns o
ase progre
l ensure th
ons
l ensure th
ubjects wh
sio
ubjects wh
igational s
ens
igational s
≥4 (from B
xten
≥4 (from B
d in
ex
d in Sectio
ext
Sectio
imekizum
d any
imekizum
c Q2W fr
an
c Q2W fr
W at Wee
ion 
W at Wee
s up to 8
lica
s up to 8
app
-f
t of bimek
ppli
t of bimek
mab 640m
app
mab 640m
se fol
ap
se fol


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 33 of 136
populations including PA0008 in subjects with active PsA, AS0008 in subjects with active AS, 
and several ongoing studies in subjects with PSO. 
Simulations were performed using a model to predict the dose response of ASAS20/40 at 
Week 12, ie, for a different endpoint than the primary efficacy endpoint being proposed in this 
study (Diderichsen and Cox, 2016). These simulations indicated that increasing doses above 
bimekizumab 320mg Q4W may not provide additional benefit in terms of efficacy. 
The dose selected in the current study is bimekizumab 160mg Q2W instead of 320mg Q4W. 
Given that the PK of bimekizumab has been established to be linear in the exposure range 
(UP0008 and PA0007), the proposed dose of bimekizumab 160mg Q2W is expected to provide 
similar overall exposure and hence response compared to a dose of 320mg Q4W. Table 5‒2
shows a comparable AUCtau between bimekizumab 320Q4W and 160mg Q2W calculated over a 
period of similar time (14 days). In conclusion, the existing data suggest that at the proposed 
dose level, bimekizumab is well tolerated and the analysis suggests that maximum benefit is 
achieved at this exposure level.
Table 5‒2:
Exposure to bimekizumab by dose
Parameter
Bimekizumab dose
160mg Q2W sc
320mg Q4W sc
640mg SD iv from 
UP0008
AUCtau or AUC0-inf (µg*day/mL)
442a,b
445a,b
3787c,d
Cmax (µg/mL)
33a
38a
260c
iv=intravenous; Q2W=every 2 weeks; Q4W=every 4 weeks; sc=subcutaneous, SD=single dose
a Median model predicted 
b Calculated over a period of 14 days 
c Median observed in UP0008 
d AUC0-inf
The dose and regimen proposed for CZP is one of the currently approved dose regimens in 
axSpA (CZP 400mg loading dose + CZP 200mg maintenance dose Q2W) and has been widely 
tested in the clinic, and is in line with the dosing guidance from the labeling. The proposed dose 
of CZP has been tested in Phase 3 studies in subjects with axSpA. The results of these studies 
have shown a favorable risk-benefit profile for the treatment of subjects with axSpA.
6
SELECTION AND WITHDRAWAL OF SUBJECTS
6.1
Inclusion criteria
To be eligible to participate in this study, all of the following criteria must be met:
1. An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written 
Informed Consent form is signed and dated by the subject. 
2. Subject is considered reliable and capable of adhering to the protocol (eg, able to understand 
and complete diaries), visit schedule, and medication intake according to the judgment of the 
Investigator.
IC COPY
Bi
Y 
Bi
Y
W sc
OP
W sc
PY
PY
PY
PY
442
C C
442a,b
C C
a,b
C
BLIC
33
IC
33
PUBLIC
Q4W=ev
UB
Q4W=ev
ys
P
ys
BL
pport any marketing authorization 
W.
o
W.
ge
th
ge
to provide
uth
to provide
Table
au
Table 5
u
5‒
u
‒2
calculated
g a
calculated
at the pro
ting
at the pro
maximum b
ketin
maximum b
ekizumab
ny 
ekizumab
y m
320mg Q
t a
320mg Q
any
o
pp
cument cannot be used to supp
pp
pp
pp
pp
ry 4 weeks
o s
ry 4 weeks
s
oposed fo
ot b
oposed fo
oading do
not 
oading do
and is in 
nno
and is in 
n tested in
can
n tested in
favorable
t ca
favorable
This do
SE
nt
SE
To be elig
docu
To be elig
1.
s d
1. A
o
A
s or variations thereof.
d over a 
eof
d over a 
oposed 
ereo
oposed 
benefit is
ther
benefit is
b dose
iat
b dose
tio
Q4W sc
var
Q4W sc
ria
445
or
445a,b
r
a,b
r
ons 
3
ation and any extensions
; sc=subcut
sion
; sc=subcut
on
or CZP is 
d any
or CZP is 
ose + CZP
nd a
ose + CZP
line with
and
line with
n Phase 3 
n a
n Phase 3 
e risk
ion
e risk-
n
-ben
n
ben
applica
ELECTI
cati
ELECTI
Inclus
plic
Inclus
gible to p
app
ible to p
ut
a
t


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 34 of 136
3. Subject is male or female and at least 18 years of age.
4. Subject has a documented diagnosis of adult-onset AS as defined by documented radiologic 
evidence (X-ray) fulfilling the Modified New York criteria for AS (1984) of at least 
3 months’ symptom duration and age of onset <45 years. 
5. Subject has moderate to severe active disease at the Screening Visit as defined by each of the 
following:

BASDAI score ≥4

Spinal pain score ≥4 on a 0 to 10 numeric rating scale (NRS) (from BASDAI Item 2)
6. Subject must have had an inadequate response to, have a contraindication to, or has been 
intolerant to at least 2 NSAIDs (inadequate response to an NSAID is defined as lack of 
response to at least 14 days of continuous NSAID therapy at the highest tolerated dose of the 
administered NSAID).
7. Subject may not have been exposed to more than 1 TNF antagonist prior to the Baseline Visit 
and may not be a primary failure to any TNF antagonist therapy (defined as no response 
within the first 12 weeks of treatment with the TNF antagonist.
8. Subject has hs-CRP levels above the ULN at the Screening Visit. One re-test of hs-CRP is 
permitted during the Screening Period upon discretion of the Investigator. 
9. Female subjects must be postmenopausal (at least 1 year; to be confirmed hormonally as part 
of the screening process, if less than 2 years since last menstrual period), permanently 
sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy) or, if of childbearing 
potential (and engaged in sexual activity that could result in procreation), must be willing to 
use a highly effective method of contraception up till 20 weeks after last administration of 
IMP, and have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first 
dose. The following methods are considered highly effective when used consistently and 
correctly.

combined (estrogen and progestogen) hormonal contraception associated with inhibition 
of ovulation (oral, intravaginal or transdermal)

progestogen-only hormonal contraception associated with inhibition of ovulation (oral, 
injectable, implantable)

intrauterine device (IUD)

intrauterine hormone-releasing system (IUS)

bilateral tubal occlusion

vasectomized partner (where postvasectomy testing had demonstrated sperm clearance)

sexual abstinence if it is in accordance with a subject’s preferred and common lifestyle. 
Subjects who use abstinence as a form of birth control must agree to abstain from 
heterosexual intercourse until 20 weeks after the final dose of IMP (anticipated 5 
half-lifes of bimekizumab). Study personnel must confirm the continued use of 
abstinence is still in accordance with the subject’s lifestyle at regular intervals during the 
study.
PUBLIC COPY 
F an
Y
F an
the Scree
OPY
the Scree
n discret
COP
n discret
sal (at le
C C
sal (at le
n 2 years
LIC 
n 2 years
ysterecto
BLIC
ysterecto
ual activi
UBL
ual activi
od of co
PU
od of co
egna
P
egna
not be used to support any marketing authorization 
Item 2)
uth
Item 2)
or has bee
g au
or has bee
ed as lack
ng 
ed as lack
tolerated
eting
tolerated
ist prior to
ark
ist prior to
py (define
ma
py (define
nist.
y
nist.
ning Visit
any
ning Visit
on of the 
rt a
on of the 
ast 1 year
por
ast 1 year
since last 
upp
since last 
my, bilater
sup
my, bilater
ty that cou
to s
ty that cou
ntraception
d to
ntraception
ncy
ed
ncy test at
ed 
test at
are consid
use
are consid
n and prog
t be
n and prog
al, intrava
ot b
al, intrava
This document cann
only hor
nno
only hor
e, implant
can
e, implant
uterine de
nt c
uterine de
ntrauterin
men
ntrauterin

bilate
um
bilate

oc

v
nd any extensions or variations thereof.
en
o
en
k o
re
k of
e
f
d dose of t
here
d dose of t
to the Bas
ns t
to the Bas
ed as no r
ions
ed as no r
it. One re
aria
it. One re
In
v
Investiga
var
vestiga
r; to be co
or 
r; to be co
t menstrua
s o
t menstrua
eral salpi
ons
eral salpin
uld result
sion
uld result
on up till 2
nsi
on up till 2
at Visit 1 (
ten
at Visit 1 (
dered high
exte
dered high
gestogen)
any
gestogen)
aginal or t
d a
aginal or t
plication an
rmonal co
and
rmonal co
table)
n a
table)
evice (IUD
tion
evice (IUD
ne hormo
cat
ne hormo
app
ral tubal 
pli
ral tubal 
ap
sectomi
ap
sectomi


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 35 of 136
Male subjects with a partner of childbearing potential must be willing to use a condom when 
sexually active, up until 20 weeks after the last administration of IMP (anticipated 5 half-
lives).
6.2
Exclusion criteria
Subjects are not permitted to enroll in the study if any of the following criteria is met:
1. Female subject who is breastfeeding, pregnant, or planning to become pregnant during the 
study or within 20 weeks following final dose of study drug. Male subject who is planning a 
partner pregnancy during the study or within 20 weeks following the final dose.
2. Subject who has previously received bimekizumab or CZP.
3. Subject has participated in another study of a medication under investigation within the last 3 
months or at least 5 half-lives of the IMP, whichever is greater, or is currently participating in 
another study of a medication under investigation.
4. Subject has a known hypersensitivity to any excipients of bimekizumab or CZP.
5. Subject has received previous treatment with a polyethylene glycolylated (PEGylated) 
compound that resulted in a severe hypersensitivity reaction or an anaphylactic reaction
6. Subject has a total ankylosis of the spine or a diagnosis of any other inflammatory arthritis 
eg, RA, systemic lupus erythematosus, sardoidosis, psoriatic arthritis, or reactive arthritis. 
Subjects with a diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as they 
have no active symptomatic disease at Screening or Baseline.
7. Subject has a secondary, noninflammatory condition (eg, osteoarthritis, fibromyalgia) that in 
the Investigator’s opinion is symptomatic enough to interfere with evaluation of the effect of 
study drug on the subject’s primary diagnosis of active AS.
8. Subject has received previous or current biological treatment other than TNFα inhibitor 
treatment.
9. Subjects must not have used medications in the manner as detailed by the exclusion criteria 
in Table 7‒2.
10. Subject has: 

a history of chronic or recurrent infections (eg, more than 3 episodes requiring systemic 
antibiotics or antivirals during the preceding year). Minor illnesses like common cold or 
transient, localized infections that may have been treated with a short course of antibiotic 
therapy (up to 7 days) need not count in this assessment.

a serious or life-threatening infection within the 6 months prior to the Baseline Visit 
(including herpes zoster) or hospitalization for any infection in the last 6 months.

any current sign or symptom that may indicate an active infection (except for common 
cold), or has had an infection requiring systemic antibiotics within 2 weeks prior to 
Baseline.

a high risk of infection in the Investigator’s opinion (eg, subjects with leg ulcers, 
indwelling urinary catheter, prior prosthetic joint infection at any time, subjects who are 
permanently bedridden or wheelchair assisted).
PUBLIC COPY
ity rea
PY 
ity rea
a diagno
OPY
a diagno
rdoidosi
CO
rdoidosi
isease or
C C
isease or
at Scree
LIC 
at Scree
lammato
UBL
lammato
symptom
PUB
symptom
primar
PU
primar
nt cannot be used to support any marketing authorization 
e
r
e
ning a 
horiz
ning a 
on within 
ng 
on within 
rently par
ting
rently par
zumab or
ark
zumab or
glycolyla
y m
glycolyla
on or an a
ny 
on or an a
is of any o
t an
is of any o
, psoriatic
ort 
, psoriatic
ulcerative
por
ulcerative
ning or Ba
upp
ning or Ba
ry conditi
su
ry conditi
atic enou
to s
atic enou
y diagnosi
d to
y diagnosi
or current
sed
or current
used med
be 
used med
y of chron
can
y of chron
otics or a
t ca
otics or a
This documen
nsient, loc
ent 
nsient, loc
therapy (u
men
therapy (u

a ser
um
a ser
(in
u
(in

tion and any extensions or variations thereof.
the last 3
reo
the last 3
rticipating
here
rticipating
r CZP.
ns t
r CZP.
ated (
tion
ated (PEG
on
PEG
anaphylac
iatio
anaphylac
other infl
vari
other infl
c a
r
c arthritis
r va
rthritis
e colitis a
or v
e colitis a
aseline.
s o
aseline.
ion (eg, o
ions
ion (eg, o
ugh to inte
nsio
ugh to inte
is of activ
ens
is of activ
t biologic
exte
t biologic
dications 
any
dications 
nic or recu
n a
nic or recu
antivirals 
tion
antivirals 
applicat
ocalized in
atio
ocalized in
(up to 7 d
lica
(up to 7 d
ious or li
ppl
ious or li
ncluding 
app
cluding 


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 36 of 136
11. Subject has a history of or current clinically active infection with Histoplasma, Coccidiodes, 
Paracoccidioides, Pneumocystis, nontuberculous mycobacteria (NTMB), Blastomyces, or 
Aspergillus or current active Candidiasis (local or systemic)
12. Subject has acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) 
infection. Subjects who have evidence of, or test positive for, hepatitis B or hepatitis C are 
excluded as follows: 

A positive test for the hepatitis B virus (HBV) is defined as: 1) positive for hepatitis B 
surface antigen (HBsAg+), or 2) positive for anti-hepatitis B core antibody (HBcAb+). 

A positive test for the hepatitis C virus (HCV) is defined as: 1) positive for hepatitis C 
antibody (anti-HCV Ab), and 2) positive via a confirmatory test for HCV (for example, 
HCV polymerase chain reaction).
13. Subjects with known TB infection, at high risk of acquiring TB infection, with latent TB 
infection (LTBI), or current or history of NTMB infection (refer to Section 12.7.5 for details 
on determining full TB exclusion criteria). 
14. Subject has a primary immunosuppressive condition, including taking immunosuppressive 
therapy following an organ transplant or has had a splenectomy.
15. Subjects with concurrent malignancy or a history of malignancy (including surgically 
resected uterine/cervical carcinoma-in-situ) during the past 5 years will be excluded with the 
following exceptions that may be included:
a. ≤3 excised or ablated basal cell carcinomas of the skin
b. One squamous cell carcinoma of the skin (stage T1 maximum) successfully excised or 
ablated only (other treatments, ie, chemotherapy, do not apply) with no signs of 
recurrence or metastases for more than 2 years prior to Screening
c. Actinic keratosis(-es)
d. Squamous cell carcinoma-in-situ of the skin successfully excised or ablated more than 
6 months prior to Screening
16. Subject has a history of a lymphoproliferative disorder including lymphoma or current signs 
and symptoms suggestive of lymphoproliferative disease.
17. Subject has a history of demyelinating disease (including myelitis) or neurologic symptoms 
suggestive of demyelinating disease.
18. Subject has a current or recent history, as determined by the Investigator, of severe, 
progressive, and/or uncontrolled renal, hepatic hematological, endocrine, pulmonary, cardiac 
(eg, congestive heart failure New York Heart Association [NYHA] Grade 3 and 4), 
gastrointestinal (GI) (note: subjects with active peptic ulcer disease are excluded; subjects 
with a history of peptic ulcer disease are allowed), or neurological disease.
19. Subjects has a history of uncompensated heart failure, fluid overload, or myocardial 
infarction, or evidence of new-onset ischemic heart disease or in the opinion of the 
Investigator other serious cardiac disease, within 12 weeks prior to Baseline.
PUBLIC COPY
a sple
PY 
a sple
story of 
OP
story of 
u) durin
CO
u) durin
uded:
C C
uded:
l carcino
LIC
l carcino
oma of th
UBL
oma of th
tments, i
PU
tments, i
for 
P
for 
ent cannot be used to support any marketing authorization 
 B
o
 B
Ab+). 
thor
Ab+). 
hepatitis C
auth
hepatitis C
(for exam
g au
(for exam
on, with l
ketin
on, with l
Section 
rke
Section 1
ing taking
y m
ing taking
ctomy.
ny
ctomy.
malignanc
t an
malignanc
g the past 
ort 
g the past 
mas of the
upp
mas of the
e skin (sta
to s
e skin (sta
e, chemoth
d to
e, chemoth
more than 
ed 
more than 
oma
be
oma-
e
-in
e u
in-si
u
si
Screening
t be
Screening
ory of a ly
not
ory of a ly
suggestiv
ann
suggestiv
s a history
t ca
s a history
ve of dem
nt c
ve of dem
This docume
ject has a
men
ject has a
progressiv
um
progressiv
(eg, con
ocu
(eg, con
gastr
oc
gastr
w
1
s
1
ation and any extensions or variations thereof.
C
f
C
mple,
of
mple,
latent TB
ther
latent TB
2.7.5
th
2.7.5 for
h
for
g immuno
tion
g immuno
cy (includ
vari
cy (includ
5 years w
r va
5 years w
e skin
ns
e skin
tage T1 m
sion
tage T1 m
therapy, d
nsi
therapy, d
n 2 years p
ten
n 2 years p
itu of the 
ny e
itu of the 
g
ymphopro
nd 
ymphopro
ve of lymp
and
ve of lymp
y of demy
on a
y of demy
myelinatin
tion
myelinatin
applic
a current o
ica
a current o
ve, and/or
plic
ve, and/or
ngestive h
app
ngestive h
intestin
ap
intestin
st


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 37 of 136
20. Subjects with presence of significant uncontrolled neuropsychiatric disorder, active suicidal 
ideation, or positive suicide behavior using the “Baseline” version of the Columbia-Suicide 
Severity Rating Scale (C-SSRS) and the Hospital Anxiety and Depression Scale (HADS) 
with either of the following criteria:

Subject has a lifetime history of suicide attempt (including an actual attempt, interrupted 
attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by 
a positive response (“Yes”) to either question 4 or question 5 of the “Screening/Baseline” 
version of the C-SSRS at screening.

HADS Depression score ≥10 or Anxiety score ≥15.
21. Subject has >2x upper limit of normal (ULN) of any of the following: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), *alkaline phosphatase (ALP), or 
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).
*An isolated elevation between 2xULN and <3xULN of ALP is acceptable in the absence of 
an identified exclusionary medical condition.
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation during the Screening Period. Upon retesting, subjects whose ALT, 
AST, or ALP remain above the thresholds defined above, should not be randomized. 
For randomized subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, 
a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
understood and recorded in the electronic Case Report form (eCRF).
If a subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at 
Screening, repeat the tests, if possible, prior to dosing to ensure there is no further ongoing 
clinically relevant increase. In case of a clinically relevant increase, inclusion of the subject 
must be discussed with the Medical Monitor.
22. Subjects with clinically significant laboratory abnormalities (eg, creatinine >1.5xULN, 
neutropenia <1.5x109/L, hemoglobin <8.5g/dL, lymphocytes <1.0 x109/L, white blood cell 
(WBC) count <3.0x109, platelets <100 x109/L). Individual screening tests for which the 
results are in error, borderline, or indeterminate for inclusion in the study, can be repeated 
once for confirmation during the Screening Period if they are within 25% of the exclusion 
limit. Upon retesting, subjects whose results remain outside this threshold should not be 
randomized. 
23. Subject has an estimated glomerular filtration rate (GFR) as measured by Chronic Kidney 
Disease Epidemiology Collaboration <60mL/min/1.73m2
24. Subject has a 12-lead ECG with changes considered to be clinically significant upon medical 
review (eg, QT corrected for heart rate [QTc] using Fridericia’s correction [QTcF] >450ms, 
bundle branch block, evidence of myocardial ischemia).
PUBLIC COPY 
25% abo
OPY
25% abo
g Period
COP
g Period
ds defin
C CO
ds defin
eline res
LIC 
eline res
cause of 
BLI
cause of 
he electro
UB
he electro
T, AST
PU
T, AST
P
annot be used to support any marketing authorization 
y 
z
y 
line”
riz
line”
g
sphatase (
ng 
sphatase (
drome). If
eting
drome). If
tionate bil
ket
tionate bil
ubin <35%
ark
ubin <35%
is accept
ma
is accept
ve the exc
t any
ve the exc
Upon rete
ort a
Upon rete
ed above, 
por
ed above, 
ult >ULN
upp
ult >ULN
any clinica
sup
any clinica
nic Case R
to s
nic Case R
or ALP t
d t
or ALP t
ossible, pr
sed
ossible, pr
In case of 
use
In case of 
e Medica
e u
e Medica
ly signific
t be
ly signific
10
n
109
o
9/L, hem
not 
/L, hem
This document ca
3.0x10
nno
3.0x109
no
9
o
error, bo
can
error, bo
onfirmati
t ca
onfirmati
Upon retes
ent 
Upon retes
omized.
men
omized.
Subject h
cum
Subject h
Diseas
ocu
Diseas
24.
do
24. Su
o
Su
nd any extensions or variations thereof.
(ALP), or
reo
(ALP), or
f subject h
here
f subject h
ilirubin to
the
ilirubin to
%).
s
%).
table in th
tion
table in th
lusion lim
aria
lusion lim
testing, su
va
testing, su
should n
or v
should n
N for AL
ns o
N for ALT
o
T
ally mean
ons
ally mean
Report fo
sio
Report fo
that does 
tens
that does 
rior to do
xte
rior to do
f a clinica
ex
f a clinica
l Monitor
y e
l Monitor
icant labo
d any
icant labo
moglobin
nd a
moglobin
application an
platelets <
and
platelets <
orderline, 
n a
orderline, 
ion during
ion 
ion during
esting, sub
atio
esting, sub
has an est
ppli
has an est
se Epidem
app
e Epidem
has
a
has


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 38 of 136
25. Subjects has received any live (includes attenuated) vaccination within the 8 weeks prior to 
Baseline (12 months prior to Baseline for the TB Bacille Calmette-Guérin [BCG] vaccine) 
(eg, inactivated influenza and pneumococcal vaccines are allowed but nasal influenza 
vaccination is not permitted). Live vaccines are not allowed during the study or for 20 weeks 
after the final dose of IMP. 
Live vaccines include, but are not limited to the following: 

Anthrax vaccine

Intranasal influenza vaccine

Measles-mumps-rubella (MMR) vaccine

Polio live oral vaccine (OPV)

Smallpox vaccine

Tuberculosis BCG vaccine (within 12 months prior to Baseline)

Typhoid live oral vaccine

Varicella vaccine

Yellow fever vaccine
26. Subject has a history of chronic alcohol or drug abuse within the previous 6 months.
27. Subjects has any other condition which, in the Investigator's judgment, would make the 
subject unsuitable for inclusion in the study.
28. Subject is Investigator site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whether 
biological or legally adopted.
29. Subject is a UCB employee or is an employee of a third-party organization involved in the 
study.
6.3
Withdrawal criteria
Subjects are free to withdraw from the study at any time, without prejudice to their continued 
care.
Subjects should be withdrawn from the study and encouraged to come for the SFU Visit 
(20 weeks after the last received dose of IMP) if any of the following events occur:
1. Subject withdraws his/her consent.
2. The sponsor or a regulatory agency requests withdrawal of the subject.
3. There is confirmation of a pregnancy during the study, as evidenced by a positive pregnancy 
test.
4. Subject develops an illness that would interfere with his/her continued participation.
PUBLIC COPY 
or drug 
C CO
or drug 
hich, in t
LIC 
hich, in t
n the stu
BLI
n the stu
ersonnel
PUB
ersonnel
is defi
PU
is defi
cument cannot be used to support any marketing authorization 
e)
a
e)
abuse with
port
abuse with
he Investig
upp
he Investig
dy.
s
dy.
directly a
to s
directly a
ned as a sp
d to
ned as a sp
or is an e
us
or is an e
awal cri
ot b
awal cri
withdraw
nno
withdraw
uld be wit
nt c
uld be wit
s after the 
ent
s after the 
ubject wit
me
ubject wit
This docu
The spo
ocu
The spo
3.
d
3. The
o
The
pplication and any extensions or variations thereof.
hin the pr
or v
hin the pr
gator's jud
s o
gator's jud
affiliated w
nsio
affiliated w
pouse, pa
ens
pouse, pa
employee
y ex
employee
teria
d an
teria
w from the
and
w from the
ithdr
tio
ithdrawn f
on
awn f
e last rece
atio
e last rece
thdraws h
plica
thdraws h
ap
onsor or a
app
onsor or a
s con
a
s con


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 39 of 136
5. Subject considered as having either a suspected new LTBI or who develops active TB or 
NTMB infection during the study (including but not limited to, conversion demonstrated by 
interferon-gamma release assay [IGRA] or other diagnostic means) must be immediately 
discontinued from IMP, and an Early Withdrawal Visit must be scheduled as soon as 
possible, but not later than the next regular visit.
Confirmed active TB is a serious adverse event (SAE) and must be captured on an SAE 
Report Form and provided to the Sponsor in accordance with SAE reporting requirements. 
As with all SAEs, periodic follow-up reports should be completed as per protocol 
requirements until such time as the TB infection resolves. 
Additional information on TB policies are provided Section 12.7.5.
6. Subject is noncompliant with the study procedures or medications in the opinion of the 
Investigator.
7. Subject uses prohibited concomitant medications as defined in this protocol (see 
Section 7.8.2) that may present a risk to the safety of the subject in the opinion of the 
Investigator and/or the Medical Monitor.
8. Subject develops laboratory abnormalities (with or without clinical symptoms) of ALT or 
AST as defined in Section Section 6.3.1; neutropenia <0.5x109/L; lymphopenia <0.5x109/L. 
Any laboratory value or change judged to be clinically significant by the Investigator should 
prompt consideration of whether the subject should continue on IMP. For clarification, 
laboratory values that are markedly abnormal as per Table 19‒2 and Table 19‒3 will be 
flagged to the Investigator and to the medical monitor but do not trigger mandatory 
withdrawal unless listed above (Refer to Section 6.3.1 for withdrawal criteria in relation to 
potential drug-induced liver injury [PDILI].)
9. Subject has active suicidal ideation as indicated by a positive response (“Yes”) to 
Questions 4 or 5 or to the suicidal behavior questions of the “Since Last Visit” version of the 
self-rated C-SSRS. The subject should be referred immediately to a Mental Healthcare 
Professional and must be withdrawn from the study.
10. Subjects with a Hospital Anxiety and Depression Scale—Depression (HADS-D) score ≥15 
must be withdrawn. Any subject who develops a HADS-D score of ≥10 during the study 
should be referred immediately to a Mental Healthcare Professional for further evaluation 
and potential withdrawal by the Investigator.
11. Subjects with newly diagnosed IBD or with IBD flares during the study must:

Be referred, as appropriate, to a health care professional treating IBD, such as a 
gastroenterologist

Discontinue IMP and be followed-up until resolution of active IBD symptoms
If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgement in deciding whether the subject should continue in the study and contact 
the Medical Monitor and UCB study physician to confirm the subject’s suitability for 
continued participation in the study.
PUBLIC COPY
h or
PY
h or with
PY 
with
utropenia
OPY
utropenia
be clini
CO
be clini
ubject sh
C C
ubject sh
abnorm
LIC 
abnorm
B
the med
BLI
the med
e (Refer 
UB
e (Refer 
r injury 
PU
r injury 
P
sed to support any marketing authorization 
s.
r
s.
opinion of
ting
opinion of
s protocol
arke
s protocol
t in the op
mar
t in the op
out clinica
any
out clinica
<0.5x10
t an
<0.5x109
n
9
cally signi
ort 
cally signi
ould conti
po
ould conti
l as per 
upp
l as per T
p
T
ical moni
sup
ical moni
to 
to
to Section
o s
Section
PDILI].)
d to
PDILI].)
tion as ind
sed
tion as ind
This document cannot be us
icidal beh
use
icidal beh
ubject sho
be u
ubject sho
be withdr
t be
be withdr
spital An
not 
spital An
awn. Any 
nno
awn. Any 
ferred imm
can
ferred imm
tial withdr
t ca
tial withdr
cts with n
ent
cts with n
Be refe
ume
Be refe
gastr
um
gastr

o

xtensions or variations thereof.
f the
ere
f the
l (see 
s th
l (see 
pinion of 
ons
pinion of 
al sympto
riat
al sympto
/L; lymp
vari
/L; lymp
ificant by
r va
ificant by
inue on IM
or 
inue on IM
Table
s o
Table 19
o
19‒
o
‒
itor but do
ons
itor but do
n 6.3.1
sio
6.3.1 for
on
for
dicated by
xte
dicated by
application and any e
havior qu
ext
havior qu
ou
n
ould be re
ny e
ld be re
rawn from
any
rawn from
nxiety and
nd a
nxiety and
subject w
and
subject w
mediately
n a
mediately
drawal by 
ion 
drawal by 
newly dia
catio
newly dia
erred, as a
plic
erred, as a
troenterolo
ppl
troenterolo
scontin
ap
scontin


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 40 of 136
In an attempt to prevent missing data during the study, efforts will be made to collect data from 
subjects who withdraw early from the study (NRC, 2010). If a subject withdraws from study 
treatment for any of the above criteria prior to Week 48, they will be asked to return for the study 
termination assessments as laid down at the Week 48/WD Visit and for the SFU Visit (20 weeks 
after final dose administration). All subjects who withdraw from the study due to an AE must be 
followed until resolution of the event or until the event is considered stable. All subjects who 
withdraw from the study due to development of a laboratory abnormality must be closely 
monitored. If a subject at any time has had an ALT and/or AST >5xULN, additional monitoring 
of hepatic markers will be performed every week or 2 weeks until resolution of the event, the 
event is considered stable, or they have reached the end of the SFU Period.
Investigators should attempt to obtain information on subjects in the case of withdrawal or 
discontinuation. For subjects considered as lost to follow up, the Investigator should make an 
effort (at least 1 phone call and 1 written message to the subject), and document his/her effort 
(date and summary of the phone call and copy of the written message in the source documents), 
to complete the final evaluation. All results of these evaluations and observations, together with a 
narrative description of the reason(s) for removing the subject, must be recorded in the source 
documents. The eCRF must document the primary reason for withdrawal or discontinuation.
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a subject in advance.
6.3.1
Potential drug-induced liver injury IMP discontinuation criteria
Subjects with potential drug-induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued. 
The PDILI criteria below require immediate discontinuation of IMP: 
Subjects with either of the following:

ALT or AST ≥5ULN

ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 

Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
Investigator. 

Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness).
Evaluation of PDILI must be initiated as described in Section 12.6.1. 
If subjects are unable to comply with the applicable monitoring schedule, IMP must be 
discontinued immediately.
PUBLIC COPY 
son
Y
son
whenev
OPY
whenev
liver inj
C CO
liver inj
ver injur
LIC
ver injur
l concom
BLI
l concom
lso be di
UB
lso be di
re imm
PU
re imm
This document cannot be used to support any marketing authorization 
oring
oriz
oring
t, the
tho
t, the
drawal or
g au
drawal or
should ma
ing 
should ma
ment his/h
eting
ment his/h
the sourc
ket
the sourc
observatio
ark
observatio
st be reco
ma
st be reco
withdrawal
y m
withdrawal
r possible
any
r possible
ury IMP 
por
ury IMP 
y (PDILI)
upp
y (PDILI)
mitant med
sup
mitant med
scontinued
to s
scontinued
mediate dis
ed t
mediate dis
ng:
us
ng:
N and coe
t be
N and coe
LT or AST
no
LT or AST
persensiti
ann
persensiti
rant pain 
can
rant pain 
ve cause),
nt c
ve cause),
ILI criteri
men
ILI criteri
stigato
ume
stigator.
m
r.
Subjec
ocu
Subjec
<2x
o
<2x
f
pplication and any extensions or variations thereof.
r r 
ake an
reo
ake an
/her effort
here
/her effort
ce docum
the
ce docum
ons, toget
ns t
ons, toget
orded in th
ons
orded in th
al or disco
atio
al or disco
e, to discu
aria
e, to discu
discont
or v
discont
) must be 
ns o
) must be 
dications 
ons
dications 
d. 
s
d. 
scontinua
tens
scontinua
existing to
d any
existing to
T ≥3xULN
nd 
T ≥3xULN
ivity. Hep
an
ivity. Hep
or tender
on a
or tender
), rash, or 
tion
), rash, or 
ion below
icat
ion below
ap
cts with A
app
cts with A
LN, an
ap
LN, an


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 41 of 136
Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are complete. All results of these evaluations and 
observations, as well as the reason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in the source documents. The eCRF must document the primary 
reason for IMP discontinuation.
6.4
Study stopping rules
During the study, planned dosing and procedures may be discontinued or suspended for all 
subjects in any part of the study and appropriate follow-up procedures established. Where it is 
possible to do so without threatening the safety of subjects, such discontinuation/suspension 
should be discussed with the UCB Study Physician prior to its implementation.
Possible reasons for discontinuation or suspension of the study include (but are not limited to):

A pattern of AEs occurs that contraindicates the further dosing of enrolled/additional 
subjects, including (but not limited to):

More than 1 subject meets any individual Withdrawal Criteria #5, #9, ro #10, or (as 
provided in Section 6.3), regardless of whether they met the same or different criteria.

Once a second subject meets any of those criteria, referral to the DMC may not be 
delayed while awaiting the outcome of either case.
If the above criteria are reached, the DMC will meet as soon as possible to determine whether 
discontinuation or suspension of the study should occur and to determine what investigations, 
analyses, procedural amendments, or other actions should occur, before making any 
recommendation regarding the possibility of recommencing the study. Further details on the role 
of the DMC are provided in Section 12.5. 

If the Sponsor or designees judges it necessary for medical, safety, regulatory, or any other 
reasons consistent with applicable laws, regulations, and Good Clinical Practice (GCP).
6.5
Retesting/rescreening
In the event of an isolated laboratory value outside the laboratory’s normal range, the evaluation 
may be repeated on 1 occasion during the Screening Period. If a value from the repeated test is 
within the screening-specified ranges, the subject maybe enrolled. 
Subjects whose Screening Period expires may be rescreened following discussion with the 
Sponsor.
Subjects who withdraw from the study may be replaced, up to a maximum of 10 subjects. 
BLIC COPY
dr
Y
dr
her they
PY 
her they
se criteri
OP
se criteri
of either 
CO
of either 
C will m
IC C
C will m
tudy 
BLIC
tudy sho
LIC
sho
PUB
or other
UBL
or other
possibili
PUB
possibili
ction
PU
ction
support any marketing authorization 
all
th
all
here it is
uth
here it is
uspension
au
uspension
are not li
eting
are not li
nrolled/ad
rke
nrolled/ad
riteria #
y m
riteria #5
m
5
met the sa
ny 
met the sa
a, referral 
rt a
a, referral 
case.
ort
case.
eet as soo
ppo
eet as soo
uld occur 
sup
uld occur 
t cannot be used to s
actions sh
o su
actions sh
y of recom
d to 
y of recom
2.5
d
2.5.
d
.
dges it ne
use
dges it ne
plicable la
e us
plicable la
g/rescre
t be
g/rescre
ated labor
not 
ated labor
n 1 occasio
nno
n 1 occasio
ning
ca
ning-
an
-spec
an
spec
ment
ose Scree
nt c
ose Scree
This docum
ects who w
ume
ects who w
ons or variations thereof.
n 
o
n 
imited to)
here
imited to)
dditional
s th
dditional
, #
ti
, #9
tio
9, ro
tio
, ro #
n
#
ame or dif
riati
ame or dif
to the DM
var
to the DM
on as poss
s o
on as poss
r and to de
ns 
r and to de
and any extensio
hould occ
ion
hould occ
mmencing
nsio
mmencing
ecessary f
ext
ecessary f
aws
y
aws, regu
y e
, regu
eening
any
eening
ratory val
nd a
ratory val
ion during
and
ion during
on 
cified rang
n a
cified rang
licatio
ening Peri
tion
ening Peri
appl
withdraw
plic
withdraw


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 42 of 136
7
STUDY TREATMENT(S)
7.1
Description of investigational medicinal product(s)
The IMPs used in this study are bimekizumab and CZP.
Bimekizumab will be supplied as a vial or in a pre-filled syringe (PFS) form as described below: 

Vial: a clear to opalescent, colorless to slightly brown, sterile, preservative-free solution in 
2mL Type I, colorless glass vials (1.0mL extractable volume) closed with a rubber stopper 
and sealed with an aluminum cap overseal. Each single-use dose vial will contain 160mg/mL 
bimekizumab in 
mM sodium acetate,
mM glycine, and 
 (w/v) polysorbate 80 at 
pH 

PFS: 1mL PFS at a concentration of 160mg/mL (
mM sodium acetate, 
mM glycine, 
 polysorbate 80 at pH 
) for sc injection.
Certolizumab pegol will be supplied as a sterile, clear, colorless-to-slightly yellow solution at 
pH
 in 1mL single-use glass PFS for sc injection. Each syringe contains an extractable volume 
of 1.0mL at a concentration of CZP 200mg/mL in 
mM sodium acetate buffer and 
mM 
sodium chloride as a tonicity agent. The syringes are stored at 2 to 8ºC, not frozen, and protected 
from light.
Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopoeia (United States Pharmacopoeia/European Pharmacopoeia) 
quality appropriate for injection.
Further details of the IMPs and their specifications are provided in the IMP Handling Manual.
7.2
Treatment(s) to be administered
The IMP is to be administered in the clinic by trained study site staff as 2 sc injections. Suitable 
areas for sc injections are the lateral abdominal wall and upper outer thigh. During each dosing 
visit, each of the 2 injections should be administered at a separate injection site. Injection sites 
should be rotated and injections should not be given into areas where the skin is tender, bruised, 
red, or hard.
The IMP (bimekizumab or CZP) will be administered at time points indicated in Table 5‒1.
At Baseline, eligible subjects will be randomized in a 2:1 ratio to the following bimekizumab or 
CZP treatment arms and will receive IMP as shown in Table 7‒1.
PUBLIC COPY 
store
Y
store
ride aqu
COP
ride aqu
d States 
C CO
d States 
r specific
BLI
r specific
to be a
PUB
to be a
n th
P
n th
y marketing authorization 
per 
ori
per 
60mg/mL 
thor
60mg/mL 
rbate 80 a
uth
rbate 80 a
mM gly
ing 
mM gly
htly yello
rke
htly yello
ontains an
mar
ontains an
m acetate b
ma
m acetate b
This document cannot be used to support any
2 to 8ºC, 
ny m
2 to 8ºC, 
ous soluti
ort a
ous soluti
Pharmaco
por
Pharmaco
ations are
sup
ations are
administ
d to 
administ
clinic by
ed 
clinic by
ral abdom
use
ral abdom
hould be a
e us
hould be a
ions s
be
ions shou
e 
hou
mab or CZ
nno
mab or CZ
gible subje
can
gible subje
t arms an
t ca
t arms an
in
tions thereof.
lycine,
reo
lycine,
ow solutio
s th
ow solutio
n extracta
ns 
n extracta
buffer and
tion
buffer and
application and any extensions or variat
, not froze
atio
, not froze
tion (phys
va
tion (phys
opoeia/Eu
or v
opoeia/Eu
e provided
ons
e provided
tered
nsio
tered
y trained s
xten
y trained s
minal wall
ext
minal wall
administe
y e
administe
uld not be
any 
uld not be
ZP) will b
and
ZP) will b
ects will b
n a
ects will b
nd will rec
ion 
nd will rec


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 43 of 136
Table 7‒1:
Treatments administered
IMP
Study period
Treatment Period 
Treatment Extension Period 
Bimekizumab
160mg sc Q2Wa
320mg sc Q4W
CZP
Loading doses of 400mg sc Q2W at Weeks 0, 2, 
and 4 followed by CZP 200mg sc Q2W
400mg sc Q4W
CZP=certolizumab pegol; IMP=investigational medicinal product, Q2W=every 2 weeks; Q4W=every 4 weeks; 
sc=subcutaneous
a In addition, subjects will receive 1 placebo injection at Baseline, Week 2, and Week 4 in order to maintain the 
blind vs the CZP loading dose at these visits.
The minimum time between doses should be no less than 10 days during the Treatment Period 
and no less than 22 days during the Treatment Extension Period. 
An IMP Handling Manual will be provided to each site containing instructions regarding drug 
preparation and dosing.
7.3
Packaging
Bimekizumab and CZP will be packaged and labeled according to Good Manufacturing Practice 
(GMP) guidelines and applicable laws or regulations. They will be suitably packaged in such a 
way as to protect the product from deterioration during transport and storage. Further 
information regarding storage and transport conditions are provided in the IMP Handling 
Manual.
7.4
Labeling
Clinical drug supplies will be labeled in accordance with the current International Council for 
Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and GMP and will include any 
locally required statements. If necessary, labels will be translated into the local language.
7.5
Handling and storage requirements
Investigational Medicinal Product must be stored under refrigerated conditions (2ºC to 8ºC) 
protected from light. The IMP must not be frozen.
The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational medicinal product stored by the Investigator is to be kept in a secured area with 
limited access according to the storage conditions mentioned on the label.
Appropriate storage conditions must be ensured either by controlling the temperature (eg, room, 
refrigeration unit) or by completion of a temperature log in accordance with local requirements 
on a regular basis (eg, once a week), showing actual and minimum/maximum temperatures 
reached over the time interval.
In case an out-of-range temperature is noted, it must be immediately reported as per instructions 
contained in the IMP Handling Manual.
PUBLIC COPY 
d labeled
CO
d labeled
regulatio
C C
regulatio
erioratio
LIC
erioratio
C
ransport 
BLI
ransport 
ment cannot be used to support any marketing authorization 
riz
4 weeks;
tho
4 weeks;
to maintain
au
to maintain
ho
g the Trea
ket
g the Trea
g instruct
ma
g instruct
according
ort 
according
ns. They w
ppo
ns. They w
during tr
upp
during tr
conditions
sup
conditions
eled in ac
use
eled in ac
es on Goo
e us
es on Goo
If necess
be 
If necess
ng and 
ot b
ng and 
dicinal Pr
nn
dicinal Pr
ight. The 
can
ight. The 
gator (or d
nt c
gator (or d
ational me
en
ational me
This docum
d access a
me
d access a
ppropriate
ocu
ppropriate
refrigera
doc
refrigera
on a r
s do
on a r
rea
s 
rea
ication and any extensions or variations thereof.
n the
f
n the
atment Pe
the
atment Pe
tions rega
tion
tions rega
g to Good
r va
g to Good
will be su
or 
will be su
ransport a
ns o
ransport a
s are prov
ions
s are prov
ccordance
ext
ccordance
od Clinica
y e
od Clinica
sary, labe
any
sary, labe
 storage
d a
 storage
roduct mu
and
roduct mu
e IMP mu
n a
e IMP mu
designee)
tion
designee)
edicinal p
cati
edicinal p
appli
according
plica
according
te storage 
app
te storage 
on unit
ap
on unit
ba
b


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 44 of 136
7.6
Drug accountability 
A Drug Accountability form will be used to record IMP dispensing and return information on a 
by-subject basis and will serve as source documentation during the course of the study. Details of 
any IMP lost, damaged (due to breakage or wastage), not used, partially used, disposed of at the 
study site, or returned to the sponsor or designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available throughout the study for UCB 
(or designee) to review.
In order to maintain the blind, all IMP documentation (eg, shipping receipts, drug accountability 
logs, and interactive response technology [IRT] randomization materials) must be maintained 
and accessed by unblinded, trained site personnel only. Designated, unblinded site personnel 
must be appropriately trained and licensed (per country guidelines) to administer injections.
The packaging identifies each kit by a unique number. Unblinded study staff will be responsible 
for preparation (breaking tamper proof sticker on kit, etc) of the clinical trial material, including 
recording the administration information on source document.
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed.
The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
site to an appropriate pharmacist/designee.
The Investigator must ensure that the IMP is used only in accordance with the protocol.
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially used, unused, damaged, and/or expired IMP must be reconciled and 
destroyed at the site according to local laws, regulations, and UCB standard operating procedures 
(SOPs). Investigational medicinal product intended for the study cannot be used for any other 
purpose than that described in this protocol.
7.7
Procedures for monitoring subject compliance
During theTreatment Period and the Treatment Extension Period, IMP will be administered in 
the clinic and compliance will be determined at the visit by study personnel. Drug accountability 
must be recorded on the Drug Accountability Form.
7.8
Concomitant medication(s)/treatment(s)
All concomitant medications, including over the counter products, herbal, traditional remedies, 
vitamin/mineral supplements, other dietary supplements, “nutraceuticals,” and hormones must be 
recorded in the subject’s source documentation (eg, clinical chart) and on the electronic Case 
Report Form (eCRF). This record should include the name of the drug, the dose, the route and 
date(s) of administration, and the indication for use.
The Investigator should examine the acceptability of all concomitant procedures, medications, 
topical preparations and dietary supplements not explicitly prohibited in this study, and if 
necessary, discuss with the Medical Monitor.
In order to ensure that appropriate concomitant therapy is administered, subjects will be 
instructed to consult with the Investigator prior to taking any medication (either 
PUBLIC COPY 
ator’s du
OPY
ator’s du
is us
C C
is used 
C
ed 
of the cli
BLIC
of the cli
damaged
UBL
damaged
o local la
PUB
o local la
nal pro
PU
nal pro
P
This document cannot be used to support any marketing authorization 
B
z
B
ntability 
thor
ntability 
intained 
uth
intained 
personne
au
personne
er injectio
ng a
er injectio
ff will
etin
ff will be 
ng
be 
trial mate
ket
trial mate
d, unused,
ma
d, unused,
ties for dr
t any
ties for dr
only in acc
ppo
only in acc
nical phas
supp
nical phas
, and/or e
o su
, and/or e
ws, regula
to 
ws, regula
duct inten
d to
duct inten
protocol.
sed
protocol.
for mon
e us
for mon
d and the
t be
d and the
ce will be
ot b
ce will be
the Drug 
no
the Drug 
oncomi
an
oncomi
tant medi
nt c
tant medi
mineral su
ent
mineral su
ed in the s
me
ed in the s
port Form 
cum
port Form 
date(s) of 
ocu
date(s) of 
The In
s do
The In
top
s 
top
application and any extensions or variations thereof.
el
of
el
ons.
eo
ons.
responsib
here
responsib
erial, inclu
the
erial, inclu
,
i
, and part
ion
and part
rug accou
aria
rug accou
ccordance
or 
ccordance
se of the s
ns 
se of the s
expired IM
ion
expired IM
ations, an
nsio
ations, an
nded for th
tens
nded for th
nitoring 
y ex
nitoring 
e Treatme
any
e Treatme
e determin
d a
e determin
Accounta
nd 
Accounta
itant
n a
itant me
a
me
ications, i
tion
ications, i
upplement
cati
upplement
subject’s 
lica
subject’s 
m (eCRF). 
ppli
m (eCRF). 
administr
app
administr
gato
a
gato


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 45 of 136
self-administered non-prescription drugs or prescription therapy prescribed by another 
physician).
7.8.1
Permitted concomitant treatments (medications and therapies)
The following concomitant medications are permitted during the study:
Subjects may use NSAIDs under the following conditions:

Subjects who are already receiving an established NSAID regimen and have been on a stable 
dose for at least 2 weeks prior to Baseline may continue their use during the study. However, 
initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a 
history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
caution and must not occur until after the Week 12 Visit.
Subjects may use corticosteroids under the following conditions:

Oral (maximum allowed ≤10mg daily total prednisone equivalent)—subjects are permitted to 
decrease their oral corticosteroid therapy dose equivalent and/or alter their regimen only after 
Week 12.
Subjects may use MTX, sulfasalazine (SSZ), or hydroxychloroquine (HCQ) under the following 
conditions:

No change in dose or dose regimen of these agents is allowed during the study except for 
reasons of intolerance/AEs. No increase of the dose is permitted. No change is permitted in 
the route of administration for MTX (intramuscular [im], sc, or oral). It is strongly 
recommended that subjects taking MTX are also taking folic acid supplements. No 
combinations of DMARDs are permitted during the study.
7.8.2
Prohibited concomitant treatments (medications and therapies)
The following concomitant medications are prohibited during the study:
Table 7‒2:
Prohibited or restricted medications and required wash-out periods 
prior to Baseline
Drug class
Dose
Exclusion criteria
Analgesics, including opioid analgesics 
(acetaminophen/paracetamol, etc)
Any dose 
Any ad hoc use in the 24 hours prior to any 
study visit. 
Stable doses of analgesics permitted.
NSAIDs/COX-2 inhibitors
Any dose regimen
Any change in dose/dose regimen in the 
14 days prior to the Baseline Visit
Oral corticosteroids
Any dose regimen
Any change in dose/dose regimen in the 
14 days prior to the Baseline Visit
Intramuscular (im)/intravenous (iv)/
intra-articular (ia) corticosteroids/bursal 
corticosteroids 
Any dose 
Use in the 28 days prior to the Baseline 
Visit. 
PUBLIC COPY
roxych
PY 
roxych
se agent
CO
se agent
e of the 
C C
e of the 
X (intram
LIC 
X (intram
g MTX 
BLIC
g MTX 
e permit
UBL
e permit
ncom
PU
ncom
ent cannot be used to support any marketing authorization 
table
oriz
table
owever,
hor
owever,
ects with a
utho
ects with a
ne with 
aut
ne with 
subjects 
rke
subjects 
alter their
ark
alter their
roquine (H
ny 
roquine (H
 is allowe
ort 
 is allowe
dose is pe
po
dose is pe
uscular [im
upp
uscular [im
are also tak
sup
are also tak
ed during 
to s
ed during 
tant trea
d to
tant trea
ations are
sed
ations are
or restri
be u
or restri
Baseline
t be
Baseline
ot
ng opioid an
ann
ng opioid an
paracetamo
ca
paracetamo
nn
This documen
Ds/COX
me
Ds/COX-
e
-2 
e
2 
en
Oral cor
doc
Oral cor
oc
s d
s
cation and any extensions or variations thereof.
s are perm
the
s are perm
r regimen
ns t
r regimen
HCQ) und
iatio
HCQ) und
ed during
r va
ed during
ermitted. N
or 
ermitted. N
im], sc, or
s o
im], sc, or
aking folic
ons
aking folic
g the study
sion
g the study
atments 
ens
atments 
e prohibite
exte
e prohibite
ricted me
ny e
ricted me
e
Do
Do
d a
d
nalgesics
an
nalgesics
ol, etc)
on
ol, etc)
an
applica
inhibitors
lica
inhibitors
ca
osteroid
ap
osteroid
ap


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 46 of 136
Table 7‒2:
Prohibited or restricted medications and required wash-out periods 
prior to Baseline
Drug class
Dose
Exclusion criteria
Intra-articular hyaluronic acid 
Any dose 
Any use in the 6 months prior to the 
Baseline Visit. 
DMARDs:
-azathioprine
-cyclosporine,
-cyclophosphamide,
-mycophenolic acid,
-mycophenylate mofetil
-any other small molecule DMARDs 
(eg tofacitinib, apremilast)
Any dose
Use within 12 weeks prior to the Baseline 
Visit.
MTX, SSZ, and HCQ
Maximum allowed: 
SSZ ≤3g daily 
HCQ ≤400mg daily 
MTX ≤25mg weekly
Use initiated and/or any change in the dose 
regimen in the 28 days prior to the Baseline 
Visit. No change is permitted in the route of 
administration for MTX (im, sc, or oral) in 
the 28 days prior to the Baseline Visit.
DMARDs:
-leflunomide 
Any dose 
Use in the 6 months prior to the Baseline 
Visit unless a cholestyramine washout has 
been performed; in which case, use up to 
28 days prior to the Baseline Visit is 
acceptable. 
TNF inhibitors
-infliximab (IFX)
-adalimumab (ADA)
-etanercept (ETN)
-golimumab (GOL)
-certolizumab pegol (CZP)
Any dose
For IFX, ADA, and GOL, any use within 
the 12 weeks prior to the Baseline Visit
For ETN, use within the 28 days prior to 
the Baseline Visit.
For CZP, any previous use
This applies to biosimilar versions of any 
TNF inhibitors.
Any non-TNF biologic medications
Any dose
Any exposure history.
ADA=adalimumab; ia=intra-articular; COX-2=cyclooxygenase 2; CZP=certolizumab pegol; 
DMARD=disease-modifying antirheumatic drug; ETN=etanercept; GOL=golimumab; 
HCQ=hydroxychloroquine; IFX=infliximab; im=intramuscular; iv=intravenous; MTX=methotrexate; 
NSAID=nonsteroidal anti-inflammatory drug; sc=subcutaneous; SSZ=sulfasalazine; TNF=tumor necrosis factor 
Subjects who are receiving an established antidepressant regimen should be on a stable dose of 
anti-depressant for 12 weeks prior to Baseline.
PUBLIC COPY 
PY
Any dos
BLI
Any dos
LIC
U
not be used to support any marketing authorization 
za
ne
ri
ne
za
za
za
nd/or any c
rke
nd/or any c
the 28 days
ark
the 28 days
 change is 
mar
 change is 
istration fo
m
istration fo
28 days pr
ny m
28 days pr
et
Use in the
any
Use in the
Visit u
rt a
Visit u
been
rt
been
2
ny
ort
up
us
anno
ic medicati
ann
ic medicati
no
cument can
ab; ia=intra
ca
ab; ia=intra
sease
t c
sease-
t c
-modi
c
modi
droxychloro
ent 
droxychloro
=nonstero
men
=nonstero
This do
an
Subjects w
doc
Subjects w
anti
do
anti-de
o
de
and any extensions or variations thereof.
change in th
the
change in th
s prior to th
s t
s prior to th
permitted i
ons
permitted i
or MTX (im
tion
or MTX (im
rior to the B
atio
rior to the B
he
e 6 months
aria
e 6 months
unless a cho
var
unless a cho
n performe
r v
n performe
8 days p
or 
days prio
rio
acceptab
s o
acceptab
ia
For 
ns
For 
thth
ns
d
on
ions
a
ions
nd
pplication a
-articular;
n a
articular;
ifying antir
tion
ifying antir
oquine; IFX
atio
oquine; IFX
idal anti
cat
idal anti-in
t
in
ap
a
who are r
app
who are r
sant
a
sant


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 47 of 136
Subjects who take prohibited medications, except topical therapies, may be withdrawn from 
study treatment, but followed until the Safety Follow-Up Visit (20 weeks after the final dose of 
IMP). The decision to withdraw a subject for taking prohibited medications should be made in 
consultation with the Medical Monitor. As noted above, subjects who use prohibited topical 
medications will be allowed to stay in the study but will be counseled to not use them further.
Vaccines
Administration of live, attenuated vaccines is not allowed during the conduct of the study or for 
20 weeks after the final dose of study drug. Subjects receiving BCG vaccinations within 
12 months prior to study drug administration are excluded (see Exclusion Criterion #25,
Section 6.2).
7.8.3
Rescue medication
There are no absolute restrictions on the use of concomitant medications to “rescue” subjects 
whose AS deteriorates during the course of the study. While the objectives of the study should be 
protected as much as possible through observance of the restrictions detailed in Table 7‒2, the 
wellbeing of the subject will always take priority, and subjects should be managed as deemed 
appropriate by the Investigator. If use of any prohibited medications is anticipated, this should be 
discussed with the Sponsor's Study Physician first, wherever possible.
7.9
Blinding
Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in order to maintain the blind vs the 
CZP loading dose at these visits. 
Investigational medicinal product injections will be prepared at the investigational sites by 
unblinded, dedicated study personnel. The unblinded personnel will not be involved in the study 
in any way other than assuring the medication is taken from the correct kit and prepared 
according to the pharmacy manual instructions, and administering the drug to the subjects.
During the study, the Sponsor will provide blinded and unblinded site monitors for the purposes 
of verifying safety, efficacy, and study drug administration and documentation records. Blinded 
study monitors and study site personnel, blinded to treatment assignment, will not discuss or 
have access to any study drug-related information.
Further details are provided in the study manuals and site blinding plan. 
7.9.1
Procedures for maintaining and breaking the treatment blind
The IMP handling manual describes the handling of bimekizumab and CZP. Appropriate training 
will be given to the site personnel to avoid any unblinding. In case the Investigator becomes 
unblinded for any subject, another assessor will perform the remaining evaluations for that 
subject.
PUBLIC COPY
ed m
Y
ed m
wherev
PY 
wherev
MPs (bim
C C
MPs (bim
ects rand
LIC 
ects rand
and We
BLI
and We
uct inje
PU
uct inje
P
ot be used to support any marketing authorization 
r
o
r for 
riz
for 
5
u
5,
ut
,
o “rescue”
ketin
o “rescue”
ves of
rke
ves of the
e
the
detailed i
mark
detailed i
ould be m
ma
ould be m
ations is a
y m
ations is a
r possible
any
r possible
mekizumab
ppo
mekizumab
omized to
upp
omized to
ek 4 (Visit
sup
ek 4 (Visit
ctions wil
d to
ctions wil
el. The un
sed
el. The un
he medica
use
he medica
anual inst
be u
anual inst
onsor will 
t be
onsor will 
This document canno
ficacy, and
not 
ficacy, and
study site
nno
study site
ny study d
can
ny study d
ils are pro
nt c
ils are pro
Pr
n
Pr
IMP hand
um
IMP hand
will be giv
ocu
will be giv
unblind
doc
unblind
subje
s d
subje
d any extensions or variations thereof.
” subjects
her
” subjects
e study sh
th
e study sh
in
n
in Table
ns t
Table 7
managed a
ions
managed a
anticipate
atio
anticipate
e.e.
ab and CZ
or 
ab and CZ
o bimekiz
ns o
o bimekiz
it 4) in ord
ons
it 4) in ord
ll be prep
tens
ll be prep
nblinded 
xte
nblinded 
ation is ta
ex
ation is ta
tructions, 
ny e
tructions, 
l provide b
any
l provide b
application and
nd study d
nd a
nd study d
e personn
and
e personn
drug
n a
drug-
a
-relat
a
relat
ovided in 
tion
ovided in 
rocedure
icat
rocedure
ndling man
pplic
ndling man
ven to the
app
ven to the
for an
ap
for an


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 48 of 136
All Sponsor and Investigator site personnel involved in the study will be blinded to the 
randomized IMP (bimekizumab or CZP) assignment with the following exceptions:

Sponsor Clinical Study Supplies manager and qualified personnel

Sponsor Patient Safety (PS) staff reporting SAEs to the regulatory authorities

Site pharmacist involved in IMP preparation and dispensing

Unblinded monitor who reviews the IMP related documentation and drug accountability

Bioanalytical staff analyzing blood samples for PK and immunogenicity, and biomarkers

Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
DMC and interim analyses. These individuals will be separate from the main blinded study 
team.

Unblinded team at PAREXEL for the purpose of sending unblinded output for the planned 
interim analyses
If necessary, the results of any planned analysis may be shared with key Sponsor’s personnel in 
order to facilitate additional Clinical Planning or Portfolio Management decisions. Only 
unblinded summary results will be provided, and individual subject data will be kept blinded. All 
individuals seeing unblinded summary data will be documented in the Trial Master File (TMF).
7.9.1.1
Maintenance of study treatment blind
All subject treatment details (bimekizumab or CZP) will be allocated and maintained by the 
interactive response technology (IRT) system.
7.9.1.2
Breaking the treatment blind in an emergency situation
In the event of an emergency, it will be possible to determine to which treatment arm and dose 
the subject has been allocated by contacting the IRT. All sites will be provided with details of 
how to contact the system for code breaking at the start of the study. The Medical Monitor or 
equivalent should be consulted prior to unblinding, whenever possible.
The Exploratory Project Manager (EPM) will be informed immediately via the IRT when a code 
is broken, but will remain blinded to specific treatment information. Any unblinding of the IMP 
performed by the Investigator must be recorded in the source documents and on the Study 
Termination eCRF page.
7.10
Randomization and numbering of subjects
An IRT will be used for assigning eligible subjects to a treatment regimen (as applicable) based 
on a predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. To enroll a subject at Visit 1, the Investigator or designee will contact the IRT and 
provide brief details about the subject to be enrolled. Each subject will receive a 5-digit number 
assigned at screening that serves as the subject identifier throughout the study. The subject 
number will be required in all communication between the Investigator or designee and the IRT 
regarding a particular subject. Subject numbers and kit numbers will be tracked via the IRT. 
PUBLIC COPY
folio
Y
folio
ndividua
PY 
ndividua
l be docu
OP
l be docu
eatmen
C CO
eatmen
mab or C
LIC 
mab or C
T) system
BLI
T) system
reatmen
PUB
reatmen
will
P
will
ment cannot be used to support any marketing authorization 
y
o
y
arkers
tho
arkers
unblinded
au
unblinded
n blinded 
g a
n blinded 
output for
ket
output for
ith key Sp
ma
ith key Sp
nagement
ny m
nagement
 subject d
any
 subject d
mented in
rt a
mented in
 blind
port
 blind
ZP) will b
upp
ZP) will b
t blind in
to s
t blind in
be possibl
ed 
be possibl
contacting
sed
contacting
ode break
us
ode break
ted prior t
be u
ted prior t
Manager
ot b
Manager
main blind
not
main blind
Investigat
ann
Investigat
CRF page.
can
CRF page.
Rand
nt c
Rand
T will be u
me
T will be u
This docu
a predeterm
um
a predeterm
designee). 
ocu
designee). 
genera
do
generat
c
t
sche
s d
sche
pr
s
pr
lication and any extensions or variations thereof.
d 
f
d 
d study 
eof
d study 
r the plan
the
r the plan
ponsor’s p
ion
ponsor’s p
t decision
atio
t decision
data will b
riat
data will b
n the Tria
var
n the Tria
be allocat
s o
be allocat
n an em
nsio
n an em
ble to dete
ten
ble to dete
g the IRT
exte
g the IRT
king at the
y ex
king at the
to unblind
ny 
to unblind
r (EPM) w
d an
r (EPM) w
nded to sp
nd 
nded to sp
tor must b
an
tor must b
o
domiza
atio
domiza
used for 
lica
used for 
app
rmined pr
pplic
rmined pr
. The rand
app
The rand
ndividu
ap
ndividu


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 49 of 136
To randomize a subject at Visit 2, the Investigator or designee will contact the IRT and provide 
brief details about the subject to be randomized. The IRT will automatically inform the 
Investigator or designee of the subject’s randomization number. The IRT will allocate kit 
numbers to the subject based on the subject number during the course of the study. The 
randomization number must be incorporated into the eCRF.
8
STUDY PROCEDURES BY VISIT 
The schedule of study assessments (Table 5‒1) provides a general overview of study 
assessments. A list of procedures to be completed at each visit is described below.

Visit windows of ±3 days on either side of the scheduled dosing are permitted; however, the 
Investigator should try to keep the subjects on the original dosing schedule. The window of 
±3 days is relative to Baseline and applicable for all subsequent visits. Changes to the dosing 
schedule outside of the 3-day window must be discussed with the Medical Monitor.

For the SFU Visit (20 weeks after the final dose of IMP), the visit should occur no more than 
3 days prior to the scheduled visit date and within 7 days after the scheduled visit date 
(-3 days to +7 days).
8.1
Screening Visit (Visit 1)
Prior to any study specific activities, subjects will be asked to read, sign, and date an ICF that has 
been approved by the Sponsor and an IEC/IRB, and that complies with regulatory requirements. 
Subjects will be given adequate time to consider any information concerning the study given to 
them by the Investigator or designee. As part of the informed consent procedure, subjects will be 
given the opportunity to ask the Investigator any questions regarding potential risks and benefits 
of participation in the study.
Two additional ICFs for substudies will be required:

Where local regulations permit, subjects will also be given the option to participate in the 
pharmacogenetic and pharmacogenomic substudy. Subjects agreeing to participate in the 
substudy will be required to complete a separate ICF. The ICF must be signed prior to 
collecting any samples for the substudy. The substudy will only be conducted where ethically 
accepted and authorized by the regulatory agencies. Refusal to participate in the substudy 
will not affect a subject’s ability to participate in the main AS0013 study.

Subjects will also be given the option to participate in the PET-MRI or PET-CT substudy at 
selected sites. Subjects who decide to participate in the substudy will need to complete a 
separate ICF following the same procedure and given the same considerations as the main 
ICF. Their willingness to participate in the substudy will be independent from their consent 
to participate in the main AS0013 study.
The following procedures or assessments will be performed at the Screening Visit:

Obtain written informed consent. 

Collect demographic and Baseline characteristics data (including lifestyle and child bearing 
potential as applicable).

Collect AS history. 
PUBLIC COPY 
will be as
COP
will be as
RB, and 
CO
RB, and 
onsider a
C C
onsider a
As part o
LIC
As part o
e
B
estigator
BL
stigator
dies w
PU
dies w
ment cannot be used to support any marketing authorization 
however, t
aut
however, t
The windo
g a
The windo
anges to th
ing 
anges to th
cal Monit
eting
cal Monit
should oc
rke
should oc
he schedu
mar
he schedu
ked to read
rt a
ked to read
hat compl
ort
hat compl
ny inform
ppo
ny inform
f the infor
upp
f the infor
any quest
sup
any quest
will be requ
ed t
will be requ
it, subject
use
it, subject
macogeno
e us
macogeno
ed to comp
be 
ed to comp
es for the
ot b
es for the
orized by
not
orized by
a subject’
ann
a subject’
will also be
t ca
will also be
d sites. Su
nt c
d sites. Su
rate ICF f
men
rate ICF f
This docum
CF. Their 
ume
CF. Their 
to partic
cum
to partic
The foll
doc
The foll

s 

ication and any extensions or variations thereof.
the
f
the
ow of 
of
ow of 
the dosing
reo
the dosing
itor.
he
itor.
ccur no m
s th
ccur no m
uled visit 
ns 
uled visit 
ad, sign, an
var
ad, sign, an
plies with
r v
plies with
mation con
or
mation con
rmed cons
ns o
rmed cons
stions rega
ions
stions rega
quired:
ten
quired:
cts will als
ext
cts will als
omic sub
y e
omic sub
mplete a se
any
mplete a se
e substudy
d an
e substudy
y the regu
nd 
y the regu
’s ability 
an
’s ability 
e given th
on 
e given th
ubjects wh
atio
ubjects wh
following
cat
following
appli
willingne
plic
willingne
cipate in t
ppl
cipate in t
wing pr
ap
wing pr


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 50 of 136

Assess if all inclusion criteria and no exclusion criteria are met.

Collect significant past medical history and concomitant diseases.

Record prior and concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the Bath Ankylosing Spondylitis Functional Index (BASFI).

Total and nocturnal spinal pain (NRS).

Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB, weight and height.

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Administer the tuberculosis questionnaire.

Perform an IGRA tuberculosis test (QuantiFERON TB test).

Perform a serum pregnancy test.

Collect samples for hematology/biochemistry/urinalysis.

Collect samples for hs-CRP.

Collect samples for HIV, hepatitis B and C, and HLA-B27 serology. 

Perform a sacroiliac joint X-ray (if subjects have a previous X-ray documenting AS meeting 
eligibility criteria, they are eligible for study entry after reconfirming their eligibility by 
central reading. If no X-ray is available one must be performed at the Screening Visit. If the 
previous X-ray is more than 1 year old, and central read criteria for randomization are not 
met, another X-ray may be performed if permitted by local guidelines).

Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks prior to Baseline.

Obtain a chest radiograph or computer tomography (CT) scan, unless one has been obtained 
within 3 months prior to the Screening Visit.

Register the subject using the interactive response technology (IRT).
Individual screening tests for which the results are borderline for inclusion in the study may be 
repeated if necessary without complete rescreening of all tests.
PUBLIC COPY 
antiFER
C CO
antiFER
y/bioche
UBL
y/bioche
P.
P
P.
P
t cannot be used to support any marketing authorization 
d sympto
ket
d sympto
ON TB tes
por
ON TB tes
mistry/urin
o su
mistry/urin
itis B and
sed
itis B and
e
-ray (if s
e us
ray (if s
are eligibl
be 
are eligibl
X
ot
X-
t
-ray is a
ot b
ray is a
more than
not 
more than
ray may b
nno
ray may b
PET
c
PET-
ca
-
This document
MRI
ca
MRI
prior to B
nt c
prior to B
ain a ches
men
ain a ches
within 3 m
um
within 3 m
Regist
ocu
Regist
Indivi
s do
Indivi
rep
s 
rep
n and any extensions or variations thereof.
oms of act
the
oms of act
st).
or
st).
inalysis.
ion
inalysis.
d C, and H
xte
d C, and H
subjects h
y ex
subjects h
le for stud
ny 
le for stud
available
d an
available
n 1 year o
nd a
n 1 year o
be perfor
and
be perfor
application
I or PET
on a
I or PET
Baseline.
tion
Baseline.
st radiogr
ica
st radiogr
months pr
plic
months pr
ter the su
app
er the su
cre
a


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 51 of 136
8.2
Baseline (Visit 2, Week 0)
The following procedures or assessments will be performed/recorded prior to administration of 
the IMP:

Verify if all inclusion criteria and no exclusion criteria are met.

Verify significant past medical history and concomitant diseases.

Record prior and concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the BASFI.

Perform the Patient’s Global Assessment of Disease Activity (PGADA).

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
then at 30 minutes and 1 hour after dosing.

Perform a 12-lead ECG.

Perform a urine pregnancy test.

Collect samples for: 

Hematology/biochemistry/urinalysis.

Bimekizumab and CZP plasma concentrations.

Anti-bimekizumab and anti-CZP antibody detection.

hs-CRP.

If the respective ICF has been provided collect blood samples for: 

Cytokines, complement, and biomarker analyses 

Pharmacogenetic variables.

Nonhereditary pharmacogenomic variables.

Collect urine samples for biomarker research if the respective ICF has been provided.

Contact the IRT for randomization.

Administer IMP after all other visit assessments are completed.

Record visit in the IRT.
PUBLIC COPY 
 and blo
C CO
 and blo
osing.
IC C
osing.
est.
PU
est.
ment cannot be used to support any marketing authorization 
(PGADA
ma
(PGADA
od pressur
por
od pressur
y/urinalys
use
y/urinalys
ZP plasm
be 
ZP plasm
ab and an
ot b
ab and an
ctive ICF
ca
ctive ICF
tokines, c
ent 
tokines, c
This docume
Pharmac
me
Pharmac

c

Non
um
Non

d

Col
o
Col

s 

cation and any extensions or variations thereof.
A).
io
A).
re) prior t
or v
re) prior t
ysis.
e
ysis.
ma concen
ny 
ma concen
nti
d
nti-
d
-CZP a
d a
CZP a
F has been
on a
F has been
compleme
atio
compleme
applic
cogenetic
lica
cogenetic
nhereditar
pp
nhereditar
t urine
ap
t urine


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 52 of 136
8.3
Week 2 (Visit 3)
The following procedures or assessments will be performed/recorded:

Record concomitant medications. 

Assess adverse events.

C-SSRS.

Determine the BASDAI. 

Determine the BASFI.

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure).

Collect samples for hematology/biochemistry/urinalysis.

Administer IMP.

Record visit in the IRT.
8.4
Week 4 (Visit 4)

Record concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the BASFI.

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Perform a urine pregnancy test.
PUBLIC COPY 
y
Y
y
B
ent cannot be used to support any marketing authorization 
FI.
o
FI.
ADA.
nno
ADA.
PhGADA
can
PhGADA
nd noctur
nt 
nd noctur
This docum
easure vita
me
easure vita
Perform
cum
Perform

d

Perf
oc
Perf
cation and any extensions or variations thereof.
A.
n
A.
rnal spina
atio
rnal spina
applic
tal signs (t
lica
tal signs (t
m a 12
ppl
m a 12-
pp
-lea
pl
lea
m a 
ap
m a ur
ap
ur


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 53 of 136

Collect samples for:

Hematology/biochemistry/urinalysis.

Bimekizumab and CZP plasma concentrations.

Anti-bimekizumab and anti-CZP antibody detection.

hs-CRP.

If the respective ICF has been provided collect blood samples for:

Cytokines, complement, and biomarker analyses.

Nonhereditary pharmacogenomic variables.

Collect urine samples for biomarker research if the respective ICF has been provided.

Administer IMP.

Record visit in the IRT.
8.5
Week 6 (Visit 5)

Record concomitant medications. 

Assess adverse events.

C-SSRS.

Determine the BASDAI. 

Determine the BASFI.

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure).

Collect samples for hematology/biochemistry/urinalysis.

Administer IMP.

Record visit in the IRT.
8.6
Week 8 (Visit 6)

Record concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the BASFI.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
en provid
ting
en provid
al pain (N
be 
al pain (N
(temperat
ot b
(temperat
for hema
nno
for hema
IMP.
ca
IMP.
visit in th
nt 
visit in th
Record
ocu
Record

d

As
o
As

s

pplication and any extensions or variations thereof.
ded.
er
ded.
NRS).
ny
NRS).
ture, puls
d a
ture, puls
atology/b
and
atology/b
he IRT.
atio
he IRT.
Week 8
plic
Week 8
ap
d concom
app
d concom
adv
a
adv


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 54 of 136

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Perform a urine pregnancy test.

Collect samples for: 

Hematology/biochemistry/urinalysis.

hs-CRP.

Administer IMP.

Record visit in the IRT.
8.7
Week 10 (Visit 7)

Record concomitant medications. 

Assess adverse events.

C-SSRS.

Determine the BASDAI. 

Determine the BASFI.

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure).

Collect samples for hematology/biochemistry/urinalysis.

Administer IMP.

Record visit in the IRT.
8.8
Week 12 (Visit 8)

Record concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the BASFI.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
al pain (N
be 
al pain (N
(temperat
ot b
(temperat
for hema
nno
for hema
IMP.
ca
IMP.
visit in th
nt 
visit in th
Record
ocu
Record

d

As
o
As

s

application and any extensions or variations thereof.
NRS).
ny
NRS).
ture, puls
d a
ture, puls
atology/b
and
atology/b
he IRT.
atio
he IRT.
Week 1
plic
Week 1
d concom
app
d concom
adv
a
adv


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 55 of 136

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB and weight.

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Administer the tuberculosis questionnaire.

Perform a urine pregnancy test.

Collect samples for:

Hematology/biochemistry/urinalysis.

Bimekizumab and CZP plasma concentrations.

Anti-bimekizumab and anti-CZP antibody detection.

hs-CRP.

If the respective ICF has been provided collect blood samples for:

Cytokines, complement, and biomarker analyses.

Pharmacogenetic variables.

Nonhereditary pharmacogenomic variables.

Collect urine samples for biomarker research if the respective ICF has been provided.

Perform a PET-MRI or PET-CT scan in at least 25 subjects at selected sites within 2 weeks 
after Week 12 Visit if PET-positive lesions were observed in the previous scan.

Administer IMP.

Record visit in the IRT.
8.9
Week 16 (Visit 9), Week 20 (Visit 10), Week 28 (Visit 12), Week 32 
(Visit 13), Week 40 (Visit 15), and Week 44 (Visit 16)

Record concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the BASFI.

Perform the PGADA.
PUBLIC COPY
etection
PY 
etection
collect b
C CO
collect b
omarker 
LIC
omarker 
ogenom
PU
ogenom
P
ument cannot be used to support any marketing authorization 
lood samp
por
lood samp
analyses.
upp
analyses.
ic variable
d to
ic variable
arker rese
sed
arker rese
T-CT scan
e us
CT scan
ET
b
ET-
be
-positiv
be 
positiv
he IRT.
nno
he IRT.
Week 1
t ca
Week 1
(Vis
nt 
(Vis
cord conc
me
cord conc
This docu
Assess 
cu
Assess 

d

C
o
C-S

s

plication and any extensions or variations thereof.
mples for:
or v
mples for:
les.
en
les.
earch if th
xte
earch if th
an in at lea
y ex
an in at lea
ive lesion
ny 
ive lesion
16 (Visi
ion 
16 (Visi
sit 13), W
atio
sit 13), W
comitant 
lica
comitant 
app
adverse e
pp
adverse e
S.
a
S.


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 56 of 136

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Blood sample for hs-CRP.

Perform a urine pregnancy test.

Administer IMP.

Record visit in the IRT.
8.10
Week 24 (Visit 11) and Week 36 (Visit 14)

Record prior and concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the BASFI.

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB.

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Administer the tuberculosis questionnaire.

Perform a urine pregnancy test.

Collect samples for:

Hematology/biochemistry/urinalysis.

Bimekizumab and CZP plasma concentrations.

Anti-bimekizumab and anti-CZP antibody detection.

hs-CRP.
PUBLIC COPY 
ain (
P
ain (
ent cannot be used to support any marketing authorization 
NRS).
ed
NRS).
ion, inclu
use
ion, inclu
to TB.
be u
to TB.
emperatu
t be
emperatu
d ECG.
no
d ECG.
he tubercu
can
he tubercu
a urine pr
nt c
a urine pr
This docume
ect sampl
men
ect sampl

Hema
um
Hema

oc

B
application and any extensions or variations thereof.
uding an e
ex
uding an e
ure, pulse,
d any
ure, pulse,
ulosis que
n a
ulosis que
pregnancy
tion
pregnancy
les for:
icat
les for:
atolo
pli
atology/b
pli
gy/b
a
mekizum
ap
mekizum


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 57 of 136

If the respective ICF has been provided collect blood samples for:

Cytokines, complement, and biomarker analyses.

Administer IMP.

Record visit in the IRT.
8.11
Week 48 (Visit 17)/Early Withdrawal Visit

Record prior and concomitant medications. 

Assess adverse events.

C-SSRS.

HADS.

Determine the BASDAI. 

Determine the BASFI.

Perform the PGADA.

Perform the PhGADA.

Total and nocturnal spinal pain (NRS).

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB and weight.

Perform a 12-lead ECG.

Administer the tuberculosis questionnaire.

Perform an IGRA tuberculosis test (QuantiFERON TB test).

Perform a urine pregnancy test.

Collect samples for:

Hematology/biochemistry/urinalysis.

Bimekizumab and CZP plasma concentrations.

Anti-bimekizumab and anti-CZP antibody detection.

hs-CRP.

If the respective ICF has been provided collect blood samples for:

Cytokines, complement, and biomarker analyses.

Pharmacogenetic variables.

Nonhereditary pharmacogenomic variables.
PUBLIC COPY 
lse, and b
IC C
lse, and b
tion, incl
PUB
tion, incl
 TB an
PU
 TB an
This document cannot be used to support any marketing authorization 
lood pres
ppo
lood pres
uding an e
to 
uding an e
d weight.
ed t
d weight.
is questio
be u
is questio
berculosis 
t be
berculosis 
pregnancy
no
pregnancy
ples for:
can
ples for:
atology/b
nt c
atology/b
Bimekizu
men
Bimekizu

Anti
um
Anti b

oc

h

s d

I
application and any extensions or variations thereof.
ssure).
s or
ssure).
evaluation
nsio
evaluation
t
onnaire.
ny e
onnaire.
s test (Qua
d any
s test (Qua
y test.
nd
y test.
biochemis
tion
biochemis
umab and 
icat
umab and 
bimekizu
pli
bimekizu
ap
-CRP.
ap
CRP.


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 58 of 136

Collect urine samples for biomarker research if the respective ICF has been provided.

Obtain a X-ray or CT scan of the chest if the QuantiFERON TB test returned a positive 
result. 

Perform a PET-MRI or PET-CT scan in at least 25 subjects at selected sites within 2 weeks 
after the Week 48/WD Visit if PET-positive lesions were observed in the previous scan. At 
the WD Visit, the PET-MRI or PET-CT must be done only, if the previous imaging 
evaluation occurred more than 12 weeks ago and if PET-positive lesions were observed in 
the previous scan.

Record visit in the IRT.
8.12
Safety Follow-Up Visit (Week 64, Visit 18, 20 weeks after the 
final dose of IMP)

Record concomitant medications. 

Assess adverse events.

Measure vital signs (temperature, pulse, and blood pressure).

Perform a 12-lead ECG.

Administer the tuberculosis questionnaire.

Perform a urine pregnancy test.

Collect samples for:

Hematology/biochemistry/urinalysis.

Bimekizumab and CZP plasma concentrations.

Anti-bimekizumab and anti-CZP antibody detection.

hs-CRP.

If the respective ICF has been provided collect blood samples for:

Cytokines, complement, and biomarker analyses.

Nonhereditary pharmacogenomic variables.

Record visit in the IRT.
8.13
Early Withdrawal Visit
Subjects withdrawing early from the study (see Section 6.3) should undergo the same 
assessments scheduled for the Week 48 Visit (see Section 8.11) as soon as possible after 
withdrawal (as an Early Withdrawal Visit) and then enter the SFU Period, completing study 
participation with the SFU Visit 20 weeks after their final dose of study medication.
8.14
Unscheduled Visit
At the Investigator’s discretion, an Unscheduled Visit may be completed at any time during the 
study but prior to the SFU Visit, if deemed necessary for the subject’s safety and well-being. 
PUBLIC COPY 
d pre
Y
d pre
e.
C
e.
ry/urinal
PUB
ry/urinal
las
P
las
nt cannot be used to support any marketing authorization 
d in
or
d in
ks after 
ing 
ks after 
e).
ny
e).
ysis.
d to
ysis.
ma concen
ed 
ma concen
nti
u
nti-
u
-CZP a
us
CZP a
F has been
ot b
F has been
compleme
nn
compleme
reditary ph
t ca
reditary ph
This documen
visit in t
ent 
visit in t
Subjects w
ocu
Subjects w
assessm
do
assessm
with
s d
with
p
s
p
ation and any extensions or variations thereof.
the 
reo
the 
ntrations.
xten
ntrations.
antibody 
ex
antibody 
en pr
d
en provide
d a
ovide
ment, and b
and
ment, and b
pharmacog
on a
pharmacog
applicat
he IRT.
atio
he IRT.
Early W
plic
Early W
withdrawi
app
withdrawi
ts sch
ap
ts sch


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 59 of 136
If an Unscheduled Visit is conducted due to safety or efficacy reasons, a C-SSRS assessment will 
be performed with the subject during the visit. If an Unscheduled Visit is conducted for reasons 
other than safety or efficacy concerns (eg, repeated collection of a laboratory specimen due to 
collection or analysis issues), an C-SSRS will not be required at these visits. 
At this visit, any of the following assessments may be performed, depending on the reason for 
the visit:

Vital signs (temperature, pulse, and blood pressure).

C-SSRS. 

Other patient-reported outcomes (HADS, BASDAI, BASFI, PhGADA, PGADA, total and 
nocturnal spinal pain) as required. 

Administer the tuberculosis questionnaire.

Perform a physical examination, including an evaluation for signs and symptoms of active 
TB and risk for exposure to TB and weight.

Record 12-lead ECG.

If medically indicated, obtain blood sample(s) for:

Standard safety laboratory tests (hematology, serum chemistry).

The blood sample may also be used for PK/PD assessments, if needed.

Obtain urine sample for standard safety laboratory tests (including urine pregnancy test).

Record concomitant medication.

Record AEs.
9
ASSESSMENT OF EFFICACY
The timing for all assessments described below is specified in the Schedule of Assessments 
(Table 5‒1).
9.1
ASDAS
The ASDAS is comprised of a number of assessments which are scored by the subject and 
Investigator and multiplied by a validated formula (van der Heijde et al, 2009) as listed:

0.121 x Total spinal pain (BASDAI Question 2 result, Section 9.3)

0.058 x Duration of morning stiffness (BASDAI Question 6 result, Section 9.3) 

0.110 x PGADA (Section 9.6)

0.073 x Peripheral pain/swelling (BASDAI Question 3 result, Section 9.4)

0.579 x (natural logarithm of the CRP [mg/L] + 1)
Spinal pain, PGADA, duration of morning stiffness, and peripheral pain/swelling are all assessed 
on a numerical scale (0 to 10 units) (Lukas et al, 2009). The results of these calculations are 
summed to calculate the ASDAS.
PUBLIC COPY 
for:
PY
for:
tology, s
COP
tology, s
d for PK
C C
d for PK
safe
BLI
safety la
LIC
ty la
on.
U
on.
annot be used to support any marketing authorization 
A, total an
au
A, total an
and sympt
rke
and sympt
erum chem
ort a
erum chem
/PD asses
ppo
/PD asses
boratory te
sup
boratory te
T OF EF
use
T OF EF
ts describe
be u
ts describe
AS
n
AS
mprised o
ann
mprised o
This document c
d multipli
ca
d multipli
x Total sp
ent 
x Total sp
058 x Dur
me
058 x Dur
0.110 x
ocu
0.110 x

d

0.0
o
0.0

s

n and any extensions or variations thereof.
and 
of
and 
toms of a
s th
toms of a
mistry).
va
mistry).
ssments, i
or 
ssments, i
ests (inclu
ns 
ests (inclu
FFICA
exte
FFICAC
e
C
bed below
ny e
bed below
of a numb
an
of a numb
application
lied by a v
on a
lied by a v
pinal pain
atio
pinal pain
ration of m
lica
ration of m
x PGADA
app
x PGADA
a
Peri
ap
Peri


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 60 of 136
The following definitions apply to ASDAS Disease Activity categories:

ASDAS-Inactive Disease: ASDAS <1.3

ASDAS-Moderate Disease activity: ASDAS ≥1.3, <2.1

ASDAS-High Disease activity: ASDAS ≥2.1; ≤3.5

ASDAS-Very High Disease activity: ASDAS >3.5
9.2
ASAS20, ASAS40, and ASAS partial remission
The ASAS20 response is defined as an improvement of at least 20% and absolute improvement 
of at least 1 unit on a 0 to 10 NRS in at least 3 of the 4 following domains:

PGADA (see Section 9.6)

Pain assessment (the total spinal pain NRS score; Section 9.8)

Function (represented by BASFI, Section 9.5)

Inflammation (the mean of the BASDAI Questions 5 and 6 results, [see Section 9.4] 
concerning morning stiffness intensity and duration)
and absence of deterioration in the potential remaining domain [deterioration is defined as a 
relative worsening of at least 20% and an absolute worsening of at least 1 unit].
The ASAS40 response is defined as an improvement of at least 40%, and absolute improvement 
of at least 2 units on a 0 to 10 NRS in at least 3 of the 4 domains above and no worsening at all 
in the remaining domain.
The ASAS partial remission response is defined as a score of ≤2 units on a 0 to 10 unit NRS 
scale in all 4 domains listed above for ASAS20.
9.3
BASDAI
The most common instrument used to measure the disease activity of AS from the subject’s 
perspective is the BASDAI (Garrett et al, 1994). The BASDAI is a validated self-reported 
instrument which consists of six 10 unit horizontal NRSs to measure severity of fatigue, spinal 
and peripheral joint pain and swelling, enthesitis, and morning stiffness (both severity and 
duration, respectively) over the last week (van Tubergen et al, 2015). The BASDAI score ranges 
from 0 to 10, with lower scores indicating lower disease activity. Question 2 of the BASDAI 
asks 
 Question 3 of 
the BASDAI asks 
 Question 6 of the BASDAI asks 
 
The BASDAI is calculated as follows: 
𝐵𝐴𝑆𝐷𝐴𝐼=
Q1 + Q2 + Q3 + Q4 + (𝑄5 + 𝑄6
2
)
5
PUBLIC COPY 
on)
Y
on)
ining do
OPY
ining do
lute wor
COP
lute wor
proveme
C C
proveme
t least 3 
LIC 
t least 3 
ponse is 
PUB
ponse is 
ove for
PU
ove for
cument cannot be used to support any marketing authorization 
provemen
uth
provemen
sults, [see
ma
sults, [see
main [dete
any
main [dete
sening of
rt a
sening of
nt of at lea
po
nt of at lea
of the 4 do
upp
of the 4 do
defined as
to 
defined as
ASAS20.
d to
ASAS20.
t used to m
e u
t used to m
I (Garrett 
be
I (Garrett 
sts of six 1
ot b
sts of six 1
pain and sw
not
pain and sw
vel
a
vely) over
ann
y) over
with lower 
can
with lower 
SDAI ask
me
SDAI ask
nt c
ent
cum
doc
docu
This do
do
s d
pplication and any extensions or variations thereof.
e
i
e Section
ons
Section
erioration
aria
erioration
at least 1
va
at least 1
east 40%, 
or 
east 40%, 
omains ab
s o
omains ab
s a score o
nsio
s a score o
.
measure t
y e
measure t
et al, 1
any
et al, 199
y
99
10 unit ho
d an
10 unit ho
swelling, 
nd 
swelling, 
r the last w
an
r the last w
r scores in
on a
r scores in
ks
li
ks
tion
cati
lica
ppli
ap
app
ap


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 61 of 136
Fatigue item of the BASDAI
Fatigue as a major symptom of AS can effectively be measured with single-item questions such 
as the BASDAI item (van Tubergen et al, 2002b). This item has shown moderate to good 
reliability and responsiveness (van Tubergen et al, 2002b). The same minimal clinically 
important difference (MCID) will be used for the fatigue item of the BASDAI as for the 
BASDAI score, ie, a change of 1 unit on the NRS.
9.4
Inflammation – BASDAI (mean of Questions 5 and 6)
Question 5 of the BASDAI (described completely in Section 9.3) measures intensity of morning 
stiffness. The subject considers the previous week and responds to the question, 
The response is indicated on a 10-point NRS in which 0=None and 10=Very severe. Question 6 
of the BASDAI measures duration of morning stiffness. The subject considers the previous week 
and responds to the question, 
The response is indicated on a 10-point NRS in which 0=0 hours, 5=1 hour, and 10=2 
or more hours. The ratings for each question are summed and divided by 2 to provide the mean 
of Questions 5 and 6. This is used in the definition of the ASAS response variables defined in 
Section 9.2.
9.5
Function – BASFI
The BASFI is a validated disease-specific instrument for assessing physical function (van der 
Heijde et al, 2005; Calin et al, 1994). The BASFI comprises 10 items relating to the past week. 
The NRS version will be used for the answering options of each item on a scale of 0 (“Easy”) to 
10 (“Impossible”) (van Tubergen et al, 2015 and van Tubergen et al, 2002a). The BASFI is the 
mean of the 10 scores such that the total score ranges from 0 to 10, with lower scores indicating 
better physical function. The MCID used to interpret scores is 7mm on a 0 to 100mm visual 
analog scale (VAS) or 17.5% of the Baseline score (Pavy et al, 2005); an MCID of 1 unit will be 
used for the NRS version. This is used in the definition of the ASAS response variables defined 
in Section 9.2.
9.6
Patient global assessment (PGADA)
Subjects will provide their global assessment of their disease activity in response to the question 
“How active was your spondylitis on average during the last week?” using a NRS where 0 is 
“not active” and 10 is “very active” (van Tubergen et al, 2015).
This is used in the calculation of ASDAS (Section 9.1) and the definition of the ASAS response 
variables defined in Section 9.2.
9.7
PhGADA
The Investigator will assess the overall status of the subject with respect to their AS signs and 
symptoms and functional capacity using an NRS in which 0=very good, asymptomatic and no 
limitations of normal activities and 10=very poor, very severe symptoms which are intolerable 
and inability to carry out normal activities. This assessment by the Investigator should be made 
blind to the PGADA.
The subject should be asked to consider both joint and skin components in their response to this 
question.
PUBLIC COPY 
he
Y
he
nstrume
C CO
nstrume
e BASF
IC C
e BASF
answeri
BLIC
answeri
et al, 201
UBL
et al, 201
the tota
PUB
the tota
MCID u
PU
MCID u
uthorization 
f morning
tho
f morning
keting au
evere. Qu
ng 
evere. Qu
ers the pr
eting
ers the pr
This document cannot be used to support any marke
hours, 5=
ark
hours, 5=
ded by 2 t
ma
ded by 2 t
 response
y m
 response
nt for asse
por
nt for asse
comprise
ppo
comprise
ng options
sup
ng options
5 and van
o su
5 and van
score ran
d to 
score ran
sed to int
ed t
sed to int
e Baseline
sed
e Baseline
is used in
us
is used in
global a
ot b
global a
e their glo
nno
e their glo
your spon
ann
your spon
d 10 is
ca
d 10 is “v
a
“v
ed in the c
ent 
ed in the c
s defined
men
s defined
The Inve
doc
The Inve
symp
s d
symp
lim
s 
lim
aut
g au
ket
hereof.
uestion 6
reo
uestion 6
revious w
here
revious w
application and any extensions or variations th
=1 hour, a
s t
=1 hour, a
to provide
ons
to provide
e variable
tion
e variable
essing phy
or v
essing phy
es 10 item
s o
es 10 item
s of each 
ons 
s of each 
n Tuberge
sion
n Tuberge
nges from
nsio
nges from
terpret sco
ten
terpret sco
ne score
exte
ne score (P
e
(P
n the defin
ex
n the defin
assessm
d an
assessm
obal asses
and
obal asses
ndylitis o
n an
ndylitis o
very activ
on 
very activ
calculatio
atio
calculatio
d in
ic
d in Sectio
ca
Sectio
PhGA
ppli
PhGA
tigator 
ap
tigator 
nd
f
of
the


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 62 of 136
9.8
Total and nocturnal spinal pain
The pain experienced by AS subjects is adequately measured by 2 separate questions: 1) total 
pain in the spine due to AS (ie, “How much pain of your spine due to spondylitis do you have?”); 
and 2) pain in the spine at night due to AS (ie, “How much pain of your spine due to spondylitis 
do you have at night?”) (Sieper et al, 2009; van der Heijde et al, 2005; Committee for Proprietary 
Medicinal Product [CPMP]/EWP/556/95). When responding to each question, the subject is to 
consider the average amount of pain in the preceding week. The total pain score is used in the 
definition of the ASAS response variables defined in Section 9.2.
9.9
hs-CRP
Blood will be collected for measurement of hs-CRP. After Screening, the hs-CRP data will not 
be sent to the Investigator to protect the blinded nature of the treatment assignments. The hs-CRP 
will be used in the calculation of ASDAS (Section 9.1).
9.10
Hospital Anxiety and Depression Scale
The HADS was chosen for its well-established psychometric properties and its use in clinical 
research on biological therapy in subjects with chronic plaque psoriasis (Langley et al, 2010; 
Dauden et al, 2009). The HADS scores for anxiety and for depression range from 0 to 21 with 
higher scores indicating worse state. A score below 8 is considered to be normal whereas a score 
of 15 and above is considered severe (Snaith and Zigmond, 1994).
9.11
PET-MRI or PET-CT scan
High bone turnover assessed by nuclear medicine methods may detect osteoproliferative 
processes regardless of the inflammatory or noninflammatory origin.
While exact localization of regions of radionuclide uptake is difficult with conventional 
scintigraphy,18F-fluoride PET-CT or PET-MRI has a much better spatial resolution and 
sensitivity (Strobel et al, 2010; Even-Sapir et al, 2007). In the present study, UCB will assess the 
regions of high bone turnover as detected by 18F PET-MRI or 18F PET-CT within the spine and 
the sacroiliac joints. 
The 18F-fluoride PET-MRIs of the whole spine will be performed by using a whole-body 
PET/MRI system. Alternatively, subjects will be examined in supine position on a combined 
PET-CT system permitting the acquisition of co-registered CT and PET images in the same 
session. The PET-MRI or PET-CT scan will be performed at time points provided in Table 5‒1
in at least 25 subjects at selected sites.
10
ASSESSMENT OF PHARMACOKINETIC/ 
PHARMACODYNAMIC/PHARMACOGENOMIC/ 
PHARMACOGENETIC VARIABLE(S)
Plasma concentrations of bimekizumab and CZP are the PK variables. 
10.1
Pharmacokinetic variables
Blood samples for measurement of PK variables will be collected at the time points specified in 
the Table 5‒1. At dosing visits, blood samples will be drawn prior to dosing, and will be drawn 
at the same time of the sampling for clinical laboratory tests. The time and date of collection will 
PUBLIC COPY
p
Y
p
and for
PY 
and for
ow 8 is c
OPY
ow 8 is c
and Zigm
COP
and Zigm
can
C C
can
ear medi
BLIC
ear medi
matory o
UBL
matory o
ions of 
PU
ions of 
CT
P
CT
nnot be used to support any marketing authorization 
he 
he 
P data wil
g au
P data wil
m
in
ments. Th
ng 
ents. Th
erties and 
ma
erties and 
soriasis (L
y m
soriasis (L
epression 
ny 
epression 
onsidered 
t an
onsidered 
ond, 1994
ort a
ond, 1994
ine metho
sup
ine metho
r noninflam
o su
r noninflam
adionuclid
d to
adionuclid
r PET
ed
r PET-
d
-MR
d 
MR
ven
us
ven-
s
-Sapir 
use
Sapir 
as detecte
e us
as detecte
MRIs of t
ot b
MRIs of t
lternative
nno
lternative
This document can
permitting
ann
permitting
ET
c
ET-
c
-MRI o
ca
MRI o
5 subjects
nt c
subjects
A
n
A
Plasm
s do
Plasm
1
s
1
and any extensions or variations thereof.
l not 
of
l not 
he hs
reo
he hs-
eo
-CR
eo
CR
d its use in
ons
d its use in
(Langley e
tion
(Langley e
n range fro
riati
n range fro
d to be nor
aria
d to be nor
4).
v
4).
ods may d
ons 
ods may d
ammatory
sion
ammatory
ide uptake
ens
ide uptake
MRI has a m
xten
MRI has a m
r et al, 200
ext
r et al, 200
ed by 18F
y e
ed by 18F
the whole
d a
the whole
ely, subjec
and
ely, subjec
ation a
g the acqu
an
g the acqu
or PET
on 
or PET-C
a
C
s at select
tion
s at select
applic
ASSESS
ica
ASSESS
PHAR
plic
PHAR
PH
pp
PH
cen
a


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 63 of 136
be recorded in the eCRF. Instructions pertaining to sample collection, processing, storage, 
labeling, and shipping are provided in the laboratory manual for this study. Detailed information 
on sample analysis will be provided in a bioanalytical report.
10.2
Pharmacodynamic variables
Blood samples for measurement of PD variables will be collected at the time points specified in 
Table 5‒1. Flow cytometry by fluorescence-activated cell sorting (FACS) analysis might 
include, but is not limited to: cluster of differentiation (CD)3, CD19, CD4, CD8, and CD69. 
Candidate biomarkers might include, but are not limited to: IL-17A/IL17-F pathway signaling, 
TNF signaling pathway, bone metabolism and AS (eg, IL-17A, IL-17F, IL-23, IL-6, TNF, DC-
STAMP, and circulating osteoclast precursors). At dosing visits, blood samples will be drawn 
prior to dosing, and will be drawn at the same time of the sampling for clinical laboratory tests. 
The time and date of collection will be recorded in the eCRF. Instructions pertaining to sample 
collection, processing, storage, labeling, and shipping are provided in the laboratory manual for 
this study. Detailed information on sample analysis will be provided in a bioanalytical report.
10.3
Nonhereditary pharmacogenomic variables
Where local regulation permit, blood samples will be drawn for exploratory RNA, proteins and 
metabolites biomarker analysis at the time points specified in Table 5‒1. Where local regulation 
permit, urine samples will be drawn for exploratory proteins and metabolites biomarker analysis 
at the time points specified in the schedule of study assessments. Collection of these samples will 
enable evaluation of biomarkers relative to disease biology and progression, drug treatment, bone 
metabolism and inflammatory and immune response processes. Instructions pertaining to sample 
collection, processing, storage, labeling, and shipping are provided in the laboratory manual for 
this study. The nature and format of these tentative analyses will be determined at a later stage. 
The samples will be stored at the secure long-term storage facility selected by UCB for up to 
20 years. 
10.4
Pharmacogenetic variables
For individuals consenting to the pharmacogenetic substudy, blood samples will be drawn for 
exploratory genetic/epigenetic, analyses at the time points specified in Table 5‒1. Collection of 
these samples will enable evaluation of genetics/epigenetics biomarkers relative to disease 
biology and progression, drug treatment, bone metabolism and inflammatory and immune 
response processes. The nature and format of these tentative analyses will be determined when 
the results of the main study are made available. A separate ICF will be required for those 
subjects who agree to participate in the pharmacogenetics substudy. The substudy will be 
conducted only where ethically accepted and authorized by the regulatory agencies. Refusal to 
participate in the substudy will not affect a subject’s ability to participate in the main study. The 
samples will be stored at -80°C at the central biorepository for up to 20 years. 
11
ASSESSMENT OF IMMUNOLOGICAL VARIABLE(S)
The immunological variables comprise detection of anti-bimekizumab and anti-CZP antibodies 
related to immunogenicity, serum complement concentrations, mononuclear cell subtypes 
(analyzed by flow cytometry/fluorescence-activated cell sorting), and other exploratory 
biomarkers.
PUBLIC COPY 
draw
Y
draw
pecified
OPY
pecified
atory pro
COP
atory pro
f study a
CO
f study a
o diseas
C C
o diseas
mune res
LIC
mune res
ling, and
BL
ling, and
t of these
PUB
t of these
he secu
PU
he secu
used to support any marketing authorization 
9.
o
9.
naling,
thor
naling,
TNF, DC
uth
TNF, DC
ll be draw
au
ll be draw
laboratory
g a
laboratory
rtaining t
ting
rtaining t
laboratory
keti
laboratory
 a bioanal
rke
 a bioanal
bles
ma
bles
or explora
ny m
or explora
in
a
in Table
any
Table 5
y
5
eins and m
rt a
eins and m
ssessment
ort
ssessment
biology a
ppo
biology a
ponse proc
upp
ponse proc
shipping 
sup
shipping 
tentative 
to s
tentative 
e long
d to
e long-
t
-ter
to
ter
cument cannot be u
netic va
us
netic va
to the pha
be 
to the pha
enetic, an
ot b
enetic, an
able evalu
not
able evalu
ess
a
ession, dru
ann
ion, dru
ses. The n
can
ses. The n
f the main
nt c
f the main
who agree 
ent
who agree 
ted only w
me
ted only w
icipate in 
um
icipate in 
This doc
amples w
ocu
amples w
11
do
11
Th
s
Th
extensions or variations thereof.
wn 
of
wn 
y tests.
eof
y tests.
to sample
ere
to sample
ry manual
ther
ry manual
alytical rep
s th
alytical rep
atory RNA
atio
atory RNA
5‒
r
‒1
ri
1. Whe
ria
. Whe
metabolit
var
metabolit
ts. Collec
r va
ts. Collec
and progr
or 
and progr
cesses. 
ns o
cesses. In
o
In
g are provi
ions
g are provi
e analyses
sio
e analyses
rm storag
ens
rm storag
pplication and any e
ariables
y ex
ariables
armacoge
any
armacoge
nalyses at 
d an
nalyses at 
uation of 
nd 
uation of 
ug treatm
an
ug treatm
nature an
n a
nature an
n study ar
tion
n study ar
e to partic
atio
e to partic
where eth
lica
where eth
n the subst
pplic
n the subst
ap
will be stor
app
will be stor
A


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 64 of 136
The Investigator or designee will obtain blood samples for these measurements at the time points 
specified in Table 5‒1. When these samples are required at a visit during which the subject is 
dosed with IMP, the blood samples will be drawn prior to dosing. Samples should be drawn at 
the same time of the sampling for clinical laboratory tests. The time and date of collection will be 
recorded in the eCRF. Instructions pertaining to sample collection, processing, storage, labeling, 
and shipping are provided in the laboratory manual for this study. The presence of antibodies to 
bimekizumab or CZP will be determined using a validated bioanalytical method. Detailed 
information on sample analysis will be provided in a bioanalytical report.
12
ASSESSMENT OF SAFETY
12.1
Adverse events
12.1.1
Definitions
12.1.1.1
Adverse event
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
In order to ensure complete safety data collection, all AEs occurring during the study (ie, after 
the signing of the Informed Consent form), including any pretreatment and posttreatment periods 
required by the protocol, must be reported in the eCRF even if no IMP was taken but specific 
study procedures were conducted. This includes all AEs not present prior to the initial visit and 
all AEs that recurred or worsened after the initial visit.
Signs or symptoms of the condition/disease for which the IMP is being studied should be 
recorded as AEs only if their nature changes considerably or their frequency or intensity 
increases in a clinically significant manner as compared to the clinical profile known to the 
Investigator from the subject’s history or the Baseline Period. 
12.1.1.2
Serious adverse event
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. An SAE must meet 1 or more of the following criteria:

Death

Life-threatening
(Life-threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.)

Significant or persistent disability/incapacity

Congenital anomaly/birth defect (including that occurring in a fetus)

Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the definition of serious
PUBLIC COPY
e 
Y
e 
m, or d
PY 
m, or d
ther or n
OPY
ther or n
llection,
C C
llection,
rm), inc
LIC
rm), inc
ported in
BLI
ported in
d. This in
UB
d. This in
ed after
PU
ed after
This document cannot be used to support any marketing authorization 
nt or clini
ark
nt or clini
sarily hav
ma
sarily hav
favorable 
y m
favorable 
ease temp
ny 
ease temp
ot related 
t any
ot related 
all AEs oc
ppo
all AEs oc
uding any
upp
uding any
the eCRF
sup
the eCRF
cludes all 
to s
cludes all 
the initia
d to
the initia
n/disease 
sed
n/disease 
ture chang
us
ture chang
ficant man
be u
ficant man
ect’s histo
t be
ect’s histo
s adver
not 
s adver
ned that a
ann
ned that a
n SAE mu
ca
n SAE mu
e
m
e-
m
-threaten
me
threaten
(Life
cum
(Life-
u
-th
m
th
a mo
oc
a mo

s d

S
application and any extensions or variations thereof.
nical inves
s th
nical inves
ve a causa
ons
ve a causa
e and unin
tion
e and unin
porally as
riati
porally as
d to the me
aria
d to the me
occurring 
or 
occurring 
y pretreatm
ns o
y pretreatm
F even if n
ons
F even if n
l AEs not 
sio
l AEs not 
l visit.
ens
l visit.
for which
xte
for which
nges consi
ex
nges consi
anner as c
ny e
anner as c
ory or the
any
ory or the
rse even
nd a
rse even
a subject 
an
a subject 
ust meet 1
on a
ust meet 1
ening
lic
ening
hreatening
pp
hreatening
e severe
ap
e severe


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 65 of 136
(Important medical events may include, but are not limited to, potential Hy’s Law [see 
Section 12.1.1.3], allergic bronchospasm requiring intensive treatment in an emergency room 
or at home, blood dyscrasias that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse.)

Initial inpatient hospitalization or prolongation of hospitalization
(A patient admitted to a hospital, even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospitalization. An emergency room visit that results in 
admission to the hospital would also qualify for the initial inpatient hospitalization criteria. 
However, emergency room visits that do not result in admission to the hospital would not 
qualify for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
definition of serious [eg, life-threatening adverse experience, important medical event].
Hospitalizations for reasons not associated with the occurrence of an AE [eg, preplanned 
surgery or elective surgery for a pre-existing condition that has not worsened or manifested 
in an unusual or uncharacteristic manner] do not qualify for reporting. For example, if a 
subject has a condition recorded on his/her medical history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospitalization as an SAE, 
since there is no AE upon which to assess the serious criteria. Please note that, if the 
pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the event would need to 
be determined.)
12.1.1.2.1
Anticipated serious adverse events
The following Anticipated SAEs are anticipated to occur in the population studied in this 
protocol at some frequency that is independent of drug exposure. 
This list does not change the Investigator’s obligation to report all SAEs (including Anticipated 
SAEs) as detailed in Section 12.1.2.3.
Table 12‒1: Anticipated serious adverse events for the population of subjects 
with AS
MedDRA system organ class
MedDRA preferred term
Skin and subcutaneous tissue disorders
Psoriasis
Eye disorders
Uveitis
Musculoskeletal and connective tissue disorders
Dactylitis
Tendonitis
Atlantoaxial instability
Gastrointestinal disorders
Colitis ulcerative
Crohn's disease
PUBLIC COPY
 s
Y
 s
rious c
PY 
rious c
fested in 
OPY
fested in 
ecessary
COP
ecessary
advers
LIC
advers
re anticip
UBL
re anticip
is indep
PUB
is indep
P
esti
P
esti
ot be used to support any marketing authorization 
riteria.
thor
riteria.
ould not 
uth
ould not 
ria in the 
au
ria in the 
dical even
g a
dical even
E [eg,
etin
E [eg, pre
ng
pre
worsened o
ket
worsened o
ting. For e
ark
ting. For e
d later has 
ma
d later has 
or hospita
y m
or hospita
eria. Plea
ny 
eria. Plea
an unusua
t any
an unusua
the seriou
ort a
the seriou
e events
upp
e events
ated to oc
o su
ated to oc
endent of 
to 
endent of 
gator’s ob
ed 
gator’s ob
2.3
s
2.3.
s
.
ed seriou
be u
ed seriou
This document cannot
organ cla
nno
organ cla
ot
taneous t
can
taneous t
nn
ders
nt
ders
ca
loskeleta
men
loskeleta
n
d
 do
Gast
do
Gast
do
s d
d any extensions or variations thereof.
o
nt].
e
nt].
eplanned 
here
eplanned 
or manife
the
or manife
example,
s th
example,
s a preplan
ons
s a preplan
alization 
tion
alization 
ase note th
riati
ase note th
al or unch
aria
al or unch
usness of 
va
usness of 
ccur in th
ion
ccur in th
f drug exp
nsio
f drug exp
bligation t
xten
bligation t
us adver
ny 
us adver
application and 
ass
an
ass
d a
tissue dis
n a
tissue dis
an
on
al and con
icat
al and con
ati
ap
stin
a
ti
ap


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 66 of 136
Table 12‒1: Anticipated serious adverse events for the population of subjects 
with AS
MedDRA system organ class
MedDRA preferred term
Cardiac disorders
Aortic valve incompetence
Atrial tachycardia
Atrioventricular block
Bundle branch block
Cardiomyopathy
Vascular disorders
Aortitis
Respiratory, thoracic and mediastinal disorders
Pulmonary fibrosis
Nervous system disorders
Cauda equina syndrome
Injury, poisoning and procedural complications
Spinal cord injury
Spinal fracture
Cervical Vertebral fracture
Lumbar Vertebral fracture
Thoracic Vertebral fracture
Immune system disorders
Amyloidosis
Psychiatric disorders
Depression
AS=ankylosing spondylitis; MedDRA=Medical Dictionary for Regulatory Activities; SAE=serious adverse 
event
Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life threatening or if they 
result in the death of the study subject.
12.1.1.3
Adverse events of special interest
An AE of special interest is any AE that a regulatory authority has mandated be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound. Potential Hy’s Law, defined as ≥3xULN ALT or 
AST with coexisting ≥2xULN total bilirubin in the absence of ≥2xULN ALP, with no alternative 
explanation for the biochemical abnormality, must ALWAYS be reported to UCB as an AE of 
special interest (AESI) (ie, without waiting for any additional etiologic investigations to have 
been concluded). Follow-up information should then be reported if an alternative etiology is 
identified during investigation and monitoring of the subject.
In addition, events that are considered as Adverse Events of Interest for CZP include:

Serious infections including opportunistic infections

Malignancies including lymphoma

Congestive heart failure

Demyelinating-like disorders

Aplastic anaemia, pancytopenia, thrombocytopenia, neutropenia and leucopenia
LIC COPY
pin
Y
pin
Cervic
PY 
Cervic
Lu
OP
Lu
OP
C C
PUBLI
LIC
A=Medic
PUB
A=Medic
ot b
P
ot b
UB
o support any marketing authorization 
iz
au
ng
drome
rke
drome
et
jury
ma
jury
ture
y
ture
l Vertebr
any
l Vertebr
mbar Vert
t a
mbar Vert
Thoracic 
ort
Thoracic 
ark
Amyl
pp
Amyl
po
up
be used to sup
D
up
up
up
up
l Dictionary
to 
l Dictionary
e regarded a
ed
e regarded a
t.
u
t.
o s
nts of sp
e u
nts of sp
ot b
i
t
i
ment canno
s any AE
t be
s any AE
dless of th
not 
dless of th
UCB prod
nno
UCB prod
ting ≥2xU
can
ting ≥2xU
or the bioc
t ca
or the bioc
rest (AES
nt c
rest (AES
ncluded). 
men
ncluded). 
This docum
ified durin
ume
ified durin
n addition
ocu
n addition

d

Se
o
Se

s

ns or variations thereof.f
eo
he
ral fractur
riat
ral fractur
ebral frac
var
ebral frac
Vertebra
r v
Vertebra
s
yloidosis
s o
yloidosis
or
ny extensions
Depressio
ion
Depressio
ns
y for Regul
nsio
y for Regul
as anticipat
xten
as anticipat
sio
pecial in
y e
pecial in
lication and a
E that a re
any
E that a re
he seriousn
d a
he seriousn
duct/comp
and
duct/comp
ULN total
n an
ULN total
chemical 
ion 
chemical 
SI) (ie, wi
atio
SI) (ie, wi
Follow
icat
Follow-
appl
u
ing invest
plic
ing invest
n, events 
app
n, events 
infe
a
infe


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 67 of 136

Serious bleeding events

Lupus and lupus-like illness

Serious skin reactions (e.g. Stevens Johnson syndrome, toxic epidermal necrolysis, and 
erythema multiforme)
12.1.1.4
Adverse events for special monitoring
UCB has identified AEs for special monitoring (AESM). An AESM is an AE or safety topic for 
which special monitoring, additional data collection activities, and/or enhanced signal detection 
activities (within UCB), are considered appropriate. Identified AESM can be of particular 
concern based on findings from the IMP clinical program to date, potential risks generally 
associated with biologic immunomodulators, or comorbidities and risk factors prevalent in the 
study population.
Adverse events for special monitoring for this study include: infections (serious, opportunistic, 
fungal, and TB, see Section 12.7.5), neutropenia, hypersensitivity, suicidal ideation and behavior 
(assessed using the C-SSRS), depression, (assessed using the HADS, see Section 9.10), major 
cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and bilirubin; 
see Section 12.6.1), malignancies, and inflammatory bowel diseases (with gastroenterology 
referral as appropriate).
12.1.2
Procedures for reporting and recording adverse events 
The subject will be given the opportunity to report AEs spontaneously. A general prompt will 
also be given at each study visit to detect AEs. For example:
“Did you notice anything unusual about your health (since your last visit)?”
In addition, the Investigator should review any self-assessment procedures (eg, diary cards) 
employed in the study.
12.1.2.1
Description of adverse events
When recording an AE, the Investigator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
and source documents should be consistent. Any discrepancies between the subject’s own words 
on his/her own records (eg, diary card) and the corresponding medical terminology should be 
clarified in the source documentation.
When recording the intensity of an AE in the eCRF (ie, mild, moderate, or severe), the 
Investigator should use the following criteria:

Mild: the subject is aware of the sign or symptom (syndrome), but it does not interfere with 
his/her usual activities and/or is of no clinical consequence

Moderate: the AE interferes with the usual activities of the subject or it is of some clinical 
consequence

Severe: the subject is unable to work normally or to carry out his/her usual activities, or the 
AE is of definite clinical consequency
Details for completion of the Adverse Event eCRF (including judgment of relationship to IMP) 
are described in the eCRF Completion Guidelines.
PUBLIC COPY
m
Y
m
y bowe
PY 
y bowe
and rec
CO
and rec
y to repo
IC C
y to repo
ect AEs
BLIC
ect AEs
ng unusu
UBL
ng unusu
ould re
PU
ould re
annot be used to support any marketing authorization 
c for 
oriz
c for 
etection 
thor
etection 
cular 
uth
cular 
enerally 
au
enerally 
revalent i
g a
revalent i
serious, o
ket
serious, o
cidal idea
arke
cidal idea
S, see
mar
S, see Se
ar
Se
tions (AL
y m
tions (AL
iseases (w
ny 
iseases (w
ording a
ort 
ording a
t AEs
ppo
t AEs spo
po
spo
For exam
supp
For exam
al about y
to s
al about y
view any s
d to
view any s
f adverse
us
f adverse
Investiga
be 
Investiga
ology, rat
ot b
ology, rat
s should b
not
s should b
ords (eg,
ann
ords (eg,
This document ca
ource do
can
ource do
rding the i
nt c
rding the i
ator shoul
men
ator shoul
Mild: the 
um
Mild: the 
his/her
ocu
his/her

d

Mo
o
Mo
and any extensions or variations thereof.
in the 
eof
in the 
opportuni
the
opportuni
ation and 
s th
ation and 
ction
ons
ction 9.1
s
9.1
LT, AST, 
tion
LT, AST, 
with gastr
iati
with gastr
adverse 
r va
adverse 
ontaneous
s or
ontaneous
mple:
ns
mple:
your heal
sion
your heal
self
en
self-
en
-f-f
en
f-f asses
ens
asses
se events
y ex
se events
ator shou
any
ator shou
ther than 
d an
ther than 
be consist
nd 
be consist
diary car
an
diary car
application 
cumentat
n a
cumentat
intensity 
atio
intensity 
ld use the
cat
ld use the
subject is
plic
subject is
r usual act
app
r usual act
t
a
te: t
a
e: t


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 68 of 136
12.1.2.2
Rule for repetition of an adverse event 
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:

The outcome date of the first AE that is not related to the natural course of the disease being 
the same as the start date of the repeated AE, and the outcome of “worsening”

The AE verbatim term being the same for the first and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first one
12.1.2.3
Additional procedures for reporting serious adverse events 
If an SAE is reported, UCB must be informed within 24 hours of receipt of this information by 
the site (see contact information for SAE reporting listed in the Serious Adverse Event Reporting 
section at the front of the protocol). The Investigator must forward to UCB (or its representative) 
a duly completed “Investigator SAE Report Form for Development Drug” (SAE Report form) 
provided by UCB, even if the data are incomplete, or if it is obvious that more data will be 
needed in order to draw any conclusions. Information recorded on this form will be entered into 
the global safety database.
An Investigator SAE Report form will be provided to the Investigator. The Investigator SAE 
Report form must be completed in English. 
It is important for the Investigator, when completing the SAE Report form, to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
and in determining whether the SAE requires reporting to the regulatory authorities in an 
expedited manner.
Additional information (eg, autopsy or laboratory reports) received by the Investigator must be 
provided within 24 hours. All documents in the local language must be accompanied by a 
translation in English, or the relevant information included in the same document must be 
summarized in the Investigator SAE Report form.
The Investigator is specifically requested to collect and report to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to 
30 days from the end of the study for each subject, and to also inform participating subjects of 
the need to inform the Investigator of any SAE within this period. Serious AEs that the 
Investigator thinks may be associated with the IMP must be reported to UCB regardless of the 
time between the event and the end of the study.
Upon receipt of the SAE Report form, UCB will perform an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the IB.
12.1.3
Follow up of adverse events
An AE should be followed until it has resolved, has a stable sequelae, the Investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. This 
follow-up requirement applies to AEs, SAEs, and AEs of special interest; further details 
regarding follow up of PDILI events is provided in Section 12.6.1.4. 
If an AE is ongoing at the end of the study for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the Investigator no longer deems that it is 
PUBLIC COPY 
the 
Y
the 
leting th
COP
leting th
en the S
C CO
en the S
or UCB t
IC C
or UCB t
equires r
BLIC
equires r
opsy or 
PU
opsy or 
ocum
P
ocum
ment cannot be used to support any marketing authorization 
rmation by
auth
rmation by
Event Rep
au
Event Rep
its repres
ng a
its repres
SAE Rep
ting
SAE Rep
more data
ket
more data
s form wil
arke
s form wil
stigator. T
y m
stigator. T
e SAE Rep
rt a
e SAE Rep
AE and th
port
AE and th
o consider
ppo
o consider
eporting t
supp
eporting t
aboratory
d to
aboratory
ents in th
ed 
ents in th
ant inform
use
ant inform
SAE Rep
e us
SAE Rep
ally reque
be
ally reque
tigator is c
ot b
tigator is c
of the stu
not
of the stu
the Inves
ann
the Inves
nks may b
can
nks may b
n the even
nt c
n the even
ceipt of th
men
ceipt of th
This docum
ted SAE. 
ume
ted SAE. 
2.1.3
ocu
2.1.3
An AE
do
An AE
dete
s d
dete
f
s
f
ication and any extensions or variations thereof.
by 
f
y
porting
of.
porting
sentative)
reo
sentative)
port form)
here
port form)
ta will be 
the
ta will be 
ill be ente
s th
ill be ente
The Inves
atio
The Inves
eport form
var
eport form
he IMP ad
or v
he IMP ad
er in asses
s or
er in asses
to the reg
ns 
to the reg
y reports) 
nsi
y reports) 
he local la
ten
he local la
mation in
exte
mation in
port form
y ex
port form
uested to c
any
uested to c
certain th
d an
certain th
udy for ea
nd 
udy for ea
stigator o
an
stigator o
be associ
on a
be associ
nt and the
tion
nt and the
he SAE R
icat
he SAE R
appl
 The asse
plic
 The asse
Foll
pp
Foll
uld b
a
uld b


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 69 of 136
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the 
Investigator must provide a justification. The follow up will usually be continued for 20 weeks 
after the subject has discontinued his/her IMP.
Information on SAEs obtained after clinical database lock will be captured through the Patient 
Safety (PS) database without limitation of time.
12.2
Pregnancy
If an Investigator is notified that a subject has become pregnant after the first intake of any IMP, 
the Investigator must immediately notify UCB’s PS department by providing the completed 
Pregnancy Report and Outcome form (for contact details see SAE reporting information at the 
beginning of this protocol). The subject should be withdrawn from the study as soon as 
pregnancy is known (by positive pregnancy test), and the following should be completed:

The subject should return for an early discontinuation visit.

The subject should immediately stop the intake of the IMP 

A Safety Follow-Up Visit should be scheduled 20 weeks after the subject has discontinued 
his/her IMP.
The Investigator must inform the subject of information currently known about potential risks 
and about available treatment alternatives.
The pregnancy will be documented on the Pregnancy Report and Outcome form provided to the 
Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome form in which the Investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to 
follow the health of the child for 30 days after birth for any significant medical issues. In certain 
circumstances, UCB may request that follow up is continued for a period longer than 30 days. If 
the subject is lost to follow up and/or refuses to give information, written documentation of 
attempts to contact the subject needs to be provided by the Investigator and filed at the site. 
UCB’s PS department is the primary contact for any questions related to the data collection for 
the pregnancy, eventual birth, and follow up.
In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, the 
Investigator or designee is asked to contact the subject to request consent of the partner via the 
Partner Pregnancy Consent form that has been approved by the responsible IRB/IEC and should 
be available in the Investigator site file. In case of questions about the consent process, the 
Investigator may contact the UCB/Contract Research Organization (CRO) contract monitor for 
the study. The Investigator will complete the Pregnancy Report and Outcome form and send it to 
UCB’s PS department (for contact details see SAE reporting information at the beginning of this 
protocol) only after the partner has agreed that additional information can be captured and has 
provided the signed Partner Pregnancy Consent form. UCB’s PS department is also the primary 
contact for any questions related to the data collection for the partner pregnancy, eventual birth, 
and follow up.
A pregnancy becomes an SAE in the following circumstances: miscarriage, abortion (elective or 
spontaneous), unintended pregnancy after hormonal contraceptive failure (if the hormonal 
contraceptive was correctly used), ectopic pregnancy, fetal demise, or any congenital 
PUBLIC COPY 
mation c
OPY
mation c
Pregnan
C C
Pregnan
egnancy 
LIC 
egnancy 
port and
BLI
port and
and of t
UB
and of t
or 30 da
PU
or 30 da
st th
P
st th
nnot be used to support any marketing authorization 
y IMP,
horiz
y IMP,
leted 
tho
leted 
ation at th
auth
ation at th
oon as
g au
oon as
complete
ng 
complete
r the subje
ma
r the subje
urrently 
t any
urrently kn
y
kn
cy Report
ppo
cy Report
and the ev
upp
and the ev
Outcome 
sup
Outcome 
he child. E
to s
he child. E
ys after bir
d to
ys after bir
at follow u
ed 
at follow u
d/or refuse
use
d/or refuse
nee
e u
needs to b
e us
ds to b
e primary 
be 
e primary 
birth, and 
ot b
birth, and 
artner of a
nno
artner of a
This document can
signee is a
ann
signee is a
ncy Cons
ca
ncy Cons
in the In
nt c
in the In
tor may c
ent
tor may c
udy. The I
me
udy. The I
CB’s PS de
cum
CB’s PS de
protocol) 
docu
protocol) 
provide
do
provide
cont
s d
cont
a
s
a
and any extensions or variations thereof.
he
f
he
ed:
r
ed:
ect has di
ion
ect has di
known abo
aria
known abo
t and Out
or 
t and Out
ventual bi
ns o
ventual bi
e form in w
ons
e form in w
Every rea
sio
Every rea
irth for an
ens
irth for an
up is cont
xten
up is cont
ses to give
exte
ses to give
be provid
y ex
be provid
y contact f
any 
y contact f
d follow u
d an
d follow u
a male su
nd 
a male su
application a
asked to 
an
asked to 
sent form 
on a
sent form 
vestigator
tion
vestigator
contact th
cati
contact th
Investigat
plica
Investigat
departmen
ppli
departmen
only afte
app
only afte
he sig
a
he sig


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 70 of 136
anomaly/birth defect of the baby. Those SAEs must be additionally reported using the 
Investigator SAE Report form.
12.3
Suspected transmission of an infectious agent
For the purposes of reporting, any suspected transmission of an infectious agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the eCRF, and followed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent.
12.4
Overdose of investigational medicinal product
Excessive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs or SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg, suicide attempt).
12.5
Safety signal detection
Selected data from this study will be reviewed periodically to detect as early as possible any 
safety concern(s) related to the IMP so that Investigators, clinical study subjects, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible.
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.
As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg, AEs, vital 
signs, laboratory or ECG results) for which data will be periodically reviewed during the course 
of the study.
In addition, an independent DMC will periodically review and monitor the safety data from this 
study and advise UCB. The DMC membership includes clinicians knowledgeable about the 
disease or the treatment. All members have experience and expertise in clinical trials. Board 
members may not participate in the study as principal or co-Investigators, or as study subject 
care physicians. The duration of membership for the DMC will be inclusive of planned analyses 
for AS0013. The DMC may also be asked to provide a review of final study results, as deemed 
appropriate. The DMC procedures will ensure that data remain blind to the study team and 
Investigators at all times throughout the conduct of the study. The detailed role, scope, 
responsibilities, and complete procedures, as well as the identity of the DMC members, will be 
described in a separate charter document. A Cardiovascular and a Neuropsychiatric Adjudication 
Committee will be in place for this study. Specific procedures will be outlined in the charter, 
which will be developed by the committee members.
12.6
Laboratory measurements
Clinical laboratory assessments consist of serum chemistry, hematology, and urinalysis, and 
pregnancy tests (serum or urine) (Table 12‒2). A centralized laboratory will be used to supply all 
laboratory test supplies and analyze all blood and urine samples for hematology, biochemistry 
and urinalysis measurements. Any unscheduled laboratory testing should also be collected using 
PUBLIC COPY
odically
PY 
odically
estigator
OP
estigator
appropri
CO
appropri
ied desig
IC C
ied desig
econcilia
BLIC
econcilia
velopme
UB
velopme
at UCB 
PU
at UCB 
) fo
P
) fo
ment cannot be used to support any marketing authorization 
us 
iz
us 
nic or 
oriz
nic or 
e) should 
g a
e) should 
dosing m
ting
dosing m
dered AE
ketin
dered AE
the excess
rke
the excess
to detect a
any
to detect a
, clinical 
rt a
, clinical 
ately and 
ort 
ately and 
nee/equiv
ppo
nee/equiv
ions in co
sup
ions in co
nt and acc
to s
nt and acc
may identi
d to
may identi
which da
ed 
which da
DMC will 
be u
DMC will 
e DMC m
t be
e DMC m
. All mem
ot b
. All mem
rticipate i
nno
rticipate i
The duratio
ann
The duratio
he DMC m
ca
he DMC m
The DM
nt c
The DM
tors at all
ent
tors at all
This docum
nsibilities,
me
nsibilities,
cr
c
cribed in 
cum
ibed in 
Committe
docu
Committe
which 
do
which 
12
s 
12
cation and any extensions or variations thereof.
d be
eo
d be
must be 
ereo
must be 
Es or SAE
ther
Es or SAE
ss medicin
s th
ss medicin
as early a
riat
as early a
study sub
var
study sub
as early a
r va
as early a
valent wil
s or
valent wil
ollaborati
ns 
ollaborati
cumulated
sio
cumulated
tify additi
ens
tify additi
ata will be
xten
ata will be
periodica
ny e
periodica
membersh
any
membersh
mbers hav
d a
mbers hav
in the stu
nd 
in the stu
ion of mem
an
ion of mem
may also 
on a
may also 
MC pr
tio
MC proced
ion
oced
l times thr
cati
l times thr
applic
s, and com
plica
s, and com
a separat
ppli
a separat
ee will be
app
e will be
be d
a
be d


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 71 of 136
the central laboratory. Testing to rule out hepatitis B, hepatitis C, and HIV (see Exclusion 
Criterion #12, Section 6.2 ) will be performed at Screening in addition to those measurements 
listed in Table 12‒2.
Specific details regarding the handling and processing of serum chemistry, hematology, and 
urinalysis samples are provided in the study laboratory manuals.
The following laboratory parameters will be measured:
Table 12‒2: Laboratory measurements
Hematology
Chemistry
Urinalysis
Serology
Basophils
Bicarbonate
Albumin
HIV
Eosinophils 
Calcium
Bacteria
HLA-B27
Lymphocytes 
Chloride
Crystals
Hepatitis B
Atypical lymphocytes 
hs-CRPa
Glucose
Hepatitis C
Monocytes 
Magnesium
pH
Neutrophils 
Potassium
RBC
Hematocrit
Sodium
WBC
Hemoglobin 
Glucose
Urine dipstick for 
pregnancy testingb
MCH 
BUN
MCHC 
Creatinine
MCV 
AST
Platelet count 
ALT
RBC count 
ALP
WBC count 
GGT
Total bilirubinc
LDH
Uric acid
Total cholesterol
Serum FSH testingd
Serum pregnancy testingb
PUBLIC COPY 
Y
PY
OP
cose
C C
cose
C
BU
BL
BU
LI
C
U
C
UB
P
d to support any marketing authorization 
rology
aut
rology
th
HIV
g a
HIV
au
HLA
ng
HLA
ng
et
ke
se
m
se
rk
pH
y
pH
ma
RBC
any
RBC
ny
W
a
W
t a
o
Ur
o
Ur
or
ppo
up
eatinine
d to
eatinine
o
ent cannot be used 
AST
ed
AST
d
A
se
e
t b
t b
t b
t b
t b
no
an
t c
This docume
um
doc
s d
ensions or variations thereof.f
A-
e
-B27
ere
B27
eo
Hepatitis 
the
Hepatitis 
he
Hepa
ns 
Hepa
s t
on
tio
at
WBC
va
WBC
ar
rine dipstic
or 
rine dipstic
pregnancy
ns o
pregnancy
r v
ns
sio
sio
sio
cation and any extensio
sio
sio
en
ALT
e
ALT
ex
ALP
any
ALP
y
G
a
G
a
T
nd
n a
n
tio
applica
ca
pl
ap


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 72 of 136
Table 12‒2: Laboratory measurements
Hematology
Chemistry
Urinalysis
Serology
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; FSH=follicle-stimulating hormone; GGT=gamma glutamyltransferase; HIV=human 
immunodeficiency virus; HLA-B27=human leukocyte antigen B27; hs-CRP=high sensitivity C-reactive 
protein; IMP=investigational medicinal product; LDH=lactate dehydrogenase; MCH=mean corpuscular 
hemoglobin; MCHC=mean corpuscular hemoglobin concentration; MCV=mean corpuscular volume; 
RBC=red blood cell; ULN=upper limit of normal; WBC=white blood cell
a hs-CRP will be tested at specified visits per Table 5‒1.
b A serum pregnancy test will be conducted at Screening – all other pregnancy tests will be performed on urine. 
Pregnancy results must be negative prior to administering IMP.
c If total bilirubin is >ULN, a direct bilirubin estimation (%) will be performed.
d A serum FSH test will be performed at Screening for all female subjects whose last menstrual cycle occurred 
between 12 and 24 months prior to the Screening Visit. 
12.6.1
Evaluation of PDILI
The PDILI IMP discontinuation criteria for this study are provided in Section 6.3.1, with the 
accompanying required follow-up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section 12.1.1.3), and, if applicable, also reported as an 
SAE (see Section 12.1.1.2). 
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table 12‒4 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section 12.6.1.1). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section 12.6.1.4). 
The results of all monitoring, including laboratory testing and other testing, should be made
available to the study site and sponsor.
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but
appropriate medical action must not be delayed waiting for the repeat result.
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative approach must be taken if the results from the 
2 laboratory tests are significantly different. Data from the local and central laboratory are to be 
recorded on the applicable eCRF pages.
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the Investigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing
any medically required concomitant medication known to be hepatotoxic to a suitable 
alternative.
PUBLIC COPY 
monit
Y
monit
dy site an
OPY
dy site an
s the crit
COP
s the crit
tion
CO
tion 12
CO
12
iagnosti
BLIC
iagnosti
nt on lab
UBL
nt on lab
ologist (i
PUB
ologist (i
ly con
PU
ly con
t cannot be used to support any marketing authorization 
on urine. 
uth
on urine. 
al cycle oc
ing 
al cycle oc
ed in 
m
ed in Sect
ma
Sect
ng detailed
ny m
ng detailed
d sponsor
any
d sponsor
erion for p
rt a
erion for p
.1.3
or
.1.3), and
ort
), and
testing an
sup
testing an
oratory re
o su
oratory re
applicabl
d to 
applicabl
sulted by 
ed t
sulted by 
isease. Th
sed
isease. Th
nvestigati
us
nvestigati
use of the 
be u
use of the 
nitoring, in
not
nitoring, in
dy site an
ann
dy site an
resulting
t ca
resulting
This document
medical a
nt c
medical a
are done l
men
are done l
ral laborat
um
ral laborat
most rapidl
ocu
most rapidl
2
d
2 labor
doc
labora
c
a
recor
s d
recor
W
s
W
ion and any extensions or variations thereof.
curred 
reo
curred 
ion
io
ion 6.3.1
on
6.3.1
d below. A
atio
d below. A
r within 2
aria
r within 2
potential 
var
potential 
d, if appli
r v
d, if appli
and con
ons
and contin
s 
tin
esults and
sion
esults and
ble; discus
nsio
ble; discus
the treati
ten
the treati
his would
exte
his would
ion and m
y ex
ion and m
 liver inju
ny e
 liver inju
ncluding 
nd 
ncluding 
nd sponso
and
nd sponso
g in abnor
on 
g in abnor
applicati
action mu
tio
action mu
locally fo
lica
locally fo
atory when
plic
atory when
dly availab
app
dly availab
ory tests
ap
ry tests
th


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 73 of 136
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may be 
fatal, and must not occur.
Table 12‒3 summarizes the approach to investigate PDILI.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 74 of 136
Table 12‒3: Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN
≥2xULNb
NA
Hepatology consult.c
Medical Monitor 
must be notified 
within 24 hours 
(eg, by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.
Immediate IMP 
discontinuationd.
Essential: Must have 
repeat liver chemistry 
values and additional 
testing completed 
ASAP (see 
Section 12.6.1.3); 
recommended to 
occur at the site with 
HCP.
Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.e
Monitoring of liver chemistry 
values at least twice per week 
for 2 weeks.e

Immediate IMP 
≥3xULN
NA
Yes
≥5xULN
NA
NA
Need for hepatology 
consult to be 
discussed. (required 
if ALT or AST 
≥8xULN). Medical 
Monitor must be 
notified within 
24hours (eg, by 
laboratory alert) and 
subject discussed 
with Medical Monitor 
ASAP.
PUBLIC COPY 
C
logy 
LIC
logy 
(required
UB
(required
or AST
PU
or AST
)
P
) M
P
M
C
to support any marketing authorization 
27 
n 
27
at
Follow up
tho
Follow up
ho
Evalu
au
Evalu
ut
g a
l: Must hav
keti
l: Must hav
t liver chem
rke
t liver chem
ues and add
ark
ues and add
testing com
mar
testing com
ASAP (s
ma
ASAP (s
Sectio
y m
Sectio
rec
y
rec
tin
y
This document cannot be used to
l
T
l
dical 
ed
dical 
st be 
se
st be 
within
us
within
urs (eg, by 
be u
urs (eg, by 
oratory ale
t be
oratory ale
subject dis
ot b
subject dis
with M
not
with M
ASA
nn
ASA
an
to
extensions or variations thereof.
uation
f
uation
e e 
mistry 
th
mistry 
ditional
s t
ditional
mpleted 
ons
mpleted 
see
ti
see
n
a
n 12.6.1.3
atio
12.6.1.3)
ommended 
iat
ommended 
occur at the
aria
occur at the
HCP.
var
HCP.
Moni
he
Moni
va
h
va
er
th
r v
and any e
ert) and 
any
ert) and 
scussed 
d a
scussed 
edical Mo
nd 
edical Mo
AP.
a
AP.
application a
e


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 75 of 136
Table 12‒3: Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN 
(and ≥2x 
baseline) 
and 
<5xULN 
(and ≥2x 
baseline)
<2xULN
No
Discussion with 
Medical Monitor 
required.
Consider need for 
hepatology consult if 
there is no evidence 
of resolution (see 
Follow-up 
requirements) c
Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section 12.6.1.2).
IMP discontinuation 
required if any of 
the following occur:

Subject cannot 
comply with 
monitoring 
schedule. 

Liver chemistry 
values continue 
to increase 

Liver chemistry 
values remain 
≥3xULN (and 
≥2xbaseline) 
after 2 weeks of 
monitoring 
without 
evidence of 
resolution
Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48hours at 
the site with HCP 
(see Section 
12.6.1.3).
discontinuation required if 
liver chemistry values 
continue to increase. After 2 
weeks of monitoring liver 
chemistry values: 

Discontinue IMP if levels 
remain ≥3xULN (and ≥2x 
baseline) without evidence 
of resolutione
Continue to monitor until values 
normalize, stabilize, or return to 
within baseline valuese.
C COPY 
2.6
Y
2.6
discontin
PY
discontin
quired if
OP
quired if
the follo
CO
the follo

C C

PUBLIC
y marketing authorization 
27 
n 
27
at
Follow up
tho
Follow up
ho
Evalu
au
Evalu
ut
g a
tial: Every
keti
tial: Every
empt must 
rke
empt must 
made to ha
ar
made to ha
repeat l
ma
repeat l
chem
y m
chem
an
y
an
tin
to support any
uation 
any
uation 
any of 
t a
any of 
wing occur
ort 
wing occur
Subject ca
ppo
Subject ca
comply
supp
comply
mon
su
mon
This document cannot be used to
l
T
l
cu
n
to
y
thereof.
uation
f
uation
didi
er
r variations th
y
t
y
be 
s t
be 
ave
n
ave
liver 
io
liver 
mistry valu
atio
mistry valu
nd addition
riat
nd addition
testing c
ari
testing c
within
va
within
the
v
the
extensions or v
ur:
r
ur:
annot 
s o
annot 
y with
ns
y with
nitoring
ion
nitoring
schedule. 
sio
schedule. 

t

Liver 
ten
Liver 
va
te
va
application and any e
pp
at
e
r v
th


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 76 of 136
Table 12‒3: Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause). 
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor. 
c Details provided in Section 12.6.1.1. The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist. 
d Details are provided in Section 12.6.1.2.1.
e Unless an alternative monitoring schedule is agreed by the Investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
PUBLIC COPY 
sulted
Y
sulted
oenterolo
PY
oenterolo
UCB resp
CO
UCB resp
B respons
C CO
B respons
ting authorization 
27 
n 
27
at
Follow up
tho
Follow up
ho
Evalu
au
Evalu
ut
g a
This document cannot be used to support any marketin
l
T
l
ransferase; 
ketin
ransferase; 
LN=upper 
rke
LN=upper 
ersensitivity
ark
ersensitivity
be discusse
m
be discusse
he treating p
ny m
he treating p
ist. 
a
ist. 
nsible phy
ort a
nsible phy
ble physicia
por
ble physicia
tin
ereof.
uation
f
uation
application and any extensions or variations ther
HCP=heal
her
HCP=heal
limit of nor
the
limit of nor
y symptom
s t
y symptom
ed with the 
tion
ed with the 
physician f
atio
physician f
sician. Det
va
sician. Det
an, as neede
or v
an, as neede
er


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 77 of 136
12.6.1.1
Consultation with Medical Monitor and local hepatologist 
Potential drug-induced liver injury events require notification of the Medical Monitor within 
24hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepatologist. The 
local hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discussion should be followed by a full 
hepatology assessment (see Section 12.6.1.3) and SAE report (if applicable).
12.6.1.2
Immediate action: Determination of IMP discontinuation
All PDILI events require immediate action, testing, and monitoring. 
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate discontinuation (see Section 6.3.1 and Table 12‒3 for details).
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The Investigator should also consider dose 
reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative. 
12.6.1.2.1
IMP restart/rechallenge
Rechallenge with a substance potentially causing drug-induced liver injury is dangerous, may be 
fatal, and must not occur.
12.6.1.3
Testing: Identification/exclusion of alternative etiology
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by the IMP are included but not 
limited to those listed in Table 12‒4 (laboratory measurements) and Table 12‒5 (additional 
information). Results of the laboratory measurements and information collected are to be 
submitted to the sponsor on the corresponding eCRF. If the medical history of the subject 
indicates a requirement for other assessments not included below, these additional assessments 
should be completed and submitted, as applicable.
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.
The following measurements are to be assessed:
Table 12‒4: PDILI laboratory measurements
Virology-
related
Hepatitis A IgM antibody
HBsAg
Hepatitis E IgM antibody
HBcAb-IgM
Hepatitis C RNA
PUBLIC COPY
cation
PY 
cation
patotoxic
OPY
patotoxic
causing 
C C
causing 
cation/e
UBL
cation/e
nal info
PU
nal info
ha
P
ha
This document cannot be used to support any marketing authorization 
f hepatitis
ting
f hepatitis
diate inves
ketin
diate inves
s).
rk
s).
suppleme
mar
suppleme
or should 
y m
or should 
d conside
ny 
d conside
to a suita
any
to a suita
drug
pp
rug-
p
-indu
ppo
indu
xclusion
o s
xclusion
rmation re
d to
rmation re
they may
sed
they may
‒4
u
4 (labor
use
(labor
boratory m
e us
boratory m
n the corre
be 
n the corre
for other a
ot b
for other a
and subm
not
and subm
s should b
ann
s should b
mple must
t ca
mple must
wing meas
ent 
wing meas
e
u
e 12
um
12‒
m
‒4
m
4:
Virology
doc
Virology
related
do
related
cu
s
application and any extensions or variations thereof.
s or 
ere
s or 
stigation)
her
stigation)
ments that 
ons 
ments that 
d also con
tion
d also con
er changin
iatio
er changin
able altern
aria
able altern
uced liver 
s or
uced liver 
n of alte
sion
n of alte
equired fo
ens
equired fo
y have bee
xten
y have bee
ratory me
ext
ratory me
measurem
y e
measurem
esponding
any
esponding
assessmen
d an
assessmen
mitted, as a
nd 
mitted, as a
be stored,
n an
be stored,
t also be s
on 
t also be s
surements
atio
surements
PDILI l
plic
PDILI l
He
pp
He
pp
pp
pp
pp


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 78 of 136
Table 12‒4: PDILI laboratory measurements
Cytomegalovirus IgM antibody
Epstein-Barr viral capsid antigen IgM antibody (if unavailable, obtain heterophile 
antibody or monospot testing)
Immunology
Anti-nuclear antibody (qualitative and quantitative)
Anti-smooth muscle antibody (qualitative and quantitative)
Type 1 anti-liver kidney microsomal antibodies (qualitative and quantitative)
Hematology
Eosinophil count
Urinalysis
Toxicology screen
Chemistry
Amylase
Sodium, potassium, chloride, glucose, BUN, creatinine
Total bilirubin, ALP, AST, ALT, GGT, total cholesterol, albumin
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Additional
Prothrombin time/INRa
Serum pregnancy test
PK sample
ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine phosphokinase; HBcAb-
IgM=hepatitis B core antibody-IgM; HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; 
INR=international normalized ratio; LDH=lactate dehydrogenase; PDILI=potential drug-induced liver injury; 
PK=pharmacokinetic; RNA=ribonucleic acid; ULN=upper limit of normal
a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).
The following additional information is to be collected:
PY 
ionate
Y
ionate
BLIC COPY
ossible m
OPY
ossible m
PY
OP
C
LIC
PUBL
spartate am
UB
spartate am
; HBsAg
PU
; HBsAg
LDH
P
LDH
BL
marketing authorization 
za
iza
za
z
ho
ut
a
ing
ke
ol, albumin
ma
ol, albumin
ar
ny m
lirubin to 
ny m
lirubin to 
support any m
uscle injury
t any
uscle injury
ny
t a
po
upp
nnot be used to s
inotransfer
to s
inotransfer
hepatitis B 
d to
hepatitis B 
lactate dehy
ed t
lactate dehy
acid; ULN
sed
acid; ULN
>8xULN, 
use
>8xULN, 
ms include 
e u
ms include 
mptoms inc
be 
mptoms inc
This document ca
s
ditional in
ann
ditional in
ions thereof.
of
re
the
n
o
n
s
iatio
obtain % d
atio
obtain % d
ons or varia io
y causing 
aria
y causing 
ia
va
or
s
and any extension
rase; CPK=
sio
rase; CPK=
surface an
nsi
surface an
ydrogenase
ten
ydrogenase
N=upper lim
xte
N=upper lim
elevations 
ex
elevations 
fatigue, na
y e
fatigue, na
lud
n
lude eosino
ny
e eosino
application a
on
nformatio
n an
nformatio


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 79 of 136
Table 12‒5: PDILI information to be collected
New or updated information
Concomitant prescription and over-the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.
Pertinent medical history, including the following:

History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)

Adverse reactions to drugs

Allergies

Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha-1 antitrypsin 
deficiency)

Recent travel 

Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by itself, 
should not be used as an explanation for significant AST and/or ALT elevations.)
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function
Alcohol and illicit drug use
Results of liver imaging or liver biopsy, if done
Results of any specialist or hepatology consult, if done
Any postmortem/pathology reports
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug-induced liver injury
12.6.1.4
Follow-up evaluation
Potential drug-induced liver injury events require follow-up monitoring as described in 
Table 12‒3. Monitoring should continue until liver chemistry values normalize, stabilize, or 
return to baseline. Determination of stabilization is at the discretion of the Investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
12.7
Other safety measurements
12.7.1
Vital signs
The Investigator or designee should measure all vital signs (systolic and diastolic blood 
pressure (BP), temperature [oral, axillary, or otic], pulse rate) after the subject has been sitting 
for at least 5 minutes, and the subject should remain seated during the measurements. Body 
temperature should be obtained prior to dosing with IMP at study visits when IMP is 
administered. At Baseline/Day 1, pulse and BP should be collected prior to IMP administration 
and then at 30 minutes and 1 hour after dosing. At all other visits pulse and BP should be 
collected prior to IMP administration.
PUBLIC COPY 
atitis 
Y
atitis 
eased app
PY
eased app
oxemia w
CO
oxemia w
CO
C C
, if done
BL
, if done
LIC
ogy cons
PUB
ogy cons
UB
PU
annot be used to support any marketing authorization 
tty 
o
tty 
a
n
a-
n
-1 antitry
ng 
1 antitry
sease to th
ark
sease to th
ALT elev
ma
ALT elev
za
ypersensiti
ny m
ypersensiti
etite, abdo
any
etite, abdo
m
ith compro
port
ith compro
rt
po
up
ult, if done
to 
ult, if done
o s
d t
spartate am
use
spartate am
se
p evalua
t be
p evalua
ed liver inj
not
ed liver inj
toring sho
ann
toring sho
This document ca
ne. Determ
can
ne. Determ
with the h
nt c
with the h
Ot
n
Ot
7.1
u
7.1
The Inve
doc
The Inve
pressu
s do
pressu
for 
s d
for 
t
and any extensions or variations thereof.
ypsin 
reo
ypsin 
he liver, by
ns t
he liver, by
vations.)
ons
vations.)
ivi
at
ivity (eg, f
atio
ty (eg, f
ominal pai
ria
ominal pai
io
omised ca
or v
omised ca
va
or
ns
io
ns
minotransfer
ext
minotransfer
xte
ation
an
ation
njury even
nd 
njury even
ould cont
an
ould cont
application
i
mination 
on a
mination 
hepatolog
tion
hepatolog
ther saf
cat
ther saf
Vital s
pplic
Vital s
tigator o
app
tigator o
P),
a
P)


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 80 of 136
12.7.2
Body weight and height
Height is collected at the Screening Visit only. Body weight will be measured by the Investigator 
or designee at the time points listed in Table 5‒1. The Investigator or designee will measure the 
height of the subject with shoes removed in meters and the weight of the subject in kilograms. 
The same scale should be utilized throughout the study where possible.
12.7.3
Physical examination
The physical examination should be conducted by the Investigator or designee at the time points 
listed in Table 5‒1 and will include general appearance; ear, nose, and throat; eyes, hair, and 
skin; respiratory; cardiovascular; GI; musculoskeletal; hepatic; neurological (including limb 
reflexes); and mental status. Findings considered clinically significant changes since the physical 
examination at the Screening Visit will be recorded as AEs.
12.7.4
12-lead electrocardiogram
The Investigator or designee will perform the ECG at time points specified in Table 5‒1. The 
ECGs will be read locally. The RR, PR, QRS, QT, and QT intervals corrected for heart rate using 
Fridericia’s formula (QTcF) including changes from Baseline ECG variables will be evaluated.
12.7.5
Tuberculosis and TB risk factor assessment and management
All subjects will be assessed for TB at the Screening Visit and at the time points specified in 
Table 5‒1 through physical examination for signs and symptoms of TB, chest X-ray or CT 
(Section 12.7.5.2), laboratory testing (Section 12.7.5.1), and subject questionnaire 
(Section 12.7.5.3). 
At the Screening Visit, all subjects will have an IGRA test (QuantiFERON TB test is 
recommended), a chest X-ray or CT (unless already performed within 3 months of screening) 
and an examination for signs and symptoms of TB. In addition, each subject will complete a TB 
questionnaire with questions directed at symptoms of TB and potential exposure to TB. 
Exclusion Criteria at Screening
Subjects with known TB infection, at high risk of acquiring TB infection, with LTBI, or current 
or history of NTMB infection.
a.
Known TB infection whether present or past is defined as:

Active TB infection or clinical signs and symptoms suspicious for TB (pulmonary or 
extra-pulmonary)

History of active TB infection involving any organ system or findings in other organ 
systems consistent with TB infection, unless adequately treated and proven to be fully 
recovered upon consult with a TB specialist.

Any evidence by radiography or other imaging modalities consistent with previously 
active TB infection that is not reported in the subject’s medical history
PUBLIC COPY
or asse
PY 
or asse
ening Vi
COP
ening Vi
signs an
CO
signs an
tion
C C
tion 12.
C C
12.
s will ha
UBL
s will ha
r CT (un
PUB
r CT (un
nd sym
P
nd sym
be used to support any marketing authorization 
points 
horiz
points 
r, and 
tho
r, and 
ng limb
auth
ng limb
nc
g
nce the ph
g au
e the ph
ified in
arke
ified in T
e
T
s correcte
mar
s correcte
CG variab
y m
CG variab
sment a
any
sment a
sit and at t
rt a
sit and at t
d symptom
port
d symptom
.5.1
pp
.5.1), and
ppo
), and
ve an IGR
o s
ve an IGR
less alread
d to 
less alread
mptoms of
ed t
mptoms of
ted at sym
sed
ted at sym
g
e
g
This document cannot be
nfection, 
t be
nfection, 
fection.
ot 
fection.
ection whe
nno
ection whe
TB infect
t ca
TB infect
a-
n
-pulmona
nt c
pulmona
History o
men
History o
system
um
system
reco
u
reco

o

ny extensions or variations thereof.
hysical
of.
hysical
Table
s th
Table 5
th
5‒
t
‒1
h
1
ed for hea
ons 
ed for hea
bles will b
tion
bles will b
and man
riat
and man
the time p
var
the time p
ms of TB
or v
ms of TB
d subject 
s or
d subject 
RA test (Q
sion
RA test (Q
ady perfor
nsi
ady perfor
f TB. In a
ten
f TB. In a
mptoms o
exte
mptoms o
application and a
at high ri
any
at high ri
hether pres
and
hether pres
tion or cli
on a
tion or cli
nary)
tio
nary)
of active T
lica
of active T
ms consist
plic
ms consist
overed up
app
overed up
y evi
a
y evi


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 81 of 136
b. High risk of acquiring TB infection is defined as:

Known exposure to another person with active TB infection within the 3 months prior to 
Screening

Time spent in a healthcare delivery setting or institution where individuals infected with 
TB are housed and where the risk of transmission of infection is high
c.
Latent TB infection is defined as:

The absence of signs, symptoms (ie, evidence of organ-specific involvement), or physical 
findings suggestive of TB infection with a positive IGRA test (or 2 indeterminate IGRA 
test results) and a chest X-ray (or other imaging) without evidence of TB infection. If the 
result of the IGRA test is indeterminate, the particular IGRA test previously performed 
may be repeated once; if positive or indeterminate on retest, the subject may not be 
randomized to IMP without further evaluation, treatment and discussion with Study 
Physician, if Latent TB infection is identified. The retest must be done during the 
protocol-defined Screening window.
Note: If available, respiratory or other specimens must also be smear and culture negative for 
TB (Centers for Disease Control [CDC] diagnosis of latent tuberculosis [LTB] infection) 
http://www.cdc.gov/TB/topic /testing/default.htm)
d. Current or history of NTMB infection despite prior or current therapy.
Signs and Symptoms
The Investigator should consider all potential sites of infection when assessing for TB during the 
physical examination, and other evaluations, and based on the subject’s medical or social history. 
The most common primary focus of TB is the lung. Other sites may include gastrointestinal 
system, bone/joints, lymph glands and meninges, etc. However, in immune compromised
patients and/or patients treated with TNF inhibitors, extra-pulmonary manifestations of TB are 
common compared to normal population.
Some common symptoms that the subject may present are dependent on the primary focus of 
infection and may include cough, blood in sputum, night sweats, lymphadenitis, joint 
pain/swelling, spinal deformity, headache/confusion, abdominal pain (mimicking inflammatory 
bowel disease), etc. Unusual presentations should always be considered.
Latent tuberculosis infection is defined in the “Exclusion Criteria” above. If the result of the 
IGRA is indeterminate, the particular IGRA previously performed may be repeated once; if 
positive or indeterminate on retest, the subject may not be randomized to IMP without further 
evaluation by a TB specialist. If LTBI or active TB is identified, subject must undergo 
appropriate study specified withdrawal procedures. The retest must be done during the protocol-
defined Screening window. Laboratory diagnosis should be undertaken via mycobacteria culture 
media (or if available by preferred nucleic acid amplification test such as the Xpert 
mycobacterium tuberculosis [MTB] rifampin [RIF] test) and result must be negative for TB 
inducing pathogens.
PUBLIC COPY
u
Y
u
is of la
PY 
is of la
htm)
OPY
htm)
spite prio
CO
spite prio
potentia
BLIC
potentia
valuatio
UBL
valuatio
us of T
PU
us of T
s
P
s
nnot be used to support any marketing authorization 
physical
hor
physical
nate IGRA
uth
nate IGRA
nfection. I
au
nfection. I
usly perfo
g a
usly perfo
ct may no
ting
ct may no
ussion wit
ketin
ussion wit
be 
be done du
rke
done du
be smear 
y m
be smear 
nt tubercu
ny 
nt tubercu
r or curre
ort 
r or curre
sites of in
sup
sites of in
ns, and bas
to s
ns, and bas
B is the lu
d to
B is the lu
and menin
sed
and menin
with TNF i
use
with TNF i
populatio
be u
populatio
s that the s
t be
s that the s
ude cough
not 
ude cough
al deformi
nno
al deformi
This document ca
etc. Unusu
can
etc. Unusu
ulosis inf
t c
ulosis inf
ndetermin
ent
ndetermin
e or indet
me
e or indet
uation by
um
uation by
ppropriat
ocu
ppropriat
defined
doc
defined
medi
s d
medi
m
s
m
and any extensions or variations thereof.
If the 
of.
If the 
ormed 
eof
ormed 
ot be
ere
ot be
th Study 
ther
th Study 
uring the
s th
uring the
and cultu
tion
and cultu
ulosis [LT
iati
ulosis [LT
ent therap
r va
ent therap
nfection w
ons
nfection w
ased on th
sion
ased on th
ung. Othe
ens
ung. Othe
nges, etc. 
xte
nges, etc. 
inhibitors
ext
inhibitors
on.
y
on.
subject m
any
subject m
h, b
d
h, blood i
d a
lood i
ity, heada
and
ity, heada
application 
ual presen
n an
ual presen
fection is
tion
fection is
nate, the p
atio
nate, the p
terminate
lica
terminate
y a T
ppli
y a TB spe
plic
B spe
te study sp
app
e study sp
reenin
ap
reenin


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 82 of 136
Test Conversion
Tuberculosis test conversion is defined as a positive IGRA result for the current test, when 
previous IGRA test results were negative. All subjects with TB test conversion must immediately 
stop IMP administration. In case of a TB test conversion, the subject must be considered as 
having either a suspected new latent or an active TB infection and be promptly referred to an 
appropriate specialist (eg, pulmonologist, infectious disease specialist) for further evaluation. If 
test conversion indicates LTBI, active TB, or NTMB then, per UCB TB working instructions, 
TB test conversion (confirmed) should be classified adequately, either as due to LTBI, active TB 
infection, or NTMB, respectively. Additional assessments (eg, blood tests or IGRA, chest 
X-rays, or other imaging) should be performed where medically relevant and documented. Such 
conversions should be reported to the UCB PS function.
Latent TB
In case the evaluation by the appropriate specialist indicates a new LTBI during the study, a 
prophylactic TB treatment should be initiated and the subject must be withdrawn.
Every related action should be discussed in advance with the Medical Monitor. 
Once withdrawn from study treatment, subjects should return for the WD Visit, complete all 
WD Visit assessments, and complete a SFU Visit (20 weeks after the final dose of IMP).
Active TB or NTMB infection 
Subjects who develop active TB or NTMB infection during the study must be withdrawn from 
the study. The subject must be immediately discontinued from IMP and an WD Visit must be 
scheduled as soon as possible, but no later than the next scheduled visit. The subject should be 
encouraged to keep the SFU Visit as specified by the protocol. Treatment should be started 
immediately.
Note that subjects with history of NTMB or active NTMB infection are excluded from the study 
regardless of prior or current therapy for this condition. 
12.7.5.1
Tuberculosis assessment by IGRA
During conduct of the study, the TB assessment by IGRA (QuantiFERON TB test is 
recommended) will be performed at Screening and should be repeated at the SFU Visit for all 
subjects. The test results will be reported as positive, negative, or indeterminate. UCB also 
recommends that a TB specialist be consulted where TB (latent or active) is suspected or if there 
are doubts regarding test results. If latent or active TB is identified, subject must undergo 
appropriate study-specified withdrawal procedures. The retest during Screening must be done 
during the protocol-defined Screening window.
12.7.5.2
Chest X-ray for tuberculosis
A plain posteroanterior chest X-ray must be performed during the Screening Period unless one 
has been performed within 3 months prior to the Screening Visit. The chest X-ray (or, if done, 
Computed Axial Tomography of the Chest) must be clear of signs of TB infection (previous or 
current) before first IMP administration. All chest imaging (particularly X-rays) should be 
available for review by the Investigator before randomization of the subject. The chest X-ray 
should be repeated only if the TB test was confirmed positive or any further evidence is 
suggestive of potential lung TB infection (eg, exposure). Radiographic findings suggestive of 
PUBLIC COPY
uld retu
PY 
uld retu
(20 wee
OPY
(20 wee
B infect
C C
B infect
iately di
LIC
iately di
no later t
UBL
no later t
it as spe
PUB
it as spe
ment cannot be used to support any marketing authorization 
s,
r
s,
tive TB
hori
tive TB
est 
th
est 
mented. Su
aut
mented. Su
during th
ket
during th
withdraw
ark
withdraw
dical Mon
ma
dical Mon
for the W
ny 
for the W
ks after th
any
ks after th
on during
ppo
on during
continued
upp
continued
han the ne
o su
han the ne
ified by t
to s
ified by t
NTMB or
sed
NTMB or
erapy for 
us
erapy for 
sis asse
be 
sis asse
study, the
ot 
study, the
be perform
nno
be perform
results w
ann
results w
hat a
ca
hat a TB s
ca
TB s
regarding 
nt c
regarding 
ate study
men
ate study
This docum
g the prot
ume
g the prot
2.7.5.2
ocu
2.7.5.2
A plain
do
A plain
has 
s d
has 
C
s
C
ation and any extensions or variations thereof.
uch
f
uch
he study, 
the
he study, 
wn.
s
wn.
nitor.
ion
nitor.
WD Visit,
iati
WD Visit,
he f
ari
he final do
aria
inal do
fif
ari
fif
g the study
s or
g the study
d from IM
ns 
d from IM
ext schedu
ion
ext schedu
the protoc
nsio
the protoc
r active N
exte
r active N
r this cond
y ex
r this cond
essment
any
essment
e TB asses
d a
e TB asses
rmed at Sc
and
rmed at Sc
will be rep
n an
will be rep
specialist
on 
specialist
g test resu
atio
g test resu
applica
y specified
cat
specified
tocol
plic
tocol-
ic
-defi
c
defi
Che
pp
Che
tero
a
tero


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 83 of 136
inactive TB or active TB may include but are not limited to: apical fibrosis, pleural thickening, 
pulmonary nodules, fibrotic scars, calcified granulomas, upper lobe infiltrates, cavitations and 
pleural effusions, calcified lung nodules, calcified hilar lymph nodes, and pericardial 
calcification.
The chest imaging must be negative for any old or recent TB infection as determined by a 
qualified radiologist and/or pulmonary physician. Any new clinically significant findings post 
Baseline on chest X-ray must be documented in the source documents and the eCRF as an AE.
12.7.5.3
Tuberculosis questionnaire 
The questionnaire “Evaluation of signs and symptoms of tuberculosis” should be used as a 
source document. The questionnaire will be completed at the Screening Visit, Weeks 12, 24, 
and 36, and the SFU Visit. The questionnaire will assist with the identification of subjects who 
may require therapy for TB. A subject who answers “Yes” to the question “Has the subject been 
in close contact with an individual with active TB, or an individual who has recently been treated 
for TB?” at Screening is excluded. A “Yes” response to any of the other questions within the 
questionnaire at Screening should trigger further careful assessment to determine if subject has 
LTB or active TB (see Exclusion Criterion #13, Section 6.2). A “Yes” response to any of the 
questions during the study should trigger further assessments to determine if the subject has 
either LTB or active TB infection. 
Subjects with a latent or active TB infection must be withdrawn from the study.
12.7.5.4
Tuberculosis management
LTB infection and active TB identified during study
During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB 
specialist (pulmonologist or infectious disease specialist) for further evaluation. Evidence of 
LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
confirmed indeterminate on repeat), or the subject’s questionnaire or history and physical 
indicates that TB infection or exposure may have occurred. Evidence of active TB includes, in 
addition to the aforementioned tests, signs and symptoms of organ involvement. In either 
situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
diagnosed with active TB or LTB infection should be withdrawn from the study and receive 
appropriate TB or prophylaxis therapy. 
Any presumptive diagnosis or diagnosis of a TB infection is a reportable event. Confirmed active 
TB must be reported as an SAE. The Investigator is to complete and submit the TB follow-up 
Form provided.
The subject should be transferred to the care of his/her physician and managed according to the 
best available standard of care. Subjects identified as having converted to active TB during the 
study must be withdrawn and scheduled to return for the WD Visit as soon as possible but no 
later than the next scheduled study visit and complete all WD Visit assessments. 
The subject should be encouraged to complete a SFU Visit (20 weeks after the final dose of 
IMP).
PUBLIC COPY
n
essmen
PY 
essmen
must be 
CO
must be 
ment
IC C
ment
ed durin
BLIC
ed durin
BL
develop e
PUB
develop e
nistratio
PU
nistratio
ti
P
ti
t be used to support any marketing authorization 
E.
ri
E.
ed as a 
auth
ed as a 
eeks
g a
eeks 12, 2
au
12, 2
of subjec
ng 
of subjec
Has the s
eting
Has the s
has recent
ket
has recent
her questio
arke
her questio
nt to determ
mar
nt to determ
“Yes” res
y m
“Yes” res
to determ
ny 
to determ
withdrawn
ort 
withdrawn
g study
sup
g study
su
vidence o
to s
vidence o
n of IMP 
d to
n of IMP 
ous diseas
sed
ous diseas
ect’s IGRA
use
ect’s IGRA
epeat), or 
be u
epeat), or 
or exposu
t be
or exposu
ment cannot
ntioned te
ot b
ntioned te
should be
no
should be
tive TB o
ann
tive TB o
or prophy
can
or prophy
mptive dia
nt 
mptive dia
t be repor
men
t be repor
This docum
m provided
ume
m provided
The subjec
ocu
The subjec
best ava
doc
best ava
study
s d
study
la
s
la
any extensions or variations thereof.
24, 
of
24, 
cts who
reo
cts who
subject be
here
subject be
ntly been t
the
ntly been t
ons withi
s th
ons withi
rmine if su
ons
rmine if su
esponse to
tion
esponse to
mine if th
iati
mine if th
n from th
r va
n from th
of LTB in
nsio
of LTB in
P and will 
ens
P and will 
se special
xte
se special
RA test con
ext
RA test con
r the subje
ny e
r the subje
ure may h
any
ure may h
pplication and 
ests, signs
d a
ests, signs
e carefull
nd 
e carefull
or LTB in
an
or LTB in
hylaxis the
on a
hylaxis the
agnosis o
atio
agnosis o
rted as an
icat
rted as an
ap
d.
p
d.
ct should 
app
ct should 
ble sta
ap
ble sta


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 84 of 136
If infection with NTMB is identified during the study, the same procedure as for active TB 
acquired during the study must be followed.
12.7.6
Pregnancy testing
A serum human chorionic gonadotropin (hCG) pregnancy test for all women of childbearing 
potential will be performed at the Screening Visit. This recommendation also applies to women 
of childbearing potential with infrequent or irregular menstrual cycles and women during 
menopause. Natural menopause is recognized to have occurred after 12 consecutive months of 
amenorrhea, for which there is no other obvious pathological or physiological cause 
(International Menopause Society, 2015).
Pregnancy testing will performed on urine at all other visits. Pregnancy test results (serum and 
urine) must be negative prior to administering IMP.
12.7.7
Assessment of suicidal ideation and behavior
Suicidal ideation and behavior will be assessed by trained study personnel using the C-SSRS. 
This scale will be used to assess suicidal ideation and behavior that may occur during the study. 
The visits at which the C-SSRS assessments will be performed are specified in the schedule of 
study assessments (Table 5‒1).
The C-SSRS is a standardized and validated instrument developed for the assessment of the 
severity and frequency of suicidal ideation and behavior (Posner et al, 2011; Mundt et al, 2010). 
Subjects respond to standardized clinical questions that are presented in a uniform fashion. The 
C-SSRS defines 5 subtypes of suicidal ideation and behavior in addition to self-injurious 
behavior with no suicidal intent. The C-SSRS takes approximately 3 to 10 minutes to complete. 
Refer to Section 6.3 for C-SSRS-related withdrawal criteria.
13
OTHER STUDY MEASUREMENTS
13.1
Demographic and Baseline characteristics
The Investigator or designee will collect demographic information for all subjects according to 
local rules and regulations. This will include age, gender, race, and ethnicity. Information will 
also be collected on Baseline characteristics for subjects including lifestyle, child bearing 
potential, as applicable, height, weight, and body mass index (BMI). Demographic and baseline 
characteristics information will be recorded in the eCRF.
13.2
Medical history
The Investigator or designee will obtain a complete medical history of AS as part of the 
screening assessment and include all clinically relevant past or coexisting medical conditions, 
responses to AS treatment as available, and surgeries. Findings will be recorded in the eCRF.
13.3
Ankylosing spondylitis history
The Investigator or designee will obtain a detailed history of AS, including the date of onset and 
past treatments for AS. Specific information related to AS history will be recorded in the eCRF.
13.4
Prior and concomitant medications
As part of the medical history, the Investigator or designee will determine prior and concomitant 
medications and record these in the eCRF. 
PUBLIC COPY 
Y
rument d
OPY
rument d
d behav
CO
d behav
uestions
C C
uestions
ideation 
LIC 
ideation 
C
BL
C-
BL
-SSR
BLIC
SSR
related 
PUB
related 
DY 
P
DY 
sed to support any marketing authorization 
s of 
ori
s of 
ts (serum 
g au
ts (serum 
nnel using
arke
nnel using
may occu
mar
may occu
are specifi
y m
are specifi
eveloped 
t an
eveloped 
or (Posne
ort 
or (Posne
that are p
po
that are p
and behav
upp
and behav
 takes app
sup
 takes app
withdrawa
to s
withdrawa
MEASU
ed t
MEASU
This document cannot be u
and Ba
use
and Ba
e will colle
be 
e will colle
s. This wi
t be
s. This wi
aseline ch
not 
aseline ch
able, heigh
nno
able, heigh
formation
an
formation
Medic
nt c
Medic
estigator o
men
estigator o
ning asse
ume
ning asse
sponses to
cum
sponses to
13.3
doc
13.3
The
s 
The
xtensions or variations thereof.
and 
of
and 
g the C
s th
g the C-S
h
S
ur during
ons 
ur during
fied in the
tion
fied in the
d for the a
vari
d for the a
er et al, 20
r va
er et al, 20
present
or
presented 
r 
ed 
vior in add
s o
vior in add
proximate
ons
proximate
al criteria
sio
al criteria
UREM
ten
UREME
application and any e
aseline c
ext
aseline c
lect demo
ny 
lect demo
will includ
any
will includ
haracterist
nd a
haracterist
gh
a
ght, weigh
and
t, weigh
n will be 
n a
n will be 
cal hist
tion
cal hist
or design
icat
or design
essment an
plic
essment an
o AS trea
pp
o AS trea
A
p
A


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 85 of 136
14
STUDY MANAGEMENT AND ADMINISTRATION 
14.1
Adherence to protocol
The Investigator should not deviate from the protocol. However, the Investigator should take any 
measure necessary in deviation from or not defined by the protocol in order to protect clinical 
study subjects from any immediate hazard to their health and safety. In this case, this action 
should be taken immediately, without prior notification of the regulatory authority, IRB/IEC, or 
sponsor.
After implementation of such measure, the Investigator must notify the EPM of the sponsor 
within 24 hours and follow any local regulatory requirements.
14.2
Monitoring
Monitoring of the study will be delegated by UCB to a CRO. The CRO will monitor the study to 
meet the CRO’s monitoring Standard Operating Procedures (SOPs), ICH-GCP guideline, and 
applicable regulatory requirements, and to ensure that study initiation, conduct, and closure are 
adequate. 
The Investigator and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the monitoring visits to answer questions sufficiently and to provide any 
missing information. The Investigator(s)/institution(s) will permit direct access to source 
data/documents for study-related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s).
The Investigator will allow UCB (or designee) to periodically review all eCRFs and 
corresponding source documents (eg, hospital and laboratory records for each study participant). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the accuracy and completeness of eCRFs, ensure that all protocol 
requirements, applicable authorities regulations, and Investigator’s obligations are being 
fulfilled, and resolve any inconsistencies in the study records.
14.2.1
Definition of source data 
All source documents must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attachments 
(such as removable self-stick notes). Photocopies and/or printouts of eCRFs are not considered 
acceptable source documents. 
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practitioner records, charts, diaries, X-rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other printouts, completed scales, quality of life 
questionnaires, or video, for example. Source documents should be kept in a secure, limited 
access area.
Source documents that are computer-generated and stored electronically must be printed for 
review by the monitor (eg, ECG reports). Once printed, these copies should be signed and dated 
by the Investigator and become a permanent part of the subject’s source documents. The 
Investigator will facilitate the process for enabling the monitor to compare the content of the 
printout and the data stored in the computer to ensure all data are consistent.
PUBLIC COPY 
perat
Y
perat
uestions 
OPY
uestions 
tion(s) w
COP
tion(s) w
, aud
CO
, audits,
CO
its,
designee
BLIC
designee
eg,
UB
eg, hosp
UBL
hosp
UCB (or 
PUB
UCB (or 
y and 
PU
y and 
nnot be used to support any marketing authorization 
or 
iz
or 
onsor 
utho
onsor 
l monitor
eting
l monitor
H-
k
-GCP gu
ket
GCP gu
n, conduct
ark
n, conduct
th UCB
ny m
th UCB (
m
(
ufficientl
any
ufficientl
ill permit
rt a
ill permit
IRB/IEC r
ort
IRB/IEC r
) to period
sup
) to period
tal and lab
o su
tal and lab
designee) 
d to 
designee) 
completen
ed t
completen
s regulati
sed
s regulati
sistencies 
us
sistencies 
of sourc
be 
of sourc
must be ac
ot b
must be ac
d be made
nno
d be made
This document can
y should n
ann
y should n
vable self
t ca
vable self
source doc
nt c
source doc
document
men
document
ital/clinic
um
ital/clinic
harmacy r
ocu
harmacy r
question
doc
question
acces
s d
acces
S
s
S
and any extensions or variations thereof.
r the study
here
r the study
uideline, a
the
uideline, a
t, and clos
ns t
t, and clos
(or design
atio
(or design
ly and to p
aria
ly and to p
t direct ac
var
t direct ac
review, a
r va
review, a
dically rev
ons 
dically rev
aboratory 
sion
aboratory 
) with the 
nsio
) with the 
ness of eC
ten
ness of eC
ions, and 
exte
ions, and 
s in the stu
y ex
s in the stu
ce data 
ny 
ce data 
ccurate, c
d a
ccurate, c
e using so
and
e using so
application a
not be ob
an
not be ob
stick not
on a
stick not
ocuments.
tion
ocuments.
nts are orig
ica
nts are orig
c/general 
plic
c/general 
records, c
app
records, c
aires, o
ap
aires, o


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 86 of 136
14.2.2
Source data verification
Source data verification ensures accuracy and credibility of the data obtained. During monitoring 
visits, reported data are reviewed with regard to being accurate, complete, and verifiable from 
source documents (eg, subject files, recordings from automated instruments, tracings [ECG], 
X-ray films, laboratory notes). All data reported on the eCRF should be supported by source 
documents, unless otherwise specified in Section 14.2.1.
14.3
Data handling
14.3.1
Case Report Form completion
The study will use electronic data capture (EDC); the Investigator will be responsible for prompt 
reporting of accurate, complete, and legible data in the eCRFs and in all required reports.
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change.
Corrections made after the Investigator’s review and approval (by means of a 
password/electronic signature) will be reapproved by the Investigator.
The Investigator should maintain a list of personnel authorized to enter data into the electronic 
eCRF. Access to the EDC will be given after training has been received. A training certificate 
will be provided and filed.
Serious AE reporting will be done using the SAE Report Form (see Section 12.1.2.3) while also 
entering the event in the appropriate eCRF section. The safety database and the clinical database 
will be reconciled during the study and discrepancies will be corrected as needed.
Detailed instructions will be provided in the eCRF Completion Guidelines.
14.3.2
Database entry and reconciliation
Case Report forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used in addition to manual review to check for discrepancies and to ensure consistency of 
the data. The data will be entered into the eCRFs once and will be subsequently verified if the 
study is performed using electronic data capture.
An electronic audit trail system will be maintained within the CDMS to track all data changes in 
the database once the data have been saved initially into the system or electronically loaded. 
Regular backups of the electronic data will be performed.
14.3.3
Subject Screening and Enrollment log/Subject Identification Code list
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
log.
The Investigator will keep a Subject Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of each subject.
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s 
participation.
PUBLIC COPY
author
PY 
author
ning has 
OPY
ning has 
e SAE R
C C
e SAE R
RF secti
LIC 
RF secti
nd discre
BLIC
nd discre
vided in 
PUB
vided in 
ry an
PU
ry an
This document cannot be used to support any marketing authorization 
ble for pro
aut
ble for pro
d reports.
g a
d reports.
a reason 
ting
a reason 
eans of a 
ark
eans of a 
ator.
m
ator.
d to enter
ny 
d to enter
been recei
any
been recei
eport Form
por
eport Form
on. The sa
upp
on. The sa
pancies w
sup
pancies w
he eCRF 
to s
he eCRF 
d rec
ed t
d reconc
d t
onc
ronic data
use
ronic data
manageme
e us
manageme
manual rev
be 
manual rev
e entered 
ot b
e entered 
ing electr
not
ing electr
dit trail sys
ann
dit trail sys
nce the da
t ca
nce the da
ckups of th
nt c
ckups of th
S
n
S
sub
cu
subject’s
um
ject’s
bjb
um
bjb
log.
do
log.
The In
s do
The In
Inv
s 
Inv
plication and any extensions or variations thereof.
ompt
f.
ompt
n for the 
here
n for the 
r data into
iatio
r data into
ived. A tr
aria
ived. A tr
rm (see
or v
rm (see Se
v
Se
afety data
s o
afety data
will be cor
ons
will be cor
Complet
sio
Complet
ciliation
ten
ciliation
a will be e
ext
a will be e
ment system
y e
ment system
view to c
ny
view to c
into the e
d an
into the e
ronic data
nd 
ronic data
ystem will
an
ystem will
ata have b
on 
ata have b
the electro
tio
the electro
Subject S
lica
Subject S
app
s screenin
ppli
s screenin
gat
a
t


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 87 of 136
14.4
Termination of the study
UCB reserves the right to temporarily suspend or prematurely discontinue this study either at a 
single site, multiple sites, or at all sites at any time for reasons including, but not limited to, 
safety or ethical issues, inaccurate or incomplete data recording, noncompliance, or 
unsatisfactory enrollment with respect to quality or quantity.
If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
Investigators/institutions and the regulatory authority(ies) of the termination or suspension and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination or suspension by the sponsor or by the Investigator/institution, as specified by the 
applicable regulatory requirement(s). In addition, arrangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study.
14.5
Archiving and data retention
The Investigator will maintain adequate records for the study, including eCRFs, medical records, 
laboratory results, Informed Consent documents, drug dispensing and disposition records, safety 
reports, information regarding participants who discontinued, and other pertinent data.
All essential documents are to be retained by the Investigator until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required by the applicable regulatory requirement(s) or by an 
agreement with UCB (CPMP/ICH/135/95, 2002 [Section 4.9.5]). The Investigator will contact 
UCB for authorization prior to the destruction of any study records or in the event of accidental 
loss or destruction of any study records. The Investigator will also notify UCB should he/she 
relocate or move the study-related files to a location other than that specified in the sponsor’s 
trial master file.
14.6
Audit and inspection
The Investigator will permit study-related audits mandated by UCB, after reasonable notice, and 
inspections by domestic or foreign regulatory authorities.
The main purposes of an audit or inspection are to confirm that the rights and wellbeing of the 
subjects enrolled have been protected, that enrolled subjects (ie, signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the 
protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.
The Investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the Investigator will immediately 
inform UCB (or designee).
PUBLIC COPY 
ntinu
Y
ntinu
Investig
OPY
Investig
region a
COP
region a
ICH reg
C CO
ICH reg
opment o
IC C
opment o
red by th
BLIC
red by th
/135/95,
UBL
/135/95,
the destr
PUB
the destr
recor
PU
recor
t be used to support any marketing authorization 
he 
i
he 
and 
ori
and 
y
t
y
r the 
uth
r the 
ified
au
ified by th
au
by th
r the retur
g a
r the retur
tudy.
ting
tudy.
ding eCRF
mark
ding eCRF
g and disp
ma
g and disp
and other 
ny m
and other 
ator until a
t any
ator until a
nd until th
ort a
nd until th
on, or at l
por
on, or at l
f the IMP
ppo
f the IMP
e applicab
sup
e applicab
2002 [Sec
o su
2002 [Sec
uction of a
d to 
uction of a
ds. The In
ed t
ds. The In
files to a 
sed
files to a 
inspect
be 
inspect
ment canno
ermit stud
ot b
ermit stud
stic or for
nno
stic or for
ses of an 
can
ses of an 
lled have 
t ca
lled have 
edures) ar
ent 
edures) ar
ve been p
men
ve been p
This docum
ocol, inve
um
ocol, inve
equiremen
ocu
equiremen
The Inv
do
The Inv
data
s d
data
in
s
in
nd any extensions or variations thereof.
the
of
the
urn of all
eof
urn of all
Fs, medic
ns 
Fs, medic
position re
tion
position re
r pertinen
atio
r pertinen
at least 2 
aria
at least 2 
here are n
va
here are n
least 2 ye
or v
least 2 ye
P. These d
s o
P. These d
ble regula
ons 
ble regula
ction
sion
ction 4.
on
4.9.
n
9.
any study
nsio
any study
nvestigato
ten
nvestigato
location 
exte
location 
ction
any
ction
lication an
dy
d
dy-
d
-related
d a
related
oreign regu
and
oreign regu
audit or i
n a
audit or i
 been pro
tion
 been pro
are approp
atio
are approp
processed
lica
processed
app
estigation
plic
estigation
nts.
ap
nts.
gato
a
gato


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 88 of 136
14.7
Good Clinical Practice
Noncompliance with the protocol, ICH-GCP, or local regulatory requirements by the 
Investigator, institution, institution staff, or designees of the sponsor will lead to prompt action 
by UCB to secure compliance. Continued noncompliance may result in the termination of the 
site’s involvement in the study.
15
STATISTICS
A description of statistical methods follows and will be described in more detail in the SAP. 
Deviations from the original SAP will be documented in the clinical study report (CSR).
15.1
Definition of analysis sets
The Enrolled Set (ES) will consist of all subjects who have given informed consent.
The Randomized Set (RS) will consist of all randomized subjects.
The Safety Set (SS) will consist of all subjects who receive at least 1 dose of the IMP.
The Full Analysis Set (FAS) will consist of all randomized subjects who receive at least 1 dose 
of the IMP and have a valid measurement of the primary efficacy variable at Baseline and at 
least 1 post-baseline efficacy assessment. 
The Per-Protocol Set (PPS) will consist of all subjects in the FAS who have no important 
protocol deviation affecting the primary efficacy variable. The subjects with important protocol 
deviations will be predefined and evaluated during a data evaluation meeting prior to unblinding 
of the data.
The Pharmacokinetics Per-Protocol Set (PK-PPS) will consist of all randomized subjects who 
receive at least 1 dose of the IMP and have at least 1 quantifiable post-dose plasma 
concentration. 
The PET Per-Protocol Set (PET-PPS) will consist of all randomized subjects who receive at least 
1 dose of the IMP and have evaluable PET-CT or PET-MRI scan data at Baseline and at 
at least 1 of the post-Baseline assessments.
Further details of each analysis set along with specifications of analyses by analysis set will be 
provided in the SAP.
15.2
General statistical considerations
Statistical evaluation will be performed by PAREXEL and supervised by the Exploratory 
Statistics and Global Statistical Sciences Departments of UCB.
All analyses will be performed using SAS® Version 9.2 or later (SAS Institute, Cary, NC, USA) 
or R Version 2.10.1 (R Development Core Team) or later, or OpenBUGS Version 3.0.6 or later.
Descriptive statistics will be used to provide an overview of the Baseline, efficacy and safety 
results. For categorical parameters, the number and percentage of subjects in each category will 
be presented by treatment group. The denominator for the percentages will be based on the 
number of subjects appropriate for the purpose of analysis. Unless otherwise noted, all 
percentages will be expressed to 1 decimal place. For continuous parameters, descriptive 
statistics will include n, mean, standard deviation (SD), median, minimum, and maximum. Two-
PUBLIC COPY 
ary e
Y
ary e
subjects 
COP
subjects 
icacy va
C CO
icacy va
ted durin
IC C
ted durin
ol Set (P
UB
ol Set (P
MP and h
PU
MP and h
ent cannot be used to support any marketing authorization 
AP. 
ho
AP. 
R).
ut
R).
nsent.
ing
nsent.
dose of th
ark
dose of th
cts who re
ma
cts who re
acy variab
y m
acy variab
n the FAS
rt a
n the FAS
iable. The
port
iable. The
g a data ev
ppo
g a data ev
K
to
K-
o
-PPS) w
to s
PPS) w
ave at lea
d to
ave at lea
PPS) will
use
PPS) will
valuable P
e u
valuable P
ne assess
be
ne assess
analysis s
not 
analysis s
P.
P.
General
can
General
evaluation
nt c
evaluation
This docume
s and Glo
men
s and Glo
analyses w
um
analyses w
r R Versi
ocu
r R Versi
Descri
do
Descri
resu
s d
resu
b
s
b
ation and any extensions or variations thereof.
he IMP.
s th
he IMP.
eceive at l
ions
eceive at l
ble at Bas
atio
ble at Bas
S who hav
va
S who hav
e subjects
or v
e subjects
evaluation
s or
evaluation
will consis
sion
will consis
ast 1 quan
ns
ast 1 quan
ll consist 
ext
ll consist 
PET
y
PET-
y
-CT o
y e
CT o
ments.
any
ments.
set along
nd a
set along
l statist
n a
l statist
n will be p
atio
n will be p
applica
obal Statis
icat
obal Statis
will be pe
pplic
will be pe
ion 2.10.1
app
on 2.10.1
stat
a
stat


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 89 of 136
sided 95% confidence intervals, geometric means, and coefficient of variation (CV) will be 
presented for selected variables as appropriate.
Baseline for each assessment is defined as either the value obtained at Baseline (Visit 2) or the 
last available value obtained prior to treatment administration at the Screening Visit (Visit 1) 
(details to be specified in the SAP).
Formal statistical testing will be conducted for this study for the primary efficacy variable. Other 
efficacy variables will be summarized descriptively by treatment group. Additional exploratory 
analyses will be conducted as deemed appropriate. 
15.3
Subject disposition 
The number of subjects who were screened, subjects included in each analysis set, and subjects 
who completed/prematurely discontinued the study, as well as the primary reason for 
discontinuation, will be presented by treatment group, and overall using frequency counts and 
percentages.
15.4
Subject characteristics
The following subject characteristics will summarized and listed as appropriate:

Demographics (including gender, age, race, and ethnicity)

Baseline characteristics (including lifestyle, childbearing potential, height, weight, and BMI) 

Medical/procedure history

Prior and concomitant medications/medical procedures 

Baseline disease characteristics
15.5
Planned efficacy analyses
The primary efficacy analyses will be based on the PPS.
15.5.1
Analysis of the primary efficacy variable
The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
Week 12 in the bimekizumab treatment group versus the CZP treatment group. Summary 
statistics will be presented by treatment group for ASDAS at each time point together with the 
changes from Baseline. 
The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
paradigm. An informative prior will be used for the model intercept coefficient which in the 
primary model is equal to the mean change from Baseline in ASDAS in the CZP group when 
centered Baseline is observed at its mean of zero (βCZP ~ Normal [-1.78, var=0.0605]). Vague 
priors will be used for all other model coefficients. All priors will be fully documented in the 
SAP and in the interim analysis SAP.
The Bayesian analysis will employ a linear regression model including treatment group and 
Baseline ASDAS (mean centered).
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
PUBLIC COPY 
d and
Y
d and
nd 
OP
nd ethni
OPY
ethni
le, child
CO
le, child
ns/medi
BLI
ns/medi
ics
PU
ics
c
P
c
t be used to support any marketing authorization 
her 
iz
her 
tory 
ori
tory 
et, and su
g a
et, and su
ason for 
ting
ason for 
equency c
ketin
equency c
ed as appr
y m
ed as appr
ity)
a
ity)
bearing po
ort 
bearing po
al proced
sup
al proced
y analys
sed
y analys
will be ba
us
will be ba
of the pri
be 
of the pri
ocument canno
nalysis w
ot 
nalysis w
ekizumab
nno
ekizumab
presented 
ann
presented 
Baseline. 
t ca
Baseline. 
tical analy
ent 
tical analy
gm. An inf
men
gm. An inf
mary mode
um
mary mode
entered B
ocu
entered B
This do
priors w
doc
priors w
SAP 
s d
SAP 
T
s
T
d any extensions or variations thereof.
ubjects
eof
ubjects
counts an
ther
counts an
ropriate:
atio
ropriate:
otential, h
r va
otential, h
dures 
on
dures 
ses
xte
ses
ased on th
y ex
ased on th
imary ef
any
imary ef
application and 
will be the 
d a
will be the 
b treatmen
and
b treatmen
d by treatm
n an
d by treatm
ysis of the
atio
ysis of the
nformative
lica
nformative
el is equa
plic
el is equa
Baseline is
app
Baseline is
l be
ap
be use
ap
use
h


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 90 of 136
groups (CZP - bimekizumab) will be summarized with means, standard deviations, 95% credible
intervals and 95% Highest Posterior Density intervals. The posterior probability that the 
difference between treatment groups in the mean change from Baseline in ASDAS is greater than 
zero will also be presented. The posterior probability that bimekizumab achieves a lower 
ASDAS score at Week 12 compared to CZP will be derived from this distribution.
The study will be considered a success if the posterior probability of the difference in the mean 
change from Baseline in ASDAS between the CZP and bimekizumab treatment groups (CZP -
bimekizumab) being greater than zero is at least 97.5% (ie, the lower bound of the 95% credible 
interval of the difference between treatment groups in the mean change from Baseline in ASDAS 
is zero or greater).
If further information (independent to this study) regarding the CZP treatment group response 
comes to light subsequent to writing this protocol then this prior may be updated prior to study 
unblinding, and details of this will be supplied in the SAP and the CSR. Note that the prior will 
not be updated based upon accrued study data at any time point.
15.5.2
Supportive analysis of the primary efficacy variable
A sensitivity analysis on the choice of the prior distribution for the CZP treatment arm will be 
conducted by repeating the primary analysis assuming vague priors for all parameters of the 
model. 
Additional sensitivity analyses will assess the primary efficacy for alternative analysis sets.
Further analyses may be performed for the primary efficacy variable adjusting for other Baseline 
covariates (to be defined in the SAP). Results from any additional analyses will not be used as a 
substitute for the planned analyses, but may be used as supplemental information for the CSR.
15.5.3
Analysis of the secondary efficacy variables
The secondary efficacy variables are listed in Section 4.1.2.
All secondary efficacy variables will be summarized descriptively by treatment group and time 
point. Estimated effects relating to the categorical variables ASDAS-MI and ASDAS-ID will be 
derived from the primary Bayesian analysis. Further details of the analysis methods for 
secondary efficacy variables will be included in the SAP.
15.5.4
Analysis of the other efficacy variables
The other efficacy variables are listed in Section 4.1.3.
The other efficacy variables will be listed and summarized descriptively by treatment group and 
time point. Any formal statistical analyses of the other efficacy variables will be described in 
more detail in the SAP.
Details of the summaries and analyses of efficacy data assessed during the Treatment Extension 
Period, will be provided in the SAP.
15.6
Pharmacokinetic analyses
Bimekizumab and CZP trough plasma concentrations will be listed and summarized by treatment 
group at each time point for all subjects in the PK-PPS using descriptive statistics. 
PUBLIC COPY
butio
Y
butio
ming vag
PY 
ming vag
he prima
C CO
he prima
the prim
LIC 
the prim
). Result
BLIC
). Result
s, but ma
UBL
s, but ma
e sec
PU
e sec
cannot be used to support any marketing authorization 
-
i
-
redible
hori
redible
in ASDA
tho
in ASDA
group resp
g a
group resp
ated prior
ting
ated prior
Note that th
ketin
Note that th
variable
mar
variable
r the CZP 
y m
r the CZP 
e priors fo
any
e priors fo
ry efficacy
port
ry efficacy
ary efficac
upp
ary efficac
from any
sup
from any
y be used
to s
y be used
ondary e
d to
ondary e
are listed i
sed
are listed i
es will be
e u
es will be
ating to th
be 
ating to th
y Bayesia
ot b
y Bayesia
ariables w
not
ariables w
nalysis o
ann
nalysis o
This document 
ficacy vari
t ca
ficacy vari
r efficacy
en
r efficacy
point. Any
me
point. Any
re detail i
cum
re detail i
Details o
doc
Details o
Perio
s do
Perio
1
s
1
on and any extensions or variations thereof.
ponse
eof
ponse
r to study 
ereo
r to study 
th
th
the prior w
ther
e prior w
o
P treatmen
atio
P treatmen
for all par
riat
for all par
y for alter
or v
y for alter
acy variab
s o
acy variab
y addition
ons
y addition
d as suppl
sion
d as suppl
efficacy 
ens
efficacy 
in
e
in Section
xte
Section
e summar
y e
e summar
he categor
any
he categor
an analysi
d an
an analysi
will be inc
nd 
will be inc
of the o
n an
of the ot
applicatio
riables are
tion
riables are
y variable
cati
y variable
y formal s
plica
y formal s
in the SA
ppl
in the SA
f the sum
ap
the sum
be
b


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 91 of 136
15.7
Immunological analyses
Immunological variables will be analyzed for all subjects in the PK-PPS.
Anti-bimekizumab and anti-CZP antibody data will be summarized at each scheduled visit, and 
the rate of ADA positive subjects for each treatment group will be calculated and presented.
15.8
Planned safety and other analyses
15.8.1
Safety analyses
All safety variables will be analyzed for all subjects in the SS.
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA®, version 19.0). The incidence of treatment-emergent adverse events (TEAEs) will be 
summarized descriptively by MedDRA system organ class, preferred term, and treatment group. 
Additional tables will summarize TEAEs by intensity and relationship to IMP, TEAEs leading to 
withdrawal from the study, serious TEAEs, and deaths. All AE information will be listed.
Laboratory values, ECGs, vital signs, physical examination, and extent of exposure will be 
presented descriptively by treatment group. The C-SSRS data will be listed only.
15.9
Handling of protocol deviations
After all data have been verified/coded/entered into a database, a data review will be performed. 
The purpose of this review will be to check all protocol deviations, define the PPS, and check the 
quality of the data. The review will also help decide how to manage problems in the subjects’ 
data (eg, missing values, withdrawals, dropouts, and protocol deviations). 
Accepted deviations from theoretical time points will be described in the appropriate documents 
and included in the Study Master File. After the pre-analysis review, resolution of all issues, and 
documentation of all decisions, the database will be locked.
15.10
Handling of dropouts or missing data
Appropriate missing data imputation methods will be used according to the variable being 
analyzed. Details will be included in the SAP.
15.11
Planned interim analysis and data monitoring
This study will include 3 informal unblinded interim analyses; the first after approximately 
45 subjects have completed 4 weeks of the study, the second when the last randomized subject 
not participating in the PET-MRI or PET-CT substudy has completed the Week 12 Visit at the 
end of the Treatment Period or has withdrawn prematurely from the study, and the third when 
the last randomized subject has completed the Week 12 Visit at the end of the Treatment Period 
or this subject’s participation has ended prematurely. 
The purpose of these interim analyses is for Sponsor key personnel to review results from the 
primary efficacy analysis and a subset of the analyses of secondary efficacy and safety outcomes 
to facilitate additional Clinical Planning or Portfolio Management decisions; consequently, none 
of the interim analyses will lead to any formal decision to alter or terminate the study. 
Interim analyses will be conducted by an unblinded study team and will follow internal SOPs for 
the formal process to control the unblinding of the study for interim analysis purposes. This 
process will ensure that no unnecessary or unintentional unblinding occurs. The unblinded team 
PUBLIC COPY 
Y
ons
PY
ons
into a d
COP
into a d
all proto
CO
all proto
help
IC
help dec
C C
dec
dropout
BLIC
dropout
cal time
UBL
cal time
er File
PU
er File A
U
A
the d
P
the d
nnot be used to support any marketing authorization 
Activities
aut
Activities
(TEAEs)
g a
(TEAEs)
nd treatme
ting
nd treatme
MP, TEA
ketin
MP, TEA
tion will b
rke
tion will b
tent of ex
mar
tent of ex
ill be liste
y m
ill be liste
atabase, a 
rt a
atabase, a 
col deviat
port
col deviat
de how to
ppo
de how to
s, and pro
supp
s, and pro
points wil
to s
points wil
After the p
d to
After the p
atabase w
ed 
atabase w
ropouts
use
ropouts
putation m
be u
putation m
ncluded i
t be
ncluded i
ned inte
not
ned inte
This document ca
nclude 3 in
an
nclude 3 in
ve compl
t ca
ve compl
ating in th
nt c
ating in th
he Treatm
men
he Treatm
st random
ume
st random
this subje
cum
this subje
The pur
doc
The pur
prim
s d
prim
to
s
to
and any extensions or variations thereof.
) will be
eof.
) will be
ment group
ereo
ment group
AEs leadin
her
AEs leadin
be listed.
the
be listed.
xposure w
ons 
xposure w
ed only.
tion
ed only.
a data revi
var
a data revi
tions, defi
or v
tions, defi
o manage 
s or
o manage 
otocol dev
ns 
otocol dev
ill be desc
sion
ill be desc
pre
n
pre-
ns
-analy
nsi
analy
will be loc
ten
will be loc
s or mis
ext
s or mis
methods w
ny 
methods w
in the SA
any
in the SA
erim ana
nd 
erim ana
application a
informal u
n an
informal u
leted 4 we
on 
leted 4 we
the PET
atio
the PET-
o
-M
ment Perio
icat
ment Perio
mized sub
plic
mized sub
ect’s parti
ppl
ect’s parti
se of t
ap
se of t


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 92 of 136
will not disclose any unblinded information to the blinded study team and the storage of all 
unblinded documentation will be held securely and separately from the rest of the study 
documentation and outputs up until the end of the study.
All analyses and unblinding instructions will be prespecified in the interim SAP.
15.12
Determination of sample size
A sufficient number of subjects will be enrolled in order to ensure at least 60 subjects are 
available at Week 12 to compare the change from Baseline in ASDAS between bimekizumab 
and CZP and at least 25 subjects will be enrolled into the PET-CT/MRI substudy.
Subjects will be randomized in a 2:1 ratio to receive bimekizumab or CZP respectively. 
The sample size was calculated to provide at least 80% power to detect a difference between 
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group mean 
change from Baseline for CZP and bimekizumab being -1.78 and -2.67 respectively) with a 
common standard deviation of 1.17 using frequentist methods for the comparison of the 
treatment group mean change from Baseline in ASDAS at Week 12 with Baseline ASDAS as a 
covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week 12 raw 
ASDAS was assumed to be 0.35. Note that the informative prior for the model intercept to be 
used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (-
1.78,var=0.0605), contributes an effective sample size of approximately 20 CZP subjects. A 
prior data conflict test will be performed and a vague prior will be used for the model intercept 
coefficient if this test indicates prior data conflict.
16
ETHICS AND REGULATORY REQUIREMENTS
16.1
Informed consent
Subject’s informed consent must be obtained and documented in accordance with local 
regulations, ICH-GCP requirements, and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the subject in both oral and written form by the Investigator (or 
designee). Each subject will have the opportunity to discuss the study and its alternatives with 
the Investigator.
Prior to participation in the study, the Informed Consent form should be signed and personally 
dated by the subject and by the person who conducted the informed consent discussion 
(Investigator or designee). The subject must receive a copy of the signed and dated Informed 
Consent form. As part of the consent process, each subject must consent to direct access to 
his/her medical records for study-related monitoring, auditing, IRB/IEC review, and regulatory 
inspection.
If the Informed Consent form is amended during the study, the Investigator (or the sponsor, if 
applicable) must follow all applicable regulatory requirements pertaining to the approval of the 
amended Informed Consent form by the IRB/IEC and use of the amended form.
All studies conducted at centers in the United States must include the use of a Health Insurance 
Portability and Accountability Act Authorization form.
PUBLIC COPY
mati
PY
mative
Y 
ve
ficacy va
OPY
ficacy va
mple size 
COP
mple size 
d a vagu
C CO
d a vagu
a conflic
IC C
a conflic
EGULA
BLI
EGULA
sent
PUB
sent
t be
P
t be
ment cannot be used to support any marketing authorization 
mab
o
mab
vely.
au
vely.
ence betw
ng 
ence betw
of 0.89 (g
ting
of 0.89 (g
espectivel
ket
espectivel
compariso
arke
compariso
2 with Ba
mar
2 with Ba
n Baseline
y m
n Baseline
rior for th
ny 
rior for th
riable, giv
t any
riable, giv
of approx
rt a
of approx
e prior wi
por
e prior wi
ATOR
sup
ATORY 
up
Y 
obtained 
ed 
obtained 
nts, and th
use
nts, and th
f Helsinki
e us
f Helsinki
d consent
t be
d consent
abl
o
able to the
ot b
e to the
ect will h
nno
ect will h
cipation in
t ca
cipation in
he subject
ent 
he subject
gator or d
men
gator or d
This docum
sent form.
um
sent form.
s/her med
ocu
s/her med
inspectio
doc
inspectio
If th
s d
If th
a
s
a
lication and any extensions or variations thereof.
ween 
eo
ween 
group mea
here
group mea
ely) with a
the
ely) with a
son of the
s th
son of the
aseline AS
ons
aseline AS
e and We
tion
e and We
he model 
iati
he model 
ven by βC
aria
ven by βC
ximately 2
va
ximately 2
ill be used
or v
ill be used
REQU
ons
REQU
and docu
xten
and docu
he ethical
ext
he ethical
ki.
y
ki.
t, informa
any
t, informa
e subject 
d a
e subject 
have the o
and
have the o
n the stud
tion
n the stud
t and by t
atio
t and by t
designee)
ica
designee)
appl
m. As part 
plic
m. As part 
dical reco
app
dical reco
n
a


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 93 of 136
Separate ICFs will be required for subjects participating in the pharmacogenetic and 
pharmacogenomic substudy and in the PET-MRI or PET-CT substudy conducted at selected 
sites.
The subject may withdraw his/her consent to participate in the study at any time. A subject is 
considered as enrolled in the study when he/she has signed the Informed Consent Form. An 
eCRF must not be started, nor may any study specific procedure be performed for a given 
subject, without having obtained his/her written consent to participate in the study.
16.2
Subject identification cards
Upon signing the Informed Consent form, the subject will be provided with a subject 
identification card in the language of the subject. The Investigator will fill in the subject 
identifying information and medical emergency contact information. The Investigator will 
instruct the subject to keep the card with him/her at all times.
16.3
Institutional Review Boards and Independent Ethics 
Committees
The study will be conducted under the auspices of an IRB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki.
The Investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies with 
the requirements of the current ICH-GCP version or applicable country-specific regulations will 
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
initiation of the study, the Investigator/UCB will forward copies of the protocol, Informed 
Consent form, IB, Investigator’s curriculum vitae (if applicable), advertisement (if applicable), 
and all other subject-related documents to be used for the study to the IRB/IEC for its review and 
approval.
Before initiating a study, the Investigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.
The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.
The Investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by the original 
approval, it may be possible for the Investigator to obtain an expedited review by the IRB/IEC as 
allowed.
As part of the IRB/IEC requirements for continuing review of approved studies, the Investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The Investigator should provide a final report to the IRB/IEC following study 
completion.
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active Investigators in accordance with applicable regulatory requirements. 
PUBLIC COPY
RB
Y
RB
ples th
PY 
ples th
propriate
CO
propriate
version 
C C
version 
nuing rev
LIC
nuing rev
tor/UCB
BLI
tor/UCB
curriculu
UB
curriculu
cument
PU
cument
This document cannot be used to support any marketing authorization 
t 
a
t 
subject 
g au
subject 
stigator w
ng 
stigator w
nt Ethics
rke
nt Ethics
as defined
y m
as defined
have their
ny 
have their
ly constitu
ort 
ly constitu
or applicab
ppo
or applicab
iew and ap
upp
iew and ap
will forwa
sup
will forwa
m vitae (i
to s
m vitae (i
 to be use
d to
 to be use
vestigator 
us
vestigator 
protocol.
be u
protocol.
o promptl
ot b
o promptl
ms in
no
ms involvin
not
volvin
diate hazar
nno
diate hazar
or will not
ca
or will not
xcept whe
nt c
xcept whe
anges to a
ent
anges to a
val, it may
me
val, it may
wed.
cum
wed.
As part o
doc
As part o
will b
s do
will b
req
s 
req
application and any extensions or variations thereof.
will
re
will
cs
s
cs
ed in local
tion
ed in local
ir origin in
riati
ir origin in
tute
r
tuted IRB/
r va
d IRB/
able count
or 
able count
approval o
ns o
approval o
ward copie
ions
ward copie
if applica
sio
if applica
ed for the
ens
ed for the
r will have
ex
r will have
ly report t
d an
ly report t
ing risks t
nd a
ing risks t
ards to sub
and
ards to sub
ot make an
on a
ot make an
ere necess
tion
ere necess
a previou
cati
a previou
ay be poss
plica
ay be poss
f the I
ap
the IRB
p
RB
on
a


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 94 of 136
The appropriate IRB/IEC will also be informed by the Investigator or the sponsor, as specified 
by the applicable regulatory requirements in each concerned country. Where applicable, 
Investigators are to provide the sponsor (or its representative) with evidence of such IRB/IEC 
notification.
16.4
Subject privacy
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by the subject number 
assigned at Screening.
The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
subject’s primary medical records that directly concerns this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospital 
admissions occurring during a subject’s study participation, and autopsy reports for deaths 
occurring during the study).
16.5
Protocol amendments
Protocol changes may affect the legal and ethical status of the study and may also affect the 
statistical evaluations of sample size and the likelihood of the study fulfilling its primary 
objective.
Significant changes to the protocol will only be made as an amendment to the protocol and must 
be approved by UCB, the IRB/IEC, and the regulatory authorities (if required), prior to being 
implemented.
17
FINANCE, INSURANCE, AND PUBLICATION
Insurance coverage will be handled according to local requirements.
Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
agreements, as applicable.
18
REFERENCES
Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of 
active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody 
infliximab. Arthritis Rheum. 2000;43:1346-52.
Braun J. Axial spondyloarthritis: thoughts about nomenclature and treatment targets. Clin Exp 
Rheumatol. 2012;30:S132-5.
Braun J, Sieper J. Ankylosing spondylitis. Lancet. 2007;369:1379-90.
Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 
2010 update of the ASAS/EULAR recommendations for the management of ankylosing 
spondylitis. Ann Rheum Dis. 2011;70:896-904.
Braun J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin 
Rheumatol. 2002;16:573-604.
PUBLIC COPY
atus of 
PY 
atus of 
lihood o
OPY
lihood o
nly be m
C C
nly be m
d the reg
LIC
d the reg
NSURA
PUB
NSURA
led
P
led
This document cannot be used to support any marketing authorization 
er 
o
er 
the releva
auth
the releva
at portion
g au
at portion
but not li
ng 
but not li
for hospi
eting
for hospi
reports fo
ket
reports fo
e study an
ny 
e study an
the study
t any
the study
de as an a
ppo
de as an a
ulatory au
upp
ulatory au
NCE,
d to
NCE, A
according
ed 
according
ion rights
use
ion rights
ENCES
t b
ENCES
Cornely D
nno
Cornely D
spondyli
ann
spondyli
thritis Rhe
t ca
thritis Rhe
Axial spon
ent 
Axial spon
atol. 2012
men
atol. 2012
aun J, Siep
cum
aun J, Siep
Braun J, 
doc
Braun J, 
2
s d
2010 
do
010 
spo
s 
spo
application and any extensions or variations thereof.
van
f
van
n of th
of
n of the
f.
e
imited to,
reo
imited to,
ital
he
ital
for deaths
the
for deaths
nd may al
iati
nd may al
y fulfilling
aria
y fulfilling
amendme
or 
amendme
uthorities 
ns o
uthorities 
AND PU
nsio
AND PU
g to local 
xten
g to local 
s are addr
ex
s are addr
S
d
S
D, Golder
and
D, Golder
itis with th
an
itis with th
heum. 200
on a
heum. 200
ndyloarthr
atio
ndyloarthr
2;30:S132
ica
2;30:S132
per J. Ank
ppli
per J. Ank
van den 
ap
an den 
of
a
f


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 95 of 136
Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, et al. Efficacy of 
sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis 
and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis. 
2006;65:1147-53.
Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to 
defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing 
Spondylitis Functional Index. J Rheumatol. 1994;2:2281-5.
Chabaud M, Lubberts E, Joosten L, van den Berg W, Miossec P. IL-17 derived from juxta-
articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis 
Res. 2001;3:168–77. 
CPMP/ICH/135/95. Note for guidance on good clinical practice. July 2002. 
CPMP/EWP/556/95. Guideline on clinical investigation of medicinal products other than 
NSAIDs for treatment of rheumatoid arthritis. Mar 2015. 
Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. Improvements 
in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or 
paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol 
Venereol. 2009;23(12):1374-82.
Diderichsen PM, Cox E (Quantitative Solutions BV, Breda, NL). Comparative effectiveness 
modeling of treatment in ankylosing spondylitis. Final Report. UCB Celltech; 2016 Feb. Project 
report No.: UCB-MBMA-AS-164.
Davis JC, Mease PJ. Insights into the pathology and treatment of spondyloarthritis: from the 
bench to the clinic. Semin Arthritis Rheum. 2008;38(2):83-100. 
Even-Sapir E, Mishani E, Flusser G, Metser U: 18F-Fluoride positron emission tomography and 
positron emission tomography/computed tomography. Semin Nucl Med. 2007;37:462–9.
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to 
defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease 
Activity Index. J Rheumatol. 1994;21:2286-91.
Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al. No efficacy of 
subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann 
Rheum Dis. 2007;66:419-21.
Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active 
ankylosing spondylitis. Ann Rheum Dis. 2005;64:124-6.
Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh KC, et al. Estimates of the 
prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis 
Rheum. 2008;58:15-25.
International Menopause Society. Cornwall, UK: Menopause Terminology; c2015. 
http://www.imsociety.org/menopause_terminology.php. Accessed 25 Jan 2016.
Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of 
certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing 
PUBLIC COPY
YSTEL
PY 
YSTEL
ns BV, B
CO
ns BV, B
dylitis. F
C C
dylitis. F
he patho
UBL
he patho
itis Rheu
PUB
itis Rheu
er G,
P
er G,
nnot be used to support any marketing authorization 
ta
th
ta-
h
-
Arthritis
uth
Arthritis
ucts other
ketin
ucts other
rtson D, e
mar
rtson D, e
ients rece
y m
ients rece
udy. J Eu
ny 
udy. J Eu
Breda, NL
ort 
Breda, NL
nal Repor
po
nal Repor
ogy and tr
o su
ogy and tr
m. 2008;3
to s
m. 2008;3
Metser U
ed t
Metser U
mputed to
sed
mputed to
dy LG, W
e u
dy LG, W
nkylosing
be 
nkylosing
matol. 1994
ot b
matol. 1994
C, Song IH
nno
C, Song IH
ument ca
thotrexate
ann
thotrexate
007;66:41
t ca
007;66:41
Rudwalei
ent 
Rudwalei
sing spond
men
sing spond
This docu
lmick CG
cum
lmick CG
prevalenc
docu
prevalenc
Rheum
do
Rheum
Int
s 
Int
and any extensions or variations thereof.
er than
her
er than
et al.
ons
et al. Imp
ns
Imp
eiving con
tion
eiving con
ur Ac
iati
ur Acad D
ati
ad D
L). Compa
r va
L). Compa
rt. UCB C
or 
rt. UCB C
treatment 
ion
treatment 
38(2):83
nsio
38(2):83
U: 18F
ten
U: 18F-
en
-Flu
n
Flu
omograph
exte
omograph
Whitelock
y e
Whitelock
g spondyl
any
g spondyl
4;21:228
d an
4;21:228
IH, Brand
and
IH, Brand
plication a
e in activ
n an
e in activ
19
o
19-
o
-21.
on
21.
eit M, Bra
atio
eit M, Bra
ndylitis. A
lica
ndylitis. A
app
G, Felson 
ppl
G, Felson 
e of arthr
app
e of arthr
08;5
a
08;5


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 96 of 136
spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann 
Rheum Dis. 2014;73:39-47.
Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, et al. Ustekinumab 
significantly improves symptoms of anxiety, depression, and skin-related quality of life in 
patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-
controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457-65. 
Lories RJU, Luyten FP, de Vlam K. Progress in spondylarthritis. Mechanisms of new bone 
formation in spondyloarthritis. Arthritis Res Ther. 2009;11:221.
Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an 
ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann 
Rheum Dis. 2009;68:18-24.
Mease PJ, Fleischmann R, Wollenhaupt J, Deodhar A, Gladman D, Hoepken B, et al. Long-term 
safety and efficacy of certolizumab pegol in patients with psoriatic arthritis with and without 
prior anti-tumor necrosis factor exposure: 96-week outcomes from the RAPID-PsA trial. 
Presented at the European League Against Rheumatism (EULAR) 2014 Congress. Abstract 
#OP0077.
Miossec P. Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and 
implication for clinical practice. RMD Open. 2017;3(1):e000284). 
Mundt JC, Greist JH, Gelenberg AJ, Katzelnick DJ, Jefferson JW, Modell JG. Feasibility and 
Validation of a Computer-Automated Columbia-Suicide severity Rating Scale Using Interactive 
Voice Response Technology. J Psychiatr Res. 2010;44(16):1224-8.
Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE. Is the incidence of 
rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007. Arthritis 
Rheum. 2010;62:1576-82.
Nam, JM. A simple approximation for calculating sample sizes for detecting linear trend in 
proportions. Biometrics. 1987;43(3):701-5.
National Research Council Panel on Handling Missing Data in Clinical Trials. The prevention 
and treatment of missing data in clinical trials. Washington DC: National Academies Press. 
2010. Ogdie A, Weiss P. The Epidemiology of Psoriatic Arthritis. Rheum Dis Clin North Am. 
2015;41(4):545-68.
Ono T, Okamoto K, Nakashima T, Nitta T, Hori S, Iwakura Y, et al. IL-17-producing γδ T cells 
enhance bone regeneration. Nat Commun. 2016;11;7:10928.
Osta B, Lavocat F, Eljaafari A, et al. Effects of interleukin-17A on osteogenic differentiation of 
isolated human mesenchymal stem cells. Front Immunol. 2014;5:425.
Overall J, Starbuck R. Sample size estimation for randomized pre-post designs. Journal of 
Psychiatric Research. 1979;15(1):51-5. 
Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for the 
bath ankylosing spondylitis indices: a prospective study. J Rheumatol. 2005;32:80-5.
Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet 
Dis. 2013;5:45-54.
PUBLIC COPY 
e pathog
OPY
e pathog
2017;3(1
COP
2017;3(1
elnick D
C C
elnick D
olumbia
LIC 
olumbia
hiatr Res
BLI
hiatr Res
remers H
PUB
remers H
sults fr
PU
sults fr
t be used to support any marketing authorization 
f an
aut
f an
ndylitis. 
g au
ndylitis. A
u
A
ken B, et a
ketin
ken B, et a
ritis with 
rke
ritis with 
he RAPID
ark
he RAPID
) 2014 Co
ma
) 2014 Co
nesis of in
any
nesis of in
:e000284
rt a
:e000284
, Jefferson
po
, Jefferson
Suicide s
upp
Suicide s
. 2010;44
sup
. 2010;44
M, Thern
to s
M, Thern
m Olmste
d to
m Olmste
tion for ca
us
tion for ca
87;43(3):7
be u
87;43(3):7
This document cannot
cil Panel 
ot b
cil Panel 
ing data i
not
ing data i
eiss P. Th
ann
eiss P. Th
68.
ca
68.
amoto K, 
nt c
amoto K, 
bone rege
men
bone rege
a B, Lavoc
um
a B, Lavoc
solated hu
ocu
solated hu
Overal
do
Overal
Psy
s d
Psy
any extensions or variations thereof.
Ann
of
Ann
al. 
h
al. Long
her
Long
and with
th
and with
D
n
D-PsA tria
ns t
PsA tria
ongress. A
ions
ongress. A
inflammat
aria
inflammat
4).
v
4).
n JW, Mo
or 
n JW, Mo
severity R
s o
severity R
4(16):1224
ons
4(16):1224
neau T
nsio
neau TM, 
io
M, 
ed County
ens
ed County
alculating
y ex
alculating
701
n
701
application and a
-
ny
-5.
ny
5.
on Hand
d an
on Hand
in clinica
nd 
in clinica
he Epidem
an
he Epidem
Nakashim
atio
Nakashim
generation
cat
generation
ocat F, Elj
plic
ocat F, Elj
uman mes
app
uman mes
Starb
a
Starb


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 97 of 136
Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, et al. Effect of 
non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial 
spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis. 
2012;71:1616-22.
Ramiro S, van der Heijde D, van Tubergen A, Stolwijk C, Dougados M, van den Bosch F, et al. 
Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 
12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73:1455-61.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The 
Columbia-Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From 
Three Multisite Studies With Adolescents and Adults. Am J Psychiatry. 2011;168(12):1266-77.
Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondyloarthritis in the United States: 
estimates from a cross-sectional survey. Arthritis Care Res (Hoboken). 2012;64:905-10.
Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral 
spondyloarthritis. Curr Opin Rheumatol. 2010;22:375-80.
Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, et al. The early 
disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception 
Cohort. Arthritis Rheum. 2009a;60:717-27.
Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The 
Assessment of SpondyloArthritis International Society classification criteria for peripheral 
spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25-31.
Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development 
of Assessment of SpondyloArthritis international Society classification criteria for axial 
spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty 
appraisal. Ann Rheum Dis. 2009b;68:770-6.
Shah et al. unpublished data/abstract submitted European League Against Rheumatism; 14–17 
June 2017. 
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment 
of SpondyloArthritis International Society (ASAS) handbook: a guide to assess 
spondyloarthritis. Ann Rheum Dis. 2009;68(Supple 2):ii1-44.
Sieper J, Kivitz A, van Tubergen A, Deodhar A, Coteur G, Woltering F, et al. Rapid 
improvements in patient-reported outcomes with certolizumab pegol in patients with axial 
spondyloarthritis, including ankylosing spondylitis: 24-Week results of RAPID-axSpA trial. 
European League Against Rheumatism (EULAR) 2013b, Congress 2013; Abstract # THU0360.
Sieper J, Rudwaleit M, van der Heijde D. Long-term safety and efficacy of certolizumab pegol in 
patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial 
spondyloarthritis: 96-week outcomes of the RAPID-axSpA trial. Presented at the European 
League Against Rheumatism (EULAR) 2014 Congress. Abstract #SAT0351.
Snaith RP, Zigmond AS. The hospital anxiety and depression scale, with the irritability-
depression-anxiety scale and the Leeds situational anxiety scale manual. 1994.
PUBLIC COPY
he Ger
PY 
he Ger
Akkoc N
CO
Akkoc N
onal Soc
C C
onal Soc
itis in ge
LIC 
itis in ge
Heijde D
UBL
Heijde D
ritis inte
PUB
ritis inte
ificatio
PU
ificatio
b
P
b
nnot be used to support any marketing authorization 
ndings Fro
uth
ndings Fro
12):1266
au
12):1266
the Unite
ng 
the Unite
2;64:905
eting
2;64:905
and periph
rke
and periph
nn E, Zeid
y m
nn E, Zeid
an Spondy
ny 
an Spondy
N, Brandt J
ort 
N, Brandt J
iety classi
po
iety classi
neral.
upp
neral. Ann
pp
Ann
, Listing J
o su
, Listing J
national S
to s
national S
n of paper
d to
n of paper
68:770
sed
68:770-
d
-6.
d
6.
ststract sub
us
ract sub
Baraliakos
ot b
Baraliakos
Internatio
not
Internatio
ocument can
Ann Rheu
ann
Ann Rheu
z A, van T
t ca
z A, van T
nts in pat
nt c
nts in pat
oarthritis, 
men
oarthritis, 
pean Leag
ume
pean Leag
ieper J, R
ocu
ieper J, R
This do
patients
doc
patients
spon
s d
spon
Le
s
Le
nd any extensions or variations thereof.
o
-
f
-77.
f
77.
ed States:
reo
ed States:
10.
e
10.
heral 
th
heral 
dler H, et
tion
dler H, et
yloarthrit
iati
yloarthrit
J, Chou C
r va
J, Chou C
ification c
or 
ification c
n Rheum 
s o
n Rheum 
J, Brandt 
ion
J, Brandt 
Society cl
nsio
Society cl
r patients 
ens
r patients 
bmitted Eu
y ex
bmitted Eu
os X, Bran
d an
os X, Bran
onal Socie
nd 
onal Socie
application a
um Dis. 2
an
um Dis. 2
Tubergen
on 
Tubergen
tient
atio
tient-
tio
-repo
io
repo
, including
cat
, including
gue Again
plic
gue Again
Rudwaleit
app
Rudwaleit
a
ith axi
ap
ith axi


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 98 of 136
Strobel K, Fischer DR, Tamborrini G, Kyburz D, Stumpe KD, Hesselmann RG, Johayem A, von 
Schulthess GK, Michel BA, Ciurea A. 18F-fluoride PET/CT for detection of sacroiliitis in 
ankylosing spondylitis. Eur J Nucl Med Mol Imaging. 2010; 37:1760–65.
van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J, et al. 
Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of 
America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis 
Rheum. 2005;52:386-94.
van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P, et al. 
Radiographic findings following two years of infliximab therapy in patients with ankylosing 
spondylitis. Arthritis Rheum. 2008;58:3063-70.
van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, et al. Adalimumab 
effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: 
long-term results from the ATLAS trial. Ann Rheum Dis. 2009;68:922-9.
van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing 
spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 
1984;27:361-68.
van Tubergen A, Black PM, Coteur G. Are patient-reported outcome instruments for ankylosing 
spondylitis fit for purpose for the axial spondyloarthritis patient? A Qualitative and Psychometric 
Analysis. Rheum. 2015;54:1842-51.
van Tubergen A, Debats I, Ryser L, Londoño J, Burgos-Vargas R, Cardiel MH, et al. Use of a 
numerical rating scale as an answer modality in ankylosing spondylitis-specific questionnaires. 
Arthritis Rheum. 2002a;47:242-8.
van Tubergen A, Coenen J, Landewé R, Spoorenberg A, Chorus A, Boonen A, et al. Assessment 
of fatigue in patients with ankylosing spondylitis: a psychometric analysis. Arthritis Rheum. 
2002b;47:8-16.
Wein MN, Jones DC, Shim JH, et al. Control of bone resorption in mice by Schnurri-3. Proc Natl 
Acad Sci. 2012;109:8173–8. 
PUBLIC COPY 
nt
O
nt-
P
-reporte
OPY
reporte
loarthrit
COP
loarthrit
ndoño J,
LIC 
ndoño J,
modality
BLI
modality
ndewé 
PU
ndewé 
i
P
i
This document cannot be used to support any marketing authorization 
, et al
tho
, et al.
o
.
ylosing
uth
ylosing
Adalimum
ng 
Adalimum
p to 2 yea
eting
p to 2 yea
.
k
.
criteria fo
mark
criteria fo
Arthritis
ma
Arthritis
d outcom
any
d outcom
s patient? 
rt a
s patient? 
Burgos
upp
Burgos-
p
-V
p
V
in ankylo
sup
in ankylo
R, Spoore
d to
R, Spoore
ng spondy
sed
ng spondy
JH, et al. 
be u
JH, et al. 
–
t
–8.
t b
8.
application and any extensions or variations thereof.
mab 
reo
mab 
ars:
he
ars:
for ankylo
ns t
for ankylo
s Rheum.
ons
s Rheum.
me instrum
aria
me instrum
? A Qualit
va
? A Qualit
Vargas R, 
s o
Vargas R, 
osing spon
ons
osing spon
enberg A, 
ens
enberg A, 
ylitis: a ps
xte
ylitis: a ps
Control o
ny 
Control o


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 99 of 136
19
APPENDICES
19.1
Modified New York (mNY) Classification Criteria for AS
Table 19‒1: Modified New York (mNY) Classification Criteria for AS
Diagnosis
1. Clinical criteria:
a.
Low back pain and stiffness for more than 3 months which improves with exercise, but is 
not relieved by rest 
b.
Limitation of motion of the lumbar spine in both the sagittal and frontal planes.
c.
Limitation of chest expansion relative to normal values corrected for age and sex.
2. Radiologic criterion:
Sacroiliitis grade ≥2 bilaterally or grade 3 to 4 unilaterally
Grading
1. Definite ankylosing spondylitis if the radiologic criterion is associated with at least 1 
clinical criterion
AS=ankylosing spondylitis; mNY=modified New York Criteria
Note: A second grading of “probably ankylosing spondylitis” is part of the modified NY criteria, but it is not 
applicable for this study. It is included here for completeness. The grading will be probable ankylosing 
spondylitis if 3 clinical criteria are present and the radiologic criterion is present without any signs or 
symptoms satisfying the clinical criteria (other causes of sacroiliitis should be considered).
COPY 
logic cri
OPY
logic cri
Y
PUBLIC C
w York C
C C
w York C
ing spond
LIC 
ing spond
ere for 
BLIC
ere for co
IC
co
esent and 
UBL
esent and 
iteria (oth
PUB
iteria (oth
C
ort any marketing authorization 
but is
tho
but is
al planes.
g a
al planes.
for age an
ting
for age an
z
riz
eti
m
erion is as
t any
erion is as
ny
This document cannot be used to suppor
iteria
po
iteria
ylitis” is pa
pp
ylitis” is pa
mpleteness. 
sup
mpleteness. 
he radiolog
su
he radiolog
r causes of
to s
r causes of
or
r variations thereof.
nd sex.
ere
nd sex.
f.
he
on
associated
aria
associated
at
application and any extensions or 
rt of the mo
s o
rt of the mo
The gradin
ns 
The gradin
ic criterion
ion
ic criterion
f sacroiliitis
sio
f sacroiliitis
r v


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 100 of 136
19.2
Markedly abnormal laboratory values
Table 19‒2: Definitions of markedly abnormal hematology values
Parameter (SI units)
Markedly Abnormal Definition
Low
High
Hemoglobin (g/dL)
<LLN 
AND 
>2.0 decrease from baseline
N/A
Hemoglobin (g/dL)
<8.0
N/A
Leukocytes (total x 1000)
<2.0
N/A
Lymphocytes (x 1000)
<0.5
N/A
Neutrophils (x 1000)
<1.0
N/A
Platelets (x 1000)
<50
N/A
LLN=lower limit of normal; N/A = Not Applicable: SI=standard international
Data source: modified from Appendix Rheumatology Common Toxicity Criteria v.2.0 presented in 
Woodworth et al, 2007
a Withdrawal criteria for neutrophils is <0.5 (Section 6.3)
Table 19‒3: Definitions of markedly abnormal biochemistry values
Parameter (SI units)
Markedly Abnormal Definition
Low 
High
Alkaline Phosphatase
N/A
>3 x ULN
ALT
N/A
>3 x ULN
AST
N/A
>3 x ULN
Calcium (mg/dL)
<7.0
>12.5
Creatinine (mg/dL)
N/A
>1.8 x ULN
Glucose (mg/dL)
<40
>250
Potassium (mmol/L)
<3.0
>6.4
Sodium (mmol/L)
<125
N/A
Total bilirubin
N/A
≥2 x ULN
Uric acid
N/A
≥3 x ULN
ALT=alanine aminotransferase; AST=aspartate aminotransferase; N/A=Not applicable; SI=standard international; 
ULN=upper limit of normal
PUBLIC COPY
inte
Y
inte
n Toxici
PY 
n Toxici
)
C
)
kedly ab
BLIC
kedly ab
BL
U
This document cannot be used to support any marketing authorization 
a
za
/A
a
/A
ut
N/A
ng
N/A
a
N/A
n
N/A
ing
ke
ar
m
nal
y
nal
Criteria v.2
ny
Criteria v.2
m
normal b
sup
normal b
s
to
ed
us
us
us
us
us
be
/dL)
no
/dL)
ot
e (mg/dL)
ann
e (mg/dL)
nn
cose (mg/d
t ca
cose (mg/d
ca
otassium (
ent
otassium (
nt
Sodiu
me
Sodiu
me
um
oc
s
ALT
s 
ALT
s d
s d
application and any extensions or variations thereof.
of
A
h
A
re
N/A
s th
N/A
the
N/A
ns
N/A
s 
2.0 present
riat
2.0 present
io
biochem
ons 
biochem
Marked
sio
Marked
on
Low 
ten
Low 
ns
N/
t
N/
te
ex
ny
d a
d
n
dL)
io
dL)
n
(mmol/L)
cati
(mmol/L)
tio
um (mmol/
plic
um (mmol/
ca
Total bili
app
Total bili
pl
Ur
a
Ur
ap


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 101 of 136
19.3
Protocol Amendment 1
Rationale for the amendment
The purpose of this protocol amendment is the following: 

Sections summarizing the use of concomitant DMARDs have been updated for internal 
consistency.

hs-CRP was added to the assessments at Screening.
In addition, minor clarifications were made and typographical errors were corrected.
Modifications and changes
Global changes
No global changes have been made.
Specific changes
Change #1 
Section 1, Summary, paragraph 8

Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
Has been changed to:

Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
order to maintain the blind vs the certolizumab pegol (CZP) loading dose at these visits. 
PUBLIC COPY 
 Week 0
LIC 
 Week 0
seline (V
BLI
seline (V
the certo
UB
the certo
e used to support any marketing authorization 
through W
upp
through W
isit 2), W
sup
isit 2), W
lizumab p
to s
lizumab p
W from We
use
W from We
at Baselin
e us
at Baselin
This document cannot be
nd vs the 
be 
nd vs the 
y extensions or variations thereof.
Week
ns o
Week 10.
o
10.
Week 2 (V
ons
Week 2 (V
pegol (CZ
sio
pegol (CZ
eek 0 thro
exte
eek 0 thro
ine (Visit 
y ex
ine (Visit 
application and any
e certolizu
ny 
e certolizu


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 102 of 136
Change #2
Table 5-1, Schedule of assessments, Screening
Study Period
S
C
r
Treatment Period
Treatment Extension Period
SF
Ua
Visitb/Week 
(Visit window 
±3 days)
V
1
V
2
V
3
V
4
V
5
V
6
V7
V8
V9
V1
0
V1
1
V1
2
V1
3
V1
4
V1
5
V1
6
V1
7
V1
8
Procedures
S
V
B
L 
W
0
W
2
W
4
W
6
W
8
W
10
W
12
W
16
W
20
W
24
W
28
W
32
W
36
W
40
W
44
W
48
/
W
D
W
64
Blood sample 
for hs-CRPk
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Has been changed to:
Study Period
S
C
r
Treatment Period
Treatment Extension Period
SF
Ua
Visitb/Week 
(Visit window 
±3 days)
V
1
V
2
V
3
V
4
V
5
V
6
V7
V8
V9
V1
0
V1
1
V1
2
V1
3
V1
4
V1
5
V1
6
V1
7
V1
8
Procedures
S
V
B
L 
W
0
W
2
W
4
W
6
W
8
W
10
W
12
W
16
W
20
W
24
W
28
W
32
W
36
W
40
W
44
W
48
/
W
D
W
64
Blood sample 
for hs-CRPk
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Change #3
Table 5-1, Schedule of assessments, footnote g
g The physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, 
height (Screening only) and weight (Baseline, Week 12 and Week 48/WD only).
Has been changed to:
g The physical examination includes the evaluation of signs and symptoms of active TB, risk for exposure to TB, 
height (Screening only) and weight (Screening, Week 12 and Week 48/WD only).
PUBLIC COPY 
Y
CO
7
C
7
V8
C C
V8
CO
CO
CO
BL C CO
PUBL
W
U
W
6
PU
6
W
UB
W
8
U
8
BL
BL
BL
PUBL
to support any marketing authorization 
at
V1
iza
V1
8
riz
8
at
at
thor zat
W
u
W
44
au
44
W
th
W
48
48
th
tho
eti g
utho
X
X
ke
X
et
et
arket
Treatment
any
Treatment
y
V9
p
V9
V1
po
V1
0
p
0
or
supp
cannot be used to su
r
W
10
d t
10
W
o s
W
12
o
12
W
su
su
su
u ed to su
u
X
u
X
u
t be
b
u
This document 
Schedu
t ca
Schedu
cal examin
ent
cal examin
Screening o
me
Screening o
as been 
cum
as been 
g
d
g The phy
doc
The phy
height 
s do
height 
ns or variations thereof.
8
/
o
/
W
reo
W
D
re
D
6
f
6
her of
X
t
X
X
h
X
he
ns the
Extension
ria
Extension
at
V1
o
V1
1
s o
1
V1
r 
V1
r v
ons
n and any extensions or v
W
s
W
16
ns
16
W
io
W
20
i
20
on
e te si n
X
e
X
e
X
e
an
applicatio
e
ule of as
tion
ule of as
nation inclu
cati
nation inclu
only) and w
lica
only) and w
n change
ppl
n change
a
cal exam
ap
cal exam
ing
a
ing


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 103 of 136
Change #4
Section 7.8.1 Permitted concomitant treatments (medications and 
therapies)
The following concomitant medications are permitted during the study:
Subjects may use NSAIDs under the following conditions:

Subjects who are already receiving an established NSAID regimen and have been on a stable 
dose for at least 2 weeks prior to Baseline may continue their use during the study. However, 
initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a 
history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
caution and must not occur until after the Week 12 Visit.
Subjects may use corticosteroids under the following conditions:

Oral (maximum allowed ≤10mg daily total prednisone equivalent)—subjects are permitted to 
decrease their oral corticosteroid therapy dose equivalent and/or alter their regimen only after 
Week 12
Subjects may use sulfasalazine and/or hydroxychloroquine under the following conditions:

Sulfasalazine (maximum SSZ ≤3g daily) and/or hydroxychloroquine (≤400mg daily) are 
allowed. No change in dose or dose regimen is allowed during the study except for reasons of 
intolerance, where the DMARD dose may be reduced or discontinued.
Subjects may use MTX under the following conditions:

No change in dose or dose regimen of MTX is allowed during the study except for reasons of 
intolerance/AEs. No increase of the MTX dose is permitted. No change is permitted in the 
route of administration for MTX (intramuscular [im], sc, or oral). It is strongly recommended 
that subjects taking MTX are also taking folic acid supplements. No combinations of 
DMARDs are permitted during the study.
Has been changed to: 
The following concomitant medications are permitted during the study:
Subjects may use NSAIDs under the following conditions:

Subjects who are already receiving an established NSAID regimen and have been on a stable 
dose for at least 2 weeks prior to Baseline may continue their use during the study. However, 
initiation of, or increase in dosage of NSAIDs during the study (especially in subjects with a 
history of GI intolerance to NSAIDs or a history of GI ulceration) should be done with 
caution and must not occur until after the Week 12 Visit.
Subjects may use corticosteroids under the following conditions:

Oral (maximum allowed ≤10mg daily total prednisone equivalent)—subjects are permitted to 
decrease their oral corticosteroid therapy dose equivalent and/or alter their regimen only after 
Week 12
Subjects may use MTX, sulfasalazine (SSZ), or hydroxychloroquine (HCQ) under the following 
conditions:
PUBLIC COPY
oquine
PY 
oquine
d/or hyd
OP
d/or hyd
men is al
CO
men is al
may be r
C C
may be r
owing c
BLIC
owing c
gimen of
UB
gimen of
se of th
PU
se of th
MTX
P
MTX
document cannot be used to support any marketing authorization 
stable
oriz
stable
However,
thor
However,
ects with 
uth
ects with 
one with 
au
one with 
—
r
—subjects
rke
subjects
alter thei
mar
alter thei
nder the f
ny 
nder the f
roxychloro
rt a
roxychloro
owed dur
ort 
owed dur
educed or
ppo
educed or
onditions:
sup
onditions:
MTX is a
to s
MTX is a
MTX do
d to
MTX do
(intramu
ed 
(intramu
also takin
use
also takin
uring the s
e us
uring the s
o: 
t
o: 
mitant med
not 
mitant med
NSAIDs 
ann
NSAIDs 
who are al
t ca
who are al
or at least 
ent 
or at least 
ation of, o
men
ation of, o
istory of 
um
istory of 
caution 
cu
caution 
This do
Subject
do
Subject

s 

application and any extensions or variations thereof.
ts are perm
s th
ts are perm
ir regimen
ns 
ir regimen
following
iati
following
roquine (≤
var
roquine (≤
ring the st
r va
ring the st
r discontin
or 
r discontin
allowed d
sio
allowed d
ose is perm
ens
ose is perm
uscular [im
xten
uscular [im
ng folic ac
ext
ng folic ac
study.
y e
study.
dications 
nd a
dications 
under the
an
under the
already rec
ion 
already rec
2 weeks 
atio
2 weeks 
or increas
icat
or increas
GI intole
plic
GI intole
and mus
pp
and mus
may us
ap
may us


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 104 of 136

No change in dose or dose regimen of these agents is allowed during the study except for 
reasons of intolerance/AEs. No increase of the dose is permitted. No change is permitted in 
the route of administration for MTX (intramuscular [im], sc, or oral). It is strongly 
recommended that subjects taking MTX are also taking folic acid supplements. No 
combinations of DMARDs are permitted during the study.
Change #5 
Table 7-2, Prohibited or restricted medications and required wash-out 
periods prior to Baseline (MTX, SSZ, and HCQ)
Drug class
Dose
Exclusion criteria
…
MTX
Any dose regimen
Use within 12 weeks prior to the Baseline 
Visit 
SSZ
Any dose
Use within 12 weeks prior to the Baseline 
Visit 
HCQ
Any dose
Use within 12 weeks prior to the Baseline 
Visit 
…
ADA=adalimumab; COX-2=cyclooxygenase 2; CZP=certolizumab pegol; DMARD=disease modifying 
antirheumatic drug; ETN=etanercept; GOL=golimumab; HCQ=hydroxychloroquine; IFX=infliximab; 
ia=intra-articular; im=intramuscular; iv=intravenous; MTX=methotrexate; NSAID=nonsteroidal 
anti-inflammatory drug; sc=subcutaneous; SSZ=sulfasalazine; TNF=tumor necrosis factor 
Has been changed to:
Drug class
Dose
Exclusion criteria
…
MTX
Any dose regimen
Use within 12 weeks prior to the Baseline 
Visit 
SSZ
Any dose
Use within 12 weeks prior to the Baseline 
Visit 
MTX, SSZ, and HCQ
Maximum allowed: 
SSZ ≤3g daily 
HCQ ≤400mg daily 
MTX ≤25mg weekly
Use initiated and/or any change in the 
dose regimen in the 28 days prior to the 
Baseline Visit. No change is permitted in 
the route of administration for MTX (im, 
sc, or oral) in the 28 days prior to the 
Baseline Visit.
HCQ
Any dose
Use within 12 weeks prior to the Baseline 
Visit 
…
PUBLIC COPY 
Y
OP
C C
ase 2; 
BL
ase 2; CZ
LI
CZ
GOL=go
UB
GOL=go
r; iv=intr
PUB
r; iv=intr
taneous
PU
taneous
LIC
This document cannot be used to support any marketing authorization 
ut 
th
ut 
a
ing
in 12 week
ma
in 12 week
ar
Use within 1
ny 
Use within 1
Visit 
an
Visit 
y m
t
Use w
rt 
Use w
V
r
V
t a
ort
po
=certolizum
sup
=certolizum
mumab; H
o s
mumab; H
venous; MT
d to
venous; MT
SSZ=sulfa
d t
SSZ=sulfa
up
D
u
D
u
be
ot
an
Z, and HC
en
Z, and HC
nt 
s d
s d
H
s d
s d
s d
application and any extensions or variations thereof.
of
re
ks prior to t
ons
ks prior to t
s
12 weeks p
iat
12 weeks p
tio
within 12 w
r va
within 12 w
isit 
o
isit 
a
o
n
mab pegol; 
ons
mab pegol; 
CQ=hydro
sion
CQ=hydro
TX=metho
nsi
TX=metho
t
salazine; T
tens
salazine; T
ns
Dose
ny
Dose
e
ny
d
An
An
d a
d
a
CQ
c
CQ
tio


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 105 of 136
Drug class
Dose
Exclusion criteria
ADA=adalimumab; COX-2=cyclooxygenase 2; CZP=certolizumab pegol; DMARD=disease modifying 
antirheumatic drug; ETN=etanercept; GOL=golimumab; HCQ=hydroxychloroquine; IFX=infliximab; 
ia=intra-articular; im=intramuscular; iv=intravenous; MTX=methotrexate; NSAID=nonsteroidal 
anti-inflammatory drug; sc=subcutaneous; SSZ=sulfasalazine; TNF=tumor necrosis factor 
Change #6
Section 8.1, Screening Visit (Visit 1)
The following bullet has been added:

Collect samples for hs-CRP.
Change #7
Section 8.1, Screening Visit (Visit 1)

Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
then at 30 minutes and 1 hour after dosing.
Has been changed to:

Measure vital signs (temperature, pulse, and blood pressure).
Change #8
Section 8.2, Baseline (Visit 2, Week 0)

Measure vital signs (temperature, pulse, and blood pressure).
Has been changed to:

Measure vital signs (temperature, pulse, and blood pressure) prior to IMP administration and 
then at 30 minutes and 1 hour after dosing.
Change #9
Section 12.7.5, Tuberculosis and TB risk factor assessment and 
management), latent TB
Latent TB
In case the evaluation by the appropriate specialist indicates a new LTBI during the study, a 
prophylactic TB treatment should be initiated and the IMP can be continued no sooner than 4 
weeks after start of prophylactic TB treatment, if it is deemed likely by the Investigator that 
prophylactic TB treatment is continued to completion.
If prophylaxis is not initiated, the subject must be withdrawn.
Has been changed to:
PUBLIC COPY 
d pres
PY
d pres
se, and b
C C
se, and b
sit 2
PU
sit 2
This document cannot be used to support any marketing authorization 
re) prior to
ny m
re) prior to
lood press
ppo
lood press
Week 0
ed t
Week 0
ture, pulse
use
ture, pulse
(temperatu
ot b
(temperatu
s and 1 ho
not
s and 1 ho
9
n
9
n 12.7.5
men
n 12.7.5
agemen
ume
agemen
atent TB
ocu
atent TB
oc
In case
do
In case
prop
s d
prop
s
application and any extensions or variations thereof.
to IMP ad
iatio
to IMP ad
sure).
s or
sure).
0)
t
0)
se, and blo
ext
se, and blo
ture, pulse
d an
ture, pulse
our after d
nd 
our after d
5, Tuber
cat
5, Tuber
nt), late
plic
nt), late
eval
a
eval


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 106 of 136
Latent TB
In case the evaluation by the appropriate specialist indicates a new LTBI during the study, a 
prophylactic TB treatment should be initiated and the subject must be withdrawn.
Change #10
Section 12.7.5.4, Tuberculosis management, LTB infection and active TB 
identified during study, paragraph 2
If a TB specialist excludes an active TB infection the subject can proceed with the IMP no earlier 
than 4 weeks after the start of an appropriate prophylactic therapy.
Has been deleted.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
no earlier 
hor
no earlier 
application and any extensions or variations thereof.


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 107 of 136
19.4
Protocol Amendment 2
Rationale for the amendment
The purpose of this amendment is to revise the withdrawal criteria section to provide instructions 
for the management of subjects with newly diagnosed IBD or with IBD flares during the study.
In the statistical analysis section of the protocol, text describing the planned analysis of the 
primary efficacy variable was updated, and text describing the planned interim analyses and 
sample size re-estimation was revised. The rationale for this is that the observed pattern of 
subject recruitment is not as expected at the time of study planning. Consequently, an insufficient 
number of subjects will have completed the Week 12 visit and be evaluable for response at the 
time of the first interim analysis. The risk of performing an analysis with a very small amount of 
data is that the estimates obtained from the analysis will be unstable and the risk of committing a 
Type II error will be inflated. To mitigate these risks it was decided to remove the formal futility 
and sample size re-estimation aspects from the first interim analysis.
In addition, it was further clarifed that PET-MRI or PET-CT scans for subjects at selected sites 
participating in the substudy will be performed at Screening and during the study at Week 12 and 
Week 48/Early Withdrawal Visit if PET positive lesions were observed in the previous scan.
Modifications and changes
Global changes
No global changes have been made.
Specific changes
Change #1
STUDY CONTACT INFORMATION
The Sponsor study physician and Clinical Trial Biostatistician have been 
changed:
Sponsor Study Physician
Name:
Address:
UCB Celltech, 208 Bath Rd, Slough, Berkshire, SL1 3WE, UK
Phone:
Fax:
PUBLIC COPY 
ons w
Y
ons w
RMA
P
RMA
t cannot be used to support any marketing authorization 
h
nsufficien
tho
nsufficien
onse at th
auth
onse at th
mall amo
g au
mall amo
sk of
ng
sk of com
g 
com
ove the fo
eting
ove the fo
or 
or subject
mark
subject
during the
ma
during the
observed 
ny m
observed 
TION
ed
TION
cian and
use
cian and
ysician
ot b
ysician
no
nn
s:s:
an
This document c
one:
ent
one:
t c
Fax:
me
Fax:
en
um
n
nd any extensions or variations thereof.
he
f
he
ount of 
of.
ount of 
mmitting a
reo
mmitting a
ormal futil
here
ormal futil
ts at selec
ns 
ts at selec
e study at
ion
e study at
d in the pr
atio
d in the pr
nd Clinic
ext
nd Clinic
nd
cation a
UCB C
on 
UCB C
a
io
applicatioioioio
tio
ca
pl
an
io


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 108 of 136
Clinical Trial Biostatistician
Name:
Address:
UCB Celltech, 208 Bath Rd, Slough, Berkshire, SL1 3WE, UK
Phone:
Fax:
Change #2 
Section 5.1, Study description
A new paragraph has been added at the end of this section:
In approximately 25 subjects at selected sites, a PET-MRI or PET-CT scan will be performed at 
Screening and during the study at Week 12 and Week 48/Early Withdrawal Visit if PET positive 
lesions were observed in the previous scan.
Change #3 
Section 5.1.2, Treatment Period (Week 0 to Week 12), bullet #1
Eligible subjects will be randomized in a 2:1 ratio to receive the following blinded study 
treatments: 

Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in 
order to maintain the blind vs the CZP loading dose at these visits. 

CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W in 
Weeks 6 to 10.
Study treatments will be prepared and administered by appropriately trained unblinded site 
personnel. 
A formal unblinded interim analysis will be conducted when approximately 45 subjects have 
completed the Week 4 Visit during the Treatment Period. In addition, an informal unblinded 
interim analysis of the primary efficacy variable is planned when the last randomized subject has 
completed the Week 12 Visit or the subject has discontinued prematurely from the study. Further 
details on the interim analyses planned for this study are included in Section 15.11 and in the 
interim Statistical Analysis Plan (SAP).
Has been changed to: 
Eligible subjects will be randomized in a 2:1 ratio to to receive the following blinded study 
treatments: 

Bimekizumab 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will 
receive 1 placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in 
order to maintain the blind vs the CZP loading dose at these visits. 
PUBLIC COPY 
Week 0 
C CO
Week 0 
a 2:1 rat
LIC 
a 2:1 rat
W from W
PUB
W from W
at Bas
PU
at Bas
t
P
t
ument cannot be used to support any marketing authorization 
can will b
rke
can will b
hdrawal V
mark
hdrawal V
to Week
port
to Week
o to recei
upp
o to recei
Week 0 thr
to 
Week 0 thr
line (Visi
d to
line (Visi
he CZP lo
sed
he CZP lo
eks 0, 2, a
e us
eks 0, 2, a
e prepared
ot b
e prepared
ded interim
can
ded interim
Week 4 V
t ca
Week 4 V
alysis of th
nt c
alysis of th
ed the We
men
ed the We
ls on the i
ume
ls on the i
This docu
terim Stat
cum
terim Stat
Has b
doc
Has b
Elig
s 
Elig
plication and any extensions or variations thereof.
be perform
th
be perform
Visit if
ns t
Visit if PE
t
PE
k 12), bu
or v
k 12), bu
ive the fo
s o
ive the fo
hrough W
nsio
hrough W
it 2), Wee
tens
it 2), Wee
oading do
xte
oading do
and 4 (loa
y ex
and 4 (loa
d and adm
d an
d and adm
m analysi
n an
m analysi
Visit duri
ion 
Visit duri
he primar
atio
he primar
eek 12 Vi
icat
eek 12 Vi
interim an
plic
interim an
app
tistical An
ppl
tistical An
n cha
ap
n cha


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 109 of 136

CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W in 
Weeks 6 to 10.
Study treatments will be prepared and administered by appropriately trained unblinded site 
personnel. 
Change #4 
Section 5.3, Imaging evaluation, paragraph 1
In a subpopulation of AS0013, a PET-MRI or PET-CT scan of the entire spine will be performed 
at selected sites in approximately 25 subjects at Screening, Week 12, and at Week 48/Early 
Withdrawal Visit. 
Has been changed to: 
In a subpopulation of AS0013, a PET-MRI or PET-CT scan of the entire spine will be performed 
at selected sites in approximately 25 subjects at Screening, and during the study at Week 12 and 
Week 48/Early Withdrawal Visit if PET positive lesions were observed in the previous scan. 
Change #5 
Section 5.7, Schedule of assessments, Table 5-1, footnote c
A separate Informed Consent Form is required for subjects participating in the 2 sub-studies: 
1) with biomarker, pharmacogenomic and nonhereditary pharmacogenomic blood-samples and 
2) PET-MRI or PET-CT scans.
Has been changed to: 
A separate Informed Consent Form is required for subjects participating in the 2 sub-studies: 
1) with biomarker, pharmacogenetic and nonhereditary pharmacogenomic blood-samples and 
2) PET-MRI or PET-CT scans.
Change #6 
Section 5.7, Schedule of assessments, Table 5-1, footnote o
A PET-MRI or Pet-CT scan should be done up to 2 weeks before Baseline and within 2 weeks 
after the W12 and W48/WD Visit. If a subject withdraws from the study early, the PET-MRI or 
PET-CT scan must be repeated at the WD visit only, if the prior examination was done more 
than 12 weeks prior to the WD visit.
Has been changed to: 
A PET-MRI or PET-CT scan should be done up to 2 weeks before Baseline and within 2 weeks 
after the W12 and W48/WD Visit if PET-positive lesions are observed in the previous scan. If 
a subject withdraws from the study early, the PET-MRI or PET-CT scan must be repeated at the 
WD visit only, if the prior examination was done more than 12 weeks prior to the WD visit and 
the previous PET-scan showed positive lesions.
PUBLIC COPY 
s
Y
s
ments, 
C C
ments, 
required
BLIC
required
mi
UB
mic and n
UBL
c and n
This document cannot be used to support any marketing authorization 
be perform
auth
be perform
k 48/Early
g au
k 48/Early
tire spine 
arke
tire spine 
ing the stu
mar
ing the stu
bserved in
y m
bserved in
Table 5
ppo
Table 5
for subje
supp
for subje
onheredit
o su
onheredit
rm is requ
use
rm is requ
genetic an
be u
genetic an
ans.
be
ans.
7, Sched
t ca
7, Sched
RI or Pet
ent
RI or Pet
e W12 an
me
e W12 an
-CT scan
cum
CT scan
han 12 we
ocu
han 12 we
Has b
s do
Has b
A
s
A
application and any extensions or variations thereof.
me
f
me
y y 
will be p
s th
will be p
tudy at W
ons
tudy at W
n the prev
tion
n the prev
1, footn
or 
1, footn
ects partic
ns 
ects partic
tary pharm
ion
tary pharm
quired for 
ex
quired for 
nd nonher
ny e
nd nonher
dule of a
ion 
dule of a
-CT scan
catio
CT scan
nd W48/W
lica
nd W48/W
n must be
ppli
n must be
eeks prio
app
eeks prio
ch
a
ch


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 110 of 136
Change #7
Section 5.7, Table 5-1 Schedule of assessments, footnote p
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W in 
Weeks 6 to 10 and 400mg Q4W from Week 12 to Week 44. Bimekizumab will be administered 
at a dose of 160mg sc Q2W from Week 0 through Week 10 and 320mg sc Q4W from Week 12 
to Week 44. The IMP will be administered at the end of the visit after all assessments have been 
completed. Subjects randomized to bimekizumab will receive 1 placebo injection at Baseline 
(Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3). 
Has been changed to: 
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W in 
Weeks 6 to 10 and 400mg Q4W from Week 12 to Week 44. Bimekizumab will be administered 
at a dose of 160mg sc Q2W from Week 0 through Week 10 and 320mg sc Q4W from Week 12 
to Week 44. The IMP will be administered at the end of the visit after all assessments have been 
completed. Subjects randomized to bimekizumab will receive 1 placebo injection at Baseline 
(Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4).
Change #8
Section 6.3, Withdrawal criteria
The following was added to the withdrawal criteria:
11. Subjects with newly diagnosed IBD or with IBD flares during the study must:

Be referred, as appropriate, to a health care professional treating IBD, such as a 
gastroenterologist

Discontinue IMP and be followed-up until resolution of active IBD symptoms
If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgement in deciding whether the subject should continue in the study and contact 
the Medical Monitor and UCB study physician to confirm the subject's suitability for 
continued participation in the study.
Change #9
Section 7.2, Treatments to be administered, paragraph 1
The IMP is to be administered in the clinic by trained study site staff as 2 sc injections. Suitable 
areas for sc injections are the lateral abdominal wall, upper outer thigh, and upper arm. During 
each dosing visit, each of the 2 injections should be administered at a separate injection site. 
Injection sites should be rotated and injections should not be given into areas where the skin is 
tender, bruised, red, or hard.
PUBLIC COPY 
re
Y
re
a
L
a
thdrawa
UBL
thdrawa
osed IBD
PU
osed IBD
P
ument cannot be used to support any marketing authorization 
z
12
ri
12
e been
hori
e been
aseline
tho
aseline
200m
etin
200mg sc
ng
g sc
ab will be
ket
ab will be
mg sc Q4W
ark
mg sc Q4W
ter all
ma
ter all ass
a
ass
placebo i
y m
placebo i
criteria:
o su
criteria:
 or with I
d to
 or with I
to a healt
sed
to a healt
d be follow
be 
d be follow
e in severi
ot b
e in severi
t in decid
no
t in decid
onitor and
ann
onitor and
articipatio
ca
articipatio
ge #9
me
ge #9
This doc
ection 7
cum
ection 7
The IM
do
The IM
areas
s d
areas
ea
s
ea
plication and any extensions or variations thereof.
c Q2W in
here
c Q2W in
e adminis
the
e adminis
W from W
s t
W from W
sessments
ons
sessments
injection 
tion
injection 
IBD flare
ens
IBD flare
th care pr
xte
th care pr
wed
ny
wed-
ny
-up u
y 
up u
rity or freq
d a
rity or freq
ding wheth
nd 
ding wheth
d UCB stu
an
d UCB stu
on in the s
on a
on in the s
app
7.2, Trea
ppl
7.2, Trea
s to be
ap
s to be


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 111 of 136
Has been changed to: 
The IMP is to be administered in the clinic by trained study site staff as 2 sc injections. Suitable 
areas for sc injections are the lateral abdominal wall and upper outer thigh. During each dosing 
visit, each of the 2 injections should be administered at a separate injection site. Injection sites 
should be rotated and injections should not be given into areas where the skin is tender, bruised, 
red, or hard.
Change #10 
Section 7.9, Blinding, paragraph 1
Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in order to maintain the blind vs the 
CZP loading dose at these visits. 
Has been changed to: 
Due to differences in presentation of the IMPs (bimekizumab and CZP), special precautions will 
be taken to ensure study blinding. Subjects randomized to bimekizumab will receive placebo at 
Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 4) in order to maintain the blind vs the 
CZP loading dose at these visits. 
Change #11 
Section 7.9.1, Procedures for maintaining and breaking the treatment blind, 
last 2 paragraphs

Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
DMC and interim analysis. These individuals will be separate from the main blinded study 
team.

Unblinded programming team at PAREXEL for the purpose of sending unblinded data cuts
Has been changed to: 

Any Sponsor staff and/or designee who is responsible for data analyses for the unblinded 
DMC and interim analyses. These individuals will be separate from the main blinded study 
team.

Unblinded team at PAREXEL for the purpose of sending unblinded output for the planned 
interim analyses
Change #12
Section 8.8, Week 12 (Visit 8), bullet #18

Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks after Week 12 Visit.
PUBLIC COPY
ekizum
PY 
ekizum
mized to
OPY
mized to
k 4 (Visi
COP
k 4 (Visi
es for m
PU
es for m
ot be used to support any marketing authorization 
al precaut
ng 
al precaut
ll receive 
eting
ll receive 
intain the
ket
intain the
b and CZP
ny 
b and CZP
bim
t a
bimekizu
any
ekizu
4) in ord
ort a
) in ord
maintain
d to
maintain
signee wh
us
signee wh
is. These i
be u
is. These i
This document canno
mming te
not
mming te
nged to
ann
nged to
nsor staff 
t ca
nsor staff 
and interi
ent 
and interi
m.
m
m.
Unblinde
cum
Unblinde
interim
ocu
interim
C
s
C
d any extensions or variations thereof.
tions will
reo
tions will
e placebo 
here
e placebo 
e blind vs
the
e blind vs
P), specia
iati
P), specia
umab will
aria
umab will
der to mai
va
der to mai
ning and
ens
ning and
ho is resp
ex
ho is resp
individua
ny e
individua
pplication and
eam at PA
nd 
eam at PA
o: 
n
o: 
f and/or de
tion
f and/or de
im analy
atio
im analys
o
s
ed team a
ppl
ed team a
ap
m analyse
app
m analyse


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 112 of 136
Has been changed to: 

Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks after Week 12 Visit if PET positive lesions were observed in the previous scan.
Change #13
Section 8.11, Week 48 (Visit 17)/Early Withdrawal Visit, bullet #21

Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks after the Week 48/WD Visit. At the WD Visit, the PET-MRI or PET-CT must be 
done only, if the previous imaging evaluation occurred more than 12 weeks ago
Has been changed to: 

Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks after the Week 48/WD Visit if PET positive lesions were observed in the previous 
scan. At the WD Visit, the PET-MRI or PET-CT must be done only, if the previous imaging 
evaluation occurred more than 12 weeks ago and if PET positive lesions were observed in 
the previous scan.
Change #14 
Section 9.7, PhGADA, paragraph 1
The Investigator will assess the overall status of the subject with respect to their AS signs and 
symptoms and functional capacity (considering both joint and skin components) using an NRS in 
which 0=very good, asymptomatic and no limitations of normal activities and 10=very poor, 
very severe symptoms which are intolerable and inability to carry out normal activities. This 
assessment by the Investigator should be made blind to the PGADA.
Has been changed to: 
The Investigator will assess the overall status of the subject with respect to their AS signs and 
symptoms and functional capacity using an NRS in which 0=very good, asymptomatic and no 
limitations of normal activities and 10=very poor, very severe symptoms which are intolerable 
and inability to carry out normal activities. This assessment by the Investigator should be made 
blind to the PGADA.
Change #15
Section 10, ASSESSMENT OF PHARMACOKINETIC/ 
PHARMACODYNAMIC/PHARMACOGENOMIC VARIABLE(S) 
Has been changed to: 
Section 10, ASSESSMENT OF PHARMACOKINETIC/ 
PHARMACODYNAMIC/PHARMACOGENOMIC/PHARMACOGENETIC
VARIABLE(S) 
PUBLIC COPY 
f P
Y
f P
ph 1
LIC
ph 1
erall stat
UBL
erall stat
ity (cons
PUB
ity (cons
atic an
PU
atic an
cannot be used to support any marketing authorization 
within
tho
within
T must be
aut
T must be
go
g
go
t selected
ket
t selected
e observe
ark
e observe
e only, if t
ma
e only, if t
ositive les
y m
ositive les
us of t
o su
us of the s
su
he s
idering bo
d to 
idering bo
d no limit
ed t
d no limit
ntolerable
sed
ntolerable
hould be 
us
hould be 
ssess the o
ot b
ssess the o
ional capa
nno
ional capa
mal activi
ann
mal activi
This document c
o carry ou
t ca
o carry ou
PGADA.
nt c
PGADA.
hange #1
cum
hange #1
Sectio
doc
Sectio
PHA
s d
PHA
H
s
H
n and any extensions or variations thereof.
e 
f
e 
d sites wit
the
d sites wit
ved in the
ns t
ved in the
the previo
ons
the previo
sions wer
atio
sions wer
subject w
sion
subject w
oth joint a
nsio
oth joint a
itations of
ten
itations of
e and inab
exte
e and inab
 made bli
ex
 made bli
overall sta
d a
overall sta
acity usin
and
acity usin
vities and 
n an
vities and 
application
ut normal 
on 
ut normal 
.
#15
pp
#15
10,
ap
10, AS
p
AS
C


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 113 of 136
Change #16
Section 12.6.1.3, Table 12-4 PDILI laboratory measurements
Chemistry
Amylase
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Has been changed to: 
Chemistry
Amylase
ALT, AST
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
And the following was added to the list of abbreviations: 
AST=aspartate aminotransferase;
Change #17
Section 15.5.1, Analysis of the primary efficacy variable 
The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
Week 12 in the bimekizumab treatment group versus the CZP treatment group. Summary 
statistics will be presented by treatment group for ASDAS at each time point together with the 
changes from Baseline. 
The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
paradigm. Informative priors will be assumed for the mean change from Baseline in ASDAS in 
the CZP treatment arm and for the effect of Baseline ASDAS. These will be derived from an 
internal UCB study (AS0001). A vague prior will be applied to the mean change from Baseline 
in ASDAS in the bimekizumab treatment group. All priors will be fully documented in the SAP 
and in the interim analysis SAP.
The Bayesian analysis will employ a linear regression model including treatment group and 
adjusting for Baseline ASDAS.
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
groups (CZP - bimekizumab) will be summarized with means, standard deviations, 95% credible 
intervals and 95% Highest Posterior Density intervals. The posterior probability that the 
difference between treatment groups in the mean change from Baseline in ASDAS is greater than 
zero will also be presented. The posterior probability that bimekizumab achieves a lower 
ASDAS score at Week 12 compared to CZP will be derived from this distribution.
PUBLIC COPY 
tion
Y
tion
he prim
BLIC
he prim
ll be the
PUB
ll be the
reatmen
PU
reatmen
atm
P
atm
upport any marketing authorization 
a
za
evation
hori
evation
riz
ho z
au
ng
btain % d
ket
btain % d
eti
causing tr
mar
causing tr
rk
ma
ent cannot be used to su
ary effic
sup
ary effic
compariso
to s
compariso
t group ve
d to
t group ve
ment group
sed
ment group
 primary 
be u
 primary 
ors will b
t be
ors will b
and for th
ot 
and for th
(AS0001)
nno
(AS0001)
bimekizu
ann
bimekizu
rim analy
t ca
rim analy
sian analy
ent 
sian analy
This docum
ng for Bas
men
ng for Bas
e posterio
cum
e posterio
bimekizu
docu
bimekizu
groups
do
groups
inte
s d
inte
d
s
d
s or variations thereof.f
eo
direct biliru
the
direct biliru
he
transamina
ns 
transamina
s t
on
cation and any extension
cacy va
ons
cacy va
on of the 
sio
on of the 
versus the 
ens
versus the 
p for ASD
xten
p for ASD
efficacy v
ny e
efficacy v
be assume
any
be assume
he effect 
d a
he effect 
). A vagu
and
). A vagu
umab trea
n an
umab trea
ysis SAP.
on 
ysis SAP.
ysis will e
atio
ysis will e
applic
aseline AS
lica
aseline AS
or distribu
ppl
or distribu
mab grou
app
mab grou
P
a
P -
a
- b


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 114 of 136
The study will be considered a success if this posterior probability is at least 97.5% (ie, the lower
bound of the 95% credible interval of the difference between treatment groups in the mean 
change from Baseline in ASDAS is greater than zero). 
If further information (independent to this study) regarding the CZP treatment group response 
comes to light subsequent to writing this protocol then this prior may be updated prior to study 
unblinding, and details of this will be supplied in the SAP and the CSR. Note that the prior will 
not be updated based upon accrued study data at any time point.
Has been changed to: 
The primary efficacy analysis will be the comparison of the change from Baseline in ASDAS at 
Week 12 in the bimekizumab treatment group versus the CZP treatment group. Summary 
statistics will be presented by treatment group for ASDAS at each time point together with the 
changes from Baseline. 
The statistical analysis of the primary efficacy variable will be conducted following a Bayesian 
paradigm. An informative prior will be used for the model intercept coefficient which in the 
primary model is equal to the mean change from Baseline in ASDAS in the CZP group when 
centered Baseline is observed at its mean of zero (βCZP ~ Normal [-1.78, var=0.0605)). Vague 
priors will be used for all other model coefficients. All priors will be fully documented in the 
SAP and in the interim analysis SAP.
The Bayesian analysis will employ a linear regression model including treatment group and 
Baseline ASDAS (mean centered).
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and 
bimekizumab groups and of the difference in mean changes from Baseline between the treatment 
groups (CZP - bimekizumab) will be summarized with means, standard deviations, 95% credible 
intervals and 95% Highest Posterior Density intervals. The posterior probability that the 
difference between treatment groups in the mean change from Baseline in ASDAS is greater than 
zero will also be presented. The posterior probability that bimekizumab achieves a lower 
ASDAS score at Week 12 compared to CZP will be derived from this distribution.
The study will be considered a success if the posterior probability of the difference in the mean 
change from Baseline in ASDAS between the CZP and bimekizumab treatment groups (CZP -
bimekizumab) being greater than zero is at least 97.5% (ie, the lower bound of the 95% credible 
interval of the difference between treatment groups in the mean change from Baseline in ASDAS 
is zero or greater).
If further information (independent to this study) regarding the CZP treatment group response 
comes to light subsequent to writing this protocol then this prior may be updated prior to study 
unblinding, and details of this will be supplied in the SAP and the CSR. Note that the prior will 
not be updated based upon accrued study data at any time point.
PUBLIC COPY 
ZP ~
Y
ZP ~
 All prio
PY
 All prio
regressi
C CO
regressi
an chan
BLI
an chan
ifferenc
UB
ifferenc
will be su
PU
will be su
rior
P
rior
ent cannot be used to support any marketing authorization 
n ASDAS
auth
n ASDAS
ummary 
g au
ummary 
ogether w
ng 
ogether w
ed follow
rke
ed follow
coefficien
mark
coefficien
DAS in the
ma
DAS in the
mal [
ny m
mal [-
y
-1.7
m
1.7
rs will be 
any
rs will be 
on model i
por
on model i
ges from B
sup
ges from B
in mean 
to s
in mean 
ummarized
d to
ummarized
Density i
ed 
Density i
ups in the 
use
ups in the 
e posterio
e us
e posterio
ompared 
be 
ompared 
dered a su
ot b
dered a su
e in ASD
nno
e in ASD
ing greate
ann
ing greate
difference
ca
difference
eater).
nt c
eater).
ocume
er informa
men
er informa
es to light
um
es to light
nblinding,
ocu
nblinding,
This do
not be up
doc
not be up
ation and any extensions or variations thereof.
S at
f
S at
with the
reo
with the
wing a Bay
s th
wing a Bay
nt which 
ns 
nt which 
he CZP gr
ion
he CZP gr
78, var=0.
atio
78, var=0.
e fully doc
ria
e fully doc
including
or v
including
Baseline i
ons
Baseline i
changes f
sio
changes f
ed with me
ens
ed with me
intervals. 
xten
intervals. 
e mean ch
ext
e mean ch
or probab
y ex
or probab
to CZP w
any 
to CZP w
uccess if t
d a
uccess if t
DAS betwe
nd 
DAS betwe
er than ze
an
er than ze
e between
on a
e between
applic
ation (ind
icat
ation (ind
t subseque
plic
t subseque
, and deta
app
, and deta
a
dated ba
ap
dated ba


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 115 of 136
Change #18
Section 15.11, Planned interim analysis and data monitoring 
A formal unblinded interim analysis will be conducted after approximately 45 subjects have 
completed 4 weeks of the study. During this interim analysis, the sample size assumptions will 
be checked and the final sample size may be modified. 
The study may be stopped for futility. Futility rules and operating characteristics will be detailed 
in the interim SAP. The futility rule will be chosen such that the overall power of the study 
remains high.
An informal unblinded interim analysis will be performed when the last randomized subject for 
this study has completed the Week 12 Visit at the end of the Treatment Period or this subject’s 
participation has ended prematurely. The purpose of this informal interim analysis is for the 
Sponsor key personnel to review results from the primary efficacy analysis and a subset of the 
analyses of secondary efficacy and safety outcomes to facilitate additional Clinical Planning or 
Portfolio Management decisions.
All analyses and unblinding instructions will be prespecified in the interim SAP.
Has been changed to: 
This study will include two unblinded interim analyses, the first after approximately 45 subjects 
have completed 4 weeks of the study and the second when the last randomized subject for this 
study has completed the Week 12 Visit at the end of the Treatment Period or this subject’s 
participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
personnel to review results from the primary efficacy analysis and a subset of the analyses of 
secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
Management decisions; consequently, neither analysis and will lead to any formal decision to 
alter or terminate the trial. Interim analyses will be conducted by an unblinded study team and 
will follow internal SOPs for the formal process to control the unblinding of the study for interim 
analysis purposes. This process will ensure that no unnecessary or unintentional unblinding 
occurs. The unblinded team will not disclose any unblinded information to the blinded study 
team and the storage of all unblinded documentation will be held securely and separately from 
the rest of the study documentation and outputs up until the end of the study.
All analyses and unblinding instructions will be prespecified in the interim SAP.
Change #19
Section 15.12, Determination of sample size, paragraph 3
The sample size was calculated to provide at least 80% power to detect a difference between 
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group means 
for CZP and bimekizumab change from baseline being -1.78 and -2.67 respectively) with a 
common standard deviation of 1.17 using frequentist methods for the comparison of group 
means with baseline as covariate (Overall and Starbuck, 1979). The correlation between Baseline 
and Week 12 raw ASDAS was assumed to be 0.35. UCB considers this sample size conservative 
PUBLIC COPY 
ci
Y
ci
analyses
COP
analyses
C
e second
C CO
e second
at the end
IC C
at the end
The purp
BLIC
The purp
e primar
UBL
e primar
utcomes
PUB
utcomes
uently
PU
uently
This document cannot be used to support any marketing authorization 
ailed 
riz
ailed 
y 
h
y 
ed subject
au
ed subject
or this sub
g a
or this sub
alysis is f
ting
alysis is f
s and a su
ketin
s and a su
nal Clinic
rke
nal Clinic
the interim
y m
the interim
the first a
rt a
the first a
when the
por
when the
of the Tr
ppo
of the Tr
ose of the
sup
ose of the
y efficacy
o su
y efficacy
to facilita
to 
to facilita
 neither a
ed t
 neither a
analyses w
sed
analyses w
e formal p
us
e formal p
ess will en
be u
ess will en
m will no
t be
m will no
f all unblin
ot b
f all unblin
document
nno
document
d unblindi
can
d unblindi
ge #19
men
ge #19
ction 15
cum
ction 15
The sam
doc
The sam
treatm
s do
treatm
for
s 
for
application and any extensions or variations thereof.
t for 
of
t for 
bject’s
eof
bject’s
for the
ereo
for the
ubset of th
ther
ubset of th
cal Plann
s th
cal Plann
m SAP.
tion
m SAP.
after appr
va
after appr
e last rand
or v
e last rand
reatment P
s or
reatment P
ese interim
ns 
ese interim
y analysis
ion
y analysis
ate additio
nsio
ate additio
analysis a
tens
analysis a
will be co
xte
will be co
process to
ex
process to
nsure that
ny e
nsure that
ot disclose
any
ot disclose
inded docu
d a
inded docu
nta
a
ntation and
and
tion and
ing instru
n a
ing instru
5.12, De
ppli
5.12, De
le size w
ap
e size w
ou
a


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 116 of 136
as the Bayesian analysis with the informative priors described in Section 15.5.1 will improve the 
probability of study success for an effective drug.
Has been changed to: 
The sample size was calculated to provide at least 80% power to detect a difference between 
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group mean 
change from Baseline for CZP and bimekizumab being -1.78 and -2.67 respectively) with a 
common standard deviation of 1.17 using frequentist methods for the comparison of the 
treatment group mean change from Baseline in ASDAS at Week 12 with Baseline ASDAS as a 
covariate (Overall and Starbuck, 1979). The correlation between Baseline and Week 12 raw 
ASDAS was assumed to be 0.35. Note that the informative prior for the model intercept to be 
used in the Bayesian modelling of the primary efficacy variable, given by βCZP ~ Normal (-
1.78,var=0.0605), contributes an effective sample size of approximately 20 CZP subjects. A 
prior data conflict test will be performed and a vague prior will be used for the model intercept 
coefficient if this test indicates prior data conflict.
PUBLIC COPY 
authorization 
AS as a 
thor
AS as a 
12 raw 
uth
12 raw 
ercept to
au
ercept to b
ng
P ~ Norma
g a
P ~ Norma
tin
CZP subje
ting
CZP subje
This document cannot be used to support any marke
or the mod
keti
or the mod
hereof.
be
f
be
mal (
eo
mal (-
eo
-
ects. A
ere
ects. A
application and any extensions or variations th
del interc
ther
del interc


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 117 of 136
19.5
Protocol Amendment 3
Rationale for the amendment
The major purpose of this protocol amendment is the following: 

Secondary and other study objectives and variables have been updated to evaluate the effect 
of bimekizumab or CZP on changes in bone formation as an “other” exploratory variable. 
It is convention that clinical study research is divided into 2 broad areas of evaluations: 
1) prospectively declared analyses and 2) hypothesis-generating or exploratory analyses. 
Prospectively declared evaluations are partitioned into primary analyses (where type I error is 
conserved) and secondary analyses that are prospectively declared in order to offer 
unambiguous interpretation. Owing to the novelty of PET-CT/MRI assessments within this 
disease indication, it is not possible to prospectively define the analyses as we are continuing 
to develop UCB’s understanding of the specific data and endpoints yielded from the imaging 
software, the distribution and covariance of these endpoints and the hypothesized difference 
owing to treatment. As a result, the analyses of the PET-CT/MRI data in this study will 
primarily be descriptive and exploratory and this is now updated in the study objectives, ie, 
the evaluation of the effect of bimekizumab or CZP on changes in bone formation is now an 
other exploratory objective or variable instead of a secondary objective or variable.

A clarification regarding the sample size is required in this protocol amendment. The planned 
sample size of 60 subjects provides sufficient power to detect meaningful treatment 
differences in the primary efficacy variable whilst also providing at least 25 subjects for the 
PET-CT/MRI substudy. However, due to complexities in the initiation of sites capable of 
performing PET-CT or PET-MRI scans, more than the planned 35 non-PET-CT/MRI 
substudy subjects were screened and randomized before it was possible to close enrolment at 
the sites not participating in the substudy. Owing to the novelty of the PET-CT/MRI 
outcomes within this disease area, it is considered important to ensure at least 25 evaluable 
subjects are included in the assessment of this exploratory objective to maximize the 
possibility of identifying the salient factors or variables that might differ between the 
treatment groups and, therefore, the total sample size is increased to at least 72 subjects. This 
sample size increase will not negatively impact the power to detect a difference in the 
primary efficacy variable at Week 12 (ie, it will remain >80%), but will ensure that the target 
number of subjects are included in the exploratory analysis of changes in bone formation at 
Week 12 and Week 48. Since the analyses of PET-CT/MRI data are exploratory and 
treatment effect sizes are unknown, formal power calculations were not performed. Clinical 
expertise does, however, indicate that a sample size of at least 25 subjects in the substudy 
will characterize broad differences between treatment groups.

Objectives related to PK and immunogenicity were downgraded from “secondary” objectives 
to “other” objectives for consistency with the classification of the corresponding variables.

Nonhereditary pharmacogenomic variables and pharmacogenetic variables are considered 
exploratory in nature and have been labelled as “other”.

A PFS as described in Section 7.1 is available for administration in addition to the vial and 
corresponding text has been added. The PFS use is expected to improve the subject 
experience.
PUBLIC COPY 
ZP on
Y
ZP on
of a seco
OPY
of a seco
s require
COP
s require
ficient p
C CO
ficient p
ariable w
IC 
ariable w
r, due to 
BLIC
r, due to 
MRI scan
UBL
MRI scan
ened and
PUB
ened and
 the s
PU
 the s
cannot be used to support any marketing authorization 
yses.
ho
yses.
ype I error
uth
ype I error
offer 
a
offer 
ents withi
g a
ents withi
as we are c
ting
as we are c
elded from
ketin
elded from
 hypothes
rke
 hypothes
I data in t
mark
I data in t
ted in the
ma
ted in the
anges in b
ny m
anges in b
ndary obj
any
ndary obj
d in this p
ort a
d in this p
wer to de
por
wer to de
whilst also 
pp
whilst also 
complexit
sup
complexit
, more tha
o su
, more tha
randomiz
d to 
randomiz
ubstudy. O
ed t
ubstudy. O
rea, it is c
sed
rea, it is c
assessmen
us
assessmen
the salien
be u
the salien
therefore
t be
therefore
e will not
ot 
e will not
y variable 
nno
y variable 
bjects are
an
bjects are
This document c
nd Week 
t ca
nd Week 
nt effect s
nt c
nt effect s
rtise does
men
rtise does
ill charac
me
ill charac
Object
ocu
Object
to “
oc
to “

s 

n and any extensions or variations thereof.
in this 
eof
in this 
continuin
ereo
continuin
m the ima
ther
m the ima
sized diff
s th
sized diff
this study
ns 
this study
e study ob
tion
e study ob
bone form
atio
bone form
jective or
aria
jective or
protocol a
va
protocol a
etect mean
or v
etect mean
o providin
s o
o providin
ties in the
ons 
ties in the
han the pla
sion
han the pla
zed befor
nsio
zed befor
Owing to 
ten
Owing to 
considered
exte
considered
ent of this 
y ex
ent of this 
nt factors 
ny e
nt factors 
e, the total
any
e, the total
t negative
d a
t negative
e at Week 
and
e at Week 
e included
n an
e included
application
48. Sinc
on 
48. Sinc
sizes are u
atio
sizes are u
s, howeve
icat
s, howeve
terize bro
plic
terize bro
tives relat
app
ives relat
her” ob
ap
her” ob


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 118 of 136

The section describing AEs of special monitoring have been updated to reflect the 
development process and to maintain consistency with other protocols. 

A third informal unblinded interim analysis when the last randomized subject has completed 
the Week 12 Visit at the end of the Treatment Period or this subject’s participation has ended 
prematurely, has been added to facilitate additional Clinical Planning or Portfolio 
Management decisions. 

Study contact details have been updated.
In addition, a few minor updates including consistency changes for PDILI-related text and a few 
clarifications and corrections of typographical errors have been made. The occurrence of 
abbreviations was updated.
Modifications and changes
Global changes
The specification of the IGRA TB test has been changed from “QuantiFERON TB GOLD test” 
to “QuantiFERON TB test”.
Specific changes
Change #1
Sponsor Study Physician
Name:
Address:
UCB Celltech, 208 Bath Rd, Slough, Berkshire, SL1 3WE, UK
Phone:
Fax:
Has been changed to: 
Name:
Address:
UCB Celltech, 208 Bath Rd, Slough, Berkshire, SL1 3WE, UK
Phone:
Fax:
Change #2
Section 1, Summary, paragraphs 3, 4, and 5
The primary objective of the study is to evaluate the efficacy of bimekizumab administered 
subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
subjects with active AS. The primary efficacy variable is the change from Baseline in 
PUBLIC COPY 
BL
Cellte
P
Cellte
PU
PUB
sed to support any marketing authorization 
and a few
tho
and a few
ce of 
aut
ce of 
ntiFERON
mark
ntiFERON
s
ch, 208 B
ed t
ch, 208 B
to
ed
e us
u
This document cannot be
be
 to: 
ot
 to: 
no
nn
s:s:
an
one:
ent
one:
t c
Fax:
me
Fax:
en
um
Cha
s d
Cha
S
s
S
use
be u
n
nd any extensions or variations thereof.
N TB GO
ns 
N TB GO
on
Bath Rd, S
ten
Bath Rd, S
ns
xte
e
ny
nd
e
ny
application a
UCB C
on 
UCB C
a
ioioioio
tio
ca
pl
2
an
io


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 119 of 136
Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12. The secondary objectives 
of the study are to evaluate the effect of bimekizumab or CZP on changes in osteoblastic activity, 
to assess the safety and tolerability of bimekizumab, and to assess the pharmacokinetics (PK) 
and immunogenicity of bimekizumab. The secondary efficacy variables include the 
determination of ASDAS inactive disease (ASDAS-ID) at Week 12, ASDAS major 
improvement (ASDAS-MI) at Week 12, and osteoblastic activity as detected by 
positron-emission tomography-magnetic resonance imaging (PET-MRI) or positron-emission 
tomography computed tomography (PET-CT) at Week 12 and Week 48. Primary safety variables 
include the incidence of adverse events (AEs), serious adverse events (SAEs), and withdrawal 
due to AEs.
Other objectives of the study are to obtain additional biomarkers and clinical and imaging data as 
applicable and to assess the efficacy and safety of bimekizumab or CZP during the Treatment 
Extension Period.
Multiple sites in North America, Europe, and the Asian-Pacific (APAC) region will randomize 
approximately 60 subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
Has been changed to: 
The primary objective of the study is to evaluate the efficacy of bimekizumab administered 
subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to CZP in the treatment of 
subjects with active AS. The primary efficacy variable is the change from Baseline in 
Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 12. The secondary objective 
of the study is to assess the safety and tolerability of bimekizumab. The secondary efficacy 
variables include the determination of ASDAS inactive disease (ASDAS-ID) and ASDAS major 
improvement (ASDAS-MI) at Week 12. Primary safety variables include the incidence of 
adverse events (AEs), serious adverse events (SAEs), and AEs leading to withdrawal from 
investigational medicinal product (IMP).
Other exploratory objectives of the study are to evaluate the effect of bimekizumab or CZP 
on changes in bone formation, to assess the pharmacokinetics (PK) and immunogenicity of 
bimekizumab, to obtain additional biomarkers and clinical and imaging data as applicable, and 
to assess the efficacy and safety of bimekizumab or CZP during the Treatment Period and the 
Treatment Extension Period.
Multiple sites in North America, Europe, and the Asian-Pacific (APAC) region will randomize at 
least 60 subjects in a 2:1 ratio to receive either bimekizumab or CZP. 
Change #3
Section 3.2, Secondary objectives
The secondary objectives of the study are as follows:

To evaluate the effect of bimekizumab or CZP on changes in osteoblastic activity 

To assess the safety and tolerability of bimekizumab

To assess the PK and immunogenicity of bimekizumab
PUBLIC COPY 
he effica
PY
he effica
2 weeks
OP
2 weeks
y variab
CO
y variab
Score
C C
Score (A
C
(A
tolerabil
LIC
tolerabil
of ASDA
BLI
of ASDA
eek 12. 
PUB
eek 12. 
adverse 
PU
adverse 
uct
P
uct
used to support any marketing authorization 
riables
oriz
riables
drawal
thor
drawal
imaging 
g au
imaging 
g the Trea
ing 
g the Trea
C) region w
rke
C) region w
mab or CZP
mark
mab or CZP
y of bime
any
y of bime
compared
rt a
compared
e is the ch
ort 
e is the ch
SDAS) at
ppo
SDAS) at
ty of bime
upp
ty of bime
AS inactiv
sup
AS inactiv
Primary sa
to s
Primary sa
events (SA
d to
events (SA
(IMP).
sed
(IMP).
f the study
us
f the study
ument cannot be
on, to ass
be u
on, to ass
additional
t be
additional
nd safety 
ot 
nd safety 
n Period.
nno
n Period.
North Am
can
North Am
ects in a 2
t ca
ects in a 2
ge #3
men
ge #3
This docu
ction 3.2
cum
ction 3.2
The seco
doc
The seco

s d

T
y extensions or variations thereof.
data as
of.
data as
atment 
reo
atment 
will rando
s th
will rando
ZP.
n
ZP.
ek
r
ekizumab
ria
izumab
d to CZP 
var
d to CZP 
hange fro
r va
hange fro
t Week
or
t Week 12
12
mekizumab
ns o
mekizumab
ve disease
ions
ve disease
afety vari
sio
fety vari
AEs), and
ens
AEs), and
y are
ex
y are to
ex
to e
plication and any
sess the p
ny e
sess the p
l biomark
any
l biomark
of bimek
d a
of bimek
America, E
n a
America, E
2:1 ratio t
tion
2:1 ratio t
app
2, Second
ppli
2, Second
ndary ob
ap
dary ob


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 120 of 136
Has been changed to: 
Section 3.2, Secondary objective
The secondary objective of the study is as follows:

To assess the safety and tolerability of bimekizumab
Change #4
Section 3.3, Other objectives
The other objectives of the study are as follows:

To assess additional biomarker, clinical, and imaging data as available

To assess the efficacy and safety of bimekizumab or CZP during the Treatment Extension 
Period
Has been changed to: 
Section 3.3, Other exploratory objectives
The other exploratory objectives of the study are as follows:

To evaluate the effect of bimekizumab or CZP on changes in bone formation 

To assess the PK and immunogenicity of bimekizumab

To assess additional biomarker, clinical, and imaging data as available

To assess the efficacy and safety of bimekizumab or CZP during the Treatment Extension 
Period
Change #5
Section 4.1.2, Secondary efficacy variables
The secondary efficacy variables for this study are as follows:

ASDAS-ID at Week 12

ASDAS-MI at Week 12

Osteoblastic activity as detected by PET-MRI or PET-CT at Week 12 and Week 48 
Has been changed to: 
The secondary efficacy variables for this study are as follows:

ASDAS-ID at Week 12

ASDAS-MI at Week 12
PUBLIC COPY
as follow
PY 
as follow
r CZP o
COP
r CZP o
ty of bim
C C
ty of bim
inical, an
BLIC
inical, an
ety of bi
UB
ety of bi
This document cannot be used to support any marketing authorization 
eatment E
eting
eatment E
s:
a
s:
n change
rt a
n change
mekizuma
ppo
mekizuma
d imaging
supp
d imaging
mekizuma
to s
mekizuma
ry effica
be u
ry effica
ariables fo
t be
ariables fo
eek 12
not
eek 12
at Week 1
an
at Week 1
stic activi
nt c
stic activi
been cha
me
been cha
e seconda
cum
e seconda

d

ASD
oc
ASD

s 

application and any extensions or variations thereof.
Extension
here
Extension
es in bone
va
es in bone
ab
ab
ng data as 
ns 
ng data as 
ab or CZP
sio
ab or CZP
acy vari
ny e
acy vari
for this stu
any
for this stu
12
n
12
vity as det
tion
vity as det
anged t
lica
anged t
ary effica
ppl
ary effica
AS
a
AS-
a
-ID a
ap
ID a


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 121 of 136
Change #6
Section 4.1.3, Other efficacy variables
Assessment time points for the other efficacy variables are specified in Table 5‒1. Other efficacy 
variables are as follows:

Change from Baseline in ASDAS

ASAS20 response

ASAS40 response

Time to ASAS20 response

Time to ASAS40 response

ASAS partial remission

Change from Baseline in BASDAI
Has been changed to: 
Section 4.1.3, Other efficacy variables
Assessment time points for the other efficacy variables are specified in Table 5‒1. The following 
efficacy variables are exploratory and are assessed over the Treatment Period and 
Treatment Extension Period, as applicable:

Change from Baseline in ASDAS

ASAS20 response

ASAS40 response

Time to ASAS20 response

Time to ASAS40 response

ASAS partial remission

Change from Baseline in BASDAI

Changes in bone formation as measured by standardized uptake value by area under 
the curve (SUVAUC) and derived from PET-MRI or PET-CT at Baseline, Week 12, and 
Week 48 
Change #7, Primary safety variables
The primary safety variables for this study are as follows:

Incidence of AEs and SAEs

Withdrawal due to AEs
Has been changed to: 
The primary safety variables for this study are as follows:
PUBLIC COPY 
ariables a
OP
ariables a
assessed
CO
assessed
able:
C C
able:
ment cannot be used to support any marketing authorization 
re specifi
rt a
re specifi
 ov
o
 over the
ort 
er the
e
b
e
on
ot
on
seline in B
nno
seline in B
bone form
can
bone form
 (SUV
t ca
 (SUV
This docum
AU
c
AU
48
n
48
nge #7,
ume
nge #7,
The prima
ocu
The prima

d

In
o
In

s

n and any extensions or variations thereof.
ied in
var
ied in Tab
ar
Tab
e Treatm
r va
e Treatm
BASDAI
nd 
BASDAI
ma
n
mation a
n a
tion a
application
C
i
C) and de
ion
) and de
, Primar
plic
, Primar
ary safety
app
ry safety
ce
a
ce
a


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 122 of 136

Incidence of AEs and SAEs

Adverse events leading to withdrawal from IMP
Change #8, Section header
4.5
Nonhereditary pharmacogenomic variables
Has been changed to: 
4.5
Other nonhereditary pharmacogenomic variables
Change #9, Section header
4.6
Pharmacogenetic variables
Has been changed to: 
4.6
Other pharmacogenetic variables 
Change #10
Section 5.1, Study description, paragraph 3
Approximately 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will 
receive either bimekizumab or CZP up to Week 44 (final dose of IMP). 
Has been changed to: 
At least 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio and will receive 
either bimekizumab or CZP up to Week 44 (final dose of IMP). 
Change #11
Section 5.5, Planned number of subjects and site(s)
It is anticipated that approximately 120 subjects will be screened in order to enroll approximately 
60 subjects at multiple sites.
Has been changed to: 
It is anticipated that approximately 120 subjects will be screened in order to enroll at least
60 subjects in the main study and at least 25 subjects in the PET-CT or PET-MRI substudy 
at multiple sites.
PUBLIC COPY 
ph 3
PY
ph 3
d to 1 of 
COP
d to 1 of 
Week
C C
Week 44 
CO
44 
mized to 
UBL
mized to 
to Week
PUB
to Week
t cannot be used to support any marketing authorization 
2 treatmen
rt a
2 treatmen
final dose
por
final dose
 of 2 trea
o su
 of 2 trea
44 (final d
to 
44 (final d
mber of 
e us
mber of 
ximately 1
t be
ximately 1
sites.
ot
sites.
ged to: 
nno
ged to: 
that appr
can
that appr
This document 
n the ma
nt c
n the ma
e sites.
ent
e sites.
on and any extensions or variations thereof.
nt arms in
va
nt arms in
e of IMP)
or v
e of IMP)
atment arm
ion
atment arm
dose of IM
nsio
dose of IM
f subjec
y ex
f subjec
120 subje
any
120 subje
roximatel
on a
roximatel
applicatio
ain study 
tion
ain study 


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 123 of 136
Change #12
Section 6.3.1, Potential drug-induced liver injury IMP discontinuation 
criteria, paragraph 2
The PDILI criteria below require immediate and permanent discontinuation of IMP: 
Subjects with either of the following:

ALT or AST ≥5ULN

ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 
Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness. Hypersensitivity symptoms include fever (without clear alternative cause), 
rash, or eosinophilia (ie, >5%).
Has been changed to: 
The PDILI criteria below require immediate discontinuation of IMP: 
Subjects with either of the following:

ALT or AST ≥5ULN

ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN 

Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).
Change #13
Section 7.1, Description of investigational medicinal product(s), 
paragraphs 1 and 2
The IMPs used in this study are bimekizumab and CZP.
Bimekizumab will be supplied as a clear to opalescent, colorless to slightly brown, sterile, 
preservative-free solution in 2mL Type I, colorless glass vials (1.0mL extractable volume) closed 
with a rubber stopper and sealed with an aluminum cap overseal. Each single-use dose vial will 
contain 160mg/mL bimekizumab in 
mM sodium acetate,
mM glycine and 
 (w/v) 
polysorbate 80 at pH 
.
PUBLIC COPY 
otal biliru
C CO
otal biliru
N who ex
LIC 
N who ex
patitis sy
BLI
patitis sy
ness. Hy
UB
ness. Hy
eosinop
PU
eosinop
ment cannot be used to support any marketing authorization 
of hepati
au
of hepati
pper quadr
g a
pper quadr
alternative
ting
alternative
MP: 
m
MP: 
bin ≥2xU
port
bin ≥2xU
hibit temp
upp
hibit temp
mptoms in
sup
mptoms in
persensitiv
to s
persensitiv
hilia (ie, >
d to
hilia (ie, >
n of inve
be u
n of inve
study are
not 
study are
l be suppl
ann
l be suppl
ee solutio
ca
ee solutio
er stopper 
nt c
er stopper 
60mg/mL
ent
60mg/mL
This docum
orbate 80 a
me
orbate 80 a
cation and any extensions or variations thereof.
itis or 
of.
itis or 
drant 
eof
drant 
e cause),
ereo
e cause),
ULN
or
ULN
mporally as
ns o
mporally as
nclude fat
ons
nclude fat
iv
s
ivity symp
sio
ity symp
>5%).
ens
>5%).
vestigati
ny e
vestigati
e bimekiz
nd a
e bimekiz
lied as a c
an
lied as a c
on in 2mL
on a
on in 2mL
r and seale
tion
r and seale
L bimekiz
cati
L bimekiz
applic
at pH 
lica
at pH 
ca


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 124 of 136
Has been changed to: 
The IMPs used in this study are bimekizumab and CZP.
Bimekizumab will be supplied as a vial or in a pre-filled syringe (PFS) form as described 
below: 

Vial: a clear to opalescent, colorless to slightly brown, sterile, preservative-free solution in 
2mL Type I, colorless glass vials (1.0mL extractable volume) closed with a rubber stopper 
and sealed with an aluminum cap overseal. Each single-use dose vial will contain 160mg/mL 
bimekizumab in 
mM sodium acetate, 
mM glycine, and 
 (w/v) polysorbate 80 at 
pH 

PFS: 1mL PFS at a concentration of 160mg/mL 
mM sodium acetate, 
mM 
glycine, 
 polysorbate 80 at pH 
) for sc injection.
Change #14
Section 8.8, Week 12 (Visit 8), PET-MRI/PET-CT scan bullet

Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 
2 weeks after Week 12 Visit if PET positive lesions were observed in the previous scan.
Has been changed to: 

Perform a PET-MRI or PET-CT scan in at least 25 subjects at selected sites within 2 weeks 
after Week 12 Visit if PET-positive lesions were observed in the previous scan.
Change #15
Section 8.11, Week 48 (Visit 17), PET-MRI/PET-CT scan bullet

Perform a PET-MRI or PET-CT scan in approximately 25 subjects at selected sites within 2 
weeks after the Week 48/WD Visit if PET positive lesions were observed in the previous 
scan. At the WD Visit, the PET-MRI or PET-CT must be done only, if the previous imaging 
evaluation occurred more than 12 weeks ago and if PET positive lesions were observed in the 
previous scan.
Has been changed to: 

Perform a PET-MRI or PET-CT scan in at least 25 subjects at selected sites within 2 weeks 
after the Week 48/WD Visit if PET-positive lesions were observed in the previous scan. At 
the WD Visit, the PET-MRI or PET-CT must be done only, if the previous imaging 
evaluation occurred more than 12 weeks ago and if PET-positive lesions were observed in 
the previous scan.
Change #16
Section 9.11, PET-MRI or PET-CT scan, last paragraph
The 18F-fluoride PET-MRIs of the whole spines will be performed by using a whole-body 
PET/MRI system. Alternatively, subjects will be examined in supine position on a combined 
PET-CT system permitting the acquisition of co-registered CT and PET images in the same 
PUBLIC COPY 
mately
Y
mately
sions we
PY
sions we
n 
C
n at lea
C C
at lea
e lesions
LIC
e lesions
t 17),
PU
t 17),
used to support any marketing authorization 
er 
ri
er 
mg/mL 
hori
mg/mL 
bate 80 at 
tho
bate 80 at 
, 
mM
g a
, 
mM
bullet
mar
bullet
subjects a
ny m
subjects a
re observe
any
re observe
t 25 subje
ppo
25 subje
were obse
upp
were obse
PET
ed t
PET-
d
-MR
t
MR
CT scan in
use
CT scan in
This document cannot be u
WD Visit i
e us
WD Visit i
he PET
be 
he PET-M
more than
ot b
more than
nged to
ann
nged to
PET
t c
PET-
c
-MR
ca
MR
e Week 4
ent 
e Week 4
WD Visit
men
WD Visit
evaluation
um
evaluation
the prev
ocu
the prev
Chan
s do
Chan
S
s
S
ng
extensions or variations thereof.
at selecte
atio
at selecte
ed in the p
ria
ed in the p
ects at se
or 
ects at se
erved in t
ns o
erved in t
RI/PET
ens
RI/PET
n approxi
ext
n approxi
application and any 
if PET po
y e
if PET po
MRI or PE
ny 
MRI or PE
n 12 week
d an
n 12 week
o: 
o: 
RI or PET
ion
RI or PET
48/WD V
atio
48/WD V
t, the PET
ica
t, the PET
n occurred
plic
n occurred
evious sca
app
evious sca
16
a
16


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 125 of 136
session. The PET-MRI or PET-CT scan will be performed at time points provided in Table 5‒1
in approximately 25 subjects at selected sites.
Has been changed to: 
The 18F-fluoride PET-MRIs of the whole spine will be performed by using a whole-body 
PET/MRI system. Alternatively, subjects will be examined in supine position on a combined 
PET-CT system permitting the acquisition of co-registered CT and PET images in the same 
session. The PET-MRI or PET-CT scan will be performed at time points provided in Table 5‒1
in at least 25 subjects at selected sites.
Change #17
Section 12.1.14, Adverse events for special monitoring, section header and 
paragraph 2
12.1.1.4
Adverse events for special monitoring
Adverse events for special monitoring for this study include: serious infections (including 
opportunistic infections and TB, see Section 12.7.5), cytopenias, hypersensitivities, suicide 
ideation or behavior (assessed using the C-SSRS), depression and anxiety (assessed using the 
HADS, see Section 9.10), major cardiovascular events and liver function test changes/enzyme 
elevations (ALT, AST, and bilirubin; see Section 12.6.1), malignancies, and inflammatory bowel 
diseases.
Has been changed to: 
12.1.1.4
Adverse events for special monitoring
Adverse events for special monitoring for this study include: infections (serious, opportunistic, 
fungal, and TB, see Section 12.7.5), neutropenia, hypersensitivity, suicidal ideation and
behavior (assessed using the C-SSRS), depression, (assessed using the HADS, see Section 9.10), 
major cardiovascular events, liver function test changes/enzyme elevations (ALT, AST, and 
bilirubin; see Section 12.6.1), malignancies, and inflammatory bowel diseases (with 
gastroenterology referral as appropriate).
BLIC COPY
yt
Y
yt
epressi
PY 
epressi
vents an
OPY
vents an
on
CO
on 12.6
COP
12.6
PUB
ecial mo
UBL
ecial mo
nitoring 
PU
nitoring 
7.5
P
7.5)
P
)
support any marketing authorization 
5
o
5‒
r
‒1
ori
1
on head
ng 
on head
us infectio
mar
us infectio
, hypersen
y m
, hypersen
n and anxi
ny 
n and anxi
d liver fun
t any
d liver fun
), malign
ort a
), malign
sed to s
nitoring
o su
nitoring
for this stu
d to
for this stu
neutrope
ed 
neutrope
This document cannot be us
SRS), dep
use
SRS), dep
ver functi
e us
ver functi
), malign
be 
), malign
al as app
ot b
al as app
sions or variations thereof.
der and
reo
der and
ons (inclu
ons
ons (inclu
ensitivities
tion
ensitivities
xiety (asse
iati
xiety (asse
nction tes
aria
nction tes
nancies, a
va
nancies, a
xten
udy inclu
ens
udy inclu
enia,
xten
enia, hyp
en
hyp
application and any ex
pression, (
exte
pression, (
ion test ch
y ex
ion test ch
nancies, an
ny 
nancies, an
propriate
d an
propriate


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 126 of 136
Change #18
Section 12.6.1, Evaluation of PDILI, Table 12-3
Table 12‒3:
Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN
≥2xULNb
NA
Hepatology consult.b
Medical Monitor 
must be notified 
within 24 hours 
(eg, by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.
Immediate, 
permanent IMP 
discontinuation.
Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section 12.6.1.3); 
recommended to 
occur at the site 
with HCP.
Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.b
Monitoring of liver chemistry 
values at least twice per week 
for 2 weeks.d

Immediate IMP 
discontinuation required if 
liver chemistry values
≥3xULN
NA
Yes
≥5xULN
NA
NA
Need for hepatology 
consult to be 
discussed. (required 
if ALT or AST 
≥8xULN) Medical 
Monitor must be 
notified within 
24hours (eg, by 
laboratory alert) and 
subject discussed 
with Medical Monitor 
ASAP.
Immediate, 
permanent IMP 
discontinuation
UBLIC COPY 
or 
BL
or 
ent IM
Y
ent IM
ntinuatio
PY
ntinuatio
C
PU
r hepato
PU
r hepato
be
P
be
UB
nnot be used to support any marketing authorization 
27 
n 
27
at
F
g a
g
k
g
ting
.
a
.
Essenti
ma
Essenti
have
y m
have
c
y
c
ma
y
to
ogy 
d t
ogy 
(required 
use
(required 
r AST
us
r AST
ULN) Medi
be u
ULN) Medi
onitor mus
t be
onitor mus
notified w
ot 
notified w
24hour
nno
24hour
labo
nn
labo
s
n
s
Im
o
Im
to
to
to 
This document can
l
T
l
en
n
to
sions or variations thereof.
Follow up
reo
Follow up
of
Evalu
her
Evalu
re
th
ial: Must
ion
ial: Must
e repeat liv
atio
e repeat liv
chemistry v
ria
chemistry v
and add
ar
and add
testin
va
testin
AS
v
AS
ns
r v
extensi
mmediate,
ens
mmediate,
permanen
xten
permanen
discon
exte
discon
si
application and any e
ical
ny
ical
st be 
an
st be 
within
d a
within
rs (eg, by 
nd
rs (eg, by 
oratory ale
an
oratory ale
subject dis
on a
subject dis
with
tion
with Me
n
Me
ASA
atio
ASA
cat
a
e


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 127 of 136
Table 12‒3:
Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN 
(and ≥2x 
baseline) 
and 
<5xULN 
(and ≥2x 
baseline)
<2xULN
No
Discussion with 
Medical Monitor 
required.
Consider need for 
hepatology consult if 
there is no evidence 
of resolution (see 
Follow-up 
requirements) c
Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section 12.6.1.2).
IMP discontinuation 
required if any of 
the following occur:

Subject cannot 
comply with 
monitoring 
schedule. 

Liver chemistry 
values continue 
to increase 

Liver chemistry 
values remain 
≥3xULN (and 
≥2xbaseline) 
after 2 weeks of 
monitoring 
without 
evidence of 
resolution 
Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48hours at 
the site with HCP 
(see Section 
12.6.1.3).
continue to increase. After 2 
weeks of monitoring liver 
chemistry values:

Discontinue IMP if levels 
remain ≥3xULN (and ≥2x 
baseline) without evidence 
of resolutiond 
Continue to monitor until values 
normalize, stabilize, or return to 
within baseline valuesd.
PUBLIC COPY
scontin
PY 
scontin
uired if a
OPY
uired if a
he follow
COP
he follow

C C

S
C
S
C
This document cannot be used to support any marketing authorization 
27 
n 
27
at
l
T
l
Follow up
tho
Follow up
ori
Evalua
auth
Evalua
th
g a
tion 
ny
tion 
y of 
a
y of 
ing occur:
rt a
ing occur:
ubject cann
po
ubject cann
comply w
upp
comply w
monit
sup
monit
sch
s
sch

al: Every 
etin
al: Every 
mpt must b
ket
mpt must b
ade to hav
ark
ade to hav
repeat liv
mar
repeat liv
chemis
y m
chemis
and
y 
and
t
y
t
ing
cu
n
to
y
thereof.
tio
f
tio
con
re
con
re
application and any extensions or variations th
nnot 
o
nnot 
with
s
with
toring
ons
toring
hedule. 
sion
hedule. 
Liver c
ens
Liver c
valu
te
valu
t
be 
t
be 
e
ver 
o
ver 
stry value
tion
stry value
additiona
atio
additiona
testing com
aria
testing com
within 4
var
within 4
the s
va
the s
(s(s
pp
at
e
r v
th


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 128 of 136
Table 12‒3:
Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal 
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause). 
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor. 
c Details provided in Section 12.6.1.1. The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist. 
d Unless an alternative monitoring schedule is agreed by the Investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
Has been changed to: 
Table 12-3:Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN
≥2xULNb
NA
Hepatology consult.c
Medical Monitor 
must be notified 
within 24 hours 
(eg, by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.
Immediate IMP 
discontinuationd.
Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section 12.6.1.3); 
recommended to 
occur at the site 
Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within baseline 
values.e
≥3xULN
NA
Yes
PUBLIC COPY
lte
Y
lte
enterolo
PY 
enterolo
responsi
OPY
responsi
ponsible p
OP
ponsible p
r PDILI
PUB
r PDILI
PU
be used to support any marketing authorization 
27 
n 
27
at
Follow up
tho
Follow up
ori
Evalua
auth
Evalua
th
g a
nsferase; H
ting
nsferase; H
N=upper lim
keti
N=upper lim
sensitivity s
rke
sensitivity s
discussed 
ma
discussed 
treating ph
y m
treating ph
t. t. 
le physician
any
le physician
hysician, as
rt a
hysician, as
ing
Immedi
ed 
Immedi
d to
on 
us
on 
ments
e us
ments
ed
nnot b
Hepatolog
ot b
Hepatolog
Medica
no
Medica
mus
nn
mus
w
n
w
This document can
l
T
l
b
n
ca
oc
oc
oc
oc
any extensions or variations thereof.
tio
f
tio
HCP=health
here
HCP=health
mit of norm
the
mit of norm
symptoms
s th
symptoms
with the M
ons
with the M
hysician for
tio
hysician for
n. Determin
aria
n. Determin
s needed.
var
s needed.
re
iate
te
iate
ns
Actio
ext
Actio
xte
e
ation and an
gy consult.
d a
gy consult.
al Monitor
nd
al Monitor
t be notifi
an
t be notifi
within 24
n a
within 24 h
a
h
(eg,
tion
(eg, by l
on
by l
alert)
atio
alert)
di
a
di
any
applicat
ap
at


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 129 of 136
Table 12-3:Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥5xULN
NA
NA
Need for hepatology 
consult to be 
discussed. (required 
if ALT or AST 
≥8xULN). Medical 
Monitor must be 
notified within 
24hours (eg, by 
laboratory alert) and 
subject discussed 
with Medical Monitor 
ASAP.
with HCP.
Monitoring of liver chemistry 
values at least twice per week 
for 2 weeks.e

Immediate IMP 
BLIC COPY 
nitor 
LIC
nitor 
PUBL
BL C
y marketing authorization 
27 
n 
27
at
Follow up
tho
Follow up
ori
Evalua
auth
Evalua
th
g a
P.
t
P.
ing
This document cannot be used to support any
l
T
l
s
y
thereof.
tio
f
tio
re
application and any extensions or variations th
on
r v
th


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 130 of 136
Table 12-3:Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
≥3xULN 
(and ≥2x 
baseline) 
and 
<5xULN 
(and ≥2x 
baseline)
<2xULN
No
Discussion with 
Medical Monitor 
required.
Consider need for 
hepatology consult if 
there is no evidence 
of resolution (see 
Follow-up 
requirements) c
Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section 12.6.1.2).
IMP discontinuation 
required if any of 
the following occur:

Subject cannot 
comply with 
monitoring 
schedule. 

Liver chemistry 
values continue 
to increase 

Liver chemistry 
values remain 
≥3xULN (and 
≥2xbaseline) 
after 2 weeks of 
monitoring 
without 
evidence of 
resolution 
Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48hours at 
the site with HCP 
(see Section 
12.6.1.3).
discontinuation required if 
liver chemistry values
continue to increase. After 2 
weeks of monitoring liver 
chemistry values:

Discontinue IMP if levels 
remain ≥3xULN (and ≥2x 
baseline) without evidence 
of resolutione
Continue to monitor until values 
normalize, stabilize, or return to 
within baseline valuese.
PUBLIC COPY
scontin
PY 
scontin
uired if a
OPY
uired if a
he follow
COP
he follow

C C

S
C
S
C
This document cannot be used to support any marketing authorization 
27 
n 
27
at
l
T
l
Follow up
tho
Follow up
ori
Evalua
auth
Evalua
th
g a
tion 
ny
tion 
y of 
a
y of 
ing occu
rt a
ing occur:
a
r:
ubject cann
po
ubject cann
comply w
upp
comply w
monit
sup
monit
sch
s
sch

al: Every 
etin
al: Every 
mpt must b
ket
mpt must b
ade to hav
ark
ade to hav
repeat liv
mar
repeat liv
chemis
y m
chemis
and
y 
and
t
y
t
ing
cu
n
to
y
thereof.
tio
f
tio
disc
re
disc
re
application and any extensions or variations th
nnot 
o
nnot 
with
s
with
toring
ons
toring
hedule. 
sion
hedule. 
Liver c
ens
Liver c
valu
te
valu
t
be 
t
be 
e
ver 
o
ver 
stry value
tion
stry value
additiona
atio
additiona
testing com
aria
testing com
within 4
var
within 4
the s
va
the s
(s(s
pp
at
e
r v
th


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 131 of 136
Table 12-3:Required investigations and follow-up for PDILI
Laboratory value
Immediate
Follow up
ALT or 
AST
Total 
bilirubin
Symptomsa of 
hepatitis or 
hypersensitivity
Consultation 
requirements
Actions
Testing
Evaluation
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug-induced liver injury; ULN=upper limit of normal
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause). 
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Monitor. 
c Details provided in Section 12.6.1.1. The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist. 
d Details are provided in Section 12.6.1.2.1.
e Unless an alternative monitoring schedule is agreed by the Investigator and UCB responsible physician. Determination of stabilization is at the discretion of the 
Investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.
PUBLIC COPY
lte
Y
lte
enterolo
PY 
enterolo
CB respo
OP
CB respo
responsib
CO
responsib
ng authorization 
27 
n 
27
at
Follow up
tho
Follow up
ori
Evalua
auth
Evalua
th
g a
This document cannot be used to support any marketing
l
T
l
nsferase; H
ting
nsferase; H
N=upper lim
keti
N=upper lim
sensitivity s
rke
sensitivity s
discussed 
ma
discussed 
treating ph
y m
treating ph
t.t.
sible physic
rt a
sible physic
e physician
ort 
e physician
ing
reof.
tio
f
tio
application and any extensions or variations there
HCP=health
here
HCP=health
mit of norm
the
mit of norm
symptoms
s th
symptoms
with the M
ons
with the M
hysician for
tio
hysician for
cian. Deter
var
cian. Deter
, as needed
r va
, as needed
re


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 132 of 136
Change #19
Section 12.6.1.2, Immediate action: Determination of IMP discontinuation, 
paragraph 2
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate and permanent discontinuation (see Section 6.3.1 and Table 12‒3 for details).
Has been changed to: 
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate discontinuation (see Section 6.3.1 and Table 12‒3 for details).
Change #20
Section 12.6.1.3, Testing: Identification/exclusion of alternative etiology, 
Table 12-4, chemistry
Chemistry
Amylase
ALT, AST
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Has been changed to: 
Chemistry
Amylase
Sodium, potassium, chloride, glucose, BUN, creatinine
Total bilirubin, ALP, AST, ALT, GGT, total cholesterol, albumin
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct bilirubin
Serum CPK and LDH to evaluate possible muscle injury causing transaminase elevation
Change #21
Section 15.1, Definition of analysis sets
The following analysis set has been added: 
The PET Per-Protocol Set (PET-PPS) will consist of all randomized subjects who receive at 
least 1 dose of the IMP and have evaluable PET-CT or PET-MRI scan data at Baseline and 
at at least 1 of the post-Baseline assessments.
Change #22
Section 15.8.1, Safety analyses, paragraph 2
Adverse events will be coded according to the most recent version of the Medical Dictionary for 
Regulatory Activities (MedDRA®). The incidence of treatment-emergent adverse events 
PUBLIC COPY 
Y
PY
btain fra
C CO
btain fra
CO
evaluate 
LIC
evaluate 
C C
LI
PU
P
This document cannot be used to support any marketing authorization 
itis or 
aut
itis or 
vestigatio
g au
vestigatio
alternati
mark
alternati
y
an
tionated b
por
tionated b
rt
possible m
upp
possible m
p
up
to
m, chloride
se
m, chloride
ed
n, ALP, AS
e u
n, ALP, AS
us
rubin ≥1.5
t be
rubin ≥1.5
be
CPK and 
not
CPK and 
t b
no
15.1, Def
nt c
15.1, Def
ollowing
men
ollowing
e PET Pe
cum
e PET Pe
least 1
doc
least 1 do
c
do
at at
do
at at l
o
l
C
s
C
pplication and any extensions or variations thereof.
on) to 
of
on) to 
tive etio
ns t
tive etio
ati
ari
bilirubin
or v
bilirubin to
v
to
v
muscle inju
ns o
muscle inju
o
ns
ns
e, glucose
exte
e, glucose
te
ST, ALT,
y e
ST, ALT,
ex
5xULN, ob
any
5xULN, ob
ny
LDH to e
nd a
LDH to e
a
nd
efinition
atio
efinition
g analys
lica
g analys
er
p
er-
p
-
ap
Proto
ppl
Proto
se of the
app
se of the
1 of
a
1 of


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 133 of 136
(TEAEs) will be summarized descriptively by MedDRA system organ class, preferred term, and 
treatment group. Additional tables will summarize TEAEs by intensity and relationship to IMP, 
TEAEs leading to withdrawal from the study, serious TEAEs, and deaths. All AE information 
will be listed.
Has been changed to: 
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA®, version 19.0). The incidence of treatment-emergent adverse events (TEAEs) will be 
summarized descriptively by MedDRA system organ class, preferred term, and treatment group. 
Additional tables will summarize TEAEs by intensity and relationship to IMP, TEAEs leading to 
withdrawal from the study, serious TEAEs, and deaths. All AE information will be listed.
Change #23
Section 15.11, Planned interim analysis and data monitoring
This study will include two unblinded interim analyses, the first after approximately 45 subjects 
have completed 4 weeks of the study and the second when the last randomized subject for this 
study has completed the Week 12 Visit at the end of the Treatment Period or this subject’s 
participation has ended prematurely. The purpose of these interim analyses is for Sponsor key 
personnel to review results from the primary efficacy analysis and a subset of the analyses of 
secondary efficacy and safety outcomes to facilitate additional Clinical Planning or Portfolio 
Management decisions; consequently, neither analysis and will lead to any formal decision to 
alter or terminate the trial. Interim analyses will be conducted by an unblinded study team and 
will follow internal SOPs for the formal process to control the unblinding of the study for interim 
analysis purposes. This process will ensure that no unnecessary or unintentional unblinding 
occurs. The unblinded team will not disclose any unblinded information to the blinded study 
team and the storage of all unblinded documentation will be held securely and separately from 
the rest of the study documentation and outputs up until the end of the study.
All analyses and unblinding instructions will be prespecified in the interim SAP.
Has been changed to: 
This study will include 3 informal unblinded interim analyses; the first after approximately 
45 subjects have completed 4 weeks of the study, the second when the last randomized subject 
not participating in the PET-MRI or PET-CT substudy has completed the Week 12 Visit at 
the end of the Treatment Period or has withdrawn prematurely from the study, and the third 
when the last randomized subject has completed the Week 12 Visit at the end of the 
Treatment Period or this subject’s participation has ended prematurely. 
The purpose of these interim analyses is for Sponsor key personnel to review results from the 
primary efficacy analysis and a subset of the analyses of secondary efficacy and safety outcomes 
to facilitate additional Clinical Planning or Portfolio Management decisions; consequently, none 
of the interim analyses will lead to any formal decision to alter or terminate the study. 
Interim analyses will be conducted by an unblinded study team and will follow internal SOPs for 
the formal process to control the unblinding of the study for interim analysis purposes. This 
process will ensure that no unnecessary or unintentional unblinding occurs. The unblinded team 
will not disclose any unblinded information to the blinded study team and the storage of all 
PUBLIC COPY
he T
Y
he T
of these 
PY 
of these 
ficacy an
OP
ficacy an
acilitate a
CO
acilitate a
ther ana
C C
ther ana
yses wil
LIC
yses wil
rmal pro
BLI
rmal pro
will ensu
UB
will ensu
ll not d
PU
ll not d
nde
P
nde
t cannot be used to support any marketing authorization 
will be
oriz
will be
nt group. 
thor
nt group. 
s leading 
uth
s leading 
e liste
au
e listed.
au
d.
ring
ket
ring
r approxim
mark
r approxim
t randomi
ma
t randomi
ment Perio
ny m
ment Perio
nterim an
any
nterim an
alysis
rt a
alysis and
a
and
dditional 
ort 
dditional 
ysis and w
ppo
ysis and w
be condu
upp
be condu
ess to con
sup
ess to con
e that no u
to s
e that no u
sclose any
d to
sclose any
d docume
ed 
d docume
on and ou
use
on and ou
nstruction
be u
nstruction
to: 
ot
to: 
de 
nn
de 3 info
no
3 info
completed
ann
completed
ing in the
t ca
ing in the
ocument 
he Treatm
nt c
he Treatm
e last ran
men
e last ran
ment Per
me
ment Per
he purpos
ocu
he purpos
This do
primary 
doc
primary 
to fac
s d
to fac
of 
s 
of 
ion and any extensions or variations thereof.
g
imately 45
ns 
imately 45
mized subj
ion
mized subj
iod or this
atio
iod or this
nalyses is 
riat
nalyses is 
d a subset
var
d a subset
Clinical P
r va
Clinical P
will lead t
or 
will lead t
ucted by a
ns o
ucted by a
ntrol the u
ions
ntrol the u
unnecess
sio
unnecess
y unblind
ens
y unblind
entation w
xten
entation w
utputs up u
ext
utputs up u
ns will be
ny e
ns will be
rmal
nd
rmal unb
d
unb
d 4 weeks
an
d 4 weeks
e PET
on a
e PET
applicatio
-M
ment Perio
tion
ment Perio
ndomized
cat
ndomized
riod or th
plica
riod or th
se of thes
app
se of thes
a
fficacy 
ap
fficacy 
ad


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 134 of 136
unblinded documentation will be held securely and separately from the rest of the study 
documentation and outputs up until the end of the study.
All analyses and unblinding instructions will be prespecified in the interim SAP.
Change #24
Section 15.12, Determination of sample size, first paragraph
A sufficient number of subjects will be enrolled in order to ensure 60 subjects are available at 
Week 12 to compare the change from Baseline in ASDAS between bimekizumab and CZP.
Has been changed to: 
A sufficient number of subjects will be enrolled in order to ensure at least 60 subjects are 
available at Week 12 to compare the change from Baseline in ASDAS between bimekizumab 
and CZP and at least 25 subjects will be enrolled into the PET-CT/MRI substudy.
PUBLIC COPY 
ing authorization 
e at 
ho
e at 
CZP.
th
CZP.
subjects ar
ng a
subjects ar
This document cannot be used to support any marketi
een bimek
ting
een bimek
RI substu
ket
RI substu
reof.
are 
re
are 
application and any extensions or variations the
ekizumab
here
ekizumab
udy.
the
udy.


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 135 of 136
20
DECLARATION AND SIGNATURE OF INVESTIGATOR
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, according to current Good Clinical Practice and local 
laws and requirements.
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this protocol.
I have received and read all study-related information provided to me.
The objectives and content of this protocol as well as the results deriving from it will be treated 
confidentially, and will not be made available to third parties without prior authorization by 
UCB.
All rights of publication of the results reside with UCB, unless other agreements were made in a 
separate contract.
Investigator:
Printed name
Date/Signature
PUBLIC COPY 
Date
CO
Date
OP
ing authorization 
be treated
uth
be treated
zation by 
au
zation by 
t any marketi
ments wer
eting
ments wer
This document cannot be used to support a
Signature
ort
Signature
t a
reof.
y
o
y
ariations the
re made in
here
re made in
application and any extensions or va
e
o
e
va


UCB
27 Feb 2019
Clinical Study Protocol
Bimekizumab
AS0013
Confidential
Page 136 of 136
21
SPONSOR DECLARATION
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


Approval Signatures
Name:
as0013-protocol-amend-3
Version:
1. 0
Document Number:
CLIN-000130278
Title:
AS0013 Protocol Amendment 3
Approved Date:
06 Mar 2019
Document Approvals
Approval
Verdict: Approved
Name: 
Capacity: Medical
Date of Signature: 05-Mar-2019 09:01:24 GMT+0000
Approval
Verdict: Approved
Name:
Capacity: Clinical
Date of Signature: 05-Mar-2019 20:20:19 GMT+0000
Approval
Verdict: Approved
Name:
Capacity: Clinical
Date of Signature: 06-Mar-2019 11:03:07 GMT+0000
C COPY 
CO
ent Ap
CO
ent Ap
UBLIC C
C C
PU
pport any marketing authorization 
rt
provals
port 
provals
to suppo
po
s
Name:
pp
Name:
Capac
sup
Capac
Da
su
Da
used to
to
This document canno
not be u
no
p
or variations thereof.
va
s
o
s
or
or
sions 
city: Medic
ons
city: Medic
te of Signa
ion
te of Signa
extensisi
xte
Name:
ens
Name:
Cap
e
Cap
D
application and
nd any e
nd
s o
s

SAP_001.pdf: 
UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 1 of 86
STATISTICAL ANALYSIS PLAN 
Study: AS0013
Product: Bimekizumab
A MULTICENTER, PHASE 2A, RANDOMIZED,
INVESTIGATOR-BLIND, SUBJECT-BLIND, 
PARALLEL-GROUP
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF
BIMEKIZUMAB AND CERTOLIZUMAB PEGOL IN SUBJECTS
WITH ACTIVE ANKYLOSING SPONDYLITIS
SAP/Amendment Number
Date
Final SAP
17 January 2018
Amendment 1
15 August 2018
Amendment 2
23 May 2019
Amendment 3
19 June 2020
Confidentiality Statement
Confidential
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.
PUBLIC COPY 
IN
Y
IN
ate
UB
ate
1
P
17
PU
7 Janu
PU
Janu
15 A
P
15 A
ocument cannot be used to support any marketing authorization 
,
D SAFE
keti
D SAFE
GOL IN
mark
GOL IN
POND
y m
POND
ary 2018
d to
ary 2018
ugust 201
ed 
ugust 201
May 201
use
May 201
19
e
19 June 
e us
June 
This doc
oc
application and any extensions or variations thereof.
ETY O
the
ETY O
N SUB
ns 
N SUB
DYLITI
atio
DYLITI
18
xt
18
19
e
19
2020
y e
2020
ap
ap


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 2 of 86
TABLE OF CONTENTS
LIST OF ABBREVIATIONS....................................................................................................7
1
INTRODUCTION ...........................................................................................................11
2
PROTOCOL SUMMARY...............................................................................................11
2.1
Study objectives...........................................................................................................11
2.1.1
Primary objective.................................................................................................11
2.1.2
Secondary objectives ...........................................................................................11
2.1.3
Other objectives...................................................................................................11
2.2
Study variables.............................................................................................................12
2.2.1
Efficacy variables ................................................................................................12
2.2.1.1
Primary efficacy variable ..........................................................................12
2.2.1.2
Secondary efficacy variables.....................................................................12
2.2.1.3
Other efficacy variables.............................................................................12
2.2.2
Safety variables....................................................................................................12
2.2.2.1
Primary safety variables ............................................................................12
2.2.2.2
Other safety variables................................................................................13
2.2.3
Pharmacokinetic variables...................................................................................13
2.2.4
Pharmacodynamic variables ................................................................................13
2.2.5
Immunological variables .....................................................................................13
2.2.6
Nonhereditary pharmacogenomic variables ........................................................13
2.2.7
Pharmacogenetic variables ..................................................................................13
2.3
Study design and conduct ............................................................................................14
2.4
Determination of sample size.......................................................................................15
3
DATA ANALYSIS CONSIDERATIONS......................................................................16
3.1
General presentation of summaries and analyses ........................................................16
3.2
General study level definitions ....................................................................................18
3.2.1
Relative day .........................................................................................................18
3.2.2
Study periods .......................................................................................................18
3.3
Definition of Baseline values.......................................................................................18
3.4
Protocol deviations.......................................................................................................20
3.5
Analysis sets.................................................................................................................21
3.5.1
Enrolled Set .........................................................................................................21
3.5.2
Randomized Set...................................................................................................21
3.5.3
Safety Set.............................................................................................................21
3.5.4
Full Analysis Set..................................................................................................21
3.5.5
Per-Protocol Set...................................................................................................21
3.5.6
Pharmacokinetics Per-Protocol Set......................................................................21
3.5.7
Pharmacodynamics Per-Protocol Set...................................................................22
LIC COPY 
.........
PY 
.........
..........
OP
..........
..........
CO
..........
.........
C C
.........
PUBLI
..........
LIC
..........
acogenom
UBL
acogenom
variables
PUB
variables
ct
P
ct .
P
.
upport any marketing authorization 
1
..
h
..11
hor
11
.....
uth
........
uth
...11
h
11
............
a
...........
............
ng
............
............
tin
............
...........
ke
...........
............
a
............
......
m
............
m
......
...
n
............
ny
.........
.....
t a
............
a
.......
.......
ort
...........
rt
....
............
p
............
annot be used to sup
............
up
............
mic variab
o su
mic variab
............
d to
............
...........
ed
...........
size
us
size.......
us
.......
NSID
e u
NSIDERA
u
ERA
on of sum
t be
on of sum
evel defin
not 
evel defin
This document ca
ve day
nno
ve day ..
n
..
udy period
can
udy period
nition of B
nt c
nition of B
rotocol de
en
rotocol de
Analys
ume
Analys
3.5.1
cu
3.5.1
3.5.2
doc
3.5.2
3
d
3
nsions or variations thereof.
12
f
12
.....
e
.....12
eof
12
.
h
...........
her
..........12
e
12
...........
th
...........
.........
ns
............
s
...
............
tio
............
............
iat
............
............
ar
............
...........
r v
...........
..............
o
..........
and any extens
...
n
............
ns
.........
bles
io
bles .......
io
.......
............
ns
............
...........
te
...........
............
ex
............
ATIONS
y e
ATIONS
mmaries an
any
mmaries an
nitions
d a
nitions .
pplication an
...........
an
...........
ds
n
ds .........
n
.........
Baseline 
tion
Baseline 
eviations
cat
eviations
sis sets
plic
sis sets....
app
Enrolle
pp
Enrolle
Ran
ap
Ran


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 3 of 86
3.5.8
PET Per-Protocol Set...........................................................................................22
3.6
Treatment assignment and treatment groups ...............................................................22
3.7
Center pooling strategy................................................................................................23
3.8
Coding dictionaries ......................................................................................................23
3.9
Changes to protocol-defined analyses .........................................................................23
4
STATISTICAL/ANALYTICAL ISSUES.......................................................................24
4.1
Adjustments for covariates ..........................................................................................24
4.2
Handling of dropouts or missing data..........................................................................24
4.2.1
Efficacy data ........................................................................................................24
4.2.1.1
ASDAS derivation.....................................................................................24
4.2.1.2
hs-CRP.......................................................................................................24
4.2.1.3
ASDAS component data ...........................................................................24
4.2.1.4
ASAS20, ASAS40 and ASAS-PR ............................................................25
4.2.1.5
BASFI data................................................................................................25
4.2.1.6
HADS data ................................................................................................25
4.2.1.7
Spinal pain and PhGADA data..................................................................25
4.2.2
Pharmacodynamic data........................................................................................25
4.2.3
Safety laboratory data..........................................................................................25
4.2.4
Pharmacokinetic data...........................................................................................25
4.2.5
Dates and times....................................................................................................26
4.3
Handling of repeated and unscheduled measurements ................................................27
4.4
Handling of measurements obtained at the EW visit...................................................27
4.5
Interim analyses and data monitoring..........................................................................28
4.5.1
Data monitoring committee .................................................................................28
4.5.2
Interim analyses...................................................................................................28
4.6
Multicenter studies.......................................................................................................29
4.7
Multiple comparisons/multiplicity...............................................................................29
4.8
Use of an efficacy subset of subjects ...........................................................................29
4.9
Active-control studies intended to show equivalence..................................................29
4.10
Examination of subgroups ...........................................................................................29
5
STUDY POPULATION CHARACTERISTICS.............................................................29
5.1
Subject disposition.......................................................................................................29
5.2
Protocol deviations.......................................................................................................30
6
DEMOGRAPHICS AND OTHER BASELINE CHARACTERISTICS ........................31
6.1
Derivation of variables.................................................................................................31
6.1.1
Calculation of body mass index...........................................................................31
6.1.2
Classification of age categories ...........................................................................31
6.1.3
Duration of disease ..............................................................................................31
LIC COPY 
......
Y
......
.........
OPY
.........
..........
CO
..........
.........
C C
.........
PUBLIC
.........
LIC
.........
..........
BL
..........
d unsche
PUB
d unsche
ents ob
PU
ents ob
o support any marketing authorization 
.24
or
24
......
th
......24
ho
24
....
a
............
au
........2
...........
g
...........
............
tin
............
............
ke
............
......
ar
............
ar
......
........
m
............
m
....
...........
y
...........
............
an
............
............
rt
...........
....
p
............
po
........
cannot be used to
.........
upp
............
pp
...
.....
s
...........
su
......
duled mea
to s
duled mea
tained at t
ed t
tained at t
monitoring
sed
monitoring
ommittee
e us
ommittee
es
b
es.........
be
.........
ies
ot
ies........
ot
........
mparisons/
nno
mparisons/
n efficacy 
can
n efficacy 
This document c
e-
t
-control 
t ca
control 
xamination
ent
xamination
TUDY PO
me
TUDY PO
Subj
um
Subj
5.2
do
5.2
P
6
s d
6
6
s
6
s or variations thereof.
4
f
4
...
e
...24
eof
24
..
e
.........
ere
.......24
e
24
....
th
............
th
........
............
s
............
............
on
............
...........
ati
...........
...
a
............
ari
.........
............
va
............
............
or
............
n and any extensions 
............
s
............
...........
on
...........
asurement
nsio
asurement
the EW v
tens
the EW v
ng
e
ng..........
xt
..........
...........
y e
...........
...........
ny
...........
............
d a
............
s/multiplic
and
s/multiplic
y subset of
n a
y subset of
applicatio
studies in
tion
studies in
on of subg
atio
on of subg
OPULAT
lica
OPULAT
ject dispo
ppl
ject dispo
ap
otocol
ap
otocol d
p
d
G


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 4 of 86
6.2
Demographics ..............................................................................................................31
6.3
Other Baseline characteristics......................................................................................32
6.4
Medical history and concomitant diseases...................................................................33
6.5
Ankylosing spondylitis history ....................................................................................33
6.6
Prior and concomitant medications..............................................................................33
6.6.1
Prior medication definition..................................................................................34
6.6.2
Concomitant medication definition .....................................................................34
7
MEASUREMENTS OF TREATMENT COMPLIANCE...............................................34
8
EFFICACY ANALYSES ................................................................................................34
8.1
Primary efficacy variable.............................................................................................34
8.1.1
Derivation of the primary efficacy variable.........................................................34
8.1.1.1
Bath Ankylosing Spondylitis Disease Activity Index...............................34
8.1.1.2
Patient’s Global Assessment of Disease Activity .....................................35
8.1.1.3
High-sensitivity C-reactive protein ...........................................................35
8.1.1.4
Calculation of Ankylosing Spondylitis Disease Activity Score................35
8.1.2
Primary analysis of the primary efficacy variable...............................................36
8.1.2.1
Bayesian modeling ....................................................................................36
8.1.2.2
Building the prior ......................................................................................37
8.1.2.3
Prior data conflict ......................................................................................38
8.1.3
Presentation of the primary analysis of the primary efficacy variable ................38
8.1.4
Presentation of Ankylosing Spondylitis Disease Activity Score.........................38
8.1.5
Presentation of component variables of Ankylosing Spondylitis Disease Activity 
Score ....................................................................................................................38
8.1.5.1
Bath Ankylosing Spondylitis Disease Activity Index...............................38
8.1.5.2
Patient’s Global Assessment of Disease Activity .....................................39
8.1.5.3
High sensitivity C-reactive protein............................................................39
8.1.6
Supportive analysis of the primary efficacy variable ..........................................40
8.1.6.1
Alternative analysis sets ............................................................................40
8.1.6.2
Alternative prior distributions ...................................................................40
8.1.6.3
Frequentist analysis – Analysis of Covariance..........................................40
8.1.6.4
Frequentist analysis – Mixed Model Repeated Measures.........................40
8.1.6.5
Frequentist analysis – Mixed Model Repeated Measures with Baseline by 
treatment group interaction .......................................................................41
8.2
Secondary efficacy variables .......................................................................................41
8.2.1
ASDAS Disease Activity States and Improvement.............................................41
8.2.1.1
Derivation of ASDAS Disease Activity States and Improvement ............41
8.2.1.2
Analysis of ASDAS Disease Activity States and Improvement ...............41
8.3
Other efficacy variables ...............................................................................................42
8.3.1
Derivation of Assessment in SpondyloArthritis International Society Response42
PUBLIC COPY 
ylitis 
Y
ylitis 
acy varia
OPY
acy varia
..........
CO
..........
.........
C C
.........
.........
LIC
.........
mary ana
BLI
mary ana
kylosing 
PUB
kylosing 
mpone
PU
mpone
used to support any marketing authorization 
.34
or
34
......
th
......34
ho
34
............
au
............3
...........
g
...........
............
tin
............
............
ke
............
............
ar
............
............
m
............
ease Activ
ny m
ease Activ
ble
a
ble........
an
........
.....
rt
............
rt
.......
........
po
............
o
....
............
upp
............
ysis of the
sup
ysis of the
Spondyliti
to s
Spondyliti
nt variable
ed t
nt variable
.....
se
............
se
.......
This document cannot be u
osing Spon
us
osing Spon
Global A
be 
Global A
sensitivit
ot b
sensitivit
ive analys
no
ive analys
Alternat
ann
Alternat
Alte
ca
Alte
6.3
en
6.3
F
.1.6.4
me
.1.6.4
8.1.6.5
um
8.1.6.5
8.2
do
8.2
8
extensions or variations thereof.
4
f
4
...
e
...34
eof
34
.........
ere
.........34
e
34
............
th
............
............
s
............
............
on
............
vity Score
atio
vity Score
............
ari
............
............
va
............
............
or
............
............
s
............
he primary
ions
he primary
tis Disease
nsio
tis Disease
les of Ank
tens
les of Ank
............
xt
............
application and any e
ondylitis D
y ex
ondylitis D
Assessmen
ny 
Assessmen
ty C
d a
ty C-
a
-react
an
react
sis of the 
nd 
sis of the 
ative analy
n an
ative analy
ernative p
ion 
ernative p
Frequenti
atio
Frequenti
Freque
lica
Freque
5
p
5
Fre
pli
Fre
onda
a
onda


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 5 of 86
8.3.2
Presentation of Assessment in SpondyloArthritis International Society Response43
8.3.2.1
ASAS20 and ASAS40 response................................................................43
8.3.2.2
Time to ASAS20 and ASAS40 response ..................................................43
8.3.2.3
ASAS-PR...................................................................................................44
8.3.3
Presentation of components of Assessment in SpondyloArthritis International 
Society .................................................................................................................44
8.3.3.1
Bath Ankylosing Spondylitis Functional Index ........................................44
8.3.3.2
Total and nocturnal spinal pain numeric rating scale................................44
8.3.4
Physician’s Global Assessment of Disease Activity ...........................................45
8.3.5
Hospital Anxiety and Depression Scale ..............................................................45
8.3.6
Change in Bone Formation (PET-MRI/PET-CT Substudy)................................45
8.3.6.1
Eligibility assessment................................................................................45
8.3.6.2
Efficacy assessment...................................................................................46
9
PHARMACOKINETICS AND PHARMACODYNAMICS ..........................................49
9.1
Pharmacokinetics .........................................................................................................49
9.2
Pharmacodynamics ......................................................................................................50
10
IMMUNOLOGICAL ANALYSES.................................................................................50
11
SAFETY ANALYSES.....................................................................................................51
11.1
Extent of exposure .......................................................................................................51
11.2
Adverse events.............................................................................................................51
11.3
Clinical laboratory evaluations ....................................................................................54
11.4
Vital signs, physical findings, and other observations related to safety......................56
11.4.1
Vital signs ............................................................................................................56
11.4.2
Electrocardiograms..............................................................................................57
11.4.3
Other safety variables ..........................................................................................58
11.4.3.1
C-SSRS......................................................................................................58
11.4.3.2
Physical examination.................................................................................58
11.4.3.3
Chest X-ray/CT scan and TB questionnaire..............................................58
12
OTHER ANALYSES ......................................................................................................58
13
REFERENCES ................................................................................................................59
14
APPENDICES .................................................................................................................60
14.1
Bath Ankylosing Spondylitis Disease Activity Index .................................................60
14.2
Bath Ankylosing Spondylitis Functional Index...........................................................60
14.3
Hospital Anxiety and Depression Scale.......................................................................61
14.4
Treatment group assignment for the TFLs...................................................................61
14.5
Adverse events for special monitoring ........................................................................62
14.5.1
Major cardiovascular events................................................................................62
14.5.2
Serious infections, including opportunistic infections and tuberculosis .............63
PUBLIC COPY 
....
Y
....
.........
PY
.........
..........
CO
..........
......
C
.........
C
...
.........
IC
.........
..........
BL
..........
ations
PUB
ations .
B
.
dings, 
PU
dings, 
This document cannot be used to support any marketing authorization 
44
or
44
.....
th
.....44
ho
44
...........
au
...........45
h
45
...........
g a
...........
............
ting
............
............
ket
............
............
ark
............
............
ma
............
...
y
...........
y
........
............
any
............
.......
rt
............
t
.....
............
po
............
............
pp
............
...........
su
...........
............
to 
............
and other 
d to
and other 
............
se
............
...........
u
...........
riables
be
riables .
RS
ot
RS........
ot
........
hysical ex
no
hysical ex
Chest X
ann
Chest X
ANALYS
t ca
ANALYS
RENCES
ent 
RENCES
PPENDIC
me
PPENDIC
Bath 
um
Bath 
14.2
doc
14.2
B
14.3
do
14.3
14
s 
14
application and any extensions or variations thereof.
5
f
5
....45
of
45
........
re
........45
eo
45
............
the
............
............
s t
............
............
on
............
...........
atio
...........
............
ria
............
............
va
............
..........
or
..............
............
s o
............
...........
on
...........
............
sio
............
observati
ens
observati
............
xt
............
............
e
............
...........
ny
...........
............
d a
............
xaminatio
nd 
xaminatio
X-ray/CT 
n an
ray/CT 
SES
on
SES .....
on
.....
S
a
S .........
ati
.........
CES
lic
CES .....
c
.....
Ankylosi
ppli
Ankylosi
ath Anky
app
th Anky
pita
a
pita


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 6 of 86
14.5.2.1
Serious infections ......................................................................................63
14.5.2.2
Fungal infections .......................................................................................63
14.5.2.3
Opportunistic infections ............................................................................63
14.5.3
Malignancies including lymphoma......................................................................64
14.5.4
Cytopenias ...........................................................................................................64
14.5.5
Neuropsychiatric events.......................................................................................64
14.5.6
Inflammatory bowel disease................................................................................65
14.5.7
Anaphylactic reaction ..........................................................................................65
14.5.7.1
Anaphylactic reaction algorithm ...............................................................65
14.5.8
Hepatic events and drug-induced liver injury......................................................69
14.6
Treatment-emergent markedly abnormal laboratory values........................................69
14.7
Treatment-emergent abnormal liver values .................................................................70
14.8
Treatment-emergent markedly abnormal vital signs values ........................................71
15
AMENDMENTS TO THE SAP......................................................................................72
15.1
Amendment 2...............................................................................................................72
15.1.1
Rationale for the amendment...............................................................................72
15.1.2
List of changes.....................................................................................................72
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE.....................................................86
LIST OF TABLES
Table 3‒1:
Definition of Baseline......................................................................................18
Table 3‒2:
Administration of investigational medicinal product ......................................22
Table 4‒1:
Calculation rules for duration of adverse events..............................................27
Table 11‒1:
Clinical laboratory measurements....................................................................55
Table 14‒1:
Bath Ankylosing Spondylitis Disease Activity Index .....................................60
Table 14‒2:
Bath Ankylosing Spondylitis Functional Index...............................................60
Table 14‒3:
Hospital Anxiety and Depression Scale...........................................................61
Table 14‒4:
Treatment group assignment for TFLs ............................................................61
Table 14‒5:
Definition of TEMA values for hematology....................................................69
Table 14‒6:
Definition of TEMA values for chemistry.......................................................69
Table 14‒7:
Definition of treatment-emergent liver function values...................................70
Table 14‒8:
TEMA/PCS criteria for vital signs...................................................................71
PUBLIC COPY 
......
Y
......
.........
OPY
.........
..
C
..........
CO
........
ATURE 
C C
ATURE 
LIST O
BLI
LIST O
eline
PUB
eline.
U
.
f inv
P
f inv
d to support any marketing authorization 
.65
or
65
......
th
......65
ho
65
............
au
............6
...........
g
...........
............
tin
............
............
ke
............
............
ar
............
............
m
............
...........
y
...........
....
a
............
an
........
............
rt
............
PAGE
por
PAGE...
o
...
OF TAB
sup
OF TAB
............
to
............
This document cannot be used
estigation
ed 
estigation
for durati
use
for durati
ratory 
be
ratory me
e 
me
kylosing S
ot b
kylosing S
Ankylosi
nno
Ankylosi
Hospital A
can
Hospital A
Treatm
nt c
Treatm
4‒5:
me
4‒5:
D
n
D
le
c
le 14‒6:
cum
14‒6:
Table
doc
Table 14
c
14
Tabl
s d
Tabl
ensions or variations thereof.
5
f
5
...
e
...69
eof
69
.
e
.........
ere
........69
e
69
............
th
............
............
s
............
....
o
............
on
........
...........
ati
...........
............
ari
............
......
v
............
va
......
............
or
............
BLES
ons
BLES
............
ns
............
application and any exte
nal medic
xten
nal medic
ion of adv
ex
ion of adv
asuremen
ny 
asuremen
Spondylit
d an
Spondylit
ing Spond
and
ing Spond
Anxiety a
n a
Anxiety a
ment grou
atio
ment grou
Definition 
lica
Definition 
Defini
ppli
Defini
‒7:
a
7:
De
p
De


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 7 of 86
LIST OF ABBREVIATIONS
ACP
above cut point
ADA
anti-drug antibodies
AE
adverse event
ALP
alkaline phosphatase
ALT
alanine aminotransferase
ALQ
above the limit of quantification
AS
ankylosing spondylitis
ASAS
Assessment in SpondyloArthritis International Society
ASAS-PR
Assessment in SpondyloArthritis International Society partial remission
ASAS20
Assessment in SpondyloArthritis International Society 20%
ASAS40
Assessment in SpondyloArthritis International Society 40%
ASDAS
Ankylosing Spondylitis Disease Activity Score
ASDAS-CII
Ankylosing Spondylitis Disease Activity Score – clinically important improvement
ASDAS-HD
Ankylosing Spondylitis Disease Activity Score – high disease activity
ASDAS-ID
Ankylosing Spondylitis Disease Activity Score – inactive disease
ASDAS-MI
Ankylosing Spondylitis Disease Activity Score – major improvement
ASDAS-vHD
Ankylosing Spondylitis Disease Activity Score – very high disease activity
AST
aspartate aminotransferase
ATC
anatomical therapeutic chemical
BASDAI
Bath Ankylosing Spondylitis Disease Activity Index
BASFI
Bath Ankylosing Spondylitis Functional Index
BCP
below cut point
BKZ
bimekizumab
BLQ
below the limit of quantification
BMI
body mass index
BP
blood pressure
CI
confidence intervals 
CP
confirmed positive
C-SSRS
Columbia-Suicide Severity Rating Scale 
CSR
clinical study report
CT
controlled terminology
CTCAE
Common Terminology Criteria for Adverse Events
CV
coefficient of variation
PUBLIC COPY
ity
Y
ity
ctivity S
PY 
ctivity S
se Activi
COP
se Activi
isease A
C C
isease A
tis Diseas
LIC
tis Diseas
dylitis D
UBL
dylitis D
notransfe
PU
notransfe
rap
P
rap
sed to support any marketing authorization 
l remission
eting
l remission
0%
rk
0%
ty 40%
mar
ty 40%
ore
a
ore –
n
– c
ny
clini
ny
lini
y Score 
rt a
y Score –
a
– h
tivity Scor
por
tivity Scor
e Activity 
upp
e Activity 
sease Activ
o su
sease Activ
rase
d t
rase
utic chem
ed 
utic chem
This document cannot be u
ng Spondy
use
ng Spondy
ylosing Sp
be u
ylosing Sp
cut point
ot b
cut point
mekizuma
no
mekizuma
below t
can
below t
bod
c
bod
P
o
P
C
d
C-
do
-SSRS
do
SSRS
CS
s 
CS
extensions or variations thereof.
n
h
n
ically 
ria
ically i
at
imp
a
mp
high 
va
high disea
var
disea
re
o
re –
or
– inacti
or v
inacti
Score
ns o
Score – m
o
m
ivity Score
ion
ivity Score
mical
xte
mical
application and any e
ylitis Dise
ex
ylitis Dise
pondylitis F
ny 
pondylitis F
ab
n
ab
the limit o
n a
the limit o
dy mass in
tion
dy mass in
blood pre
cati
blood pre
conf
ic
conf


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 8 of 86
CZP
certolizumab pegol
DEM
data evaluation meeting
DMC
data monitoring committee
ECG
electrocardiogram
eCRF
electronic case report form
ES
enrolled set
EW
early withdrawal
FAS
full analysis set
FDA
Food and Drug Administration
geoCV
geometric coefficient of variation
HADS
Hospital Anxiety and Depression Scale
HADS-A
Hospital Anxiety and Depression Scale – Anxiety
HADS-D
Hospital Anxiety and Depression Scale – Depression
HIV
human immunodeficiency virus
HLA-B27
human leukocyte antigen B27
HLGT
high level group term
HLT
high level term
hs-CRP
high sensitivity C-reactive protein
IA1
Interim Analysis 1
IA2
Interim Analysis 2
IA3
Interim Analysis 3
ICH
International Council for Harmonization
IL-17A
interleukin 17-A
IL-17F
interleukin 17-F
IMP
investigational medicinal product
IPD
important protocol deviation
LLN
lower limit of normal
LLT
low level term
LLOQ
lower limit of quantification
LSMeans
least squares means
MACE
major adverse cardiovascular event
MedDRA
Medical Dictionary for Regulatory Activities
MMRM
Mixed Model Repeated Measures
mNY
modified New York
PUBLIC COPY 
reactive 
BL
reactive 
sis 1
PU
sis 1
sis 2
P
sis 2
This document cannot be used to support any marketing authorization 
sion
y m
sion
rotein
su
rotein
is 3
us
is 3
al 
b
al C
be
Council
e u
ouncil
ukin 17
t be
ukin 17-
b
-A
e
A
erleukin 1
not
erleukin 1
investiga
ann
investiga
impo
ca
impo
LOQ
cu
LOQ
LS
do
LSM
do
Mea
o
ea
MA
s d
MA
application and any extensions or variations thereof.
l for 
y
l for H
y e
Harm
y e
arm
7
n
7-
nd
-F
nd
F
ational
an
ational me
n
me
ortant pro
ion 
ortant pro
lower lim
atio
lower lim
low l
ica
low l
lolo


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 9 of 86
n
number of available observations
NCP
not confirmed positive
NRS
numeric rating scale
PCS
potentially clinically significant
PD
pharmacodynamics
PDILI
potential drug-induced liver injury
PD-PPS
pharmacodynamics per-protocol set
PET-CT
positron emission tomography-computed tomography
PET-MRI
positron emission tomography-magnetic resonance imaging
PhGADA
physician’s global assessment of disease activity
PK
pharmacokinetics
PK-PPS
pharmacokinetic per-protocol set
PoC
proof-of-concept
PPS
per-protocol set
PT
preferred term
Q2W
every 2 weeks
Q4W
every 4 weeks
QTcF
Fridericia’s QTc interval
RCTC
Rheumatology Common Toxicity Criteria
RS
randomized set
SAE
serious adverse event
SAP
statistical analysis plan
Sc
subcutaneous
SD
standard deviation
SDTM
Study Data Tabulation Model
SE
standard error
SFU
safety follow-up
SIJ 
sacroiliac joint
SMQ
standardized MedDRA query
SOC
system organ class
SS
safety set
SUVauc
standard uptake value corrected for individual integrated whole blood activity
concentration
TB
tuberculosis
TEAE
treatment-emergent adverse event
PUBLIC COPY 
nterval
BL
nterval
y
P
y Commo
PUB
Commo
et
P
et
This document cannot be used to support any marketing authorization 
n Toxicity
to 
n Toxicity
event
use
event
nalysis pla
be u
nalysis pla
aneous
t be
aneous
ndard dev
not
ndard dev
Study D
ann
Study D
stan
ca
stan
MQ
c
MQ
SOC
do
SOC
SS
s d
SS
application and any extensions or variations thereof.
y Criteria
nsio
y Criteria
an
n
an
iation
nd
iation
Data Tabula
an
Data Tabula
dard error
on 
dard error
safety fol
atio
safety fol
sacro
ica
sacro
s


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 10 of 86
TEMA
treatment-emergent markedly abnormal
TFLs
tables, figures and listings
TNF
tumor necrosis factor
ULN
upper limit of normal
VOI
volume of interest
VUMC
VU University Medical Center
WHODD
World Health Organization Drug Dictionary
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 11 of 86
1
INTRODUCTION
The purpose of this statistical analysis plan (SAP) is to provide all information that is necessary 
to perform the required statistical analysis of study AS0013. It also defines the summary tables, 
figures and listings (TFLs) to be included in the final clinical study report (CSR) according to the 
protocol.
This SAP is based on, and assumes familiarity with, the following documents:
•
Protocol amendment 1, dated 30 May 2017
•
Protocol amendment 2, dated 5 March 2018
•
Protocol amendment 3, dated 27 February 2019
Unless specified in the sections below, the study will be analyzed as described in the most recent 
version of the protocol. If a future protocol amendment necessitates a substantial change to the 
statistical analysis of the study data, this SAP will be amended accordingly. In addition, if 
analysis definitions need to be modified or updated prior to database lock, a SAP amendment 
will be required. If, after database lock, additional analyses are required to supplement the 
planned analyses described in this SAP, these changes will be described in the CSR together with 
the associated rationale.
The content of this SAP is compatible with the International Council for Harmonization 
(ICH)/Food and Drug Administration (FDA) E9 Guidance documents (ICH, 1998).
UCB is the Sponsor and PAREXEL is the Contract Research Organization for this study.
2
PROTOCOL SUMMARY
2.1
Study objectives
2.1.1
Primary objective
The primary objective of the study is to evaluate the efficacy of bimekizumab (BKZ) 
administered subcutaneously (sc) every 2 weeks (Q2W) for 12 weeks compared to certolizumab 
pegol (CZP; Cimzia®) in the treatment of adult subjects with active ankylosing spondylitis (AS).
2.1.2
Secondary objectives
The secondary objectives of the study are as follows: 
•
To assess the safety and tolerability of BKZ
2.1.3
Other objectives
The other objectives of the study are as follows:
•
To evaluate the effect of BKZ or CZP on changes in bone formation
•
To assess the pharmacokinetics (PK) and immunogenicity of BKZ
•
To assess additional biomarker, clinical, and imaging data as available
•
To assess the efficacy and safety of BKZ or CZP during the Treatment Extension Period
PUBLIC COPY 
s wil
Y
s wil
e Interna
COP
e Interna
A) E9 Gu
C CO
A) E9 Gu
the
LIC
the Cont
LIC
Cont
UMMA
UBL
UMMA
ives
PU
ives
not be used to support any marketing authorization 
ed in the m
ting
ed in the m
stantial ch
ketin
stantial ch
ngly. In ad
rke
ngly. In ad
e lock, a S
mar
e lock, a S
equired to 
ma
equired to 
descri
ny m
described
y m
bed
ional Cou
ort a
ional Cou
idance do
por
idance do
ract Resea
upp
ract Resea
RY
o s
RY
e
tudy is to 
e us
tudy is to 
y 
b
y (
b
(sc)
be
sc) eve
e 
eve
the treatm
ot b
the treatm
This document cann
ondary o
nno
ondary o
bjectives 
can
bjectives 
s the safe
nt c
s the safe
Ot
n
Ot
other obj
cum
other obj
•
d
•
To ev
oc
To ev
•
s d
•
T
d any extensions or variations thereof.
most rece
ere
most rece
hange to t
ther
hange to t
addition, i
s th
addition, i
SAP amen
ns 
SAP amen
o supplem
tion
o supplem
d in the C
atio
d in the C
uncil for H
va
uncil for H
ocuments 
or v
ocuments 
arch Orga
ns o
arch Orga
evaluate 
y e
evaluate 
ery 2 wee
any 
ery 2 wee
ment of 
d an
ment of a
n
a
application and
bjective
nd 
bjective
of the stu
n a
of the stu
ety and to
tion
ety and to
ther obje
icat
ther obje
jectives o
pplic
jectives o
a
aluate th
app
aluate th


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 12 of 86
2.2
Study variables
2.2.1
Efficacy variables
2.2.1.1
Primary efficacy variable
The primary efficacy variable for this study is the change from Baseline in Ankylosing 
Spondylitis Disease Activity Score (ASDAS) at Week 12.
2.2.1.2
Secondary efficacy variables
The secondary efficacy variables for this study are as follows:
•
Ankylosing Spondylitis Disease Activity Score-inactive disease (ASDAS-ID) at Week 12
•
Ankylosing Spondylitis Disease Activity Score-major improvement (ASDAS-MI) at 
Week 12
2.2.1.3
Other efficacy variables
Other efficacy variables, assessed over the Treatment Period and Treatment Extension Period,
are as follows: 
•
Change from Baseline in ASDAS
•
Assessment in SpondyloArthritis International Society (ASAS) 20% (ASAS20) response
•
ASAS 40% (ASAS40) response
•
Time to ASAS20 response
•
Time to ASAS40 response
•
ASAS partial remission
•
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
•
Change from Baseline in total Hospital Anxiety and Depression Scale – Anxiety (HADS-A)
and total Hospital Anxiety and Depression Scale – Depression (HADS-D)
•
Change from Baseline in Physician’s Global Assessment of Disease Activity (PhGADA)
•
Change from Baseline in Patient’s Global Assessment of Disease Activity (PGADA)
•
Changes in bone formation as measured by standardized uptake value corrected for 
individual integrated whole blood activity concentration (SUVauc) for each PET-positive 
lesion identified together with the maximum of the SUVauc values  across all lesions within 
the spine and sacroiliac joint (SIJ).  SUVauc will be derived from positron-emission 
tomography magnetic resonance imaging (PET-MRI) or positron-emission tomography 
computed tomography (PET-CT) scans at Baseline, Week 12, and Week 48
2.2.2
Safety variables
2.2.2.1
Primary safety variables
The primary safety variables for this study are as follows:
•
Incidence of adverse events (AEs) and serious adverse events (SAEs)
PUBLIC COPY 
nal Soci
COP
nal Soci
This document cannot be used to support any marketing authorization 
t Week
aut
t Week 12
t
12
AS
n
AS-
g
-MI) at
ng a
MI) at
eatment E
mar
eatment E
ety
rt
ety (ASAS
rt a
(ASAS
Ankylosi
sed
Ankylosi
otal
e
otal Hosp
e us
Hosp
ety and D
be 
ety and D
ine in Phy
ot 
ine in Phy
Base
an
Baseline in
ann
line in
n bone for
t ca
n bone for
ual integra
nt c
ual integra
n identifie
men
n identifie
e spine an
me
e spine an
tomogra
cum
tomogra
comp
oc
comp
2.2.2
s d
2.2.2
2
s
2
pplication and any extensions or variations thereof.
2
f
2
t t 
Extension
ns 
Extension
S)
v
S) 20% 
var
20% (A
r
(A
ing Spond
exte
ing Spond
pital Anxi
y e
pital Anxi
Depression
any
Depression
ysician’s 
d a
ysician’s 
n Patient’
and
n Patient’
rmation a
on 
rmation a
ated whol
atio
ated whol
ied toget
cat
ied togeth
nd sacroil
plica
nd sacroil
aphy
pp
aphy magn
ppl
magn
ap
uted tom
app
uted tom


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 13 of 86
•
Withdrawal due to AEs
2.2.2.2
Other safety variables
The other safety variables for this study are as follows:
•
Change from Baseline in vital signs (blood pressure, temperature, pulse rate) and body 
weight
•
Change from Baseline in physical examination
•
Change from Baseline in standard 12-lead electrocardiogram (ECG) intervals (RR, PR, QRS,
QT, and QT intervals corrected for heart rate using Fridericia’s formula [QTcF])
•
Change from Baseline in clinical laboratory values (hematology, biochemistry, and 
urinalysis)
2.2.3
Pharmacokinetic variables
The PK variables are plasma concentrations of BKZ and CZP.
2.2.4
Pharmacodynamic variables
The pharmacodynamic (PD) variables are the blood or blood derivative (eg, plasma) 
concentrations of cytokines and chemokines of relevance to interleukin-17A (IL-17A) or 
interleukin-17F (IL-17F) signaling pathway, tumor necrosis factor (TNF) signaling pathway, AS 
biology, and bone metabolism. Additional variables may include, but will not be limited to, 
serum complement concentrations and mononuclear cell subtypes.
2.2.5
Immunological variables
Anti-BKZ antibody and anti-CZP antibody (collectively anti-drug antibody [ADA]) detection 
prior to and following study treatment will be evaluated.
2.2.6
Nonhereditary pharmacogenomic variables
Where local regulations permit, blood and urine will be collected and stored for up to 20 years to 
allow for potential exploratory analyses of ribonucleic acid, proteins, and metabolite biomarkers 
relevant to AS, bone metabolism, and the inflammatory and immune response processes. The 
nature and format of these tentative analyses will be determined at a later stage and will not form 
part of the CSR and are not further described in this SAP.
2.2.7
Pharmacogenetic variables
Additional blood samples will be collected from subjects who consent to participate in the
pharmacogenetic substudy and stored at -80°C for up to 20 years. Pharmacogenetic biomarkers 
may be measured to evaluate the relationship to response to treatment with BKZ, AS disease 
biology, bone metabolism, and inflammatory and immune response processes. The nature and 
format of these tentative substudy analyses will be determined when the results of the main study 
are made available. The results of these analyses will not form part of the CSR and are not 
further described in this SAP.
PUBLIC COPY
d or bloo
PY 
d or bloo
elevance
OPY
elevance
umor ne
CO
umor ne
variable
C C
variable
mononuc
LIC 
mononuc
riables
BL
riables
ZP antib
PUB
ZP antib
atmen
P
atmen
used to support any marketing authorization 
PR, QRS
tho
PR, QRS
try, and 
g a
try, and 
d derivativ
any
d derivativ
to interle
t an
to interle
rosis fact
ort 
rosis fact
s may incl
por
s may incl
lear cell s
upp
lear cell s
dy 
d t
dy (
to
(collec
to 
collec
t will be e
ed t
t will be e
pharmac
use
pharmac
ment cannot be
mit, blood 
be u
mit, blood 
atory analy
t be
atory analy
etabolism
ot b
etabolism
th
n
these ten
no
ese ten
nd are not
ann
nd are not
Pharm
t ca
Pharm
al blood s
ent
al blood s
This docum
acogeneti
me
acogeneti
y be meas
cum
y be meas
biology, b
docu
biology, b
format 
do
format 
are m
s d
are m
fu
s
fu
y extensions or variations thereof.
ve (eg, pl
riat
ve (eg, pl
eukin
vari
eukin-
ar
-17A
ri
17A
tor
v
tor (TNF)
r va
(TNF)
lude, but 
or v
lude, but 
subtypes.
s o
subtypes.
ectively 
nsi
ectively an
an
evaluated
ten
evaluated
cogenom
ext
cogenom
cation and any
and urine
ny e
and urine
lyses of
any
lyses of ri
y
ri
m
d
m, 
d
, and the
d a
and the
ntative
nd
ntative a
d
an
ot further d
n an
ot further d
macogen
tion
macogen
samples w
cati
samples w
applic
tic substud
lica
tic substud
sured to e
ppli
sured to e
bone meta
app
one meta
hese 
a
hese


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 14 of 86
2.3
Study design and conduct
AS0013 is a multicenter, randomized, subject-blind and investigator-blind, parallel-group study 
to evaluate the efficacy and safety of BKZ compared to CZP in adult subjects with active 
adult-onset AS. 
It is planned that at least 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 ratio 
and will receive either BKZ or CZP up to Week 44 (final dose of investigational medicinal 
product [IMP]).
The study will include a Screening Period of 2 to 4 weeks, a 12-week Treatment Period, a 
36-week Treatment Extension Period, and a 20-week Safety Follow-up (SFU) Period (starting 
after the final dose of IMP). Therefore, the maximum duration of the study will be 68 weeks.
At the start of the Treatment Period, eligible subjects will be randomized in a 2:1 ratio to receive 
the following blinded study treatments:
•
BKZ 160mg sc Q2W from Week 0 through Week 10. In addition, subjects will receive 1 
placebo injection at Baseline (Visit 2), Week 2 (Visit 3), and Week 4 (Visit 3) in order to 
maintain the blind versus the CZP loading dose at these visits.
•
CZP 400mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200mg sc Q2W at 
Weeks 6 to 10.
After completing the 12-week Treatment Period, subjects will enter a 36-week Treatment
Extension Period and will receive the following treatments:
•
Subjects randomized to BKZ during the Treatment Period will receive BKZ 320mg sc every 
4 weeks (Q4W) from Week 12 to Week 44.
•
Subjects randomized to CZP during the Treatment Period will receive CZP 400mg Q4W 
from Week 12 to Week 44.
Subjects not responding to treatment during the Treatment Period will be withdrawn from the 
study as per Investigator’s discretion and will not enter the Treatment Extension Period. 
In a substudy of AS0013, a PET-MRI or PET-CT scan of the entire spine will be performed at 
selected sites in approximately 25 subjects at Screening and during the study at Week 12 and 
Week 48 or Early Withdrawal Visit if PET positive lesions were observed in the previous scan.
All subjects who complete the study or who discontinue from the study early, including those 
withdrawn from the IMP treatment, will have a SFU Visit at 20 weeks after their final dose of 
IMP. 
Three unblinded interim analyses will be conducted:
•
Interim Analysis 1 (IA1): when approximately 45 subjects have completed the Week 4 visit 
during the Treatment Period. 
•
Interim Analysis 2 (IA2): when all subjects not participating in the PET-MRI/PET-CT 
sub-study have completed the Week 12 visit at the end of the Treatment Period.
•
Interim Analysis 3 (IA3): when the last randomized subject has completed the Week 12 visit
at the end of the Treatment Period, or the subject has discontinued prematurely from the 
study. 
PUBLIC COPY
he
Y
he
ding dos
PY 
ding dos
eriod, su
C CO
eriod, su
lowing t
IC C
lowing t
ring the 
BLI
ring the 
2 to We
UB
2 to We
P duri
PU
P duri
cannot be used to support any marketing authorization 
d, a 
th
d, a 
d (
a
d (starting
auth
starting
e 68 week
g au
e 68 week
a 2:1 
tin
a 2:1 ratio
ng
ratio
subjects w
arke
subjects w
Week 4 (V
mar
Week 4 (V
ts.
y
ts.
) followe
any
) followe
bjects
por
bjects will
ort
will
reatments
ppo
reatments
Treatment
sup
Treatment
k 44.
to s
k 44.
ng the Tre
ed t
ng the Tre
tment dur
e us
tment dur
discretion 
be 
discretion 
3, a PET
ot b
3, a PET
oximately
no
oximately
Withdraw
ann
Withdraw
This document c
who compl
t ca
who compl
from the 
nt 
from the 
ee
ee unblind
cum
unblind
•
d
•
Interi
oc
Interi
du
o
du
•
s
•
n and any extensions or variations thereof.
ng
f
ng
eks.
of
eks.
to receiv
reo
to receiv
will
s t
will recei
s th
recei
Visit 3) in
ons
Visit 3) in
ed by CZP
riat
ed by CZP
l enter a 3
or v
l enter a 3
s:
s
s:
t Period w
ons
t Period w
eatment P
tens
eatment P
ring the T
y ex
ring the T
and will 
ny 
and will 
MRI or P
d a
MRI or P
y 25 subje
nd 
y 25 subje
wal Visit
an
wal Visit
applicatio
plete the st
ion 
plete the st
IMP trea
atio
IMP trea
nded interi
pplic
nded interi
m Analy
app
m Analy
he T
a
he T


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 15 of 86
Further details on the interim analyses planned for this study are included in the interim SAP.
A data monitoring committee (DMC) will review the data on an ongoing basis. The composition
and roles of the DMC are described in a separate DMC Charter. The analyses required and data
to be presented are described in a separate DMC SAP.
2.4
Determination of sample size
A sufficient number of subjects will be enrolled to ensure that at least 60 subjects are available in 
the main study at Week 12 to compare the change from Baseline in ASDAS between BKZ and 
CZP.  This will also provide at least 25 subjects enrolled in the PET-CT or PET-MRI substudy 
from multiple sites. Subjects will be randomized in a 2:1 ratio to receive BKZ or CZP 
respectively.
The sample size was calculated to provide at least 80% power to detect a difference between
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group mean
change from Baseline for CZP and BKZ being -1.78 and -2.67 respectively) with a common 
standard deviation (SD) of 1.17 using frequentist methods for the comparison of the treatment 
group mean change from Baseline in ASDAS at Week 12 with Baseline ASDAS as a covariate 
(Overall and Starbuck, 1979).
The correlation between Baseline and Week 12 raw ASDAS was assumed to be 0.35. Note that 
the informative prior for the model intercept to be used in the Bayesian modelling of the primary 
efficacy variable, given by 𝛽𝐶𝑍𝑃~ Normal (-1.78, var=0.0605), contributes an effective sample 
size of approximately 20 CZP subjects. Prior data conflict will be investigated, and a vague prior 
will be used for the model intercept coefficient if prior data conflict is evident.
Note that a clarification regarding the sample size for this study was provided in protocol 
amendment 3. As indicated above, the planned sample size of at least 60 subjects provides 
sufficient power to detect meaningful treatment differences in the primary efficacy variable 
whilst also providing at least 25 subjects for the PET-MRI or PET-CT substudy. However, due 
to complexities in the initiation of sites capable of performing PET-MRI or PET-CT scans, more 
than the planned 35 non-PET-MRI/CT substudy subjects were screened and randomized before it 
was possible to close enrolment at the sites not participating in the substudy. Owing to the 
novelty of the PET-MRI/CT outcomes within this disease area, it is considered important to 
ensure at least 25 evaluable subjects are included in the assessment of this exploratory objective 
to maximize the possibility of identifying the salient factors or variables that might differ 
between the treatment groups and, therefore, the total sample size is increased to at least 72 
subjects. This sample size increase will not negatively impact the power to detect a difference in 
the primary efficacy variable at Week 12 (ie, it will remain >80%), but will ensure that the target 
number of subjects are included in the exploratory analysis of changes in bone formation at 
Week 12 and Week 48. Since the analyses of PET-MRI/CT data are exploratory and treatment 
effect sizes are unknown, formal power calculations were not performed. Clinical expertise does, 
however, indicate that a sample size of at least 25 subjects in the substudy will characterize 
broad differences between treatment groups.
PUBLIC COPY 
w
OP
w ASD
OPY
ASD
o be
CO
o be used
COP
used
(
C
( 1.78,
C CO
1.78, v
CO
v
P
I
Prior dat
IC C
rior dat
oefficien
BLIC
oefficien
g the sam
UB
g the sam
ove, t
PU
ove, the 
PU
he 
ngf
P
ngf
This document cannot be used to support any marketing authorization 
le
ri
le in
iz
in
and 
hori
and 
ub
th
ubstudy 
tho
study 
P
a
P
erence be
ting
erence be
2 of 0.89 
ketin
2 of 0.89 
vely) with
rke
vely) with
mparison
mark
mparison
aseline A
ma
aseline A
AS was as
any
AS was as
in the Ba
ort a
in the Ba
ar=0.0605
por
ar=0.0605
conflict w
ppo
conflict w
t if prior d
sup
t if prior d
ple size
to s
ple size fo
s
fo
planned sa
d to
planned sa
ul treatmen
ed 
ul treatmen
ubjects fo
use
ubjects fo
n of sites c
e us
n of sites c
T
b
T-
b
-MRI/
be 
MRI/C
olment at
ot b
olment at
RI
n
RI/CT
not
/CT ou
t
ou
valuable s
nn
valuable s
possibilit
can
possibilit
reatment 
t ca
reatment 
This samp
ent 
This samp
mary 
me
mary effic
men
effic
ber of sub
um
ber of sub
Week 12 an
ocu
Week 12 an
effect si
doc
effect si
howe
s d
howe
br
s
br
application and any extensions or variations thereof.
etween
reo
etween
(group m
ther
(group m
h a
s t
h a comm
th
comm
n of the
ns 
n of the trtr
ASDAS as
tion
ASDAS as
ssumed to
aria
ssumed to
ayesian m
va
ayesian m
5), contrib
or v
5), contrib
will be
s o
will be inin
data confl
ns 
data confl
for this stu
sio
for this stu
ample siz
ens
ample siz
ent differe
xten
ent differe
or the PET
ext
or the PET
capable o
y e
capable o
CT substu
any 
CT substu
t the sites
d an
t the sites
utcomes w
nd a
utcomes w
subjects a
and
subjects a
ity of iden
n a
ity of iden
t groups a
tion
t groups a
ple size in
atio
ple size in
cacy varia
lica
cacy varia
bjects are
plic
bjects are
and Week
app
and Week
s are u
ap
s are u
i


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 16 of 86
3
DATA ANALYSIS CONSIDERATIONS
3.1
General presentation of summaries and analyses
Statistical evaluation will be performed by PAREXEL and supervised by the Exploratory 
Statistics and Global Statistical Sciences Departments of UCB.
The datasets will follow the UCB analysis data model data specifications.
All analyses will be performed using SAS version 9.2 or higher (SAS Institute, Cary, North 
Carolina, USA). R Version 2.10.1 (R Development Core Team) or later, and/or OpenBUGS 
Version 3.0.6 or later may be used for complementary analysis.
Descriptive statistics will be used to provide an overview of the Baseline, efficacy, PD, PK and 
safety results.  Formal statistical testing will be conducted for the primary and secondary efficacy 
variables only in this study.  Other efficacy variables will be summarized descriptively by 
treatment group. 
Continuous variables will be summarized by treatment, visit and time point (where applicable) 
including number of subjects (n), mean, SD, median, minimum and maximum. First and third 
quartiles (Q1 and Q3 respectively) and 95% confidence intervals (CI) for the mean will also be 
included where stated in the SAP. 
Categorical variables will be summarized by treatment, visit and time point (where applicable) 
with frequency counts and percentages. Geometric coefficient of variation (geoCV), geometric 
mean and 95% CI for the geometric mean will also be presented in the descriptive statistics for 
the PK concentration and hs-CRP data. In all outputs the 95% confidence limits will be restricted 
to the possible values that the variable can take.
When reporting relative frequencies or other percentage values, the following rules apply:
•
For values where all subjects fulfill certain criteria, the percentage value will be displayed as 
100
•
For values where the absolute frequency is zero, there will be no percentage displayed at all
•
All other percentage displays will use 1 decimal place
•
Unless otherwise stated, the denominator for the percentages will be based on the number of 
subjects in the respective analysis set and treatment group. 
Percentages displayed based on continuous data (eg, percentage changes from Baseline) will be 
displayed to 1 decimal place. 
When reporting descriptive statistics, the following rules will apply in general (with the 
exception of PK and hs-CRP data, for which additional rules are stated below):
•
n will be an integer
•
Mean, SD, median and CIs will use 1 decimal place more (or 1 more significant figure, 
depending on the original data reporting format) than the original data
•
Coefficient of variation will be reported as a percentage to 1 decimal place
PUBLIC COPY 
ce in
Y
ce in
reatment
COP
reatment
ometric 
C CO
ometric 
n will al
IC C
n will al
a. In all 
BLIC
a. In all 
able can 
UBL
able can 
ncies or
PU
ncies or
f
P
f
This document cannot be used to support any marketing authorization 
o
UGS
tho
UGS
y, PD, PK
g au
y, PD, PK
secondar
ng 
secondar
escriptive
eting
escriptive
me point (w
mark
me point (w
nd maxim
ma
nd maxim
als (CI)
ny m
als (CI) fo
m
fo
visit and
ort a
visit and
oefficient
por
oefficient
so be pres
ppo
so be pres
outputs the
sup
outputs the
ake.
o s
ake.
other perc
d to
other perc
ulfill certa
sed
ulfill certa
solute freq
be 
solute freq
e displays
ot b
e displays
se stated, 
nno
se stated, 
he respect
can
he respect
displayed
nt c
displayed
d to 1 deci
ent
d to 1 deci
n reportin
ume
n reportin
ception o
cum
ception o
•
d
•
n w
o
n w
•
s 
•
application and any extensions or variations thereof.
K and 
of
K and 
ry efficacy
reo
ry efficacy
ely by 
here
ely by 
where app
ns 
where app
mum. Firs
ion
mum. Firs
or the me
atio
or the me
d time poi
va
d time poi
nt of variat
or v
nt of variat
sented in t
s o
sented in t
he 
he 95% 
ns
95% co
s 
co
rcentage v
ens
rcentage v
ain criteri
xte
ain criteri
equency is
ny 
equency is
s will use 
d a
s will use 
the denom
and
the denom
tive analy
n a
tive analy
d based o
tion
d based o
imal plac
cati
imal plac
ng descrip
plic
ng descrip
of PK 
pp
of PK and
pp
and
be an 
ap
be an 


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 17 of 86
•
Minimum and maximum will be reported using the same number of decimal places as the 
original data
•
If no subjects have data at a given time point, then only n=0 will be presented. If n<3, then 
only n, minimum and maximum will be presented. If n=3, then only n, median, minimum 
and maximum will be presented. The other descriptive statistics will be left blank.
When reporting individual values and descriptive statistics for PK concentration and hs-CRP 
data, the following rules will apply with regard to rounding and precision: 
•
Individual values will be reported to the same level of precision as received from the 
bioanalytical laboratory
•
Descriptive statistics will be reported to the same level of precision as the individual data for
the minimum and maximum, to 1 additional significant figure for the mean (arithmetic and
geometric), median, Q1, Q3, SD, and to 2 additional significant figures for the 95% CI for
the geometric mean
•
The geoCV will be reported as a percentage to 1 decimal place
All statistical tests will be carried out 2-tailed at the 5% level of significance unless otherwise 
stated. The following rules will apply for the presentation of any results relating to inferential 
statistical analysis:
•
P-values will be presented to 4 decimal places; p-values less than 0.0001 will be presented as 
“<0.0001” and p-values greater than 0.9999 will be presented as “>0.9999”
•
Posterior probabilities associated with the Bayesian analyses will be presented as percentages 
to 1 decimal place
•
Means, SDs, medians, 95% credible intervals and highest posterior density intervals obtained 
from the Bayesian analyses will be presented to 1 decimal place 
All statistical output will be presented in statistical appendices where appropriate.
Time to response data (Section 8.3.2.2) will be analyzed for the Treatment Period and across the 
study (Treatment Period + Treatment Extension Period). All other data tabulations will be 
performed by treatment group, visit and time point (where applicable) and no separate analyses 
based on study period will be presented.
The treatment groups will be displayed as follows in the TFLs, where BKZ refers to 
bimekizumab and CZP refers to certolizumab pegol:
•
BKZ 
•
CZP
Data listings containing all documented data and all derived data will be generated.  Subjects 
enrolled in the PET-MRI/PET-CT substudy will be flagged in the data listings.
If Study Data Tabulation Model (SDTM) controlled terminology (CT) is defined for selected 
variables, it will be displayed similarly in the TFLs.
Yes/No responses will be presented as Y/N consistent with the YN CT and Male and Female will 
be replaced with M/F respectively in the TFLs.
PUBLIC COPY 
% le
Y
% le
ntation o
OPY
ntation o
places; 
C CO
places; 
0.9999 
IC 
0.9999 
d with th
BLI
d with th
credi
PU
credi
used to support any marketing authorization 
he
t
he
ndividual 
g a
ndividual 
an (arithm
ting
an (arithm
es for the 9
keti
es for the 9
of signific
ny m
of signific
f any resu
any
f any resu
p values le
por
values le
will be pre
pp
will be pre
e Bayesian
sup
e Bayesian
ble interva
ed t
ble interva
ll be prese
sed
ll be prese
document cannot be 
esented in
e us
esented in
tion
b
tion 8.3.2
be
8.3.2
d + Treatm
ot b
d + Treatm
ent group
nno
ent group
riod will 
ann
riod will 
t groups w
t ca
t groups w
ab and C
nt 
ab and C
This do
KZ
m
KZ
CZP
cu
CZP
Data lis
do
Data lis
enro
s d
enro
extensions or variations thereof.
data for
eof
data for
metic and
ere
metic and
95% CI f
ther
95% CI f
cance unl
atio
cance unl
ults relatin
aria
ults relatin
ess than 0
or v
ess than 0
esented as
s o
esented as
an analyse
ions
an analyse
als and hi
ten
als and hi
ented to 1
exte
ented to 1
application and any 
n statistic
y e
n statistic
2.2
a
2.2) will b
any
) will b
ment Exte
d a
ment Exte
p, visit an
and
p, visit an
be presen
an
be presen
will be dis
ion 
will be dis
CZP refers
atio
CZP refers
gs con
ap
gs con


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 18 of 86
3.2
General study level definitions
3.2.1
Relative day
Relative day for an event will be derived with the date of the first administration of IMP as 
reference date.
Relative day for an event or measurement occurring before the reference date will be calculated 
as follows:
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒𝐷𝑎𝑦= 𝐸𝑣𝑒𝑛𝑡𝐷𝑎𝑡𝑒−𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒𝐷𝑎𝑡𝑒
The relative day for an event or measurement occurring on or after the reference date, up to the 
date of the last administration of IMP, will be calculated as follows:
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒𝐷𝑎𝑦= (𝐸𝑣𝑒𝑛𝑡𝐷𝑎𝑡𝑒−𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒𝐷𝑎𝑡𝑒) + 1
For events or measurements occurring after the date of the last administration of IMP, relative 
day will be prefixed with ‘+’ in the data listings and will be calculated as follows:
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒𝐷𝑎𝑦= 𝐸𝑣𝑒𝑛𝑡𝐷𝑎𝑡𝑒−𝐷𝑎𝑡𝑒𝑜𝑓𝐿𝑎𝑠𝑡𝐴𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑟𝑎𝑡𝑖𝑜𝑛
There is no relative Day 0. Relative day will not be calculated for partial dates in cases where 
relative day is shown in a subject data listing. In such cases, relative day should be presented as 
‘-‘ in the subject data listings.
3.2.2
Study periods
For each subject completing the study, the maximum study duration will be 68 weeks and will 
comprise the following: 
•
Screening Period: ≥2 weeks with a maximum of 4 weeks prior to randomization
•
Treatment Period: 12 weeks
•
Treatment Extension Period: 36 weeks
•
Safety Follow-Up Period: 20 weeks after the last dose of IMP (scheduled at Week 44, 4 
weeks prior to the end of the Treatment Extension Period)
The end of the study is defined as the date of the last visit of the last subject in the study.
3.3
Definition of Baseline values
Baseline will be the last available value prior to the first administration of IMP. Scheduled or
unscheduled measurements can be used as the Baseline value. Measurement-specific Baseline
definitions (based on the schedule of assessments in the protocol) are presented in Table 3‒1.
Table 3‒1:
Definition of Baseline
Category
Measurement
Definition of Baseline
Efficacy
BASDAI
Visit 2 (Week 0); Screening result if 
missing at Week 0
PGADA
Visit 2 (Week 0)
PUBLIC COPY 
alcula
Y
alcula
uch case
OPY
uch case
the max
LIC
the max
with a m
PUB
with a m
document cannot be used to support any marketing authorization 
e, up to th
auth
e, up to th
1
i
1
ation of IM
keti
ation of IM
as follow
arke
as follow
𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑟
ma
𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑟
for partia
ny m
for partia
, relative 
any
, relative 
mum stud
upp
mum stud
maximum 
d to 
maximum 
36 week
us
36 week
d: 20 wee
be 
d: 20 wee
d of the T
ot b
d of the T
is defined
nno
is defined
efinitio
can
efinitio
ll be the la
nt c
ll be the la
led measu
ent
led measu
ions
m
ions (bas
me
(bas
Table
ocu
Table 3
cu
3‒
This do
Categ
s d
Categ
do
s 
E
s
E
s
application and any extensions or variations thereof.
he
f
MP, relati
the
MP, relati
ws:
s
ws:
𝑟𝑎𝑡𝑖
on
𝑟𝑎𝑡𝑖𝑜𝑛
ons
𝑜𝑛
al dates in
iatio
al dates in
e day shou
aria
e day shou
dy duratio
ns o
dy duratio
of 4 week
nsio
of 4 week
ks
ks
eks after t
any 
eks after t
Treatment
d an
Treatment
ed as the d
and
ed as the d
on of 
n a
on of B
a
Ba
last availa
tion
last availa
urements
cati
urements
sed on the
lica
sed on the
1
a
1:
a
:
Def
pp
Def
a


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 19 of 86
Table 3‒1:
Definition of Baseline
Category
Measurement
Definition of Baseline
hs-CRP
Visit 2 (Week 0); Screening result if 
missing at Week 0
PET-MRI/PET-CT
Visit 1 (Screening)
BASFI
Visit 2 (Week 0); Screening if missing 
at Week 0
Total and nocturnal spinal pain 
numeric rating scale (NRS)
Visit 2 (Week 0); Screening if missing 
at Week 0
PhGADA
Visit 2 (Week 0)
HADS
Visit 2 (Week 0); Screening if missing 
at Week 0
Safety
Vital signs
Visit 2 (Week 0); Screening if missing 
at Week 0
12-lead ECG
Visit 2 (Week 0); Screening if missing 
at Week 0
Clinical laboratory tests
Visit 2 (Week 0); Screening if missing 
at Week 0
Body weight
Visit 1 (Screening)
C-SSRS
Visit 2 (Week 0); Screening if missing 
at Week 0
Immunological
ADA
Visit 2 (Week 0)
Pharmacodynamic
Cytokines, chemokines, serum 
complement levels, mononuclear 
cell subtypes
Visit 2 (Week 0)
ADA=anti-drug antibody; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; BASFI=Bath Ankylosing 
Spondylitis Functional Index; C-SSRS=Columbia-Suicide Severity Rating Scale; ECG=electrocardiogram; 
HADS=Hospital Anxiety and Depression Scale; hs-CRP=high sensitivity C-reactive protein;
PET-CT=positron-emission tomography-computed tomography; PET-MRI=positron-emission 
tomography-magnetic resonance imaging; PGADA=Patient’s Global Assessment of Disease Activity;
PhGADA=Physician’s global assessment of disease activity.
The change from Baseline to any subsequent post-Baseline visit will be calculated as the simple 
difference between that post-Baseline visit’s value and the Baseline value, as below:
𝑃𝑜𝑠𝑡𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒𝑉𝑖𝑠𝑖𝑡𝑉𝑎𝑙𝑢𝑒−𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒𝑉𝑖𝑠𝑖𝑡𝑉𝑎𝑙𝑢𝑒
The percentage change from Baseline to any subsequent post-Baseline visit will be calculated as
follows:
100 × (𝑃𝑜𝑠𝑡𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒𝑉𝑖𝑠𝑖𝑡𝑉𝑎𝑙𝑢𝑒−𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒𝑉𝑖𝑠𝑖𝑡𝑉𝑎𝑙𝑢𝑒) / (𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒𝑉𝑖𝑠𝑖𝑡𝑉𝑎𝑙𝑢𝑒)
PUBLIC COPY 
Y
ts
C
ts
CO
IC
BL
P
d to support any marketing authorization 
za
issing
ori
issing
iza
za
z
ng if missi
aut
ng if missi
th
g
0)
k
0); Screen
keti
; Screen
tin
(Week 0)
ma
(Week 0)
Week 0
y m
Week 0
ar
Visit 2 (W
any
Visit 2 (W
at Wee
t an
at Wee
y
rt
Vi
t
Vi
rtrtrtrt
pp
su
nnot be used 
d
nes, chemo
us
nes, chemo
plement lev
be u
plement lev
ll subtype
t be
ll subtype
se
t b
ASDAI=
ot 
ASDAI=B
ndex
n
ndex; C
no
; C
This document can
-
o
-SS
o
SS
ety and De
ann
ety and De
emission to
can
emission to
gnetic reson
t ca
gnetic reson
hysician’s g
nt 
hysician’s g
ange from
men
ange from
erence bet
um
erence bet
The p
s d
The p
fol
s 
fol
ensions or variations thereof.
ing
f
ing
eo
ning if mis
the
ning if mis
er
); Screenin
ons
; Screenin
s
Week 0)
riat
Week 0); S
at
; S
ek 0
a
ek 0
ati
isit 2 (Wee
or v
isit 2 (Wee
at Week 
or
at Week 
va
s
Visit
ns 
Visit
s o
ns
on
V
and any exten
n
en
okines, ser
y ex
okines, ser
evels, mon
ny e
evels, mon
es
a
es
xt
a
Bath Ankylo
d a
Bath Ankylo
application a
RS=
nd
RS=Colum
nd
Colum
epression S
an
epression S
omography
n a
omography
nance imag
ion
nance imag
global asses
atio
global asses
m Baselin
lica
m Baselin
tween tha
plic
tween tha


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 20 of 86
The same Baseline value will be used in the calculations of changes from Baseline and 
percentage changes from Baseline at all visits during the Treatment Period and Treatment 
Extension Period.
3.4
Protocol deviations
Important protocol deviations (IPDs) are deviations from the protocol which potentially could 
have a meaningful impact on the primary objective of the study. The criteria for identifying such 
protocol deviations will be defined within the IPD document which is part of the data cleaning 
plan. Important protocol deviations will be classified according to the following categories: 
•
Inclusion/exclusion criteria deviations
•
Administration of prohibited concomitant medications
•
Deviations relating to withdrawal criteria
•
Visit schedule deviations
•
Study IMP administration deviations (including incorrect treatment received, handling and 
storage deviations and incorrect dosage received)
•
Treatment non-compliance
•
Procedural non-compliance
•
Missing data
•
Other
Important protocol deviations will be reviewed as part of the ongoing data cleaning process and 
data evaluation. 
At least 4 data evaluation meetings (DEMs) will be performed at the following times, prior to 
each of the following analysis milestones:
•
IA1
•
IA2
•
IA3
•
The final analysis after all data have been verified/coded/entered into the database 
Additional DEMs may be conducted as deemed necessary.
The purpose of these DEM reviews will be to review all protocol deviations, define the analysis 
sets as defined in Section 3.5, and check the quality of the data. The reviews will also help 
decide how to manage problems in the subjects’ data (eg, missing values and withdrawals).
Accepted deviations from theoretical (scheduled) time points will be described in the appropriate 
documents and included in the Study Master File. After the pre-analysis review, resolution of all 
issues, and documentation of all decisions (including inclusion into each of the analysis sets) at 
the final DEM, the database will be locked.
PUBLIC COPY 
l be revi
UB
l be revi
P
ent cannot be used to support any marketing authorization 
uch
iz
uch
ning
ori
ning
ies
th
ies: 
h
: 
ment rece
ma
ment rece
ewed as p
to s
ewed as p
(DEMs) w
sed
(DEMs) w
milestones
use
milestones
nalysis aft
ca
nalysis aft
DEMs m
ent 
DEMs m
This docum
urpose of t
me
urpose of t
as define
um
as define
decide how
ocu
decide how
Accep
s do
Accep
doc
s 
doc
i
cation and any extensions or variations thereof.
eived, han
ons
eived, han
part of the
sio
art of the
will be pe
xte
will be pe
:
fter all dat
on a
fter all dat
may be con
atio
may be con
applic
these DE
lica
these DE
d in
pli
d in Sect
plic
Sect
w to man
app
w to man
evia
a
evia


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 21 of 86
3.5
Analysis sets
3.5.1
Enrolled Set
The Enrolled Set (ES) will consist of all subjects who have given informed consent (ie, all 
subjects screened). The ES will therefore include screening failures.
3.5.2
Randomized Set
The Randomized Set (RS) will consist of all randomized subjects.
3.5.3
Safety Set
The Safety Set (SS) will consist of all randomized subjects who receive at least 1 dose (full or 
partial) of the IMP. The safety analysis will be conducted on the SS.
3.5.4
Full Analysis Set
The Full Analysis Set (FAS) will consist of all randomized subjects who received at least 1 dose 
(full or partial) of the IMP and had a valid Baseline and a post-Baseline measurement for at least 
one efficacy variable (as defined in Section 2.2.1). The FAS will be used for the supportive and 
sensitivity analyses of the primary efficacy variable, the analyses of the secondary efficacy 
variables, other efficacy variables and the primary efficacy component data.
3.5.5
Per-Protocol Set
The Per-Protocol Set (PPS) will consist of all subjects in the FAS who have no IPDs affecting 
the primary efficacy variable. The subjects with IPDs will be predefined and evaluated during a 
DEM prior to unblinding of the data. The PPS will be used for the primary analyses and 
supportive and sensitivity analyses of the primary efficacy variable, for the analysis of the 
component variables of the primary efficacy variable and for the analysis of the secondary 
efficacy variables.
Protocol deviations will be reviewed at the DEMs and any exclusions from analysis sets will be 
documented as described in Section 3.4. It is anticipated that the PPS for the final analysis will 
differ from the PPS defined at the interim analyses due to additional information obtained on 
subjects during the SFU Period. Similarly, the PPS as defined at IA1, IA2 and IA3 may differ 
across the 3 IAs, due to potential additional data or information obtained during the time between 
each analysis. 
Following the final DEM, the inclusion into each of the analysis sets for all subjects will be 
confirmed. The DEM minutes will document the final agreed PPS to be applied to the final 
analysis, as well as document any changes to the PPS relative to the previously agreed PPS at the 
interim(s), if applicable.
3.5.6
Pharmacokinetics Per-Protocol Set
The Pharmacokinetics Per-Protocol Set (PK-PPS) will consist of all randomized subjects who 
receive at least 1 dose (full or partial) of the IMP and have at least 1 quantifiable post-dose 
plasma concentration. The summaries of the PK concentration data and the immunological data 
will be based on the PK-PPS.
PUBLIC COPY
he a
Y
he a
efficacy
PY 
efficacy
all subje
C CO
all subje
cts with
IC 
cts with
The
BLI
The PPS
LIC
PPS
U
of the
UBL
of the
L
m
P
mary effi
PUB
ary effi
be used to support any marketing authorization 
ose 
a
ose (full o
aut
(full o
o received
ket
o received
ne measu
ark
ne measu
e used fo
ma
e used fo
es of the s
y m
es of the s
omponen
any 
omponen
ts in the F
por
ts in the F
PD
p
PDs will 
pp
s will 
will be u
sup
will be u
rimary eff
o su
rimary eff
cacy varia
d to 
cacy varia
wed at the
use
wed at the
ction
e u
ction 3.4
us
3.4
ment cannot be
at the int
be 
at the int
Period.
ot b
Period. S
b
S
to potenti
not
to potenti
final DEM
t ca
final DEM
The DEM
nt c
The DEM
as well a
men
as well a
This docum
m(s), if ap
me
m(s), if ap
5.6
c
5.6
The Ph
do
The Ph
rece
s d
rece
p
s
p
extensions or variations thereof.
or 
f
or 
d at least 1
the
d at least 1
urement fo
s t
urement fo
or the supp
ons
or the supp
secondary
atio
secondary
nt data
riat
nt data.
a
.
FAS who
or v
FAS who
be predef
s o
be predef
sed for th
ns 
sed for th
fficacy var
sion
fficacy var
able
ns
able and f
nsio
and f
e DEMs a
ext
e DEMs a
ication and any 
. It is anti
y e
. It is anti
terim
ny
terim ana
y
ana
imil
d a
imilarly, 
an
arly, 
ial additio
nd 
ial additio
M, the inc
on 
M, the inc
M minutes
tio
M minutes
as docume
cat
as docume
appli
pplicable.
plica
pplicable.
Phar
pp
Phar
acok
ap
acok


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 22 of 86
3.5.7
Pharmacodynamics Per-Protocol Set
The Pharmacodynamics Per-Protocol Set (PD-PPS) is a subset of the FAS, consisting of those 
subjects who had no IPDs potentially affecting the PD data, as confirmed during a pre-analysis 
review of the data prior to database lock. 
3.5.8
PET Per-Protocol Set
The PET Per-Protocol Set (PET-PPS) will consist of all randomized subjects who receive at least 
1 dose of the IMP and have evaluable PET-MRI or PET-CT scan data at Baseline and at least 1 
of the post-Baseline assessments.
3.6
Treatment assignment and treatment groups
Listings and summaries will be presented by treatment group and/or overall, as applicable
(Table 14‒4). 
The following order will be used in the TFLs:
•
Not randomized
•
CZP
•
BKZ
•
All subjects
The dosing schedule and number of injections given at each visit for each treatment group are 
described in Table 3‒2.  
The IMP will be administered in the clinic as 2 sc injections. Suitable areas for sc injection are 
the lateral abdominal wall, upper outer thigh, and upper arm. During each dosing visit, each of 
the 2 injections will be administered at a separate injection site.
In addition, subjects randomized to BKZ will receive 1 placebo injection at Baseline, Week 2, 
and Week 4 in order to maintain the blind vs the CZP loading dose at these visits.
The minimum time between doses should be no less than 10 days during the Treatment Period
and no less than 22 days during the Treatment Extension Period.
Table 3‒2:
Administration of investigational medicinal product
Visit
Treatment group
Bimekizumab
Certolizumab Pegol
Treatment Period
Baseline, Weeks 2, 4
160mg 
400mg
Weeks 6, 8, 10
160mg
200mg
Treatment Extension Period
Weeks 12 to 44, every 4 
weeks
320mg
400mg
PUBLIC COPY 
tions giv
C C
tions giv
he clinic
UBL
he clinic
er outer
PUB
er outer
tered
P
tered
This document cannot be used to support any marketing authorization 
least 
riz
least 
ast
o
ast 1
ori
1
applicab
ng a
applicab
en at each
ppo
en at each
as 2 sc inj
o s
as 2 sc inj
high, and 
d to 
high, and 
at a separa
ed t
at a separa
to BKZ
use
to BKZ w
e
w
in the 
e u
in the blin
u
blin
en doses s
t be
en doses s
ys during t
ot 
ys during t
Administr
ann
Administr
ca
atment Pe
um
atment Pe
me
Baseline
ocu
Baseline
u
Week
do
Week
do
s d
s 
T
s d
s d
s
application and any extensions or variations thereof.
ble
re
ble
h visit
s or
h visit for
or
for
njections. 
sion
njections. 
d upper ar
nsi
d upper ar
rate inject
ten
rate inject
will receiv
ext
will receiv
ind vs the
y e
ind vs the
should be
any
should be
the Treatm
d a
the Treatm
tration o
an
tration o
n
eriod
plic
eriod
ica
Week
app
Weeks
pp
s 2
pp
2
p
10
a
10
ap


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 23 of 86
In the case of dosing administration errors during the Treatment Period, all statistical analyses of 
safety data will be conducted according to the actual treatment received, ie, treatment assignment 
for the SS will be based on actual treatment with the following rule:
•
Subjects who received any doses of a treatment to which they were not randomized will be 
assessed at the DEM for the treatment group assignment, as it will depend on how many 
doses of each of the treatments were taken and at what time point during the study
Subjects receiving the incorrect treatment at a particular visit will be excluded from the PPS, 
PD-PPS and the PK-PPS as this would be considered as an IPD. Subjects may be excluded from 
the analysis at a particular visit (or visits) only or overall, following discussion at the DEMs, and 
will be included in the analyses according to their randomized treatment (which would be 
equivalent to an analysis according to their actual treatment).
All summaries of the PK and immunological data will be conducted according to the actual 
treatment received, ie, treatment assignment for the PK-PPS will be based on actual treatment.
Similarly, all statistical analyses of the PD data will be conducted according to the actual 
treatment received, ie, treatment assignment for the PD-PPS will be based on actual treatment.
3.7
Center pooling strategy
Due to the small number of subjects per site, it is planned to pool all subjects within the study.
The data summaries and statistical analyses will not be performed by site or country.
3.8
Coding dictionaries
Adverse events and medical history will be coded using the Medical Dictionary for Regulatory 
Activities (MedDRA®) version 19.0.
Medications will be coded according to the World Health Organization Drug Dictionary 
(WHODD) version SEP2015. Medical procedures will not be coded.
3.9
Changes to protocol-defined analyses
The following changes relative to the protocol-defined analyses have been included in the SAP:
•
The PD-PPS was included as an additional analysis set in the SAP and was not part of the 
clinical study protocol. This was added as it was deemed appropriate to review protocol 
deviations separately in relation to the PD data and to define a separate analysis set 
accordingly.
•
The HADS data are not included under the list of Other efficacy variables in the protocol.  
These data are, however, collected as supportive efficacy data and therefore the changes from 
Baseline in the total HADS-A and HADS-D scores are included in this SAP under 
Section 2.2.1.3 for Other efficacy variables.
•
The PhGADA data are not included under the list of Other efficacy variables in the protocol.  
These data are, however, collected as supportive efficacy data and therefore the change from 
Baseline in PhGADA is included in this SAP under Section 2.2.1.3 for Other efficacy 
variables.
•
The protocol defines the FAS as all randomized subjects who receive at least 1 dose of the 
IMP and have a valid measurement of the primary efficacy variable at Baseline and at least 1 
PUBLIC COPY 
s planne
OP
s planne
will not b
CO
will not b
will be c
BLI
will be c
.0
U
.0.
UB
.
ording 
PU
ording 
d
P
d
nnot be used to support any marketing authorization 
S,
o
S,
ded from
thor
ded from
DEMs, an
uth
DEMs, an
ould be
au
ould be
ing to the
eting
ing to the
d on actu
ket
d on actu
cord
mar
cording to
ark
ing to
be based 
ma
be based 
d to pool a
t an
d to pool a
e perform
ort 
e perform
oded usin
sup
oded usin
o the Wor
d to
o the Wor
ical proce
sed
ical proce
protoco
e us
protoco
ative to th
t be
ative to th
ncluded a
not 
ncluded a
rotocol. T
nno
rotocol. T
This document ca
parately i
can
parately i
ly.
t
ly.
HADS dat
ent
HADS dat
ese data a
me
ese data a
Baseline 
um
Baseline 
Sectio
ocu
Sectio
•
d
•
Th
o
Th
and any extensions or variations thereof.
e actual
here
e actual
ual treatm
the
ual treatm
to the actu
ns 
to the actu
on actual
ion
on actual
all 
va
all subjec
var
subjec
med by 
r va
med by sit
va
sit
ng the Me
ons
ng the Me
orld Health
tens
orld Health
edures wi
xte
edures wi
ol
y
ol-define
y ex
define
he protoco
any
he protoco
as an addi
nd a
as an addi
This was a
and
This was a
application 
in relation
n a
in relation
ta are not 
cati
ta are not 
are, howe
lica
are, howe
in the tot
ppli
in the tot
n
a
n 2.2.1.3
app
2.2.1.3
GA
a
GA


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 24 of 86
post-Baseline efficacy assessment.  The definition of the FAS in the SAP has been updated to 
include all randomized subjects who received at least 1 dose (full or partial) of the IMP and 
had a valid Baseline and a post-Baseline measurement for at least 1 efficacy variable. Since 
the primary efficacy variable is a composite endpoint based on BASDAI, PGADA and 
hs-CRP, the use of the protocol definition would omit any subjects with at least one missing 
component of the composite endpoint from the efficacy analyses.
4
STATISTICAL/ANALYTICAL ISSUES
4.1
Adjustments for covariates
The Bayesian analyses will employ a linear regression model adjusting for Baseline ASDAS as a 
covariate. Further exploratory analyses may be performed for the primary efficacy variable 
adjusting for other Baseline covariates.
4.2
Handling of dropouts or missing data
4.2.1
Efficacy data
4.2.1.1
ASDAS derivation
If 1 component for the ASDAS is missing at a given visit, and the visit prior to the visit with the 
missing component data is not the Baseline or Screening visit, the following will apply: the 
missing component will be imputed by carrying the last observation for the given component 
forward, and the ASDAS will be calculated accordingly.
If no value is available for that component before the missing visit, or if the visit prior to the visit 
with the missing component data is either the Baseline or Screening visit, then the next 
observation will be carried backwards, and the ASDAS will be calculated accordingly.
If an unscheduled or repeat visit with non-missing data for the given ASDAS component is 
available and this visit is closer to the scheduled visit where the component data is missing, then 
the component data from the unscheduled/repeat visit will be used in the derivation of the 
ASDAS score.
If more than one component for the ASDAS is missing, ASDAS will not be calculated and 
treated as missing.
Any measurements of hs-CRP that are below 2 mg/L will be imputed with a fixed value of 2 
mg/L for the purpose of deriving the ASDAS. 
The statistical analysis will be performed based on the resulting derived values of ASDAS.
4.2.1.2
hs-CRP
Any measurements of hs-CRP that are below the limit of quantification (BLQ) will be imputed 
with the midpoint between zero and the lower limit of quantification (LLOQ) for the purpose of 
the calculation of summary statistics and changes from Baseline. Measurements for hs-CRP that 
are above the upper limit of quantification (ALQ), if applicable, will be imputed to the upper 
quantification limit.
4.2.1.3
ASDAS component data
Except for the descriptive statistics of hs-CRP as described above, no imputation of missing data 
will be performed for the summaries of the ASDAS component efficacy variables.
PUBLIC COPY 
n visit, 
PY
n visit, 
reening 
OPY
reening 
ng the la
COP
ng the la
d accordi
C CO
d accordi
nent befo
LIC
nent befo
either th
BLI
either th
ards
UB
ards, an
UB
, an
it with
PU
it with
P
ed to support any marketing authorization 
ASDAS
aut
ASDAS
cy variabl
g a
cy variabl
d the visit
ny 
d the visit
visit
t a
visit, the f
any
, the f
t observat
ort a
t observat
ngly
po
ngly.
po
.
re the mis
upp
re the mis
 Baseline
sup
 Baseline
d the ASD
to s
d the ASD
non
ed
non-
d
-missi
d t
missi
ument cannot be use
he schedu
sed
he schedu
scheduled
use
scheduled
ent for th
t b
ent for th
ts of hs
ann
ts of hs-C
n
C
urpose of 
ca
urpose of 
cal analys
ent 
cal analys
2
h
This docu
ny measur
cum
ny measur
with the m
doc
with the m
the
do
the cal
o
cal
are 
s 
are 
tensions or variations thereof.
as 
f
as 
le
e
le
it prior to 
iati
it prior to 
following
aria
following
ation 
v
ation for th
va
for th
ssing visit
ns o
ssing visit
e or Scree
ons
e or Scree
DAS will 
sio
DAS will 
sing data
tens
sing data f
s
f
plication and any ext
uled visit 
xte
uled visit 
d/repeat v
ex
d/repeat v
he ASDAS
d any
he ASDAS
CRP that a
an
CRP that a
f deriving 
on a
f deriving 
ysis will b
atio
ysis will b
hs
li
hs-
ic
-CRP
lica
CRP
app
rements o
ppl
rements o
midpoint 
app
midpoint 
ion
a
ion


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 25 of 86
4.2.1.4
ASAS20, ASAS40 and ASAS-PR
For all non-missed visits, in the calculation of ASAS20, ASAS40 and ASAS-PR responses, if 
any of the component data are missing, then the following rules will be applied:
•
If all the component values are missing from Baseline to the post-Baseline visit being 
considered, the percentage change from Baseline to that visit for the given component will be 
imputed as 0%. The unit improvement will be imputed as 0.
•
If the component value at a given post-Baseline visit is missing and the Baseline value is 
present, the missing component will be replaced by the last non-missing post-Baseline 
observation (LOCF) for that component.
4.2.1.5
BASFI data
In case of missing answers to 1 or 2 of the single items within the BASFI questionnaire, the 
BASFI score will be calculated by imputing missing items with the mean of the completed items. 
Then, the BASFI score will be calculated as described in Section 8.3.3.1. If more than 2 of the 
items are missing, the BASFI score will be left missing.
4.2.1.6
HADS data
Any missing data for the total score for HADS-A and HADS-D will be handled as follows:
•
If a maximum of 1 item is missing in HADS-A or HADS-D, the missing item will be
imputed with the mean score from the remaining completed items within the HADS-A or
HADS-D respectively.
•
If more than 1 item is missing in HADS-A or HADS-D, the total score will not be calculated.
4.2.1.7
Spinal pain and PhGADA data
Missing data for Total and nocturnal spinal pain NRS and PhGADA data will not be imputed and 
will be analyzed as far as data are available.
4.2.2
Pharmacodynamic data
For the PD data, measurements that are BLQ will be imputed with half of the LLOQ for the 
purpose of calculating summary statistics and changes from Baseline. Measurements that are 
ALQ, if applicable, will be imputed to the upper quantification limit.
4.2.3
Safety laboratory data
The rules for handling values that are BLQ or ALQ in the safety laboratory data will be the same 
as those described for PD data in Section 4.2.2.
4.2.4
Pharmacokinetic data
Concentrations that are BLQ will be imputed with half of the LLOQ for the respective analyte 
(BKZ or CZP) for the purpose of calculating the geometric mean and its 95% CI, the geoCV, the 
arithmetic mean and SD for summaries and figures. 
For the individual figures, any concentrations that are BLQ will be regarded as missing, with the 
exception of pre-dose BLQ concentrations at Visit 2 (Week 0), which will be imputed with zero 
for linear scale plots.
PUBLIC COPY 
and HA
OPY
and HA
DS
C
DS-
CO
-A or
CO
A or
remainin
C C
remainin
n
U
n HADS
BL
HADS
nd PhG
PU
nd PhG
rna
P
rna
be used to support any marketing authorization 
e is
ho
e is
ine
th
ine
uestionnai
eting
uestionnai
n of the co
ket
n of the co
.1
a
.1. If mo
arke
. If mo
DS
a
DS-
a
-D will
any
D will
HADS
ort
HADS-
t
-D
g complet
po
g complet
A or HAD
su
A or HAD
ADA data
d to
ADA data
l spinal pa
sed
l spinal pa
 availabl
use
 availabl
ynamic d
be u
ynamic d
ocument cannot 
ements th
ot b
ements th
g summary
not
g summary
, will be i
ann
, will be i
Safety la
t ca
Safety la
for handlin
ent 
for handlin
describe
men
describe
4
This do
Concentr
doc
Concentr
(BKZ
s do
(BKZ
arit
s 
arit
any extensions or variations thereof.
aire, the 
here
aire, the 
ompleted 
the
ompleted 
re than 2 
s th
re than 2 
l be handl
aria
l be handl
D, the miss
r va
D, the miss
eted items
or 
eted items
DS
io
DS-
on
-D, th
on
D, th
ta
n
ta
pain NRS
xten
pain NRS
e.
e
e.
data
ny
data
application and a
hat are BL
d an
hat are BL
ry statistic
nd 
ry statistic
imputed t
and
imputed t
laborato
on a
laborato
ing values
atio
ing values
d for PD 
icat
d for PD 
Pharm
ppli
Pharm
ations
ap
tions th
p
th
ZP)
a
ZP)


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 26 of 86
4.2.5
Dates and times
Partial dates may be imputed for the following reasons:
•
Classification of AEs as treatment-emergent
•
Classification of medications as prior or concomitant
Imputed dates will not be shown in the listings; all dates will be displayed as reported in the
database.
The following rules will be applied for partial start dates:
•
If only the month and year are specified and the month and year of the first dose of IMP is 
not the same as the month and year of the start date then the 1st of the month will be used, or 
the date of Screening if this is later (if the latter imputation results in an end date that is 
earlier than the start date, then the 1st of the month will be used). If time is missing this will 
be imputed as 00:00 h
•
If only the month and year are specified and the month and year of the first dose of IMP is 
the same as the month and year of the start date, then the date of the first dose of IMP will be 
used. If this results in an imputed start date that is after the specified end date, then the 1st of 
the month will be used, or the date of Screening if this is later (if the latter imputation results 
in an end date that is earlier than the start date, then the 1st of the month will be used). If the 
imputed date is the same as the date of the first dose of IMP then time will be imputed as the 
start time of the first injection (ie, an AE will be regarded as treatment-emergent and a 
medication will be classified as concomitant)
•
If only the year is specified, and the year of the first dose of IMP is not the same as the year 
of the start date then January 01 of the year of the start date will be used. If time is missing 
this will be imputed as 00:00 h
•
If only the year is specified, and the year of the first dose of IMP is the same as the year of 
the start date, then the date of the first dose of IMP will be used. If this results in an imputed 
start date that is after the specified end date, then January 01 of the year of the start date will 
be used, or the date of Screening if this is later (if the latter imputation results in an end date 
that is earlier than the start date, then January 01 will be used). If the imputed date is the 
same as the date of the first dose of IMP then time will be imputed as the start time of the 
injection (ie, an AE will be regarded as treatment-emergent and a medication will be 
classified as concomitant)
The following rules will be applied to partial stop dates:
•
If only the month and year are specified, then the last day of the month will be used
•
If only the year is specified, then December 31 of the known year will be used
•
If the stop date is completely unknown, the stop date will not be imputed
Missing or partially missing dates and/or times will be imputed as described in Table 4‒1 for the 
calculation of duration of each AE. AE duration will be computed in and reported in day and 
time format: xx d hh:mm.
PUBLIC COPY
s after
PY 
s after
ng
OP
ng if this
OPY
if this
date, the
COP
date, the
P
he first d
C CO
he first d
AE will
IC C
AE will
oncomita
BLIC
oncomita
nd the y
UB
nd the y
ry 01 of
PU
ry 01 of
0 h
P
0 h
not be used to support any marketing authorization 
e o
a
e of IMP 
aut
f IMP 
h will be u
g a
h will be u
nd date th
ting
nd date th
me is miss
ketin
me is miss
r of the fir
mar
r of the fir
e of the fi
y m
e of the fi
e specifie
ny 
e specifie
is later (i
any
is later (i
the 1st of
rt a
the 1st of
ose of IM
por
ose of IM
be regard
ppo
be regard
nt)
s
nt)
ar of the 
to s
ar of the 
the year o
d to
the year o
and the y
use
and the y
te of the fi
be u
te of the fi
he specifi
t be
he specifi
This document cann
of 
o
of Screen
ot b
Screen
n the start
nno
n the start
te of the 
ann
te of the 
e, an AE 
t ca
e, an AE 
d as conc
nt c
d as conc
lowing ru
men
lowing ru
If only th
cum
If only th
•
d
•
If on
oc
If on
•
s d
•
d any extensions or variations thereof.
is
f
is
used, or 
eof.
used, or 
hat is
ere
hat is
sing this w
her
sing this w
irst dose o
ons
irst dose o
first dose 
tion
first dose 
ed end dat
iati
ed end dat
if the latte
aria
if the latte
of the mon
va
of the mon
MP then ti
or v
MP then ti
ded as trea
s or
ded as trea
first dose
sio
first dose
of the star
ens
of the star
year of the
ex
year of the
first dose 
ny e
first dose 
fied end da
any
fied end da
application an
ning
d a
ning if thi
a
if thi
rt date, the
and
rt date, the
first d
an
first dose
n
ose
will be re
on a
will be re
comitant)
tion
comitant)
ules will b
ica
ules will b
he month 
ppli
he month 
a
y the ye
ap
y the ye


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 27 of 86
Table 4‒1:
Calculation rules for duration of adverse events
Data availability
Onset 
date/time
Outcome 
date/time
Calculation rules
Complete data
D1/T1
D2/T2
Duration = [(D2 – D1)*24 + (T2 – T1)]/24 d
End time missing
D1/T1
D2/--
End time is substituted by time 23:59h (=23.98 in 
decimal format) 
Duration = <[(D2 – D1)*24 + (23.98 – T1)]/24 d
Start time missing
D1/--
D2/T2
Onset time is substituted by time 00:00h
Duration = <[(D2 – D1)*24 + T2]/24 d
Start and end time 
missing
D1/--
D2/--
Duration = <D2 – D1 + 1
Start day and time 
missing
--/--
D2/T2
Duration = [(D2 – D0)*24 + (T2 – T0)]/24 d
For a subject in the SS, D0 and T0 are the date and 
time of first administration of IMP and for screen 
failures, D0 is the date of the Screening visit and T0 = 
00:00h
End day and time 
missing
D1/T1
--/--
If the stop date is missing, duration will not be 
calculated.
Start and end date 
missing
--/--
--/--
If the stop date is missing, duration will not be 
calculated.
4.3
Handling of repeated and unscheduled measurements
All repeated and unscheduled measurements will be presented in the data listings, where 
applicable. The following general rules will apply to all repeated and unscheduled 
measurements:
•
For repeated measurements obtained prior to the first dose of IMP the latest value (which
may be scheduled or unscheduled) will be used in the calculation of the descriptive statistics
•
For repeated measurements obtained at the designated Baseline visit, the latest value (which 
may be scheduled or unscheduled) will be defined as the Baseline provided that this occurred 
prior to the first dose of IMP
•
For repeated measurements obtained at any time point after the first dose of IMP, the values 
will not be included in the calculation of descriptive statistics or changes from Baseline.
•
Unscheduled measurements performed for the Early Withdrawal (EW) visit will be assigned
to the appropriate visit (Section 4.4) and analyzed accordingly
4.4
Handling of measurements obtained at the EW visit
Subjects withdrawing early from the study should undergo the same assessments scheduled for 
the Week 48 visit as soon as possible after withdrawal (as an EW visit) and then enter the SFU 
Period, completing study participation with the SFU Visit 20 weeks after their final dose of IMP. 
PUBLIC COPY 
s, D0
Y
s, D0
0h
PY
0h
If the sto
COP
If the sto
calcu
CO
calcu
OP
C C
I
C C
C C
C C
BL C C
epeate
PUB
epeate
measu
P
measu
be used to support any marketing authorization 
24 d
ho
24 d
za
d
g
d
tho
g
4 + (T2
rke
4 + (T2 – T
S, D0 and T
mar
S, D0 and T
stration of
ma
stration of
e date of t
ny m
e date of t
ket
p date is m
rt a
p date is m
ated.
o
ated.
a
the stop d
upp
the stop d
calculate
sup
calculate
po
su
d 
d and un
to 
and un
rements w
ed 
rements w
rules will
use
rules will
nt cannot b
ments obta
t be
ments obta
r unsched
ot b
r unsched
easuremen
nno
easuremen
duled or 
can
duled or u
e first dos
t ca
e first dos
This docume
epeated m
ent
epeated m
ll not be i
me
ll not be i
Unsched
cum
Unsched
to the
oc
to the
4.4
s d
4.4
ny extensions or variations thereof.
eo
T0)]/24 d
s th
T0)]/24 d
T0 are the
ns 
T0 are the
f IMP and 
ion
f IMP and 
the
at
the Screen
atio
Screen
the
missing, du
va
missing, du
ar
date is mis
s o
date is mis
d.d.
or
on
nsched
nsio
nsched
will be pre
ten
will be pre
ll apply to
exte
ll apply to
tion and an
ained prio
any
ained prio
duled) wil
d a
duled) wil
nts obtain
and
nts obtain
unschedul
n a
unschedul
se of IMP
ion 
se of IMP
applica
measureme
cati
measureme
included i
lica
included i
eduled me
pp
eduled me
appropr
ap
appropr


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 28 of 86
The following rules will apply with regard to the inclusion of the results obtained at the EW visit
in the descriptive summaries:
•
Any measurements conducted at the EW visit should be included in the summaries for the 
respective scheduled visit, if the EW visit occurs at the time of the next scheduled visit. For 
example, if the EW visit occurs on Day 42, the results would be summarized together with 
the Visit 6 (Week 6, Day 42) results
•
If the EW visit does not correspond to the day of a scheduled visit, the assessments of the 
EW visit should be mapped to the nearest scheduled visit, relative to the Baseline visit date, 
following the last scheduled visit where assessments are available
•
If the date of the EW visit is equidistant between 2 scheduled visits at which no scheduled 
assessments were performed, the assessments from the EW visit will be mapped to the 
earliest of these visits
•
If an EW visit mapping results in data being mapped to a visit where the specific assessment 
is not actually collected per the protocol schedule of assessments, these data will not be 
included in the summary statistics and will be listed only
•
The only exception to the above rule is for ADA (for both BKZ and CZP) assessments, in 
which all early withdrawal visit assessments will be assigned to the next scheduled visit at 
which ADA are assessed. The rationale for this is that ADA positivity is summarized over a 
given study period. As part of that summary, a table indicating the first visit at which ADA
positivity is observed will be presented. In order to match the number of subjects who were 
ADA positive at specific visits with the overall positivity for the period, it is necessary to 
ensure that ADA positivity is attributed to a visit where ADA antibody assessments were 
performed
Assessments from the EW visit will be displayed as the mapped visit and will be flagged in the
by-visit data listings.
4.5
Interim analyses and data monitoring
4.5.1
Data monitoring committee
The conduct of the study and monitoring of the safety data will be supervised by an independent 
DMC to optimize subjects’ safety and to identify any safety signals. Full details of the 
composition and roles of the DMC will be provided in a separate DMC Charter.
The data to be reviewed by the DMC will be as detailed in the DMC Charter and will include 
unblinded safety data. The details regarding the outputs to be produced and the analyses to be
performed will be provided in a separate DMC SAP.
4.5.2
Interim analyses
Three unblinded informal IAs are planned for this study. 
IA1 will be performed when approximately 45 subjects have completed the Week 4 visit. 
IA2 will be performed when the last randomized subject not participating in the 
PET-MRI/PET-CT has completed the Week 12 visit at the end of the Treatment Period or has 
withdrawn prematurely from the study.
PUBLIC COPY
A (for b
PY 
A (for b
will be a
OPY
will be a
r this is 
CO
r this is 
mary, a 
C C
mary, a 
ted. In o
LIC 
ted. In o
ith the o
BLIC
ith the o
ttribute
UBL
ttribute
wil
P
wil
nt cannot be used to support any marketing authorization 
he
o
he
sit date, 
thor
sit date, 
no schedu
g au
no schedu
apped to t
ing 
apped to t
re the spe
rke
re the spe
s, these da
mar
s, these da
h BKZ an
ny 
h BKZ an
ssigned to
t an
ssigned to
hat 
or
hat ADA
ort a
ADA
able indic
por
able indic
der to ma
upp
der to ma
verall posi
sup
verall posi
to a visit
o s
to a visit
be displa
sed
be displa
alyses a
be u
alyses a
onitoring
ot b
onitoring
tudy and 
nno
tudy and 
subjects’
ann
subjects’
This documen
nd r
t c
nd roles o
ca
oles o
o be revie
ent 
o be revie
ed safety 
men
ed safety 
ormed 
um
ormed wil
m
wil
4.5.2
oc
4.5.2
Three
s do
Three
IA
s
IA
n and any extensions or variations thereof.
uled 
of
uled 
the
re
the
ecific asse
s th
ecific asse
data will n
ns 
data will n
nd CZP)
riat
nd CZP)
o the next
aria
o the next
positivity
r va
positivity
cating the
or v
cating the
atch the nu
s o
atch the nu
itivity for
ons
itivity for
t where 
ion
t where A
n
A
ayed as th
xten
ayed as th
and
ny
and d
y e
data
y e
ata
g commi
d an
g commi
monitorin
and
monitorin
’ safety an
an
’ safety an
application
of the DM
on 
of the DM
ewed by th
atio
ewed by th
y data. The
lica
y data. The
ll be prov
plic
ll be prov
Inte
pp
Inte
nde
a
d


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 29 of 86
IA3 will be performed when the last randomized subject has completed the Week 12 visit at the 
end of the Treatment Period or has withdrawn prematurely from the study.
The purpose of the IAs is for key Sponsor personnel to review the results of the primary efficacy, 
selected secondary and other efficacy analyses and safety outcomes to facilitate additional 
Clinical Planning or Portfolio Management decisions.
All analyses and unblinding instructions will be pre-specified in the Interim Analysis SAP.
4.6
Multicenter studies
The data summaries and statistical analyses will not be performed by center.
4.7
Multiple comparisons/multiplicity
Not applicable.
4.8
Use of an efficacy subset of subjects
In order to investigate the impact on the efficacy analyses, the PPS will be used to evaluate the 
subset of subjects in the FAS with no IPDs.
4.9
Active-control studies intended to show equivalence
Not applicable.
4.10
Examination of subgroups
Not applicable.
5
STUDY POPULATION CHARACTERISTICS
5.1
Subject disposition
The number and percentage of subjects who were randomized into the study (and into the PET-
MRI/PET-CT substudy), subjects who completed or prematurely discontinued the study, as well 
as the primary reason for discontinuation will be presented by treatment group and for all 
subjects, based on the RS. A subject who completed the study is defined as a subject who 
completed all visits up to the last scheduled study visit, ie, Visit 18 (Week 64). An additional 
summary of subject disposition in the PET-MRI/PET-CT substudy will also be presented
separately by treatment group and for all subjects, based on the RS.
In addition, disposition of subjects during the Treatment Period and Treatment Extension Period 
will be summarized separately. The number and percentage of subjects who completed Week 4 
and Week 12 of the Treatment Period, or prematurely discontinued the study during the 
Treatment Period, together with the primary reason for discontinuation will be presented by 
treatment group.  The number and percentage of subjects who completed Week 48 (ie, the 
Treatment Extension Period) or prematurely discontinued during the Treatment Extension 
Period, together with the primary reason for discontinuation will be presented by treatment 
group. A subject is defined as completing Week 4, Week 12 and Week 48, respectively, if 
adequate efficacy data are available in the database to calculate the primary efficacy variable at 
the respective visit.
PUBLIC COPY 
ed to
Y
ed to
oups
C CO
oups
ATION
BL
ATION
osition
PU
osition
bj
P
bj
This document cannot be used to support any marketing authorization 
will be use
ark
will be use
how
ny
how e
y 
equ
qu
 CHA
su
 CHAR
u
R
ects who 
sed
ects who 
s who com
use
s who com
ontinuatio
be u
ontinuatio
A subject
t be
A subject
o the last 
ot b
o the last 
disposition
no
disposition
tment gro
ann
tment gro
isposition
t ca
isposition
mmarized 
ent 
mmarized 
ek 12 of th
men
ek 12 of th
tment Peri
ume
tment Peri
eatment gr
cum
eatment gr
Treatmen
doc
Treatmen
Period
s do
Period
gr
s
gr
application and any extensions or variations thereof.
ed to eval
ns t
ed to eval
uivalen
iatio
uivalen
RACTER
ions
RACTER
were rand
xte
were rand
mpleted o
ext
mpleted o
on will be
ny e
on will be
t who com
any
t who com
t schedule
d a
t schedule
on in the
nd 
on in the P
oup and 
an
oup and fo
n
fo
n of subjec
ion 
n of subjec
separatel
atio
separatel
the Treatm
icat
the Treatm
riod, toget
plic
riod, toget
group.  Th
pp
group.  Th
t Extens
ap
Extens
the
a
th


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 30 of 86
The number and percentage of subjects who discontinued due to AEs will be separately 
summarized by treatment group and for all subjects, based on the RS. This will be used for 
European Union Drug Regulating Authorities Clinical Trials (EudraCT) reporting.
The number and percentage of subjects included into each of the analysis sets will be 
summarized by treatment group and for all subjects based on all subjects screened. Percentages 
will be based on the RS for the purpose of this summary.
Screen failure reasons will be summarized, based on all subjects screened. A listing of subjects 
who did not meet study eligibility criteria (including glossary) will also be presented for all 
subjects screened.
In addition, the following listings will be presented by treatment group:
•
Subject disposition (ES [all subjects screened])
•
Study discontinuation (RS)
•
Visit dates (SS)
•
Subject analysis sets (ES [all subjects screened])
The listing of subject disposition will include:
•
the date of informed consent
•
for subjects participating in the respective pharmacogenomics, pharmacogenetic and PET
MRI/CT substudies: date of respective informed consent
•
date and time of first and last dose of IMP
•
date of premature study termination and primary reason (if applicable)
•
date of final contact
•
if applicable, the date and reason for premature unblinding
The listing of study discontinuation will include the reason for discontinuation and the number of 
days on IMP.
The number of days on IMP will be calculated as follows:
𝑁𝑢𝑚𝑏𝑒𝑟𝑜𝑓𝑑𝑎𝑦𝑠𝑜𝑛𝐼𝑀𝑃= (𝐷𝑎𝑡𝑒𝑜𝑓𝐿𝑎𝑠𝑡𝐷𝑜𝑠𝑒𝑅𝑒𝑐𝑒𝑖𝑣𝑒𝑑−𝐷𝑎𝑡𝑒𝑜𝑓𝐹𝑖𝑟𝑠𝑡𝐷𝑜𝑠𝑒𝑅𝑒𝑐𝑒𝑖𝑣𝑒𝑑) + 1
5.2
Protocol deviations
Important protocol deviations will be identified and classified by the deviations types listed in 
the IPD document.
A listing of all IPDs will be presented for all subjects in the RS and will include the deviation 
type and description.
The number and percentage of subjects with IPDs will be summarized by treatment group and 
for all subjects for each deviation type, based on the RS. This summary will be repeated for the 
FAS (if this analysis set is different to the RS).
PUBLIC COPY 
ive phar
C C
ive phar
ive
LIC
ive infor
LIC 
infor
ose of IM
BL
ose of IM
mination
PU
mination
This document cannot be used to support any marketing authorization 
ects
ori
ects
all
th
all
macogeno
po
macogeno
med conse
upp
med conse
P
and prim
d to
and prim
eason for 
e us
eason for 
tinuation w
be
tinuation w
on IMP w
nno
on IMP w
𝑦𝑠
c
𝑦𝑠𝑜𝑛
ca
𝑜𝑛𝐼𝑀𝑃
an
𝐼𝑀𝑃
Proto
nt c
Proto
ant protoc
men
ant protoc
PD
u
PD docum
um
docum
A listing 
docu
A listing 
type an
do
type an
Th
s 
Th
application and any extensions or variations thereof.
omics, ph
or 
omics, ph
ent
s
ent
mary reaso
nsi
mary reaso
r prematur
y ex
r prematur
will inclu
any
will inclu
will be ca
and
will be ca
=
n
= (
n a
(𝐷𝑎𝑡
a
𝐷𝑎𝑡
ocol
tio
ocol d
o
de
col deviat
lica
col deviat
ment.
plic
ment.
of all 
ap
of all IPD
pp
IPD
scrip
a
scrip


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 31 of 86
6
DEMOGRAPHICS AND OTHER BASELINE 
CHARACTERISTICS
6.1
Derivation of variables
6.1.1
Calculation of body mass index
The body mass index (BMI) in kg/m2 is calculated based on the height (in m) and the weight (in 
kg) using the following formula: 
𝐵𝑀𝐼=
𝑊𝑒𝑖𝑔ℎ𝑡
(𝐻𝑒𝑖𝑔ℎ𝑡)2
The BMI will be automatically derived by and recorded on the electronic case report form 
(eCRF).
6.1.2
Classification of age categories
Age will be classified into categories based on requirements for European Union Drug 
Regulating Authorities Clinical Trials (EudraCT) and clinicaltrials.gov reporting.
For the EudraCT reporting, the categories will include:
•
18 to <65 years
•
65 to <85 years
•
≥85 years
For the clinicaltrials.gov reporting, the categories will include:
•
≤18 years
•
19 to <65 years
•
≥65 years
6.1.3
Duration of disease
The duration of disease will be calculated as follows and will be presented in years to 1 decimal 
place:
𝐷𝑢𝑟𝑎𝑡𝑖𝑜𝑛= 𝐷𝑎𝑡𝑒𝑜𝑓𝑆𝑐𝑟𝑒𝑒𝑛𝑖𝑛𝑔−𝐷𝑎𝑡𝑒𝑜𝑓𝐷𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠
In the event that the date of diagnosis is incomplete, it will be imputed to the most recent feasible 
date (ie, the imputed date must be before the date of Screening):
•
If only the day is missing, it will be imputed to the last day of the known month
•
If the day and month are missing, it will be imputed to December 31 in the known year
•
If the date of diagnosis is completely missing or if the imputed date is not feasible, the 
duration of disease will not be calculated
6.2
Demographics
A by-subject listing of Baseline demographic characteristics will be presented by treatment 
group. This will include the year of birth (if available), age (in years), sex, race, ethnicity, height
(in cm), weight at Screening (in kg) and body mass index (BMI) for all subjects screened. The 
PUBLIC COPY 
e:
Y
e:
the categ
BLI
the categ
ment cannot be used to support any marketing authorization 
n
z
n
eport form
g a
eport form
pean Uni
ark
pean Uni
s.gov repo
ma
s.gov repo
ories will 
sup
ories will 
disease
be 
disease
will be ca
ot b
will be ca
𝐷𝑢𝑟𝑎𝑡𝑖
an
𝐷𝑢𝑟𝑎𝑡𝑖
that the d
nt c
that the d
he impute
ent
he impute
This docum
f only the 
ume
f only the 
If the d
ocu
If the d
•
d
•
If 
o
If 
lication and any extensions or variations thereof.
m
e
m
ion Drug
ns t
ion Drug
orting.
ons
orting.
l include:
ions
l include:
e
alculated 
d a
alculated 
𝑖𝑜𝑛
n
𝑖𝑜𝑛=
a
= 𝐷
date of dia
tion
date of dia
ed date m
catio
ed date m
appl
e day is m
plic
e day is m
day and m
app
day and m
te o
a
te o


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 32 of 86
age and BMI will be obtained from the electronic case report form (eCRF) and will not be 
re-calculated for the reporting of demographic data. 
All Baseline demographic characteristics (with the exception of year of birth) will be 
summarized by treatment group and for all subjects based on the SS. The summary of age will 
include descriptive statistics and categorical summaries, the latter based on requirements for 
EudraCT and clinicaltrials.gov reporting. This summary will be repeated for subjects in the SS 
who were randomized in the PET-MRI/CT substudy. Childbearing potential will be listed for the 
SS.
6.3
Other Baseline characteristics
The following Baseline disease characteristics will be presented in a by-subject listing for the SS:
•
Duration of disease (as calculated in Section 6.1.3), including confirmation of sacroiliac joint 
X-ray and the date on which the sacroiliac joint X-ray was performed
•
hs-CRP
•
BASDAI score
•
PGADA
•
ASDAS
•
ASDAS disease activity states (ASDAS-ID, ASDAS-Moderate Disease activity 
[ASDAS-MD], ASDAS-High Disease activity [ASDAS-HD] and ASDAS-Very High 
Disease activity [ASDAS-vHD])
•
BASFI score
•
Total and nocturnal spinal pain NRS
•
PhGADA
•
Total HADS-A and HADS-D scores
The calculation of Baseline ASDAS and the classification of the ASDAS disease activity states 
will be based on the Baseline BASDAI, PGADA and hs-CRP values. The Baseline for each of 
the variables listed above is defined in Table 3‒1.
Baseline disease characteristics will be summarized using descriptive statistics by treatment 
group and for all subjects based on the SS.  This summary will be repeated for subjects in the SS 
who were randomized in the PET-MRI/PET-CT substudy and will also include summary 
statistics for SUVauc in the SIJ and spine at Baseline derived from the PET-MRI/PET-CT scans 
performed at Screening. SUVauc values for each of the PET-positive lesions identified in the SIJ 
and spine will be pooled across subjects and across the SIJ and anatomical locations in the spine 
for the purpose of this summary.  In addition, the maximum SUVauc value across the SIJ and 
spine for each subject at Baseline will be summarized.
The above Baseline disease characteristics will be listed for the SS.
Subject lifestyle details (alcohol use, smoking history and caffeine use) will be listed, based on 
the SS.
PUBLIC COPY 
ID,
C C
ID, AS
CO
AS
se activit
IC C
se activit
pain N
PU
pain N
annot be used to support any marketing authorization 
r the
riz
r the
sting for 
g au
sting for 
on of sacr
ting
on of sacr
DAS
po
DAS-
o
-Mod
or
Mod
y [
p
y [ASDA
ppo
ASDA
RS
ed
RS
S
b
S-
e
-D score
be u
D score
ne ASDA
t b
ne ASDA
aseline B
not 
aseline B
above is d
nno
above is d
t ca
e
This document
characte
can
characte
or all subj
nt c
or all subj
randomi
ent
randomi
cs for 
me
cs for SU
e
SU
formed at
cum
formed at
and spine 
ocu
and spine 
for the 
do
for the 
spin
s d
spin
n and any extensions or variations thereof.
the SS:
of.
the SS:
roiliac joi
ereo
roiliac joi
derate Dis
or v
derate Dis
S
s
S-HD
s o
HD]
o
] an
an
es
es
AS and the
d any
AS and the
A
d
ASDAI, 
nd a
SDAI, 
defined in
and
defined in
application
teristics w
on a
teristics w
jects
tio
jects base
on
base
zed
at
zed in th
ati
in th
UV
li
UVauc
lic
auc in th
ca
in th
t Screenin
ppli
t Screenin
will be p
app
will be p
pose 
ap
pose 


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 33 of 86
6.4
Medical history and concomitant diseases
Medical history (except for AS) will be listed for the RS and summarized for the SS by treatment 
group and for all subjects, MedDRA® system organ class (SOC) and preferred term (PT). The 
reported term will be included in the listing. The summary will include the number and 
percentage of subjects and will be sorted alphabetically by SOC and by descending incidence of 
PT within each SOC, based on the ‘All Subjects’ column. This summary will be repeated for 
subjects in the SS who were randomized in the PET-MRI/CT substudy. A glossary of all medical 
history conditions will be presented for the RS including the SOC, PT and reported term.
Procedure history will be listed separately for the RS by treatment group for previous procedures
relating to AS and previous procedures not relating to AS.  Concomitant medical procedures 
performed during the study will be listed for the RS.
6.5
Ankylosing spondylitis history
Date of initial diagnosis of AS and the date that AS symptoms first started will be listed.
6.6
Prior and concomitant medications
Prior and concomitant medications (Section 6.6.1 and Section 6.6.2) will be listed for the RS by 
treatment group and subject, and summarized for the SS by WHODD Anatomical Main Group 
(Level 1), Pharmacological Subgroup (Level 3) and PT. The reported term will be included in 
the listing, together with flags to identify AS, rescue and prohibited medications, respectively. 
The flags for prohibited, AS and rescue medications will be confirmed and documented at the 
final DEM.
Prohibited medications will be listed separately.
Separate summaries will be presented for prior medications and concomitant medications and 
these will be presented by treatment group and for all subjects. Prior medications which 
continued into the study period are also classified as concomitant and are included in both 
summaries.  
Separate summaries will be presented for the following, identified using WHODD Anatomical 
Main Group codes, the indication recorded on the eCRF and medical review of the recorded 
data:
•
Prior and concomitant AS medications
•
Rescue medication during study
All AS medications and rescue medication given during the study will be identified via medical 
review of the concomitant medications and confirmed at the DEMs prior to unblinding.
These summaries will be repeated for subjects in the SS who were randomized in the PET-
MRI/PET-CT substudy.
All tabulations will be sorted alphabetically by Level 1 term, alphabetical Level 3 term within 
Level 1 and decreasing frequency of PT in the ‘All Subjects’ column. 
A glossary of all prior and concomitant medications will be presented for the SS including the 
Anatomical Main Group (Level 1), Pharmacological Subgroup (Level 3), PT and reported Term.
PUBLIC COPY 
Sec
Y
Sec
he SS by
PY
he SS by
and PT.
COP
and PT.
, rescue
CO
rescue
edicatio
C C
edicatio
ed separ
UBL
ed separ
esented
PU
esented
ment
P
ment
annot be used to support any marketing authorization 
dical
riz
dical
procedur
uth
procedur
procedure
au
procedure
rted will b
rke
rted will b
6.6.2
y
6.6.2) wil
y m
) wil
WHODD
any
WHODD
The repor
rt a
The repor
and prohib
ort 
and prohib
s will be 
po
will be 
tely.
o s
tely.
or prior m
d to
or prior m
group and
ed 
group and
e also cla
use
e also cla
e presente
t be
e presente
indication
ot b
indication
This document ca
ncomitant
can
ncomitant
medicatio
nt c
medicatio
medicatio
men
medicatio
w of the c
ume
w of the c
These sum
ocu
These sum
MRI/
do
MRI/PE
o
PE
All
s 
All
on and any extensions or variations thereof.
es
o
es
be listed.
s th
be listed.
ill be liste
atio
ill be liste
D Anatom
ria
D Anatom
rted term 
var
rted term 
bited
r v
bited med
va
med
confirme
or 
confirme
medication
ens
medication
nd for all s
xten
nd for all s
assified as
ext
assified as
ed for the
any
ed for the
n recorde
d a
n recorde
applicatio
t t AS
n a
AS med
a
med
on during 
tion
on during 
ons
c
ons and re
cat
and re
concomit
plic
concomit
mmaries w
app
mmaries w
CT su
ap
CT su


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 34 of 86
Any medications with partially missing dates and/or times will be handled as described in 
Section 4.2.5 to classify them as prior or concomitant.
6.6.1
Prior medication definition
A medication with a start date that is prior to the date of first dose of IMP will be classified as a
‘prior medication’. 
6.6.2
Concomitant medication definition
A medication with a start date that is on or after the date of first dose of IMP will be classified as 
a ‘concomitant medication’.
Any medication that started prior to the first dose of IMP and continued after will be classified as 
both prior and concomitant. Such medications will therefore be counted in the tabulations for 
both prior and concomitant medication.
7
MEASUREMENTS OF TREATMENT COMPLIANCE
During the Treatment Period of this study, IMP will be administered in the clinic and compliance 
will be determined at the visit by study personnel. 
The number of injections administered at each visit will be included in the listing of IMP
administration as specified in Section 11.1.
In addition, the percentage of planned injections administered will be calculated and presented 
on the listing.  
This will be calculated as follows:
% 𝑃𝑙𝑎𝑛𝑛𝑒𝑑𝐼𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠𝐴𝑑𝑚𝑖𝑛𝑖𝑠𝑡𝑒𝑟𝑒𝑑= 𝑇𝑜𝑡𝑎𝑙𝑁𝑢𝑚𝑏𝑒𝑟𝑜𝑓𝐼𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠𝑅𝑒𝑐𝑒𝑖𝑣𝑒𝑑
𝑇𝑜𝑡𝑎𝑙𝑁𝑢𝑚𝑏𝑒𝑟𝑜𝑓𝑃𝑙𝑎𝑛𝑛𝑒𝑑𝐼𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛𝑠× 100
where the planned number of injections for subjects who have completed the study is 14 for the 
Treatment Period and 16 for the Treatment Period (total of 30 injections).  For subjects who have 
discontinued prematurely from the study, the planned number of injections will be the number of 
planned injections up to the date of discontinuation.
Any deviations from the planned dosing schedule will be addressed at the DEMs (including 
evaluation of any impact on the statistical analysis) and described in the CSR. No formal 
calculations of compliance will be presented as all IMP will be administered on site.
8
EFFICACY ANALYSES
8.1
Primary efficacy variable
8.1.1
Derivation of the primary efficacy variable
The ASDAS will be calculated based on individual component assessments of spinal pain, 
duration of morning stiffness and peripheral pain/swelling from the BASDAI together with the 
PGADA and hs-CRP values at the corresponding visit.  
8.1.1.1
Bath Ankylosing Spondylitis Disease Activity Index
The BASDAI is the most commonly used instrument to measure the disease activity of AS from 
the subject’s perspective. The BASDAI is a validated self-reported instrument which consists of 
PUBLIC COPY
will be
PY 
will be
ions adm
CO
ions adm
𝑚𝑖𝑛𝑖𝑠𝑡𝑒
PUB
𝑚𝑖𝑛𝑖𝑠𝑡𝑒
ocument cannot be used to support any marketing authorization 
ified as
hor
ified as
be classif
au
be classif
tabulation
ng a
tabulation
PLIANC
rket
PLIANC
d in the c
mar
d in the c
ncluded i
any
ncluded i
inistered 
port
inistered 
𝑒𝑑
t
𝑒𝑑=
to
= 𝑇𝑜𝑡𝑎𝑙
o s
𝑇𝑜𝑡𝑎𝑙
𝑇
o
𝑇
o
tions for s
sed
tions for s
Treatmen
use
Treatmen
m the stud
be u
m the stud
he date of 
t be
he date of 
he planne
not 
he planne
mpact on 
nno
mpact on 
omplianc
can
omplianc
EFFI
nt c
EFFI
P
n
P
This do
.1
c
.1
The ASD
doc
The ASD
durati
s do
durati
PG
s 
PG
ation and any extensions or variations thereof.
fied as
of.
fied as
ns for 
eof
ns for 
CE
th
CE
clinic and 
ons
clinic and 
in the listi
riat
in the listi
will be c
or v
will be c
𝑙𝑁𝑢𝑚𝑏𝑒𝑟
sio
𝑁𝑢𝑚𝑏𝑒𝑟
𝑜𝑡𝑎𝑙
n
𝑜𝑡𝑎𝑙𝑁𝑢𝑚
ns
𝑁𝑢𝑚
s
subje
xte
subjects w
te
cts w
nt Period 
ex
nt Period 
udy, the pl
ny e
udy, the pl
f discontin
any
f discontin
ed dosing 
nd a
ed dosing 
the statis
and
the statis
ce will be 
n a
ce will be 
CACY 
tion
CACY 
applica
rimary 
lica
rimary 
Deriva
ppli
Deriva
AS
a
AS will
ap
will
mo
a


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 35 of 86
6 questions scored on a 0 to 10-unit horizontal numeric rating scale (NRS) to measure the 
severity of the 5 major symptoms: fatigue, spinal and peripheral joint pain and swelling, 
enthesitis, and morning stiffness (both severity and duration, respectively) over the last week. 
Questions 2, 3 and 6 of the BASDAI are used in the calculation of ASDAS.  
Question 2 asks 
Question 3 of the BASDAI 
Question 6 of the BASDAI 
(Section 8.1.1.4).  
The full BASDAI questionnaire is shown in Section 14.1.
8.1.1.2
Patient’s Global Assessment of Disease Activity
Subjects will provide a global assessment of their disease activity in response to the question 
“How active was your spondylitis on average during the last week?” using a NRS where 0 is 
“not active” and 10 is “very active”.
8.1.1.3
High-sensitivity C-reactive protein
Blood will be collected for the measurement of hs-CRP. 
8.1.1.4
Calculation of Ankylosing Spondylitis Disease Activity Score
Each of the individual component assessments described above in Section 8.1.1.1,
Section 8.1.1.2 and Section 8.1.1.3 are multiplied by a validated factor (van der Heijde et al, 
2005) as listed below:
•
0.121 x Total spinal pain (BASDAI Question 2 result)
•
0.058 x Duration of morning stiffness (BASDAI Question 6 result) 
•
0.110 x PGADA 
•
0.073 x Peripheral pain/swelling (BASDAI Question 3 result)
•
0.579 x (natural logarithm of the hs-CRP [mg/L] + 1)
The results of these individual calculations or weighted components are then summed to obtain 
the ASDAS.
Handling of missing data and values of hs-CRP that are below 2 mg/L will be handled as 
described in Section 4.2.1.1.
ASDAS will be calculated at Baseline and at each post-Baseline visit per the schedule of 
assessments in the protocol.
The primary efficacy analysis will be based on the change from Baseline in ASDAS at Week 12.
PUBLIC COPY 
ease a
PY 
ease a
ng the la
OPY
ng the la
ive pro
C C
ive pro
ement of
LIC
ement of
nkylosi
UBL
nkylosi
ent asse
PU
ent asse
3
P
3
This document cannot be used to support any marketing authorization 
ctivity
ma
ctivity
vity in res
ny m
vity in res
st week?”
any
st week?”
ein
po
ein
hs
u
hs-
u
-CRP.
upp
CRP.
ng Spond
o su
ng Spond
ssments de
d to
ssments de
re
e
re multip
ed 
multip
(BASDA
be u
(BASDA
morning s
ot b
morning s
pheral
can
pheral pai
n
pai
(natural lo
nt c
(natural lo
ults of the
men
ults of the
SDAS.
um
SDAS.
Handling 
ocu
Handling 
describ
do
describ
AS
s 
AS
hori
tho
g a
ting
application and any extensions or variations thereof.
sponse to
iatio
sponse to
” using a N
aria
” using a N
ndylitis D
sion
ndylitis D
described 
ens
described 
plied by a 
xten
plied by a 
AI Questio
ny e
AI Questio
stiffness (
d an
stiffness (
in/swellin
n a
in/swellin
logarithm 
tion
logarithm 
ese indivi
icat
ese indivi
of missin
app
of missin
n
a
n Sec
ap
Sec
eof
ereo


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 36 of 86
8.1.2
Primary analysis of the primary efficacy variable
The primary efficacy analysis of the primary efficacy variable will be based on the PPS.
The primary efficacy analysis is the comparison of the change from Baseline in ASDAS at 
Week 12 in the BKZ treatment group versus the CZP treatment group in the PPS. 
8.1.2.1
Bayesian modeling
The primary statistical analysis of the primary efficacy variable at Week 12 will be conducted 
following a Bayesian paradigm.  The Bayesian analysis will be performed using a linear
regression model including treatment group and Baseline ASDAS (mean centered using the 
overall ASDAS mean). The model will be parameterized such that the effect of CZP is 
represented by the intercept parameter whilst the effect of BKZ is additive to this. An
informative prior will be used for the model for the intercept coefficient which, in the primary 
model, is equal to the mean change from Baseline in ASDAS in the CZP group when the 
centered Baseline mean is zero (βCZP ~ Normal [-1.78, var=0.0605]). Vague priors will be used
for the other model coefficients, ie, centered Baseline coefficient and additive effect of BKZ. 
Proof of Concept (PoC) will be declared if the posterior probability of a positive difference in the 
mean change from Baseline in ASDAS at Week 12 between the CZP and BKZ treatment groups 
(CZP-BKZ) is 0.975 or greater (ie, the lower bound of the 95% credible interval of the difference 
between treatment groups in the mean change from Baseline in ASDAS is zero or greater).
The model to be used is as follows:
𝑦𝑖~𝛽𝐶𝑍𝑃+ 𝛽𝑏𝑙𝑥𝑖,𝑏𝑙+ 𝛽𝐵𝐾𝑍𝑥𝑖,𝐵𝐾𝑍
Where 𝑖indexes the 𝑖= 1, … , 𝑁subjects, 𝑦𝑖is the change from Baseline in ASDAS at Week 12 
for subject 𝑖, 𝑥𝑖,𝑏𝑙is the centered Baseline ASDAS for subject 𝑖, 𝑥𝑖,B𝐾𝑍is a variable equal to 1 if 
subject 𝑖was randomized to the BKZ group and 0 if not, 𝛽𝐶𝑍𝑃is the model intercept, 𝛽𝑏𝑙is the 
coefficient for the centered Baseline ASDAS, and 𝛽𝐵𝐾𝑍is the additive effect of BKZ in addition 
to the effect of CZP.
The prior distributions for the model parameters are:
𝛽𝐶𝑍𝑃~𝑁(−1.78, 𝜎𝐶𝑍𝑃
2
= 0.0605)
𝛽𝑏𝑙~𝑁(0, 𝜎𝑏l
2 = 106)
𝛽𝐵𝐾𝑍~𝑁(0, 𝜎𝐵𝐾𝑍
2
= 106)
where the prior for 𝛽𝐶𝑍𝑃is worth approximately 20 subjects (Section 2.4). The sample sizing for 
this study was based on the assumption that 𝜎2=1.1 which was based on the CZP data available 
from a single internal study (Section 8.1.2.2). 
In addition to the primary Bayesian analysis where subjects with missing data will be excluded 
from the analysis, a supportive analysis based on imputed or predicted values for the change 
from Baseline in ASDAS at Week 12 will be performed.
Predicted Week 12 values for the subjects who do not have ASDAS values for the Week 12 visit 
will be obtained from a Mixed Model Repeated Measures (MMRM) analysis. The model will 
include treatment group, visit and the treatment group by visit interaction as fixed effects (visit as 
a categorical variable) and Baseline ASDAS as a continuous covariate. Subject-level random 
intercepts and slopes (visit as a continuous variable) will be included in the model and a 2 x 2 
PUBLIC COPY 
Y
etwee
Y
etwee
nd of the
OPY
nd of the
from Ba
COP
from Ba
𝐶𝑍𝑃
L
𝐶𝑍𝑃+
LIC
+ 𝛽
IC
𝛽
ubjects, 
UBL
ubjects, 
d
P
d Basel
PU
Basel
BK
P
BK
nt cannot be used to support any marketing authorization 
ed 
r
ed 
ng the 
utho
ng the 
P is
au
P is
s.
g
s. An
g a
An
h
i
h, in the p
ting
, in the p
group
keti
group whe
tin
whe
Vague pri
rke
Vague pri
additive
ark
additive
lity
y
lity of a p
y m
of a p
he
n
he CZP a
ny 
CZP a
95% cred
any
95% cred
eline in A
rt a
eline in A
𝑥𝑖,
su
,𝑏𝑙
u
𝑏𝑙+
upp
+ 𝛽
pp
𝛽
𝑦
t
𝑦𝑖
to
𝑖is the ch
to s
is the ch
ne ASDA
d to
ne ASDA
Z group an
ed 
Z group an
ne ASDA
use
ne ASDA
the model
t be
the model
rior for 
nt c
rior for 𝛽
c
𝛽
This docume
y was base
ent
y was base
a single in
me
a single in
addition 
cum
addition 
from the
doc
from the
fro
s do
from B
do
m B
P
s
P
ation and any extensions or variations thereof.
primary 
ereo
primary 
en the
her
en the
iors will b
th
iors will b
effect of
ns t
effect of
positive di
tion
positive di
and BKZ 
iatio
and BKZ 
dible inter
aria
dible inter
ASDAS is
va
ASDAS is
𝐵𝐾𝑍
ns
𝐵𝐾𝑍𝑥
ns
𝑥𝑖
s
𝑖,
s
,𝐵𝐾
s
𝐵𝐾
change fro
sion
change fro
AS for sub
nsi
AS for sub
nd 0 if no
ten
nd 0 if no
AS, and 
exte
AS, and 𝛽
e
𝛽
el paramet
any
el paramet
𝛽
nd
𝛽𝐶𝑍𝑃
nd
𝐶𝑍𝑃~𝑁
a
𝑁
applica
𝐶𝑍𝑃
ti
𝐶𝑍𝑃is wor
tion
is wor
ed on the 
cati
ed on the 
nternal stu
lica
nternal stu
to the pri
pp
to the pri
analysis
ap
nalysis
ne
a


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 37 of 86
unstructured covariance matrix for these random effects will be used, along with a simple 
covariance structure for the within-subject errors.
If the model fails to converge then the simpler subject-level model including the intercept as only 
random effect will be fitted. If there are still problems with convergence and/or if the estimated 
response covariance matrices (random effects and response) are not positive definite, then 
alternative models will be considered, eg, allowing the random effects covariance parameters to 
be unbounded, or modelling the response covariance structure without using random effects.
The combination of observed and predicted values of change from Baseline in ASDAS at Week 
12 obtained from the MMRM will then be modelled as the response variable in this supportive 
Bayesian analysis.
8.1.2.2
Building the prior
The CZP prior for this study has been built based on UCB study AS0001.
Study AS0001 was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study 
to evaluate the efficacy and safety of 2 dose regimens of CZP in subjects with active axial 
spondyloArthritis (axial SpA).  Subjects were randomized in a 1:1:1 ratio to receive one of three 
treatment regimens:
•
CZP administered subcutaneously (sc) at the dose of CZP 400mg every 2 weeks (Q2W) at 
Weeks 0, 2, and 4 followed by CZP 200mg Q2W sc; 
•
CZP administered sc at the dose of CZP 400mg Q2W at Weeks 0, 2, and 4 followed by CZP 
400mg every 4 weeks (Q4W) sc; 
•
Placebo.
In this study AS0001, one of the secondary efficacy variables was the change from Baseline in 
ASDAS; the primary efficacy variable for the current study AS0013.
To build the prior using these data, subjects in the CZP 400mg treatment group were removed 
since their CZP responses were sufficiently different from those of the CZP 200mg subjects 
(leaving 105 CZP 200mg subjects with Baseline and Week 12 data available), and the linear 
model detailed in Section 8.1.2.1 was fitted to just the Placebo and CZP 200mg treatment groups 
with Placebo as the additive treatment effect (a treatment group by Baseline ASDAS interaction 
was also included in the model for this historical).
The estimated model was used to estimate the distribution 𝛽𝐶𝑍𝑃~𝑁(−1.78, 𝜎𝐶𝑍𝑃
2
= 0.0078) and 
might be used as a prior for the CZP mean response. However, in order to take into account 
expected study to study variation in the estimated CZP parameter 𝛽𝐶𝑍𝑃, this prior was discounted 
(the SD was inflated) to arrive at the prior given in Section 8.1.2.1 (by inflating the SD by 2.788 
to give an effective sample size of approximately 20 subjects).
The historical data in study AS0001 gave the opportunity to build an informative prior for the 
overall effect of Baseline ASDAS in the proposed study (ignoring treatment group since a 
Baseline by treatment group interaction is not expected).  However, since the AS0001 study only 
included Placebo and CZP treatment group data there is currently no data available with which to 
confirm whether or not the estimated Baseline ASDAS coefficient of -0.66 for CZP is also 
similar for BKZ. Accordingly, whilst a Baseline by treatment group interaction in the proposed 
PUBLIC COPY 
Y
e dose of
OP
e dose of
mg Q2W
CO
mg Q2W
ZP 400m
IC C
ZP 400m
e seco
PU
e seco
i
P
i
nt cannot be used to support any marketing authorization 
z
at Week 
thor
at Week 
upportive 
uth
upportive 
placebo
arke
placebo-
e
bjects wit
mar
bjects wit
:1:1 rati
y m
:1:1 ratio
CZP 400m
t an
CZP 400m
sc;
o
sc;
mg Q2W a
ppo
mg Q2W a
ndary effic
d to
ndary effic
ble for the
sed
ble for the
ata, subje
us
ata, subje
ere suffic
be u
ere suffic
subjects w
t be
subjects w
on
o
on 8.1.2.
ot 
8.1.2.
additive t
nno
additive t
d in 
a
d in the m
an
the m
d model w
t c
d model w
This documen
used as a 
ent
used as a 
ed study t
me
ed study t
SD was i
cum
SD was i
o give an 
ocu
o give an 
The hi
s do
The hi
ove
s 
ove
tion and any extensions or variations thereof.
controlled
s th
controlled
th active a
ons
th active a
to receiv
tion
to receiv
mg every
vari
mg every
at Weeks 
s or
at Weeks 
cacy varia
ens
cacy varia
he current 
xte
he current 
ects
y e
ects in the
y ex
in the
ciently dif
ny 
ciently dif
with Base
any
with Base
1
d
1 was fitt
nd a
was fitt
treatment
and
treatment
model for 
n a
model for 
was used
tion
was used
applica
prior for 
catio
prior for 
to study v
lica
to study v
inflated) 
ppli
inflated) 
effective
app
effective
al d
a
al d


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 38 of 86
study is not expected, to account for this uncertainty a non-informative prior was used for the 
Baseline ASDAS coefficient. 
8.1.2.3
Prior data conflict
Prior data conflict will be investigated for all informative priors through use of graphical 
displays.  If there is evidence of prior data conflict for a given parameter, then a vague prior will 
be used for that parameter.
8.1.3
Presentation of the primary analysis of the primary efficacy variable
The Bayesian analysis will be implemented using multiple chains each utilizing different starting 
values for the model specified parameters. The posterior samples from each chain will be 
combined into one dataset from which the posterior summaries will be estimated. Missing data 
will be handled as described in Section 4.2.1
The posterior distributions of the mean changes from Baseline in ASDAS in the CZP and BKZ
groups and of the difference in mean changes from Baseline between the treatment groups 
(CZP – BKZ) will be summarized using means, medians, SDs, 95% credible intervals and 95% 
highest posterior density intervals. The posterior probability that the difference between 
treatment groups in the mean change from Baseline in ASDAS at Week 12 is greater than zero 
will also be presented.
The posterior probability that BKZ achieves a lower ASDAS score at Week 12 compared to CZP 
will be derived from this distribution.  
8.1.4
Presentation of Ankylosing Spondylitis Disease Activity Score
All component data, the derived ASDAS values and changes from Baseline at each visit will be 
listed by treatment group and subject, including each of the ASDAS disease activity states and 
disease improvement categories defined in Section 8.2.1.1, based on the FAS. Observed ASDAS 
values and changes from Baseline will be summarized by treatment group and visit, using 
descriptive statistics, based on the PPS and repeated for the FAS.
Observed mean values and changes from Baseline, including 95% CI for the means, will be 
plotted versus time, with both treatment groups overlaid on the same axes, based on the PPS and 
repeated for the FAS.
8.1.5
Presentation of component variables of Ankylosing Spondylitis 
Disease Activity Score
All data presentations in this section will be based on the PPS and repeated for the FAS.
8.1.5.1
Bath Ankylosing Spondylitis Disease Activity Index
The BASDAI score ranges from 0 to 10, with lower scores indicating lower disease activity.
The BASDAI questionnaire contains 6 questions, each of which has a possible value ranging 
from 0 to 10, and the overall score is calculated as follows:
𝐵𝐴𝑆𝐷𝐴𝐼=
𝑄1 + 𝑄2 + 𝑄3 + 𝑄4 + (𝑄5 + 𝑄6
2
)
5
PUBLIC COPY
in ASD
PY 
in ASD
a lower A
CO
a lower A
kylosing
LIC
kylosing
ASDAS v
UBL
ASDAS v
ubject, 
PU
ubject, in
U
in
P
defi
P
defi
be used to support any marketing authorization 
iable
hori
iable
ent startin
utho
ent startin
will be
aut
will be
d. Missing
g a
d. Missing
S in the C
keti
S in the C
the treatm
arke
the treatm
% credible
mar
% credible
the differ
y m
the differ
AS at Week
ny 
AS at Week
ASDAS sc
ort 
ASDAS sc
 Spondy
upp
 Spondy
alues and 
o s
alues and 
cluding e
d to
cluding e
ed 
ed
ed in
ed t
in Sec
d t
Sec
will be su
sed
will be su
he 
he PPS an
us
PPS an
ument cannot b
changes f
be 
changes f
h both trea
ot b
h both trea
esentat
ann
esentat
Disease
t ca
Disease
resentatio
ent 
resentatio
This doc
1
B
he BASD
ocu
he BASD
The BA
do
The BA
from
s d
from
any extensions or variations thereof.
g data 
eof
g data 
CZP and 
the
CZP and B
ment group
s th
ment group
e intervals
ons
e intervals
erence bet
tion
erence bet
ek 12 is gr
iatio
ek 12 is gr
core at W
r va
core at W
ylitis Dis
ns 
ylitis Dis
d changes 
sion
d changes 
each of th
nsi
each of th
ction
ten
ction 8.2.
en
8.2.
ummarize
xte
ummarize
and repeat
y ex
and repeat
ication and a
from 
any
from Bas
ny
Bas
atment gr
d an
atment gr
ion of c
an
ion of c
e Activit
on 
e Activit
ons in this
atio
ons in this
applic
Bath An
plica
Bath An
DAI score 
app
DAI score 
AI qu
ap
AI qu


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 39 of 86
To give each symptom equal weighting, the average of the 2 scores relating to morning stiffness 
(questions 5 and 6) is taken. The sum of the scores from questions 1 to 4 and the average of the 
scores from questions 5 and 6 result in a total score ranging from 0 to 50.  This is divided by 5 to 
give a final BASDAI score between 0 and 10, with lower scores indicating lower disease 
activity.
The individual question responses from the BASDAI together with the derived BASDAI score 
will be listed by treatment group and visit for each subject, including changes from Baseline for 
the BASDAI score. Additionally, for each subject the mean result from questions 5 and 6, 
together with the change from Baseline and percentage change from Baseline in this mean value, 
will be listed.
The observed BASDAI score and changes from Baseline will be summarized by treatment group 
and visit.
Additionally, the mean of question 5 and 6, together with the corresponding changes from 
Baseline and percentage changes from Baseline will be summarized by treatment group and visit.
Observed mean BASDAI score and changes from Baseline, including 95% CI for the means, will 
be plotted versus time, with both treatment groups overlaid on the same axes.
The full BASDAI questionnaire is shown in Section 14.1. A glossary of the BASDAI 
questionnaire will be presented.
8.1.5.2
Patient’s Global Assessment of Disease Activity
Patient’s Global Assessment of Disease Activity will be listed by treatment group, subject and 
visit, including changes from Baseline and percentage changes from Baseline.
Observed values, changes from Baseline and percentage changes from Baseline will be 
summarized by treatment group and visit.
Observed mean PGADA and changes from Baseline, including 95% CI for the means, will be 
plotted versus time, with both treatment groups overlaid on the same axes.
8.1.5.3
High sensitivity C-reactive protein
Measurements of hs-CRP will be listed by treatment group, subject and visit for each subject 
including changes from Baseline and ratio to Baseline. The latter will be calculated as follows:
𝑅𝑎𝑡𝑖𝑜𝑡𝑜𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒= ℎ𝑠--– -𝐶𝑅𝑃𝑎𝑡𝑃𝑜𝑠𝑡– 𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒𝑉𝑖𝑠𝑖𝑡/ ℎ𝑠– -𝐶𝑅𝑃𝑎𝑡𝐵𝑎𝑠𝑒𝑙𝑖𝑛𝑒𝑉𝑖𝑠𝑖𝑡
Observed values, changes from Baseline and ratio to Baseline will be summarized by treatment 
group and visit. Summary statistics will include n, arithmetic mean, SD, geometric mean, 95% 
CI for the means, geoCV, median, Q1, Q3, minimum and maximum. 
The geoCV will be calculated as a percentage as: 
𝑔𝑒𝑜𝐶𝑉(%) = 100 × √exp(𝑆𝐷𝐿
2) −1,
where SDL represents the standard deviation of the natural logarithm transformed value.  
Observed mean hs-CRP values, changes from Baseline and ratio to Baseline, including 95% CI 
for the means, will be plotted versus time, with both treatment groups overlaid on the same axes.
PUBLIC COPY 
erlai
Y
erlai
on
OP
on 14.1
OPY
14.1
sment o
C C
sment o
se Activi
LIC
se Activi
ine and 
UBL
ine and 
m Baselin
PU
m Baselin
and 
P
and 
nt cannot be used to support any marketing authorization 
for 
riz
for 
h
ean value
tho
ean value
y treatmen
g a
y treatmen
ing chang
ket
ing chang
by treatme
ark
by treatme
ding 95%
ma
ding 95%
the same 
ny m
the same 
A glossar
any
A glossar
f Diseas
po
f Diseas
y will be 
upp
y will be 
ercentage
o su
ercentage
e and perc
d to
e and perc
visit.
ed
visit.
nges from
use
nges from
treatment
e u
treatment
sitivity C
t be
sitivity C
CRP will b
not
CRP will b
from Base
ann
from Base
men
𝑎𝑠𝑒𝑙𝑖𝑛𝑒
ca
𝑎𝑠𝑒𝑙𝑖𝑛𝑒
values, ch
ent 
values, ch
nd visit. S
men
nd visit. S
This docum
or the mea
um
or the mea
The geoC
docu
The geoC
w
s
w
tion and any extensions or variations thereof.
nt group
eof
nt group
ges from
the
ges from
ent group 
s th
ent group 
% CI for
ions
% CI for th
s
th
e axes
atio
e axes.
ti
.
ry of the B
aria
ry of the B
se Activi
or 
se Activi
listed by 
ns 
listed by 
e
i
e changes
ion
changes
centage ch
nsi
centage ch
m B
ex
m Baselin
ext
aselin
nt groups o
y e
nt groups o
C-
a
-reactiv
any
reactiv
be listed 
nd 
be listed 
seline and
and
seline and
pplicat
= ℎ
on
ℎ𝑠
n
𝑠--
n 
--–
hanges fro
atio
hanges fro
Summary
ica
Summary
ap
ans,
pli
ans, geoC
plic
geoC
V will be
app
V will be


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 40 of 86
The rules for handling any observed concentration values that are BLQ or ALQ are described in 
Section 4.2.1.2.
8.1.6
Supportive analysis of the primary efficacy variable
8.1.6.1
Alternative analysis sets
The primary efficacy analysis set is the PPS; however, the primary analysis and all supportive 
analyses of the primary efficacy variable will be repeated using the FAS.  These analyses will be 
performed in order to evaluate the effect that any IPDs may have had on the results of the 
analysis. The results will be presented as specified in Section 8.1.3.
8.1.6.2
Alternative prior distributions
The primary analysis will be repeated for each of the following prior distribution alternatives:
•
A vague prior distribution for all parameters in the model (including the CZP effect).
•
An informative prior for the Baseline effect [𝛽𝑏𝑙~𝑁(−0.66, 𝜎𝑏l
2 = 25)] and an informative 
prior for the CZP effect.
•
An informative prior for the Baseline effect [𝛽𝑏𝑙~𝑁(−0.66, 𝜎𝑏𝑙
2 = 25)] and a vague prior for 
the CZP effect [𝛽𝐶𝑍𝑃~𝑁(0, 𝜎𝐶𝑍𝑃
2
= 106)].
The results will be presented as specified in Section 8.1.3.
8.1.6.3
Frequentist analysis – Analysis of Covariance
A frequentist analysis of the change from Baseline in ASDAS at Week 12 will be performed 
using an analysis of covariance (ANCOVA).  The ANCOVA model will match the Bayesian 
model, ie, including treatment group (CZP and BKZ) as a fixed effect and Baseline ASDAS as a 
covariate.
Least squares means (LSMeans), SEs and associated 95% CIs for the changes from Baseline in 
ASDAS at Week 12 in each treatment group will be presented.  In addition, the estimated 
treatment difference in LSMeans (CZP – BKZ), SE, corresponding 95% CI, and p-value for the 
treatment comparison will be presented.
8.1.6.4
Frequentist analysis – Mixed Model Repeated Measures
A frequentist analysis of the change from Baseline in ASDAS will be performed using a 
MMRM.  This model will use all available change from Baseline in ASDAS data at all post-
Baseline visits during the Treatment Period up to and including Week 12.  Treatment group 
(CZP and BKZ), visit, and the treatment group by visit interaction will be included as fixed 
effects and Baseline ASDAS will be included as a covariate.
An unstructured covariance matrix will be used to model the within-subject errors.  If the model 
fails to converge, and/or if the estimated unstructured covariance matrix is not positive definite, 
then simpler alternative covariance structures will be considered (eg, compound symmetry).
Least squares means, SEs and associated 95% CIs for the changes from Baseline in ASDAS in 
each treatment group will be presented by visit.  In addition, the estimated treatment difference 
in LSMeans (BKZ – CZP), SE, corresponding 95% CI, and p-value for the treatment comparison 
will be presented for each visit.  Week 12 will be the primary time point of interest from this 
analysis.
PUBLIC COPY 
𝑁
Y
𝑁(
Y
(
ction
COP
ction 8.1
OP
8.1
Analysi
C C
Analysi
om Base
LIC
om Base
NCOVA)
BL
NCOVA)
oup (CZ
PUB
oup (CZ
be used to support any marketing authorization 
l be
riz
l be
on alterna
ng a
on alterna
e CZP eff
etin
e CZP eff
25
r
25)
ark
)]
rk
] and 
ke
and 
, 𝜎
y
𝜎𝑏
y
𝑏
𝜎𝑏
𝜎
y
𝜎𝑏
𝜎𝑙
y
𝑙
2
y
2 =
y m
= 25
m
25
3
r
3.
rt
.
s of Cova
por
s of Cova
ine in AS
upp
ine in AS
  The AN
su
  The AN
P and BK
to s
P and BK
SEs and as
sed
SEs and as
atment gro
us
atment gro
eans (CZP
be u
eans (CZP
ocument cannot b
l be prese
t be
l be prese
entist an
not
entist an
lysis of th
ann
lysis of th
model w
ca
model w
sits during
nt c
sits during
d BKZ),
men
d BKZ), v
s and Bas
me
s and Bas
n unstruc
cu
n unstruc
This do
fails to c
doc
fails to c
then s
s d
then s
L
s
L
d any extensions or variations thereof.
atives:
eof
atives:
ffect)
he
ffect).
e
.
an inform
s th
an inform
5
a
5)
at
)]
ati
] and a
tio
and a
variance
or v
variance
SDAS at W
ns o
SDAS at W
NCOVA m
ions
NCOVA m
KZ) as a fi
sio
KZ) as a fi
associated
exte
associated
roup will b
y ex
roup will b
P
n
P
application and
–
y
– BKZ)
ny 
BKZ)
ented.
an
ented.
analysis
nd 
analysis
he change
an
he change
ill use all
on 
ill use all
g the Trea
tio
g the Trea
v
c
visit, and 
cat
isit, and 
eline AS
lica
eline AS
tured cov
pp
tured cov
a
nverge,
ap
nverge,


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 41 of 86
The LSMeans for the changes from Baseline, including 95% CI, will be plotted versus time, with 
both treatment groups overlaid on the same axes.
8.1.6.5
Frequentist analysis – Mixed Model Repeated Measures with 
Baseline by treatment group interaction
A frequentist analysis of the change from Baseline in ASDAS will be performed using a MMRM 
as specified in Section 8.1.6.4.  In addition, the model will include the Baseline ASDAS by 
treatment group interaction. 
The results presentation, and the covariance matrix structures, as specified in Section 8.1.6.4,
will be applied.
8.2
Secondary efficacy variables
Secondary efficacy variables will be listed and summarized by treatment group and visit for the 
PPS and repeated for the FAS.
8.2.1
ASDAS Disease Activity States and Improvement
8.2.1.1
Derivation of ASDAS Disease Activity States and Improvement
Cut-offs for 4 disease activity states based on ASDAS will be defined for each subject at 
Baseline and at each post-Baseline visit as follows:
•
ASDAS-Inactive Disease (ASDAS-ID): ASDAS < 1.3
•
ASDAS-Moderate Disease activity (ASDAS-MD): ASDAS ≥1.3 to < 2.1
•
ASDAS-High Disease activity (ASDAS-HD): ASDAS ≥2.1 to ≤3.5
•
ASDAS-Very High Disease activity (ASDAS-vHD): ASDAS > 3.5
In addition, the following cut-offs for 2 levels of improvement in ASDAS will be defined for 
each subject at each post-Baseline visit based on the change from Baseline in ASDAS:
•
ASDAS Clinically Important Improvement (ASDAS-CII): a reduction (improvement) from 
Baseline in ASDAS ≥ 1.1 units
•
ASDAS Major Improvement (ASDAS-MI): a reduction (improvement) from Baseline in 
ASDAS ≥ 2.0 units 
ASDAS-Inactive Disease (ASDAS-ID) and ASDAS-Major Improvement (ASDAS-MI) at Week 
12 are the secondary efficacy variables defined for this study. Subjects with missing ASDAS at 
Week 12 will not be classified in terms of their ASDAS disease activity state or improvement 
according to the above definitions.
8.2.1.2
Analysis of ASDAS Disease Activity States and Improvement
The number and percentage of subjects classified in each of the disease activity state categories 
(ASDAS-ID, ASDAS-MD, ASDAS-HD and ASDAS-vHD) and each disease improvement 
category (ASDAS-CII [yes/no] and ASDAS-MI [yes/no]) and will be tabulated by treatment 
group and visit including the 95% CIs calculated using a Wilson approximation.
PUBLIC COPY
AS will
PY 
AS will
ws:
O
ws:
ASDAS
CO
ASDAS
(ASDAS
LIC 
(ASDAS
ASDAS
BL
ASDAS
e activity
PUB
e activity
fs f
P
fs f
ot be used to support any marketing authorization 
1.6.4
tho
1.6.4,
h
,
oup and v
ting
oup and v
ment
ark
ment
tes and I
ma
tes and I
e defined
any 
e defined
< 1.3
ort
1.3
MD)
upp
MD): AS
pp
: AS
HD)
su
HD): AS
su
: AS
(ASDAS
d to 
(ASDAS
or 2 levels
ed 
or 2 levels
e visit bas
use
e visit bas
rtant Impr
be u
rtant Impr
1.1 units
t be
1.1 units
This document canno
mprovemen
not
mprovemen
units
nn
units
ve Dise
ca
ve Diseas
a
as
econdary 
nt c
econdary 
 will not b
men
 will not b
ding to th
me
ing to th
2.1.2
cu
2.1.2
The nu
do
The nu
(
s d
(AS
d
AS
c
s
c
d any extensions or variations thereof.
visit for th
here
visit for th
Improve
tion
Improve
d for each
riat
d for each
SDAS ≥
s o
SDAS ≥1
DAS ≥
ions
DAS ≥2
s
2
-vHD
nsi
vHD)
si
): A
i
: A
s of impro
xten
s of impro
sed on the
ext
sed on the
rovement
ny e
rovement
application and
ent (ASDA
nd 
ent (ASDA
se (ASDA
on 
se (ASDA
y efficacy 
tio
y efficacy 
be classif
cat
be classif
he above d
plica
he above d
Ana
pp
Ana
er and
ap
er and


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 42 of 86
Additionally, inferential treatment effects for ASDAS-ID and ASDAS-MI at Week 12 will be 
derived from the Bayesian analysis as described in Section 8.1.2.1.  ASDAS-ID and ASDAS-MI 
rates at Week 12 will be presented.
8.3
Other efficacy variables
8.3.1
Derivation of Assessment in SpondyloArthritis International Society
Response
The following ASAS-based variables will be derived:
•
ASAS20 response is defined as an improvement of at least 20% (percentage change from 
Baseline of -20% or more negative), and an absolute improvement of at least 1 unit (change 
from Baseline of -1 or more negative) in at least 3 of the 4 following domains: 
−
PGADA (Section 8.1.5.2)
−
Function (represented by BASFI, Section 8.3.3.1)
−
Pain assessment (the total spinal pain NRS score, Section 8.3.3.2)
−
Inflammation (the mean of the BASDAI Questions 5 and 6 results, Section 8.1.5.1,
concerning morning stiffness intensity and duration)
In addition, absence of deterioration in the potential remaining domain is required. 
Deterioration is defined as the presence of both of the following:
−
percentage change from Baseline of 20% or more;
−
change from Baseline of 1 unit or more.
•
The ASAS40 response is defined as an improvement of at least 40% (percentage change 
from Baseline of -40% or more negative), and an absolute improvement of at least 2 units 
(change from Baseline of -2 or more negative) in at least 3 of the 4 domains above. In 
addition, no worsening (a change from Baseline that is non-positive [ie, negative or zero]) in 
the remaining domain is required.
•
Time to ASAS20 response: defined as the time (in days) from the first dose of IMP to the 
first instance (if more than one instance) of an ASAS20 response.
−
This will be calculated for the Treatment Period and across the entire study period 
(Treatment Period + Treatment Extension Period) separately.
−
For time to ASAS20 response during the Treatment Period: 
−
Subjects who discontinue early prior to an ASAS20 response will be censored on 
the date of their last efficacy assessment during the Treatment Period.
−
Subjects who do not have an ASAS20 response during the Treatment Period will be 
censored on the date of their Week 12 efficacy assessment (ie, end of the Treatment 
Period).
−
For time to ASAS20 response during the study (Treatment Period + Treatment Extension 
Period):
PUBLIC COPY
tion
Y
tion
duration
PY 
duration
potentia
COP
potentia
of both 
C CO
of both 
e
L
e of 
LIC
of 20%
C 
20%
unit
UB
unit or m
BL
or m
efined a
PU
efined a
ore n
P
ore n
nt cannot be used to support any marketing authorization 
ge from
uth
ge from
unit (chan
aut
unit (chan
ns:
g
ns:
3.3.2
ma
3.3.2)
ar
)
nd 6 resul
y m
nd 6 resul
 remainin
rt a
 remainin
of the follo
port
of the follo
or more
upp
or more
ore.
s
ore.
an impro
d to
an impro
negative), 
ed 
negative), 
r more ne
use
r more ne
hange fro
e us
hange fro
required.
be 
required.
sponse: d
ot b
sponse: d
more than
nno
more than
be calcul
can
be calcul
ment Peri
t ca
ment Peri
This docume
or time to
ent
or time to
−
m
−
S
ation and any extensions or variations thereof.
ange
of
ange
lts,
at
lts, Sectio
atio
Sectio
ng domain
va
ng domain
owing:
or v
owing:
;
ovement o
ens
ovement o
and an ab
ten
and an ab
egative) in
exte
egative) in
om Baseli
y ex
om Baseli
defined as
d a
defined as
n one inst
nd 
n one inst
lated for t
n a
lated for t
riod 
io
riod + Tre
on 
+ Tre
applica
o ASAS20
cati
o ASAS20
Subjects w
plic
ubjects w
the date
app
the date
Sub
ap
Sub


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 43 of 86
−
Subjects who discontinue early prior to an ASAS20 response will be censored on 
the date of their last efficacy assessment during the study (Treatment Period + 
Treatment Extension Period).
−
Subjects who do not have an ASAS20 response during the study will be censored 
on the date of their Week 48 efficacy assessment (ie, end of the Treatment
Extension Period).
•
Time to ASAS40 response: defined as the time (in days) from the first dose of IMP to the 
first instance (if more than one instance) of an ASAS40 response. As described above for 
time to ASAS20 response, time to ASAS40 response will be calculated based on the 
Treatment Period and also across the study period (Treatment Period + Treatment Extension 
Period) separately and the same censoring rules will be applied.
•
The ASAS partial remission (ASAS-PR) response is defined as a score of ≤2 units in all 4 
domains listed above.
In order for a subject to be defined as a responder (ASAS20, ASAS40 or ASAS-PR, 
respectively) at a given visit, the criteria stated must be met all together that visit.
Missing component data for the derivation of the ASAS20, ASAS40 and ASAS-PR will be 
handled as described in Section 4.2.1.4.
8.3.2
Presentation of Assessment in SpondyloArthritis International 
Society Response
8.3.2.1
ASAS20 and ASAS40 response
A by-subject listing showing ASAS20 and ASAS40 response status will be presented by 
treatment group and visit for the FAS. 
The number and percentage of subjects classified as ASAS20 and ASAS40 at each post-Baseline 
visit will be tabulated by treatment group for the FAS including the 95% CI calculated using a 
Wilson approximation.
8.3.2.2
Time to ASAS20 and ASAS40 response
A by-subject listing showing time to ASAS20 response and time to ASAS40 response will be 
presented by treatment group and visit for the FAS. This listing will include flags for censored 
observations.
The time to ASAS20 response and time to ASAS40 response during the Treatment Period and 
during the study (Treatment Period + Treatment Extension Period) will be summarized for the 
FAS separately using the following statistics:
•
Number and percentage of subjects that are responders
•
Number and percentage of subjects that are censored
•
Minimum, maximum and Kaplan-Meier estimates of the 25th percentile, median and 75th
percentile, with corresponding 95% CIs
Kaplan-Meier response rates for ASAS20 and ASAS40 will be presented for each treatment, 
including the cumulative number of events and the number of subjects at risk at each study visit. 
PUBLIC COPY
SAS20
PY 
SAS20
ent in S
CO
ent in S
40
L
40 resp
LIC
resp
AS20 and
UB
AS20 and
e FAS
PU
e FAS
b
P
b
nnot be used to support any marketing authorization 
he
o
he
e for 
tho
e for 
the
ut
the
ment Exten
au
ment Exten
of ≤
eti
of ≤2 un
ting
2 un
40 or ASA
mar
40 or ASA
ogether 
ma
ogether tha
a
tha
ASAS40 a
ny 
ASAS40 a
pondylo
ort 
pondylo
onse
sup
onse
ASAS40
to s
ASAS40
ects class
sed
ects class
ent group 
use
ent group 
ASAS20 
t be
ASAS20 
howing 
not
howing ti
t
ti
This document can
ment grou
ann
ment grou
 ASAS20
nt c
 ASAS20
he study
men
he study (
separately
ume
separately
Numbe
ocu
Numbe
•
d
•
Nu
o
Nu
•
s
•
nd any extensions or variations thereof.
nsion
of
nsion
nits
he
nits in all 
here
in all 
AS
n
AS-
ns
-PR,
ns 
PR,
at
i
at visit.
ion
visit.
and ASAS
riati
and ASAS
oArthriti
r va
oArthriti
0 response
sio
0 response
sified as 
xte
sified as A
for the FA
ex
for the FA
and AS
any
and AS
ime to 
nd
ime to 
application a
AS
 
AS
up and vis
an
up and vis
0 respons
atio
0 respons
(Treatmen
cat
(Treatmen
y u
pli
y using th
plic
sing th
er and per
app
er and per
r an
a
r an


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 44 of 86
This will be presented separately for the Treatment period and across the study (Treatment 
Period + Treatment Extension Period). 
Kaplan-Meier curves will be presented for time to ASAS20 response and time to ASAS40 
response for the Treatment Period and across the study (Treatment Period + Treatment Extension 
Period) separately, with both treatment groups overlaid on each plot. The plot will start at zero 
(ie, no responders at time zero) and be non-decreasing.
8.3.2.3
ASAS-PR
A by-subject listing showing ASAS-PR response status will be presented by treatment group and 
visit for the FAS.
The number and percentage of subjects classified as ASAS-PR at each post-Baseline visit will be 
tabulated by treatment group for the FAS including the 95% CI calculated using a Wilson 
approximation.
8.3.3
Presentation of components of Assessment in SpondyloArthritis 
International Society
8.3.3.1
Bath Ankylosing Spondylitis Functional Index
The BASFI is a validated index used to determine the degree of functional limitation in subjects 
with AS.  The BASFI questionnaire comprises 10 questions, each of which has a possible value 
ranging from 0 ("Easy") to 10 ("Impossible").  The first 8 questions evaluate activities related to 
functional anatomical limitations due to AS and the final 2 questions evaluate a subject's ability 
to cope with everyday life.  The BASFI will be administered at all visits per the schedule of 
events. 
The BASFI score is the arithmetic mean of the 10 individual scores giving a value between 0 and 
10, with lower scores indicating better physical function.
Missing data for the BASFI questionnaire will be handled as described in Section 4.2.1.5.
The BASFI results will be listed by treatment group and visit for each subject in the FAS
including the results from each of the individual 10 questions, the BASFI score, changes from 
Baseline and percentage changes from Baseline in the BASFI score.
The full BASFI questionnaire is shown in Section 14.2. A glossary of the BASFI questionnaire 
will be presented.
Observed values, changes from Baseline and percentage changes from Baseline in the BASFI 
score will be summarized by treatment group and visit for the FAS.
8.3.3.2
Total and nocturnal spinal pain numeric rating scale
The pain experienced by subjects due to AS will be assessed by the following questions, 
referring to the average experience over the past week:
•
Total pain in the spine: How much pain of your spine due to spondylitis do you have?
•
Nocturnal spinal pain: How much pain of your spine due to spondylitis do you have at night?
The response to these questions will be rated by the subjects on a scale from 0 (no pain) to 10 
(most severe pain) and the response will be recorded on the eCRF.
PUBLIC COPY 
cti
Y
cti
the degr
OPY
the degr
10 quest
COP
10 quest
).  The f
CO
).  The f
AS and t
C C
AS and t
FI will be
LIC
FI will be
etic mean
PUB
etic mean
g bett
P
g bett
cument cannot be used to support any marketing authorization 
group and
tho
group and
eline visit
g a
eline visit
ing a Wils
ting
ing a Wils
Spondy
arke
Spondy
Index
y m
Index
ee of func
any
ee of func
ions, each
rt a
ions, each
rst 8 ques
port
rst 8 ques
he final 2 q
ppo
he final 2 q
administe
upp
administe
of the 10
d to 
of the 10
r physica
ed t
r physica
tionnaire 
use
tionnaire 
sted by tre
be u
sted by tre
each of th
t be
each of th
e changes
ot 
e changes
estionnair
nn
estionnair
d.
c
d.
alues, cha
nt c
alues, cha
l be summ
en
be summ
.2
u
.2
This doc
The pain e
ocu
The pain e
referrin
do
referrin
•
s 
•
pplication and any extensions or variations thereof.
t 
e
t will be
eof.
will be
lson 
ere
lson 
yloArthr
s th
yloArthr
ctional lim
aria
ctional lim
h of which
var
h of which
stions eva
or v
stions eva
questions
s or
questions
tered at al
ns 
tered at al
0 individu
nsi
0 individu
al function
ten
al function
will be h
ext
will be h
eatment g
ny e
eatment g
the individ
any
the individ
s from Ba
d a
s from Ba
re is show
and
re is show
anges from
tion
anges from
marized b
cati
marized b
Total a
plic
Total a
ap
experienc
app
experienc
o the a
ap
o the a


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 45 of 86
The Total and Nocturnal spinal pain scores will be listed by treatment group and visit for each 
subject in the FAS including changes from Baseline and percentage changes from Baseline. 
Observed values, changes from Baseline and percentage changes from Baseline will be 
summarized by treatment group and visit for the FAS for each of Total and Nocturnal spinal pain 
scores.
8.3.4
Physician’s Global Assessment of Disease Activity
The Investigator will assess the overall status of the subject with respect to their AS signs and 
symptoms and functional capacity (considering both joint and skin components) using an NRS 
where 0=very good, asymptomatic and no limitations of normal activities and 10=very poor, 
very severe symptoms which are intolerable and inability to carry out normal activities. 
A by-subject listing will present the PhGADA results by treatment group and visit for the FAS, 
including changes from Baseline.  Observed values and changes from Baseline will be 
summarized by treatment group and visit for the FAS.
8.3.5
Hospital Anxiety and Depression Scale 
The HADS was chosen for its well-established psychometric properties and its use in clinical 
research on biological therapy in subjects with other inflammatory skin diseases (Dauden et al, 
2009; Langley et al, 2010). 
The HADS is a commonly used instrument to determine the levels of anxiety and depression that 
a subject is experiencing. The HADS is a 14-item scale that generates ordinal data. Seven items 
relate to anxiety (assessed in the HADS-A) and seven relate to depression (assessed in the 
HADS-D). Individual item scores range from 0 to 3 and are summed to give a total score on each 
of the individual HADS-A and HADS-D scales. These total scores range from 0 to 21 with 
higher scores indicating a worse state.
In case of missing data, the rules in Section 4.2.1.6 will apply.
The full HADS questionnaire is shown in Section 14.3. A glossary of the HADS questionnaire 
will be presented.
Scores for each item on the HADS-A and HADS-D will be listed at each visit by treatment group 
for each subject in the FAS. This listing will also include the total HADS-A and HADS-D scores 
together with the changes from Baseline in the total HADS-A and total HADS-D scores at each 
visit. Summary statistics will be presented by treatment group for the observed total HADS-A 
and HADS-D scores together with changes from Baseline at each visit for the FAS.
8.3.6
Change in Bone Formation (PET-MRI/PET-CT Substudy)
To evaluate the effect of BKZ or CZP on changes in bone formation, an independent assessment 
of SIJ radiographs at Screening (to assess eligibility of subjects for the PET-MRI/PET-CT 
substudy) and PET-MRI/PET-CT scans of the entire spine and SIJ (to assess positivity and 
efficacy in subjects eligible for the substudy) at Baseline, Week 12 and Week 48 will be 
conducted.
8.3.6.1
Eligibility assessment
SIJ radiographs at Screening will be independently assessed in a blinded fashion by two 
reviewers.  An image quality assessment will be performed, modified New York (mNY) scores 
PUBLIC COPY
ome
Y
ome
er inflam
PY 
er inflam
to determ
CO
to determ
14
C
14-
C
-item
C C
item
S
L
S-
L
-A) an
LIC
A) an
ange fro
UBL
ange fro
HADS
PUB
HADS-
UB
-D
B
D
e state
PU
e state
used to support any marketing authorization 
and 
ho
and 
an NRS
tho
an NRS
ery poor, 
auth
ery poor, 
vities.
g au
vities.
visit
ting
visit for 
g
for 
eline will 
ketin
eline will 
roperties a
y m
roperties a
matory sk
any
matory sk
mine the le
port
mine the le
scale that
ppo
scale that
d seven rel
upp
d seven rel
m 0 to 3 an
su
m 0 to 3 an
scales. Th
to s
scales. Th
n Section
sed
Section
ument cannot be 
is shown 
e u
is shown 
the HAD
ot 
the HAD
he FAS
nno
he FAS. T
o
. T
changes f
ann
changes f
y
t
y statistic
t ca
statistic
D scores 
nt c
D scores 
C
n
C
This docu
evaluate 
cum
evaluate 
of SIJ rad
docu
of SIJ rad
substu
do
substu
effic
s d
effic
s
nd any extensions or variations thereof.
the FAS
reo
the FAS
l be 
he
l be 
and its us
atio
and its us
kin disease
riat
kin disease
evels of an
or v
evels of an
t generate
s or
t generate
elate to de
ns 
elate to de
and are su
ion
and are su
hese total
nsio
ese total
4.2.1.6
xte
4.2.1.6
plication an
w
e
w
in
y
in Sectio
y e
Sectio
DS
d
DS-
d
-A and
d a
A and
This listin
and
This listin
from Bas
n an
from Bas
cs will be 
on 
cs will be 
s together 
atio
s together 
Change i
lica
Change i
app
the effect
ppl
the effect
iographs
app
ographs
nd P
a
nd P


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 46 of 86
recorded and a subject’s eligibility determined (subjects must be mNY-positive to be randomized
into the substudy).  If there is disagreement between the two primary reviewers in the assessment 
of eligibility, then a third reviewer will perform an adjudication based on an independent 
assessment of the images.  The results of the adjudication of eligibility will be considered as the 
final assessment.
All data recorded for the eligibility assessment, including imaging date, quality of image, right 
and left SIJ sacroiliitis scoring and radiograph assessment (mNY-positive/negative) will be listed 
by treatment group for each primary reviewer and for the adjudicator (if applicable).  The listing 
will include all subjects in the SS who were randomized into the PET-MRI/PET-CT substudy.
8.3.6.2
Efficacy assessment
SIJ and spine PET-CT and PET-MRI scans will be independently assessed at each time point 
(Baseline, Week 12 and Week 48) in a blinded fashion by two reviewers, with an additional 
adjudication read by a third reviewer, if applicable.  Independent reviewers will assess PET-
MRI/PET-CT examinations quantitatively using VU University Medical Center (VUMC)’s in-
house software (ACCURATE).
Initially, two primary readers will independently assess the images visually to identify PET-
positive lesions in the SIJ and spine.  The readers will dichotomously score the presence or 
absence (1 versus 0) of PET-positive lesions in each side of the SIJ (Left and Right) and at each 
of the 24 spinal levels and 4 spinal regional levels [C2-C7 (Cervical), T1-T12 (Thoracic), L1-L5
(Lumbar), Sacrum] in each of the following 8 spinal locations:
•
Process spinosus
•
Costo-vertebral (right)
•
Costo-vertebral (left)
•
Facet joint (right)
•
Facet joint (left)
•
Anterior vertebra
•
Posterior vertebra
•
Vertebra (other)
For each subject, PET-positive lesions may be identified in one or both sides of the SIJ and in 
one or more of the 192 possible anatomical locations (spinal location/level combinations).  It is 
expected that only one lesion for a subject may be separated/identified in each side of the SIJ or
individual anatomical location in the spine, therefore, there is a direct mapping of a subject’s 
lesion to a SIJ side or spinal location/level.
If there is a discrepancy between the two primary readers in the presence of PET-positive lesion 
assessment (Yes versus No for lesions in any side of the SIJ and 1 versus 0 for lesions in any 
spinal location), a consensus adjudication will take place with a third reader who will also be 
blinded to the clinical data. This reader will make an independent assessment and the results of 
the adjudication will be considered as the final assessment of the presence of PET-positive 
lesions.
PUBLIC COPY
ss th
Y
ss th
will
PY
will dich
PY 
dich
each sid
OP
each sid
evels
CO
evels [
O
[C
O
C
ng
C
ng 8
C C
8 spin
C C
spin
cument cannot be used to support any marketing authorization 
isted 
riz
isted 
listing
hori
listing
ubstudy.
tho
ubstudy.
each time 
ng 
each time 
ith an
etin
ith an add
ng
add
ers will as
ket
ers will as
cal Cente
ark
cal Cente
ages visua
y m
ages visua
otomously
any
otomously
of the SI
t a
of the SI
-
o
-C7
ort
C7 (Cer
rt 
(Cer
al location
ppo
al location
a
her)
ca
her)
bject, PET
nt c
bject, PET
re of the 
ent
re of the 
ed
m
ed that o
me
that o
vidual
um
vidual an
m
an
This doc
esion to a
ocu
esion to a
If ther
s do
If ther
ass
s 
ass
cation and any extensions or variations thereof.
e point 
reo
e point 
ditional
ere
ditional
ssess PET
the
ssess PET
er (
s
er (VUMC
s th
VUMC
ually to ide
atio
ually to ide
y scor
riat
y score
a
e th
t
th
IJ (Left an
var
IJ (Left an
rvical)
r va
rvical), T
va
, T
ns:
o
ns:
T
t
T-
ti
-positive
tion
positive
192
at
92
applic
poss
ati
poss
nly one le
lica
nly one le
natomical
ppli
natomical
a SIJ
ap
SIJ side
pp
side
dis
a
dis


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 47 of 86
Another reader who has not been involved in the visual identification of the PET-positive 
lesions, either as a primary reader or an adjudicator, will then draw volumes of interest (VOIs) 
on the pre-identified PET-positive lesions. In the case that no PET-positive lesions have been 
identified for a subject, then the final review step to draw VOIs will not occur. Efficacy PET-
MRI/PET-CT review will occur provided that an acceptable PET-CT or PET-MRI scan is 
available and that PET-positive lesions were identified on the previous scan (for the Week 12 
and Week 48 visits). During the PET-positive lesion VOI review, the independent reviewer will
perform a quantitative assessment in ACCURATE and record the standard uptake values of 18F-
fluoride in VOIs, corrected for both body weight and individual integrated whole blood activity 
concentration (SUVauc) for each PET-positive lesion identified during the PET-positive lesion 
identification review.
Data from the visual identification of PET-positive lesions and the results of the quantitative VOI 
review (i.e. SUVauc) will be listed, for each independent reader and adjudicator (if applicable), 
for each anatomical location in the spine, and for each side of the SIJ, by treatment group and 
visit for subjects in the SS who were enrolled into the PET-MRI/PET-CT substudy.
No formal statistical modelling of the PET-MRI/PET-CT imaging data will be performed for this 
substudy; only summaries will be presented together with 95% CIs for mean values, as 
applicable. 
The summaries described below based on the visual identification of PET-positive lesions will 
include the final assessment data, ie, if adjudication was performed, then the adjudicated data 
will be summarized, otherwise data from one of the primary reviewers will be summarized.
All summaries will be presented for the PET-PPS.
Since the attenuation correction and quantification is variable in PET-MRI scans, PET-MRI 
imaging data will be listed but will not be aggregated with the PET-CT imaging data in the 
summaries.
Due to the predicted sparseness of the number of PET-positive lesions in each of the individual 
anatomical locations of the spine, data will be pooled as follows for the purpose of some of the 
summaries:
•
In the SIJ and spine overall (across the SIJ and all anatomical locations in the spine);
•
In the SIJ overall (across both sides), and split by Left and Right side;
•
In the spine overall (across all anatomical locations in the spine), and split by spinal 
regional level (Cervical, Thoracic, Lumbar, Sacrum), and, depending on the 
distribution of lesions across the spine, further by spinal levels and spinal locations in 
which at least 1 PET-positive lesion is identified.
An overview of the total number of PET-positive lesions identified in the spine across all 
subjects in each of the individual anatomical locations will be presented by visit.
The presence of PET-positive lesions identified in the SIJ and spine will be summarized by visit.  
The summary will include the number and percentage of subjects at each visit with any PET-
positive lesions in the spine or the SIJ, in both the spine and the SIJ, in the SIJ overall (and split 
by Left and Right side) and in the spine overall [and split by spinal regional level (Cervical, 
Thoracic, Lumbar and Sacrum) and level/location, as applicable].  This summary will also 
PUBLIC COPY 
with 
Y
with 
visual id
COP
visual id
udication
C CO
udication
m one of 
IC 
m one of 
the PET
BLI
the PET
and qua
PUB
and qua
will no
PU
will no
t cannot be used to support any marketing authorization 
ill
iz
ill
f 
o
f 18
or
18F
ori
F-
ri
-
activity 
tho
activity 
ve lesion 
uth
ve lesion 
he
n
he quantit
ing 
quantit
ator (if ap
eting
ator (if ap
y treatmen
ket
y treatmen
CT subs
ark
CT subs
g data wil
ma
g data wil
% CIs for m
ny m
% CIs for m
ntificatio
rt a
ntificatio
was perfo
por
was perfo
he primar
pp
he primar
PPS.
su
PPS.
ntification
to 
ntification
t be aggre
ed t
t be aggre
s of the nu
e us
s of the nu
spine, dat
be 
spine, dat
and spine
nno
and spine
ocument
e SIJ
ca
e SIJ over
an
over
In the spi
nt c
In the spi
region
men
region
di
me
dist
e
st
This do
m
An over
doc
An over
subje
s d
subje
T
s
T
and any extensions or variations thereof.
tative VO
reo
tative VO
pplicable)
here
pplicable)
nt group a
the
nt group a
study.
ns t
study.
ill be perf
tion
ill be perf
mean val
atio
mean val
on of PET
va
on of PET
ormed, th
or v
ormed, th
ry review
s o
ry review
n is variab
nsio
n is variab
egated wi
tens
egated wi
umber of 
y ex
umber of 
ta will be 
ny 
ta will be 
ne overall
nd 
ne overall
plication 
erall (acro
n a
erall (acro
ine
ati
ine overal
atio
overal
nal level (
icat
nal level (
tribution 
plic
tribution 
app
which at l
ppl
which at l
ew of t
ap
ew of t


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 48 of 86
include a total count of PET-positive lesions across subjects for each of the pooled locations 
described above.  In the spine, the incidence and the total number of lesions will only be 
presented for the anatomical locations in which at least 1 PET-positive lesion is identified.
The number of PET-positive lesions per subject in the SIJ and spine (overall and in pooled 
locations, as described above) will be calculated and summarized by visit using frequency counts 
and percentages, and/or descriptive statistics, as applicable. In addition, in the spine and SIJ 
overall, in the spine overall and in each spinal regional level, the changes in the number of PET-
positive lesions per subject from Baseline to Week 12 and Week 48, and the changes from Week 
12 to Week 48 will be summarized using descriptive statistics.
Bar charts summarizing the total number of PET-positive lesions identified in the SIJ and in the 
spine will be presented by treatment group and visit for each of the pooled locations described 
above. 
Observed SUVauc values for each lesion will be pooled across subjects and summarized by visit 
for each of the pooled locations, as described above.  In the spine, the observed SUVauc values
will only be summarized for the anatomical locations in which at least 1 PET-positive lesion is 
identified. Descriptive statistics will be presented including 95% CIs for the mean observed 
SUVauc values.  In addition, changes and percentage changes in SUVauc values between visits 
will be calculated for each subject’s PET-positive lesion in the SIJ and spine, i.e. Week 12 -
Baseline, Week 48 - Baseline and Week 48 - Week 12.  These changes in SUVauc values will be
pooled across subjects and summarized by visit for each of the pooled locations described above. 
Descriptive statistics will be presented including 95% CIs for mean changes and percentage 
changes in SUVauc values between visits. 
Spaghetti plots of observed SUVauc values for lesions in the SIJ and spine will be presented over 
time for the SIJ overall, the spine overall, and for each spinal regional level (Cervical, Thoracic, 
Lumbar, Sacrum) by treatment group.
In addition, percentage changes in SUVauc values for lesions in the SIJ and spine will be 
summarized using waterfall plots.  These plots will identify subjects’ lesions by treatment group 
and will be presented by pooled location (as described above, as applicable) and for each visit 
comparison (Week 12 – Baseline, Week 48 – Baseline and Week 48 – Week 12).
The maximum of a subject’s observed SUVauc values will be calculated across the pooled 
locations described above. This maximum SUVauc value per subject will be summarized at each 
visit together with changes and percentage changes from Baseline between visits. Descriptive 
statistics will be presented including 95% CIs for the mean and the mean changes/percentage 
changes in the maximum SUVauc values.
The mean and 95% CI for the maximum SUVauc values per subject in the SIJ and spine over 
scheduled time will also be presented by treatment group.  The same plot will be repeated for the 
changes and percentage changes in the maximum SUVauc value per subject with treatment group 
overlaid on the same plot.
In addition, percentage changes in the maximum of SUVauc values per subject in the SIJ and 
spine will be summarized using waterfall plots.  These plots will identify subjects by treatment 
group and will be presented for each visit comparison (Week 12 – Baseline, Week 48 – Baseline 
and Week 48 – Week 12).
PUBLIC COPY
chang
PY 
chang
e lesion i
OPY
e lesion i
Week 12
COP
Week 12
visit for 
C CO
visit for 
ncluding
IC C
ncluding
its. 
BLI
its. 
uc
U
uc values
UB
values
P
ne over
PU
ne over
rou
P
rou
support any marketing authorization 
ET
ri
ET-
iz
-
m Week 
hori
m Week 
IJ and in
aut
IJ and in
ions descr
g a
ions descr
nd summa
ket
nd summa
observed
arke
observed
ast 1 PET
mar
ast 1 PET
% CIs for t
y m
% CIs for t
in SUV
ny 
in SUVa
n the SIJ a
t any
n the SIJ a
 These ch
ort a
 These ch
each of
por
each of the
r
the
95% CIs f
ppo
95% CIs f
t cannot be used to 
for lesion
to s
for lesion
ll, and for
d to
ll, and for
p.
in SUV
use
in SUVa
lots.  The
be u
lots.  The
ooled loca
t be
ooled loca
Baseline
ot b
Baseline
subject’s
nno
subject’s
ed above
an
ed above
with chan
t ca
with chan
This documen
ill be pres
ent 
ill be pres
in the ma
men
in the ma
m
u
mean and
um
ean and
cheduled 
ocu
cheduled 
changes
do
changes
over
s d
over
extensions or variations thereof.
the
f
the
cribed 
eof
cribed 
arized by 
the
arized by 
SUV
s th
SUVauc
t
auc
T-positive
ons
positive
the mean 
tion
the mean 
uc
i
uc values b
iati
values b
and spine
aria
and spine
hanges in
va
hanges in
he pooled 
or v
he pooled 
for mean 
s o
for mean 
n and any ex
ns
s
ns in the S
sio
in the S
r
e
r each 
ns
each spi
s
spi
c values f
ex
values f
ese plots w
ny e
ese plots w
cation
any
cation (as 
ny
(as 
e, Week 4
d a
e, Week 4
observed
and
observed
. This ma
n a
. This ma
tion
n
applicat
ges and p
ion 
ges and p
esented in
atio
esented in
aximum S
icat
aximum S
d 95% CI
pli
d 95% CI
d time will
app
time will
nd per
ap
nd per


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 49 of 86
Additional exploratory analyses may include examining the relationship between changes from 
Baseline in bone formation and changes from Baseline in ASDAS at Week 12 (primary efficacy 
variable) and Week 48, and also whether there are any differences in bone formation in clinical 
responders according to ASAS20 versus clinical non-responders at Weeks 12 and 48. Statistical 
modelling which accounts for multiple PET-positive lesions per subject may be used in these 
analyses.
9
PHARMACOKINETICS AND PHARMACODYNAMICS 
9.1
Pharmacokinetics
There will be no calculation of PK parameters for this study. The analysis of PK data for this 
study will focus on the concentrations of CZP and BKZ only. Any additional PK analyses will be 
performed only if required.
The actual blood sampling times for BKZ and CZP concentrations will be obtained in days 
relative to the start time of the first administration of IMP for all sampling time points. 
Individual blood sampling times and concentrations of BKZ and CZP will be listed by treatment 
group for the SS and will include the actual sampling time in days relative to the first. 
Individual concentrations will be summarized at each scheduled time point based on the PK-PPS, 
using n, mean, median, SD, minimum, maximum, geometric mean and 95% CI, and geoCV 
(assuming log-normally distributed data). 
Individual concentration versus time (day) profiles will be presented graphically on linear and 
semi-logarithmic scales with all subjects overlaid on the same plot (spaghetti plots). Geometric 
mean profiles, separately for BKZ and CZP, will also be presented on both linear and 
semi-logarithmic scales respectively with and without the corresponding lower and upper limit of 
the 95% CI. All semi-logarithmic plots will include the respective LLOQ marked on the y-axis.
The following rules will apply for PK data listings and summaries:
•
Values below the LLOQ will be reported as BLQ in the listings
•
Descriptive statistics of concentrations will be calculated if at most ⅓ of the individual data 
points are missing or are not quantifiable (<LLOQ). Values that are BLQ will be replaced by 
the numerical values of the LLOQ/2 in this instance. However, if n≤3, then only n, minimum
and maximum will be presented (where ‘n’ refers to the number of quantifiable values). The 
other descriptive statistics will be left blank.
•
The 95% CI for the geometric mean will be left blank if the SD is 0
The geoCV (%) will be calculated using the following formula where SDL is the standard 
deviation from the log-transformed data:
𝑔𝑒𝑜𝐶𝑉(%) = 100 × √exp(𝑆𝐷𝐿
2) −1
PUBLIC COPY 
f 
Y
f BK
Y
BK
ng time 
PY
ng time 
at each s
COP
at each s
imum, g
C CO
imum, g
).
I
).
 (day) p
BLI
 (day) p
ubjects o
UB
ubjects o
KZ and 
PU
KZ and 
vely
P
vely
annot be used to support any marketing authorization 
K data for 
ng a
K data for 
l PK analy
ting
l PK analy
ll be obta
ark
ll be obta
ampling ti
ma
ampling ti
nd CZP
y m
nd CZP w
m
w
n days re
any
n days re
cheduled 
rt a
cheduled 
eometric m
por
eometric m
ofiles wil
sup
ofiles wil
verlaid on
to s
verlaid on
CZP,
d to
CZP, will
to
will
with and 
ed 
with and 
plots wil
use
plots wil
y for PK d
be u
y for PK d
OQ will b
t b
OQ will b
tics of co
nno
tics of co
sing or ar
ann
sing or ar
ment c
cal values
ca
cal values
imum wi
nt c
imum wi
descriptiv
ent
descriptiv
docum
The 95% C
um
The 95% C
The geoCV
ocu
The geoCV
This do
deviatio
do
deviatio
n and any extensions or variations thereof.
r this
eof
r this
lyses wil
ere
lyses will
ained in d
s t
ained in d
ime
on
ime point
ns
point
will be list
atio
will be list
elative to t
aria
elative to t
time
va
time poin
va
poin
mean and
or v
mean and
ll be prese
ons
ll be prese
n the sam
sio
n the sam
l also be p
ens
l also be p
d without 
xten
d without 
ll include 
ext
ll include 
data listin
ny e
data listin
be reporte
d any
be reporte
oncentrati
nd 
oncentrati
re not qua
an
re not qua
lication
s of the LL
on a
s of the LL
ll 
t
ll be pres
tion
be pres
ve statisti
cati
ve statisti
appl
CI for the
plic
CI for the
V (%) wi
app
V (%) wi
from t
ap
from t


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 50 of 86
9.2
Pharmacodynamics
All PD variables will be listed by treatment group, subject and visit including changes from 
Baseline, based on the SS. 
Observed values and changes from Baseline will be summarized by treatment group and visit 
based on the PD-PPS. 
Figures of mean and mean changes from Baseline over time will be presented with separate plots 
for each variable and both treatment groups overlaid on the same plot.
The rules for handling any values that are BLQ or ALQ are described in Section 4.2.2.
10
IMMUNOLOGICAL ANALYSES
The results for the ADA measurements will be listed by treatment group and time point based on 
the SS, including the Screening assay, confirmatory assay and titre (if applicable).
A cut point will be determined by the bioanalytical laboratory that will be used to determine the 
status of ADA as above the cut point (ACP) or below the cut point (BCP). For any ADA levels 
that are ACP, a further confirmatory assay will be performed, the results of which will be 
determined as either ‘confirmed positive’ (CP) or ‘not confirmed positive’ (NCP). For samples 
that are CP, a further titre assay will be performed and the ADA titre will be reported. The
following definitions will be applied:
•
An ADA status for a given time point of positive will be concluded for any subject with an 
ADA level that is ACP and CP at any time point
•
An ADA status of negative for a given time point will be concluded for any subject with an 
ADA level that is either BCP or ACP and NCP at any time points
•
A subject will be classified as having ADA positivity at Baseline if the Visit 2 (Week 0), 
pre-dose result is ACP and CP
•
A subject will be classified as having treatment-induced ADA positivity when meeting 1 of 
the following criteria:
−
The Baseline result is either BCP or ACP and NCP, and at least 1 post-Baseline time
point is ACP and CP
−
The Baseline result is positive (ACP and CP) and at least 1 post-Baseline measurement 
shows a pre-defined fold increase in titre from the Baseline value (the fold increase from 
Baseline required to meet this criterion will be defined with the development of the assay 
and will be included in the TFLs)
•
A subject will be classified as overall positive if at least 1 post-Baseline measurement is ACP 
and CP (this includes subject who have negative results at Baseline)
•
A subject will be classified as overall negative if at all post-Baseline visits the ADA status is 
negative (this includes subjects who have positive [ACP and CP] results at Baseline)
The ADA status (positive/negative) will be summarized as a categorical endpoint (number and 
percentage of subjects) by treatment group, for all time points and overall, based on the PK-PPS. 
In addition, the first occurrence of treatment-induced ADA positivity (based on the definitions 
PUBLIC COPY
ot conf
PY 
ot conf
d and the
OPY
d and the
of positi
C C
of positi
ny time
LIC
ny time
a given 
UBL
a given 
P or AC
PUB
P or AC
as h
P
as h
not be used to support any marketing authorization 
plots 
riz
plots 
.
time poin
ting
time poin
licable).
ketin
licable).
l be used 
arke
l be used 
(BCP). F
mar
(BCP). F
e results o
y m
e results o
med posit
ny 
med posit
ADA titr
t any
ADA titr
ve will be
ppo
ve will be
point
up
point
ime point
o su
ime point
and NCP
to 
and NCP
ving ADA
ed 
ving ADA
ed as havin
be u
ed as havin
esult is ei
not 
esult is ei
This document cann
P and CP
nno
P and CP
seline res
ca
seline res
ws a pre
nt c
ws a pre-d
c
d
aselin
ent
aseline re
nt
e re
and will
me
and will
A subje
ocu
A subje
and C
oc
and C
•
s d
•
n and any extensions or variations thereof.
nt based o
ereo
nt based o
d to determ
s th
d to determ
For any A
ons
For any A
of which 
tion
of which 
tive’ (
iati
tive’ (NC
ati
NC
re will be 
aria
re will be 
e conclude
or 
e conclude
t will be c
ion
will be c
P 
n
P at any
nsio
at any t
o
t
A positivi
xten
A positivi
ing treatm
ny e
ing treatm
ither BCP
nd a
ither BCP
application
sult is pos
on a
sult is pos
defined fo
tion
defined fo
equired to
cati
equired to
l be inclu
plica
l be inclu
ect will be
app
ect will be
P (this i
ap
P (this i


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 51 of 86
above) will be summarized by treatment group (number and percentage of subjects) at each 
post-Baseline visit, based on the PK-PPS. This tabulation will count the number of subjects at 
each post-Baseline visit who fulfill at least 1 of the above defined criteria for treatment-induced 
positivity; subjects will be counted in the numerator based on the earliest visit at which 1 of these 
criteria is fulfilled. At other visits, subjects will be counted in the denominator (assuming a 
measurement is available).  For all tabulations, percentages will be based on the number of 
observations at each visit.
Separate listings will be presented (based on the PK-PPS) showing the BKZ and CZP
concentrations and ADA measurements in the same output in adjacent columns. The listing will 
include the BKZ and CZP concentration, ADA status (ACP or BCP) and confirmatory assay 
results if applicable (NCP or CP), together with the titre for results that are CP. In addition, the 
time since the previous administration of IMP will be reported (in days). 
Finally, individual subject plots (based on the PK-PPS) will be presented displaying ADA titre, 
BKZ and CZP concentrations overlaid on the same figure using a semi-logarithmic scale.
The rules for handling values that are BLQ in the BKZ and CZP concentration data are described 
in Section 4.2.4. For the ADA data, any negative results for which there are no titres available at 
a specific visit will be substituted with 0.001 for the purpose of the figure.
11
SAFETY ANALYSES
All analysis of safety variables will be performed using the SS.
11.1
Extent of exposure
All IMP administration details (including date and time of administration, body site and side of 
administration) will be listed. Additionally, the time between each dose will be listed.
The duration of exposure to BKZ (days) will be calculated separately for the Treatment Period 
and the Treatment Extension Period, where the last and first dose in each equation will be the last 
and first dose of IMP within the Treatment Period and Treatment Extension Period respectively:
𝐸𝑥𝑝𝑜𝑠𝑢𝑟𝑒= (𝐷𝑎𝑡𝑒𝑜𝑓𝐿𝑎𝑠𝑡𝐷𝑜𝑠𝑒−𝐷𝑎𝑡𝑒𝑜𝑓𝐹𝑖𝑟𝑠𝑡𝐷𝑜𝑠𝑒) + 140 𝑑𝑎𝑦𝑠
The duration of exposure to CZP (days) will be calculated as follows:
𝐸𝑥𝑝𝑜𝑠𝑢𝑟𝑒= (𝐷𝑎𝑡𝑒𝑜𝑓𝐿𝑎𝑠𝑡𝐷𝑜𝑠𝑒−𝐷𝑎𝑡𝑒𝑜𝑓𝐹𝑖𝑟𝑠𝑡𝐷𝑜𝑠𝑒) + 70 𝑑𝑎𝑦𝑠
The number of days added to the BKZ and CZP exposure calculations are 5 times the half-life of 
each drug, respectively: 5 x 28 days for BKZ and 5 x 14 days for CZP. 
Missed doses will not be accounted for in the calculation above. 
The number of injections received and duration of exposure will be listed for each subject and 
summarized by treatment group for the Treatment Period and Treatment Extension Period 
separately using descriptive statistics. This summary will be repeated for subjects in the SS who 
were randomized in the PET-MRI/CT substudy.
11.2
Adverse events
Adverse events with start date prior to the first dose of IMP are defined as pre-treatment AEs. 
Adverse events with a start date prior to the first dose of IMP will be defined as pre-treatment 
AEs. A treatment-emergent AE (TEAE) is defined as any AE with a start date/time at the time of 
PUBLIC COPY
ts 
Y
ts 
purpo
PY 
purpo
ormed u
C CO
ormed u
L
cluding d
UBL
cluding d
dditiona
PUB
dditiona
Z (d
P
Z (d
ot be used to support any marketing authorization 
sting will
tho
sting will
ory assay 
aut
ory assay 
n addition
g au
n addition
displaying
ketin
displaying
logarithm
rke
logarithm
ncentrati
ma
ncentrati
ch there a
y m
ch there a
of the fig
ny 
of the fig
ing the SS
por
ing the SS
ate and
o su
ate and tim
u
tim
ly, the tim
d to 
ly, the tim
ays) will b
ed 
ays) will b
od, where
use
od, where
he Treatme
e us
he Treatme
(
t
(𝐷𝑎𝑡𝑒
be
𝐷𝑎𝑡𝑒𝑜𝑓
e
𝑜𝑓
ument canno
ure to CZ
not 
ure to CZ
𝑠𝑢𝑟𝑒
ann
𝑠𝑢𝑟𝑒=
nn
= (
f days add
t ca
f days add
respective
nt 
respective
This docu
dose
me
doses wi
e
s wi
e number
cum
e number
summariz
doc
summariz
separa
s do
separa
wer
s d
wer
d any extensions or variations thereof.
n, the
of
the
ng ADA t
ther
ng ADA ti
mic scale.
s th
mic scale.
on data a
ons
on data a
are no titr
tion
are no titr
gure.
riat
gure.
S.
o
S.
me of 
ion
me of adm
n
adm
me betwe
nsio
me betwe
be calcula
xten
be calcula
e the last 
ext
e the last 
ment Perio
y e
ment Perio
𝑓
cation and
𝐿𝑎𝑠𝑡
any
𝐿𝑎𝑠𝑡𝐷𝑜
ny
𝐷𝑜
ZP (days) 
nd a
ZP (days) 
(𝐷𝑎𝑡𝑒
an
𝐷𝑎𝑡𝑒𝑜𝑓
n
𝑜𝑓
dded to the
ion 
dded to the
vely: 5 x 2
atio
vely: 5 x 2
applic
ill not be 
lica
ill not be 
r of inject
ppl
r of inject
ed by tre
app
ed by tre
usin
a
usin


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 52 of 86
or after the first dose of IMP up until 140 days after the last dose of IMP. Any AE with onset 
later than 140 days after the last dose of IMP will not be considered as treatment-emergent and 
therefore will not be included in the tabulations of TEAEs. Selected summaries will be presented 
separately for TEAEs during the Treatment Period (any AE with a start date/time at the time or 
after the first dose of IMP up until the Week 12 Visit) and TEAEs during the study (as per the 
definition of TEAEs given above).
Where dates are missing or partially missing, AEs will be assumed to be treatment-emergent, 
unless there is clear evidence to suggest that the AE started prior to dosing or later than 140 days 
post-last dose. Handling of missing dates/times for classification of AEs as TEAEs is described 
in Section 4.2.5.
All AEs will be recorded in the eCRF from informed consent until study completion or 
termination. All AEs will be coded and categorized by intensity (mild/moderate/severe) and 
relationship to IMP (related/not related).
An overview of the number and percentage of subjects who experience TEAEs will be presented 
by treatment group, based on the SS. Separate tabulations will be presented for TEAEs during 
the Treatment Period and TEAEs during the study and will include the number and percentage of 
subjects with any TEAEs, serious TEAEs, related TEAEs, discontinuation due to TEAEs, severe 
TEAEs, AEs leading to death and TEAEs leading to death; event counts will also be included.  
The summary of TEAEs during the study will be repeated for subjects in the SS who were 
randomized in the PET-MRI/PET-CT substudy.
In addition, the following summaries will be presented by treatment group, SOC, high level term 
(HLT) and PT, based on the SS:
•
Incidence of TEAEs[a] [b]
•
Incidence of TEAEs, stratified by overall ADA status (positive/negative) as defined in 
Section 10
•
Incidence of serious TEAEs[a] [b]
•
Incidence of non-serious TEAEs[b]
•
Incidence of TEAEs by relationship
•
Incidence of TEAEs by maximum relationship
•
Incidence of TEAEs by maximum intensity
•
Incidence of fatal TEAEs by relationship
•
Incidence of non-serious TEAEs by relationship
•
Incidence of serious TEAEs by relationship
•
Incidence of non-serious TEAEs above threshold of 5% of subjects
•
Incidence of non-serious TEAEs above threshold of 5% of subjects by relationship
•
Incidence of TEAEs by SOC and PT (including the number and percentage of subjects and 
individual subject numbers for each PT stratified by intensity, relationship and seriousness) 
PUBLIC COPY
w
Y
w
EAEs, 
PY 
EAEs, 
g to deat
OPY
g to deat
be repea
COP
be repea
tudy.
C C
tudy.
will be pr
LIC
will be pr
ed b
P
ed b
ument cannot be used to support any marketing authorization 
,
40 days
hori
40 days
described 
tho
described 
etion or 
g a
etion or 
ate/severe
ting
ate/severe
ce TEAEs
ark
ce TEAEs
presented 
ma
presented 
ude the nu
y m
ude the nu
scontinua
ny 
scontinua
h; event co
t any
h; event co
ted for su
ort a
ted for su
esented by
upp
esented by
y overall A
ed 
y overall A
Es
be
Es[a]
e
[a] [b]
e u
[b]
ous TEAE
t b
ous TEAE
AEs by re
nno
AEs by re
TEAEs b
can
TEAEs b
ce of TEA
nt c
ce of TEA
dence of f
men
dence of f
This docu
Incidence
cum
Incidence
•
d
•
Incid
oc
Incid
•
s d
•
I
plication and any extensions or variations thereof.
re) and 
ereo
re) and 
s will be p
s th
s will be p
for TEAE
ons
for TEAE
umber an
tion
umber an
ation due 
iati
ation due 
ounts wil
aria
ounts wil
ubjects in 
va
ubjects in 
y treatmen
ns o
y treatmen
ADA stat
xten
ADA stat
Es
Es[b]
a
[b]
elationship
and
elationship
by maxim
n a
by maxim
AEs by ma
tion
AEs by ma
fatal TEA
icat
fatal TEA
app
e of non
ppli
e of non
nce o
ap
nce of s
p
f s


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 53 of 86
[a] These summaries will be presented separately for TEAEs during the Treatment Period and 
TEAEs during the study.
[b] These summaries will be repeated for subjects in the SS who were randomized in the PET-
MRI/PET-CT substudy and will be based on TEAEs during the study
In addition, separate summaries by treatment group, SOC, HLT and PT will be included for the 
following AEs for special monitoring (AESM): 
•
Major cardiovascular events
•
Serious infections, including opportunistic infections and tuberculosis (TB)
•
Malignancies including lymphoma
•
Cytopenias
•
Neuropsychiatric events
•
Inflammatory bowel disease
•
Anaphylactic reaction (hypersensitivity and anaphylactic reactions)
•
Hepatic events and drug-induced liver injury
The criteria for identifying and additional criteria for reporting AESM are provided in
Section 14.5.
All summary tables (including those for AESM) will contain the number and percentage of 
subjects and the number of events where applicable. A subject who has multiple events in the 
same SOC, HLT and PT will be counted only once in the subjects counts but all events will be 
included.
In summaries including relationship to IMP, the following relationship categories will be 
included:
•
Related
•
Not related
Subjects who experience the same event multiple times will be included in the most related 
category for tabulations by maximum relationship. Events with missing relationship will be 
considered as ‘Related’ for summary purposes but shown as missing in the data listings. 
In summaries including intensity, the following categories will be summarized:
•
Mild
•
Moderate
•
Severe
Subjects who experience the same event multiple times will be included in the most severe 
category for tabulations by maximum intensity. Events with missing intensity will be considered 
as ‘Severe’ for summary purposes. All data will be presented as recorded in the database for the 
listings.
PUBLIC COPY 
Y
ria for re
COP
ria for re
r AESM
LIC 
r AESM
here app
BLIC
here app
ounted o
UBL
ounted o
hi
P
hi
This document cannot be used to support any marketing authorization 
actions)
y m
actions)
porting A
rt a
porting A
will cont
upp
will cont
icable. A 
sup
icable. A 
nly once i
to s
nly once i
p to IMP, 
sed
p to IMP, 
ience the 
nno
ience the 
lations by
can
lations by
‘Related’
t ca
‘Related’
ries inclu
ent
ries inclu
ild
m
ild
Modera
ocu
Modera
•
d
•
Se
o
Se
Su
s 
Su
application and any extensions or variations thereof.
AESM are
va
AESM are
tain the nu
s o
tain the nu
A subject w
ons
A subject w
in the sub
sion
in the sub
the follow
xte
the follow
same eve
and
same eve
y maximu
n an
y maximu
’ for summ
ion 
’ for summ
uding inte
atio
uding inte
ate
ap
ate


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 54 of 86
Adverse event summaries will be ordered by alphabetical SOC, alphabetical HLT within SOC 
and decreasing frequency of PT in the ‘BKZ’ column for tables including event counts. For 
tables including only number and percentage of subjects, summaries will be ordered by 
alphabetical SOC, alphabetical HLT within SOC and decreasing incidence of PT within HLT 
and SOC in the ‘BKZ’ column. 
Listings will be presented by treatment group and subject for all AEs, serious adverse events 
(SAEs), AEs leading to death and AEs leading to withdrawal. Listings will include the onset 
date/time and outcome date/time of the event (including relative days), the AE duration 
(derived), days since first dose of IMP, days since most recent dose of IMP, pattern of event, 
intensity, relationship, action taken and outcome. In addition, the listing will flag AEs that led to 
discontinuation, TEAEs, AESM and SAEs. All AE listings will be based on all subjects 
screened.
A glossary of all TEAE terms will be provided including the SOC, HLT, PT and reported term.
11.3
Clinical laboratory evaluations
Laboratory data (chemistry, hematology, and urinalysis) and changes from Baseline (if 
applicable) for numeric variables will be listed by treatment group and visit. Any laboratory 
variables that are BLQ or ALQ will be handled as described in Section 4.2.3. Values outside the 
reference range for the numeric variables will be flagged in the listings and, in addition, will be 
listed separately. The reference ranges will also be reported in the listings. 
Chemistry and hematology variables presented in Table 11‒1 will be summarized by treatment 
group at each visit, for both observed values and changes from Baseline. Figures of mean and 
mean change from Baseline will be presented by treatment for the absolute neutrophil count 
(ANC). All treatment groups will be overlaid on the same plot and the plot will include the error 
bars based on the SD (ie, mean +/-SD).
Laboratory variables will be grouped according to the laboratory function panel and categorized 
as normal, high or low, if applicable, based on the reference range supplied by the analytical 
laboratory. For selected variables that are identified in Table 11‒1, the change in category from 
Baseline will be presented in shift tables at all post-Baseline visits.
The number and percentage of subjects with treatment-emergent markedly abnormal (TEMA) 
values will be tabulated by treatment group and visit. Markedly abnormal laboratory values will 
generally be defined as those categorized as Grade 3 or Grade 4 as per the Rheumatology 
Common Toxicity Criteria (RCTC). Communication with the lead author of the RCTC 
publication has revealed that the reference ranges for absolute lymphocyte counts (ALC) are in 
error, therefore ALC criteria will follow the ranges defined as per the Common Terminology 
Criteria for Adverse Events (CTCAE) Version 4.03 (United States Department of Health and 
Human Services, 2010). Additional laboratory variables (not present in the RCTC publication) 
will also be categorized as per the CTCAE Version 4.03. The criteria for identifying TEMA 
values are presented in Table 14‒5 and Table 14‒6 for hematology and chemistry values 
respectively.
Laboratory measurements meeting the criteria for TEMA will be listed separately for 
hematology and chemistry. The listings will include all measurements for any variable with at 
least one TEMA result for each subject. 
PUBLIC COPY 
atme
Y
atme
describe
PY
describe
e flagge
COP
e flagge
lso be re
CO
lso be re
sented in
IC C
sented in
values a
BLIC
values a
e present
UBL
e present
ll be ove
PUB
ll be ove
+/
P
+/-
P
-SD
PU
SD
used to support any marketing authorization 
event,
tho
event,
Es that led
aut
Es that led
ubjects
g au
ubjects
PT and re
ketin
PT and re
nges from
ma
nges from
roup and v
ny m
roup and v
d in
an
d in Sectio
any
Sectio
d in the lis
rt a
d in the lis
ported in t
ort 
ported in t
Table
ppo
Table 11
po
11
nd change
sup
nd change
ed by trea
o su
ed by trea
rlaid on th
d to 
rlaid on th
).
e
).
ped accor
use
ped accor
This document cannot be u
icable, ba
e us
icable, ba
iables tha
be 
iables tha
d in shift 
ot b
d in shift 
centage of
nno
centage of
ulated by 
ann
ulated by 
efined as t
ca
efined as t
oxicity Cr
nt c
oxicity Cr
on has rev
ent
on has rev
therefore 
me
therefore 
teria for A
cum
teria for A
Human Se
docu
Human Se
will als
do
will als
valu
s d
valu
r
s
r
extensions or variations thereof.
d to
f
d to
eported te
ther
eported te
m Baseline
tion
m Baseline
visit. Any
atio
visit. Any
on
ri
on 4.2.3
ria
4.2.3
stings and
var
stings and
the listing
r va
the listing
‒1
s
1 will b
s o
will b
es from B
ns 
es from B
atment for
ion
atment for
the same p
nsio
the same p
rding to th
ext
rding to th
application and any 
ased on th
y e
ased on th
at are iden
any 
at are iden
t tables at 
d an
t tables at 
of subjects
nd 
of subjects
y treatmen
an
y treatmen
those cate
on a
those cate
riteria (RC
tion
riteria (RC
vealed tha
cati
vealed tha
e ALC crit
plica
e ALC crit
Adverse E
ppli
Adverse E
ervices, 2
app
rvices, 2
e cate
a
e cate


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 55 of 86
Any additional laboratory variables not included in the outputs described previously will be 
listed separately. These will include the following:
•
Serology
•
Urine drug screen
•
Pregnancy tests (serum and urine)
•
Follicle stimulating hormone (FSH) (only for women whose last menstrual cycle occurred 
between 12 and 24 months prior to the Screening Visit)
•
The results of the Quantiferon tuberculosis (TB) Gold test will be listed separately.
Subjects with treatment-emergent liver function test abnormalities at any post-Baseline visit will 
be summarized (number and percentage of subjects) by treatment group. The criteria for this 
tabulation are presented in Table 14‒7.
Table 11‒1: Clinical laboratory measurements
Category
Panel
Variable
Serology
Serology
human immunodeficiency virus 
(HIV), Hepatitis B and C, human 
leukocyte antigen (HLA)-B27
(HLA-B27)
Hematology
Red blood cell
red blood cell counta, 
hemoglobina, hematocrit
Red blood cell indices
mean corpuscular hemoglobin, 
mean corpuscular hemoglobin 
concentration, mean corpuscular 
volume
Platelet
Platelet
White blood cell
white blood cell counta
White blood cell differential
Absolute counts: absolute 
neutrophilsa, basophils, 
eosinophils, absolute 
lymphocytes, monocytes; 
atypical lymphocytes
Percentages:
neutrophils/leukocytesa,
basophils/leukocytesa,
eosinophils/leukocytesa,
lymphocytes/leukocytesa,
monocytes/leukocytesa.
Chemistry
Electrolytes
Sodium, chloride, potassium, 
magnesium, total calcium, 
bicarbonate
BLIC COPY 
Y
ood cell
LIC
ood cell
C
PUB
Red blo
PUB
Red blo
UB
P
support any marketing authorization 
ed 
or
ed 
ly.
a
ly.
aseline v
g a
aseline v
criteria f
ting
criteria f
Variab
y m
Variab
ma
y
hum
y
hum
y
ny
pp
ot be used to s
d cell indi
to 
d cell indi
s
Platel
e u
Platel
us
be
W
be
be
be
be
s document cannot 
ot
This
ions or variations thereof.
isit will
eof
isit will
for this
ereo
for this
ble
ti
ble
on
uman immu
riat
uman immu
(H
va
(HIV
ari
IV)
ari
), He
ri
, He
leukoc
r va
leukoc
(HL
r v
(HL
ati
or
o
d any extensio
o
ices
si
ices
io
et
n
et
e
White bloo
an
White bloo
ny
and a
White 
nd 
White 
d a
application an
an


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 56 of 86
Table 11‒1: Clinical laboratory measurements
Category
Panel
Variable
Kidney function
BUN, creatinine, uric acid, 
glomerular filtration rate
Proteins
hs-CRPbc
Liver function
ASTa, ALTa, GGTa, ALPa, LDHa, 
total bilirubin, direct bilirubin (if 
indicated), indirect bilirubin (if 
indicated)
Lipids
Total cholesterola
Hormones
FSH (postmenopausal females 
only)
Fertility
Pregnancy testd
Substrates
Glucose
Urinalysis
Dipstick
pH, albumin, glucose, blood 
(RBC, WBC)
Urine sediment
RBC, WBC, crystals, bacteria 
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; GGT=gamma glutamyl transferase; FSH=follicle stimulating hormone; HIV=human immunodeficiency 
virus; HLA-B27= human leukocyte antigen B27; hs-CRP=high sensitivity C-reactive protein; LDH=lactate 
dehydrogenase; RBC=red blood cell; WBC=white blood cell
a Shift tables will be presented for these variables.
b hs‑CRP will be included in the listings and tabulations for the efficacy data and will not be included in the safety
data outputs.
c hs-CRP will be tested at specified visits per the study schedule of events.
d Serum pregnancy test to be performed at Screening; urine pregnancy test to be performed at subsequent.
11.4
Vital signs, physical findings, and other observations related to 
safety
11.4.1
Vital signs
The following vital signs measurements will be obtained:
•
Pulse rate
•
Systolic and diastolic blood pressure
•
Temperature
A by-subject listing of all vital sign measurements and changes from Baseline will be presented 
by treatment group and visit. The listing will include a flag for measurements identified as 
TEMA/potentially clinically significant (PCS) as calculated by the criteria outlined in Table 14‒
8. Body weight will be included in the listing.
BLIC COPY 
Y
ent
C
ent
CO
C C
ransferas
C C
ransferas
FSH=folli
LIC
FSH=folli
PUB
B27
BL
B27; hs
BLI
; hs
BC=white
UB
BC=white
ese variab
PU
ese variab
ngs an
P
ngs an
support any marketing authorization 
za
 LDH
oriz
 LDHa
riz
a,
lirubin (if 
tho
lirubin (if 
ilirubin (if
uth
ilirubin (if
iza
za
z
erol
ng
erola
g
a
a
stmenopau
etin
stmenopau
ing
regnancy t
mar
regnancy t
rk
Glucos
y m
Glucos
ma
y
pH
y
pH
y
ny
rt
po
AST=aspa
ppo
AST=aspa
le stimulati
upp
le stimulati
This document cannot be used to su
RP=high s
sup
P=high s
blood cell
to s
blood cell
es.
d
es.
tabulations
ed t
tabulations
its per the 
us
its per the 
med at Scr
be u
med at Scr
ns,
t b
ns, p
b
phy
be
hy
y
al s
an
al signs
nn
igns
g vital sign
t ca
g vital sign
rate
en
rate
ystolic an
ume
ystolic an
Tempe
ocu
Tempe
A by
do
A by-
by t
s d
by t
T
s
T
ns or variations thereof.
of
usal femal
her
usal femal
re
test
n
testd
ns
d
s t
e
t
e
on
H, 
H, albumin
riat
albumin
(RBC, W
vari
(RBC, W
ati
RBC
r v
RBC
va
or
or
or
or
artate amin
s or
artate amin
ing hormon
ns 
ing hormon
application and any extension
ensitivity C
ons
ensitivity C
s for the ef
ten
s for the ef
study sche
ex
study sche
eening; uri
y e
eening; uri
ysical
any
ysical f
ny
fin
y
in
ns measu
ion 
ns measu
nd diastoli
plic
nd diastoli
erature
app
erature
ct lis
a
ct lis


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 57 of 86
Descriptive statistics will be reported for all vital sign measurements. Observed values and 
changes from Baseline will be summarized by treatment group for each vital signs variable and 
visit.
Figures of mean change from Baseline over time will be presented for each variable by treatment 
group.
The number and percentage of subjects with TEMA/PCS vital sign values will be summarized by 
treatment group at each visit. The denominator for the percentages will be the number of subjects 
with a non-missing measurement for the variable at the specific visit.
11.4.2
Electrocardiograms
The following ECG variables will be reported together with the Investigator’s interpretation of 
the ECG profile:
•
PR interval
•
RR interval
•
QRS interval
•
QT interval
•
Heart rate
•
QT corrected for heart rate using Fridericia’s formula (QTcF)
Electrocardiogram results will be reported in the by-subject listings. The listing will also include 
the changes from Baseline and percentage changes from Baseline and will be presented by 
treatment group and visit. 
Observed results, changes and percentage changes from Baseline will be summarized for each 
ECG variable by treatment group and visit. 
The following cut points in QTcF (observed data and change from Baseline) will be summarized 
categorically by treatment group (number and percentage of subjects) and visit. The denominator 
for the percentages will be the number of subjects with a non-missing measurement for the 
variable at the specific visit.
Observed QTcF data:
•
<450msec
•
≥450msec to <480msec
•
≥480msec to <500msec
•
≥500msec
Change from Baseline in QTcF:
•
<30msec
•
≥30msec to <60msec
•
≥60msec
PUBLIC COPY 
ricia’s fo
C C
ricia’s fo
rted in th
LIC
rted in th
centage c
UBL
centage c
perce
P
perce
This document cannot be used to support any marketing authorization 
by 
iz
by 
ubjects
oriz
ubjects
nterpretati
g a
nterpretati
rmula (QT
po
rmula (QT
e by
up
e by-
up
-subj
upp
subj
hange
o su
hanges
su
s fro
u
fro
ntage chan
ed t
ntage chan
and v
sed
and visit.
sed
isit.
TcF (
e u
TcF (obse
u
obse
group (nu
be 
group (nu
be the num
ot b
be the num
c visit.
not
c visit.
data:
an
data:
c
msec to <
en
msec to <
≥480msec
um
≥480msec
•
≥500m
oc
≥500m
Chan
s d
Chan
application and any extensions or variations thereof.
ion of 
eof
ion of 
QTcF)
or
QTcF)
ject listing
ns 
ject listing
om Basel
ion
om Basel
nges from
ten
nges from
erved
y e
erved data
y e
data
umber and
any
umber and
umber of s
d an
umber of s
<480msec
cat
<480msec
c to <500
plic
c to <500
msec
ap
msec
B


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 58 of 86
Electrocardiogram findings including the Investigator’s interpretation will be listed separately.
11.4.3
Other safety variables
11.4.3.1
C-SSRS
The C-SSRS is divided into 2 time intervals and further sub divided as shown:
•
C-SSRS at Baseline – assessed at the Screening visit
−
Suicidal Ideation – over Lifetime and over Past 6 Months
−
Intensity of Ideation – over Lifetime and over Past 6 Months
−
Suicidal Behavior – over Lifetime and over Past 2 Years
•
C-SSRS Since Last Visit – assessed at all visits after Screening
−
Suicidal Ideation – Since Last Visit
−
Intensity of Ideation – Since Last Visit
−
Suicidal Behavior – Since Last Visit
For Suicidal Ideation questions, only those questions where “Yes” has been answered will be 
listed. For Intensity of Ideation questions and Suicidal Behavior questions, any question for 
which an answer has been recorded will be listed. 
Results, as specified above, will be listed by treatment group, subject and visit.
11.4.3.2
Physical examination
Subjects with abnormalities in the physical examination will be listed including details of the 
abnormality.
11.4.3.3
Chest X-ray/CT scan and TB questionnaire
The results of the chest X-ray and the TB questionnaire will be listed for each subject.
12
OTHER ANALYSES 
Not applicable.
UBLIC COPY
ns wher
PY 
ns wher
icidal B
OPY
icidal B
ted.
CO
ted.
by treat
C C
by treat
PU
on
BL
on
e physic
PUB
e physic
o support any marketing authorization 
“Yes” has
any
“Yes” has
havior qu
t an
havior qu
ment group
ppo
ment group
be used to
al examina
to s
al examina
can and
sed
can and
and the TB
e us
and the TB
This document cannot b
ANALY
t be
ANALY
ions or variations thereof.
as been an
riat
as been an
uestions, a
vari
uestions, a
up, subjec
s or
up, subjec
application and any extens
nation will
sio
nation will
d TB que
xte
d TB que
TB questio
y ex
TB questio
YSES 
any
YSES 


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 59 of 86
13
REFERENCES
Common Terminology Criteria for Adverse Events (CTCAE); Version 4.03 June 2010.U.S.
Department of Health and Human Services
Guidance for Industry: E9 Statistical Principles for Clinical Trials. US Department of Health and 
Human Services, Food and Drug Administration. ICH 1998.
Mundt JC, Greist JH, Gelenberg AJ, Katzelnick DJ, Jefferson JW, Modell JG. Feasibility and 
Validation of a Computer Automated Columbia Suicide severity Rating Scale Using Interactive 
Voice Response Technology. J Psychiatr Res. 2010;44(16):1224 8.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia 
Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings from Three 
Multisite Studies with Adolescents and Adults. Am J Psychiatry. 2011;168(12):1266 77.
Snaith RP, Zigmond AS. The hospital anxiety and depression scale, with the irritability 
depression anxiety scale and the Leeds situational anxiety scale manual. 1994.
Van der Heijde D, Sharp J, Wassenberg S, Gladman DD. Psoriatic arthritis imaging: a review of 
scoring methods. Ann Rheum Dis. 2005;64;ii61-ii64. 
PUBLIC COPY 
marketing authorization 
d d 
ractive
hori
ractive
he Colum
au
e Colum
s s from
g a
from Th
a
Th
2):1266 7
ting
2):1266 7
h the irrita
ket
h the irrita
al.
a
al. 1994.
ark
1994.
This document cannot be used to support any m
c arthritis
ma
c arthritis
ns thereof.
bia
f
bia
hree
eof
hree
77.
er
77.
ability 
the
ability 
application and any extensions or variatio
s imaging
ion
s imaging


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 60 of 86
14
APPENDICES
14.1
Bath Ankylosing Spondylitis Disease Activity Index
The BASDAI is shown in Table 14‒1. All questions are answered on a scale from 0 to 10; for 
questions 1 to 5, 0 = none and 10 = very severe; for question 6, 0 = 0 hours, 10 = 2 or more 
hours.
14.2
Bath Ankylosing Spondylitis Functional Index
The BASFI is shown in Table 14‒2. All items are scored on a scale from 0 (“Easy”) to 10
(“Impossible”). The first 8 items evaluate activities related to functional anatomical limitations 
due to ankylosing spondylitis and the final 2 items evaluate a subject's ability to cope with 
everyday life.
PUBLIC
Spondy
BLIC
Spondy
2
U
2. All
UB
. All i
B
i
PU
ms evalu
PU
ms evalu
d th
P
d th
IC COPY 
to support any marketing authorization 
ylitis Fun
supp
ylitis Fun
ems
to
ems are
o s
are sc
s
sc
This document cannot be used t
te activiti
d to
te activiti
e final 2 it
ed 
e final 2 it
pport any marketing authoriza
This document cannot be u
ensions o
unctiona
ns 
unctiona
cored
sio
cored on 
o
on 
exte
ies re
ns
ies related
ns
lated
items eva
xten
items eva
s or variations thereof.
application and any e


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 61 of 86
14.3
Hospital Anxiety and Depression Scale
The individual items on the HADS-A and HADS-D scales are listed in Table 14‒3.
14.4
Treatment group assignment for the TFLs
Data will be summarized in the TFLs according to the treatment groupings as displayed in
Table 14‒4.
Table 14‒4: Treatment group assignment for TFLs
TFL group
CZP
BKZ
All Subjects
Subject disposition 
X
X
X
Protocol deviations
X
X
X
Demographics
X
X
X
AS history and Baseline
Disease characteristics
X
X
X
Medical history
X
X
X
PUBLIC COPY 
cument cannot be used to support any marketing authorization 
nt group
t be
nt group
zed in the
not
zed in the
Treatm
t ca
Treatm
up
me
up
nt
ect disposi
um
ect disposi
me
docu
Protocol d
ocu
Protocol d
This docu
Demo
s do
Demo
do
s
A
s
A
s
izati
be used to support any marketing aut
pplication and any extensions or variations thereof
up assig
any
up assig
e TFLs ac
nd 
e TFLs ac
ment gro
tion
ment gro
tititio
ati
ition 
pli
ition 
ica
app
eviations
app
viations
app
s
ap
ny extensions or variations thereof.


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 62 of 86
Table 14‒4: Treatment group assignment for TFLs
TFL group
CZP
BKZ
All Subjects
Prior/concomitant 
medications
X
X
X
AEs
X
X
Safety data (including 
vital signs, ECG, 
laboratory tests, 
physical examination,
body weight, C-SSRS)
X
X
Pharmacodynamic data
X
X
Efficacy data
X
X
Pharmacokinetic data
X
X
ADA
X
X
ADA= anti-drug antibodies; AE=adverse event; C-SSRS=Columbia-Suicide Severity Rating Scale; 
ECG=electrocardiogram
14.5
Adverse events for special monitoring
The following AESM are defined for BKZ and will be summarized separately as described in 
Section 11.2:
•
Major cardiovascular events
•
Serious infections, including opportunistic infections and TB
•
Malignancies including lymphoma
•
Cytopenias
•
Neuropsychiatric events
•
Inflammatory bowel disease
•
Anaphylactic reaction (hypersensitivity and anaphylactic reactions)
•
Hepatic events and drug-induced liver injury
14.5.1
Major cardiovascular events
Major adverse cardiovascular events (MACE) will be tabulated separately and will be identified
using the following UCB-defined search criteria:
•
All serious TEAEs which code to a PT included in the Scope=Broad and/or Scope=Narrow
groups of the following standardized MedDRA queries (SMQ):
−
Haemorrhagic central nervous system vascular disorders
−
Ischaemic central nervous system vascular disorders
PUBLIC COPY
umbia
PY
umbia-
Y
-S
Y 
S
cial
CO
cial mo
CO
mo
KZ and w
IC C
KZ and w
g oppo
PU
g oppo
ment cannot be used to support any marketing authorization 
za
iza
za
z
ng
eti
rk
rk
rk
rk
ark
ma
y
a
cide Severi
ny
cide Severi
nitoring
ort 
nitoring
ill be sum
ppo
ill be sum
rtunistic i
d to
rtunistic i
homa
use
homa
nts
t
nts
wel diseas
no
wel diseas
c reaction 
can
c reaction 
events and
nt c
events and
This docu
M
n
M
or adverse
um
or adverse
sing the f
ocu
sing the f
•
d
•
Al
o
Al
ation and any extensions or variations thereof.
eo
he
s t
on
at
at
at
ati
ty Rating S
riat
ty Rating S
g
mmarized 
s or
mmarized 
infections
tens
infections
ase
n
ase
n (hyperse
n a
n (hyperse
nd drug
tion
nd drug-in
n
in
applica
ajor card
icat
ajor card
se cardiov
plic
se cardiov
following
app
following
ous
a
ous


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 63 of 86
•
All serious TEAEs which code to a PT included in the HLT = ‘Ischaemic coronary artery
disorders’ except events coding to PT = ‘Chest pain’ or PT = ‘Chest discomfort’
•
All serious TEAEs which code to a PT = ‘Cardiac failure congestive’
14.5.2
Serious infections, including opportunistic infections and 
tuberculosis
14.5.2.1
Serious infections
Serious infections are based on MedDRA classification using the SOC = ‘Infections and
Infestations’. Such events will be included in the tabulations of SAEs and no separate summary
tabulations will be presented.
14.5.2.2
Fungal infections
Fungal infections will be summarized separately based on all TEAEs coding to the high level
group term (HLGT) = ‘Fungal infectious disorders’.
14.5.2.3
Opportunistic infections
Opportunistic infections (including TB) will be summarized in a separate table including all
TEAEs identified using search criteria defined by UCB.
Opportunistic infections are identified in 2 steps:
•
Step 1: Refer to column B of the spreadsheet which identifies the PTs to be classified as 
opportunistic infections using either a single ‘x’ or a double ‘xx’
−
All TEAEs which code to a PT flagged with a single ‘x’ need to also be serious in order
to be considered an opportunistic infection
−
All TEAEs which code to a PT flagged with a double ‘xx’ are considered to be an
opportunistic infection, regardless of seriousness.
All serious TEAEs in the study database which code to a PT flagged with a single ‘x’ and all
TEAEs in the study database which code to a PT flagged with a double ‘xx’ will be summarized
as an opportunistic infection in the stand-alone table.
•
Step 2: Refer to column C of the spreadsheet which identifies the PTs that need to be
evaluated on a case-by-case basis by the study physician in order to determine whether it is a
true opportunistic infection or not. The process for physician review is as follows:
−
Study programming team creates a spreadsheet which lists all of the subjects with a
TEAE present in the database which codes to a PT identified as needing case-by-case
review. Information from the AE dataset to be included in the spreadsheet: Subject ID,
AE verbatim term, SOC, HLT, Low Level Term (LLT), PT, AE start date, AE end date,
seriousness, severity, relationship to IMP, action taken. Additionally, a column will be 
included where the study physician can document their decision on the case
−
Study physician reviews the cases in the spreadsheet and indicates in the additional
column which AEs are confirmed to be opportunistic infections via a single ‘x’
PUBLIC COPY 
ariz
Y
ariz
UCB.
PY
UCB.
s:
CO
s:
dsheet w
C CO
dsheet w
a single
LIC 
a single
PT flagg
UBL
PT flagg
ortunisti
PUB
ortunisti
o a
P
o a
This document cannot be used to support any marketing authorization 
summary
uth
summary
ng to the h
etin
ng to the h
a separate
y m
a separate
hich identi
por
hich identi
‘x’ or a do
pp
‘x’ or a do
ed with a
o su
ed with a
infection
d to 
infection
PT flagge
sed
PT flagge
egardless
use
egardless
udy databa
be 
udy databa
base which
t be
base which
fection in 
not 
fection in 
to column
ann
to column
n a case
ca
n a case-b
ortunistic
nt c
ortunistic
Study pro
men
Study pro
TEAE 
um
TEAE 
revi
u
revi
A
plication and any extensions or variations thereof.
high leve
her
high leve
e table in
atio
e table in
tifies the P
or v
tifies the P
double ‘xx
s o
double ‘xx
a single
ion
a single ‘x
n
ed with a 
xten
ed with a 
s of serio
ex
s of serio
base which
ny 
base which
ch code to
d any
ch code to
the stand
nd a
the stand
n C of the
an
n C of the
by
on
by-
n
-case b
on a
case b
c infection
tion
c infection
ogrammin
icat
ogrammin
 present i
plic
 present i
app
iew. Infor
app
iew. Infor
E verbat
ap
E verbat
us
a


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 64 of 86
−
Study programming team incorporates these decisions into the ADAE dataset by merging
the study physician decisions for individual subjects / PTs and flagging the confirmed
opportunistic infections as such in the dataset
All subjects with an AE reported that has been confirmed by the study physician to be an 
opportunistic infection (based on case-by-case review) will be summarized as such in the 
stand-alone table, together with all of the events identified in Step 1 of this process.
Following the initial physician review of case-by-case events, subsequent reviews will be based 
on the cumulative set of case-by-case events present in the database at each time point of 
spreadsheet creation. Physician decisions from previous runs should be retained in each 
subsequent run. The final run of the spreadsheet, with all study physician decisions on the full set 
of case-by-case events, will be archived at the end of the study.
14.5.3
Malignancies including lymphoma
Malignancies will be presented in 2 separate tables based on the following SMQs:
•
Malignant or unspecified tumors
•
Malignant tumors
Events included in the ‘Malignant tumors’ tabulation will be a subset of the events in the 
‘Malignant or unspecified tumors’ tabulation. The SMQ search should include all TEAEs which 
code to a PT included in the Scope=Narrow group within each SMQ.
The output tables will include 2 different overall incidence rows:
•
The first overall incidence row will summarize ‘Any malignancies (including unspecified)’ 
or ‘Any malignancies’ (depending on the table) and this row will summarize the incidence of 
all AEs flagged for inclusion in the table, regardless of the HLT it codes to
•
The second overall incidence row will summarize ‘Any malignancy (including unspecified, 
excluding non-melanomic skin cancers)’ or ‘Any malignancy (excluding non-melanomic 
skin cancers)’ (depending on the table) and this row will summarize the incidence of AEs 
flagged for inclusion in the table, excluding those which code to an HLT of ‘skin neoplasms 
malignant and unspecified (excl melanoma)’
14.5.4
Cytopenias
Cytopenias will be tabulated separately based on the SMQ = ‘Haematopoietic cytopenias’. Only
serious TEAEs will be included in the tabulation. The SMQ search should include all serious 
TEAEs which code to a PT included in the Scope=Broad and/or Scope=Narrow groups within 
the SMQ.
14.5.5
Neuropsychiatric events
Neuropsychiatric events (in particular depression, anxiety and suicide ideation or behavior) will 
be tabulated separately based on the SMQ = ‘Depression and suicide/self-injury’. The SMQ 
search should include all TEAEs which code to a PT included in the Scope=Broad and/or 
Scope=Narrow groups within the SMQ.
PUBLIC COPY 
ion will
OPY
ion will
The SMQ
COP
The SMQ
group w
C CO
group w
nt overal
LIC 
nt overal
will sum
UBL
will sum
nding on
PUB
nding on
on in th
PU
on in th
This document cannot be used to support any marketing authorization 
ased 
oriz
ased 
f 
th
f 
ch 
u
ch 
s on the fu
au
s on the fu
ing SMQ
rke
ing SMQ
be a subse
any
be a subse
Q search s
rt a
Q search s
ithin each
port
ithin each
incidenc
upp
incidenc
marize ‘A
o su
marize ‘A
the table)
to 
the table)
e table, re
d to
e table, re
row will s
use
row will s
skin cance
e us
skin cance
g on the t
be 
g on the t
in the tab
t be
in the tab
pecified (
not 
pecified (
topenias
ann
topenias
ill be tabu
t ca
ill be tabu
AEs will b
nt c
AEs will b
which cod
men
which cod
MQ.
um
MQ.
4.5.5
ocu
4.5.5
Neuro
do
Neuro
be t
s d
be t
s
application and any extensions or variations thereof.
full set
of.
full set
Qs:
s
Qs:
et of the e
aria
et of the e
should inc
va
should inc
h SMQ.
or v
h SMQ.
e rows:
s o
e rows:
Any malig
ion
Any malig
e) and this
nsio
e) and this
t
gardless 
tens
gardless 
summariz
exte
summariz
ers)’ or ‘A
y ex
ers)’ or ‘A
table) and
ny 
table) and
ble, exclud
d any
ble, exclud
(excl mela
nd a
(excl mela
s
ulated sep
ion 
ulated sep
be includ
atio
be includ
de to a PT
icat
de to a PT
Neu
pp
Neu
hiatr
a
hiatr


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 65 of 86
14.5.6
Inflammatory bowel disease
Inflammatory bowel disease events will be tabulated separately, based on the HLGT = ‘Colitis 
excl infective’.
14.5.7
Anaphylactic reaction
Anaphylactic reactions will be summarized together in a stand-alone table with the following 
incidence rows:
•
The first row within the body of the table will be labeled ‘Any hypersensitivity/anaphylactic 
reaction’ and will represent the overall incidence of subjects who reported at least one 
hypersensitivity reaction or at least one anaphylactic reaction
•
The second row within the body of the table will be labeled ‘Any hypersensitivity reaction’ 
and will represent the overall incidence of subjects who reported at least one hypersensitivity 
reaction
•
The third row within the body of the table will be labeled ‘Any anaphylactic reaction’ and 
will represent the overall incidence of subjects who reported at least one anaphylactic 
reaction 
Following these three overall incidence rows, all TEAEs that have been identified as either a 
hypersensitivity reaction or an anaphylactic reaction will be summarized by SOC, HLT and PT 
(these will not be presented by subcategory). 
Hypersensitivity reactions and anaphylactic reactions will be identified as follows:
•
Hypersensitivity reactions: all TEAEs with onset (start date/time) within 24 hours after any 
administration of IMP, which code to a PT which contains the term ‘hypersensitivity’ will be 
considered as a hypersensitivity reaction and included in the summary table.
•
Anaphylactic reactions: An algorithmic approach will be used to identify TEAEs that are 
considered to be anaphylactic reactions. Preferred terms are separated into 4 distinct 
categories (A, B, C, D) prior to the algorithmic approach being applied.
All TEAEs with onset (start date/time) within 24 hours after any administration of IMP, and 
which fulfill any of the 3 criteria described in Section 14.5.7.1 will be included in the summary 
table.
Any TEAEs with missing start time will be assumed to have occurred at the time of or after 
dosing for this purpose, if the event date is on the same day as a dosing date.
14.5.7.1
Anaphylactic reaction algorithm
The SMQ = ‘anaphylactic reaction’ consists of 3 parts:
•
A narrow search containing PTs that represent core anaphylactic reaction terms. If a subject 
reports any TEAE which codes to a PT included in Category A, then the event will be 
flagged as an anaphylactic reaction and summarized as such in the table
−
Category A
1. Anaphylactic reaction
PUBLIC COPY 
TEAEs t
OPY
TEAEs t
action w
COP
action w
).
C
).
actic reac
LIC 
actic reac
TEAEs w
UBL
TEAEs w
h code to
PUB
h code to
ivity re
PU
ivity re
cument cannot be used to support any marketing authorization 
hylactic 
hor
hylactic 
one
uth
one
sitivity re
ng 
sitivity re
t one hype
eting
t one hype
naphylact
mark
naphylact
at least on
ma
at least on
hat have b
any
hat have b
ll be summ
rt a
ll be summ
tions will
upp
tions will
ith onset 
o su
ith onset 
a PT whi
to 
a PT whi
action and
d to
action and
gorithmic 
use
gorithmic 
tic reactio
e us
tic reactio
prior to th
be 
prior to th
et (start da
not
et (start da
of the 3 cr
ann
of the 3 cr
s with mi
nt c
s with mi
for this pu
men
for this pu
5.7.1
um
5.7.1
This do
The SMQ
doc
The SMQ
•
s d
•
A
lication and any extensions or variations thereof.
eaction’
reo
eaction’
ersensitiv
here
ersensitiv
ctic reactio
ns t
ctic reactio
ne anaphy
ions
ne anaphy
been iden
aria
been iden
mmarized b
va
mmarized b
l be identi
s o
l be identi
(start dat
ion
(start dat
hich conta
nsio
hich conta
nd include
tens
nd include
c approach
exte
c approach
ons. Prefe
y ex
ons. Prefe
he algorith
ny 
he algorith
ate
n
ate/time) 
nd 
/time) 
riteria des
an
riteria des
issing sta
atio
issing sta
urpose, if 
icat
urpose, if 
applic
Anaph
pplic
Anaph
= ‘anap
app
= ‘anap


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 66 of 86
2. Anaphylactic shock
3. Anaphylactic transfusion reaction
4. Anaphylactoid reaction
5. Anaphylactoid shock
6. Circulatory collapse
7. Dialysis membrane reaction
8. Kounis syndrome
9. Shock
10. Shock symptom
11. Type I hypersensitivity
•
A broad search: If a subject reports any TEAE which codes to a PT included in Category B 
AND reports any TEAE which codes to a PT included in Category C, and both TEAEs have 
the same start date, then both events will be flagged as anaphylactic reactions and 
summarized as such in the table
−
Category B
1. Acute respiratory failure
2. Asthma
3. Bronchial oedema
4. Bronchospasm
5. Cardio-respiratory distress
6. Chest discomfort
7. Choking
8. Choking sensation
9. Circumoral oedema
10. Cough
11. Cyanosis
12. Dyspnoea
13. Hyperventilation
14. Irregular breathing
15. Laryngeal dyspnea
16. Laryngeal oedema
17. Laryngospasm
18. Laryngotracheal oedema
PUBLIC COPY 
d a
Y
d a
This document cannot be used to support any marketing authorization 
PT includ
ark
PT includ
gory C, an
ma
gory C, an
hylactic r
y m
hylactic r
ema
nn
ema
sis
e
sis
yspnoea
me
yspnoea
. Hyperve
cum
Hyperve
14.
do
14. Irre
oc
Irre
15.
s 
15.
application and any extensions or variations thereof.
ded in Cat
s t
ded in Cat
nd both T
ons
nd both T
reactions 
tion
reactions 
ventilation
pp
ventilation
ar bre
ap
ar bre


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 67 of 86
19. Mouth swelling
20. Nasal obstruction
21. Oedema mouth
22. Oropharyngeal spasm
23. Oropharyngeal swelling
24. Respiratory arrest
25. Respiratory distress
26. Respiratory dyskinesia
27. Respiratory failure
28. Reversible airways obstruction
29. Sensation of foreign body
30. Sneezing
31. Stridor
32. Swollen tongue
33. Tachypnoea
34. Throat tightness
35. Tongue oedema
36. Tracheal obstruction
37. Tracheal oedema
38. Upper airway obstruction
39. Wheezing
−
Category C
1. Allergic oedema
2. Angioedema
3. Erythema
4. Eye oedema
5. Eye pruritis
6. Eye swelling
7. Eyelid oedema
8. Face oedema
9. Flushing
10. Generalized erythema
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
a
a
ma
n
ma
e oedema
me
e oedema
Eye prur
cum
Eye prur
6.
d
6. Eye 
oc
Eye 
7.
s d
7.
application and any extensions or variations thereof.
ritis
pp
ritis
a
welling
ap
welling


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 68 of 86
11. Injection site urticarial
12. Lip oedema
13. Lip swelling
14. Nodular rash
15. Ocular hyperaemia
16. Oedema
17. Periorbital oedema
18. Pruritis
19. Pruritis allergic
20. Pruritis generalized
21. Rash
22. Rash erythematous
23. Rash generalized
24. Rash pruritic
25. Skin swelling
26. Swelling
27. Swelling face
28. Urticaria
29. Urticaria popular
−
Category D
1. Blood pressure decreased
2. Blood pressure diastolic decreased
3. Blood pressure systolic decreased
4. Cardiac arrest
5. Cardio-respiratory arrest
6. Cardiovascular insufficiency
7. Diastolic hypertension
8. Hypotension
•
An algorithmic approach: If a subject reports any TEAE which codes to a PT included in 
Category D AND reports (either a TEAE which codes to a PT included in Category B OR a 
TEAE which codes to a PT included in Category C), and both TEAEs have the same start 
date, then both events will be flagged as anaphylactic reactions and summarized as such in 
the table.
PUBLIC COPY 
ument cannot be used to support any marketing authorization 
d
b
d
tolic decr
ot b
tolic decr
systolic d
nno
systolic d
st
c
st
respirator
nt c
respirator
diovascu
me
diovascu
This docu
Diastolic
cum
Diastolic
8.
d
8. Hyp
oc
Hyp
•
s
•
plication and any extensions or variations thereof.
reased
d a
reased
decreased
and
decreased
ory arrest
atio
ory arrest
lar insu
lica
lar insuff
a
ff
app
c hyperte
ppl
c hyperte
ension
ap
ension


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 69 of 86
14.5.8
Hepatic events and drug-induced liver injury
Hepatic events will include:
•
Events based on the SMQ = ‘Drug related hepatic disorders - comprehensive search’ 
(excluding sub-SMQs = ‘Liver neoplasms, benign [incl cysts and polyps]’ and ‘Liver 
neoplasms, malignant and unspecified’). All AEs should be included in the tabulation 
(including those considered both related and not related to the IMP) which code to a PT 
included in the Scope=Narrow group within each SMQ
•
Hy’s Law cases will also be summarized separately in a table of liver function abnormalities 
as described in Section 11.3 (with adjudication for potential drug-induced liver injury 
[PDILI] cases)
14.6
Treatment-emergent markedly abnormal laboratory values
The criteria for identifying TEMA laboratory values are provided for hematology in Table 14‒5
and for chemistry in Table 14‒6.
Table 14‒5: Definition of TEMA values for hematology
Variable (SI units)
Source
Markedly abnormal definition
Low Grade 4
Low Grade 3
High Grade 3
High Grade 4
Hemoglobin (g/L)
RCTC
<70 OR 
decrease from 
Baseline of 
≥30
70 to <80 OR 
value <LLN 
and decrease 
from Baseline 
of 21 to 29
NA
NA
ALC (10^9/L)
CTCAE
<0.2
0.2 to <0.5
NA
NA
ANC (10^9/L)
RCTC
<0.5
0.5 to <1.0
NA
NA
WBC (10^9/L)
RCTC
<1.0
1.0 to <2.0
NA
NA
Platelets (10^9/L)
RCTC
<2.0
20 to <50
NA
NA
ALC=absolute lymphocyte count; ANC=absolute neutrophil count; CTCAE=Common Terminology Criteria for
Adverse Events (CTCAE 2010); LLN=lower limit of normal; NA=not applicable; RCTC=Rheumatology Common
Toxicity Criteria; WBC=white blood cell.
Table 14‒6: Definition of TEMA values for chemistry
Variable (SI 
units)
Source
Markedly abnormal definition
Low Grade 4
Low Grade 3
High Grade 3
High Grade 4
ALP (U/L)
RCTC
NA
NA
>3.0 to 5.0 x 
ULN
>5.0 x ULN
ALT (U/L)
RCTC
NA
NA
>3.0 to 8.0 x 
ULN
>8.0 x ULN
AST (U/L)
RCTC
NA
NA
>3.0 to 8.0 x 
ULN
>8.0 x ULN
PUBLIC COPY 
Y
Marke
PY
Marke
Y
e 4
CO
e 4
Lo
OP
Lo
OP
OP
OP
OP
R 
C
R 
rease fro
IC 
rease fro
Baseline 
BLIC
Baseline 
≥30
UBL
≥30
CO
PU
O
E
P
E
PU
PU
PU
PU
ot be used to support any marketing authorization 
ormalities
tho
ormalities
njury 
auth
njury 
ory valu
ting
ory valu
matology 
ket
matology 
y
y
y
dly abnorm
any
dly abnorm
y
w Grade 3
rt a
w Grade 3
a
m 
m 
f 
s
f 
70
p
70 to <80
po
to <80
value 
pp
value 
and
p
and
f
ort
up
<0.2
ed
<0.2
d t
<0.5
use
<0.5
se
u
TC
be
TC
<
u
<
u
RCTC
t b
RCTC
be
ocument cannot
e count; AN
not
e count; AN
AE 2010); L
nn
AE 2010); L
WBC=white 
can
WBC=white 
‒6
e
6:
en
: Defi
nt 
Defi
ble (SI
ume
ble (SI
its)
c
its)
me
This doc
ALP (U
do
ALP (U
oc
s
d any extensions or variations thereof.
ues
ere
ues
y in
th
y in Table
the
Table
mal defin
ria
mal defin
at
3
High 
va
High 
ar
v
0 OR 
or
0 OR 
<LLN
s o
<LLN
d decrease
ns
d decrease
from Base
ion
from Base
of 21 to
nsio
of 21 to
N
r v
n
v
0.2
n
0.2
ns
en
xte
1.0
ny
1.0
e
<2.0
d an
<2.0
ny
application and a
NC=absolu
nd 
NC=absolu
LLN=lowe
and
LLN=lowe
blood cell
n a
blood cell
finition o
atio
finition o
Source
plic
Source
ca
p
app
ap


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 70 of 86
Table 14‒6: Definition of TEMA values for chemistry
Variable (SI 
units)
Source
Markedly abnormal definition
Low Grade 4
Low Grade 3
High Grade 3
High Grade 4
Creatinine 
(μmol/L)
RCTC
NA
NA
>1.8 to 3.0 x 
ULN
>3.0 x ULN
GGT (U/L)
CTCAE
NA
NA
>5.0 to 20.0 x 
ULN
>20.0 x ULN
Potassium
(mmol/L)
RCTC
<2.5
2.5 to <3.0
>6.4 to 7.0
>7.0
Sodium
(mmol/L)a
RCTC
<120
120 to <125
>155 to 160
>160
Total bilirubin 
(μmol/L)
RCTC
NA
NA
≥2.0 to 3.0 x 
ULN
>3.0 x ULN
Calcium
(mmol/L)
RCTC
<1.63
1.63 to <1.75
>3.125 to 
3.375
>3.375
Cholesterol 
(total) 
(mmol/L)
CTCAE
NA
NA
>10.34 to 
12.92
>12.92
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; CTCAE=Common
Terminology Criteria for Adverse Events (CTCAE 2010); GGT=gamma glutamyl transferase; NA=not applicable;
RCTC=Rheumatology Common Toxicity Criteria; ULN=upper limit of normal.
a For sodium High Grade 3 and 4 are taken from CTCAE.
14.7
Treatment-emergent abnormal liver values
The criteria for identifying treatment-emergent liver function abnormalities are presented in 
Table 14‒7. Subjects will be counted in all applicable categories for the tabulations ie, a subject 
with ≥5 x upper limit of normal (ULN) in AST will also be counted in the ≥3 x ULN in AST 
category, the ≥3 x ULN in aspartate aminotransferase (AST) or alanine aminotransferase (ALT)
category and the ≥5x ULN in AST or ALT category.
Table 14‒7: Definition of treatment-emergent liver function values
Criterion
≥3 x ULN increase for AST
≥5 x ULN increase for AST
≥10 x ULN increase for AST
≥20 x ULN increase for AST
≥3 x ULN increase for ALT
≥5 x ULN increase for ALT
≥10 x ULN increase for ALT
PUBLIC COPY 
o
Y
o
NA
OP
NA
PY
C CO
otransfera
LIC 
otransfera
TCAE 20
BLIC
TCAE 20
Criteria; 
UBL
Criteria; 
aken from
PUB
aken from
ument cannot be used to support any marketing authorization 
za
ULN
ori
ULN
iza
za
z
7.0
au
7.0
th
g
>16
g
>16
g
ng
to 3.0 x
rke
to 3.0 x
LN
ma
LN
ket
>3.125
y m
>3.125
3.37
y 
3.37
ma
ny
any
ny
ny
pp
ny
e; AST=asp
upp
e; AST=asp
0); GGT=g
sup
0); GGT=g
ULN=upper
o su
ULN=upper
CTCAE.
to 
CTCAE.
rgent ab
sed
rgent ab
atment
e us
atment-
u
-em
s
em
e counted
be 
e counted
normal (
ot b
normal (U
LN in
not
LN in aspa
ot
aspa
5x ULN i
ann
5x ULN i
Definit
t ca
Definit
nt
ULN incre
um
ULN incre
me
docu
≥5 x ULN 
ocu
≥5 x ULN 
This docu
≥10 x 
s do
≥10 x 
do
s
≥2
s
≥2
s
pplication and any extensions or variations thereof.
60
60
eo
>3.0 x
s th
>3.0 x
the
s
to 
ti
to 
5
i
5
on
>10.34 to
ari
>10.34 to
12.92
va
12.92
ria
or
o
partate ami
s o
partate ami
gamma glut
ons
gamma glut
r limit of no
ion
r limit of no
bnorma
exte
bnorma
mergent li
y e
mergent li
d in all ap
any
d in all ap
ULN
d a
ULN)
an
) in A
an
in A
artate ami
nd 
artate ami
in
a
in AST or
an
AST or
tion of tr
ion
tion of tr
tio
ease for A
plic
ease for A
ica
app
increase f
app
increase f
app
ncr
ap


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 71 of 86
Table 14‒7: Definition of treatment-emergent liver function values
Criterion
≥20 x ULN increase for ALT
≥3 x ULN increase for AST or ALT
≥5 x ULN increase for AST or ALT
≥10 x ULN increase for AST or ALT
≥20 x ULN increase for AST or ALT
≥1 x ULN increase for bilirubin
≥1.5 x ULN increase for bilirubin
≥1.5 x ULN increase for ALP
≥1 x ULN increase for bilirubin and 3 x ULN increase of either AST or ALT (at the same visit)
≥2 x ULN increase for bilirubin and 3 x ULN increase of either AST or ALT (at the same visit)
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of 
normal.
14.8
Treatment-emergent markedly abnormal vital signs values
The criteria for identifying TEMA/PCS vital signs values are provided in Table 14‒8.
Table 14‒8: TEMA/PCS criteria for vital signs
Variable
Unit
Lowa
Higha
Systolic blood pressure
mmHg
Value ≤90 and ≥30 
decrease from Baseline
Value ≥180 and ≥40 
increase from Baseline
Diastolic blood pressure
mmHg
Value ≤50 and ≥20 
decrease from Baseline
Value ≥105 and ≥30 
increase from Baseline
Pulse rate
bpm
Value ≤50 and ≥30 
decrease from Baseline
Value ≥120 and ≥30 
increase from Baseline
bpm=beats per minute; mmHg=millimeters of mercury; PCS=potentially clinically significant; TEMA=treatment-
emergent markedly abnormal.
Note: the change in measurement (increase or decrease) will be calculated relative to the value obtained at Baseline.
a Both conditions must be satisfied for a measurement to be considered PCS.
UBLIC COPY 
Y
ST=asp
PY
ST=asp
rkedly 
COP
rkedly 
tal signs
C C
tal signs
a for vit
BLI
a for vit
PUB
UB
PU
d to support any marketing authorization 
a
za
riz
tho
au
g
tin
T (at the s
ark
T (at the s
ke
r ALT (at 
ma
r ALT (at 
ma
y m
te aminotra
ny 
te aminotra
abnorm
ort a
abnorm
values are
ppo
values are
al signs
sup
al signs
t be used to s
o s
d t
g
e
g
us
annot b
bpm
ot
bpm
t b
nn
nn
nn
nt c nn
e;
a
; mmHg=
ann
mmHg=
y abnormal
ca
y abnormal
ge in measu
nt c
ge in measu
This documen
tions must
ent
tions must
ions or variations thereof.f
eo
er
same visit)
ns t
same visit)
th
the same v
tion
the same v
ns
tio
ansferase; U
iatio
ansferase; U
mal vital 
va
mal vital 
re provide
or 
re provide
nsio
Low
nsi
Lowa
si
a
any extensio
Value
ten
Value
de
te
de
ns
xte
ex
and any ex
an
tion an
an
=millimeter
an
=millimeter
l.
o
l.
urement (in
tion
urement (in
applicat
be satisfie
atio
be satisfie


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 72 of 86
15
AMENDMENTS TO THE SAP
15.1
Amendment 2
15.1.1
Rationale for the amendment
Various updates were suggested with the introduction of the PET-MRI/PET-CT substudy, and to 
align with the changes made to protocol amendment 3.
15.1.2
List of changes
Change #1
List of Abbreviations
The following abbreviations were added to the list:
•
CSR = clinical study report
•
mNY = modified New York
•
SIJ = sacroiliac joint
•
SUVauc = standard uptake value corrected for individual integrated whole blood activity 
concentration
•
VOI = volume of interest
•
VUMC = VU University Medical Center
Change #2
Secondary objectives (Section 2.1.2)
The following bullets were removed:-
•
To evaluate the effect of BKZ or CZP on changes in osteoblastic activity
•
To assess the pharmacokinetics (PK) and immunogenicity of BKZ
Change #3
Other objectives (Section 2.1.3)
The following bullets were added:
•
To evaluate the effect of BKZ or CZP on changes in bone formation
•
To assess the pharmacokinetics (PK) and immunogenicity of BKZ
Change #4
Other Efficacy Variables (Section 2.2.1.3)
The following bullets were added to the end:
•
Change from Baseline in Patient’s Global Assessment of Disease Activity (PGADA)
•
Changes in bone formation as measured by standardized uptake value corrected for 
individual integrated whole blood activity concentration (SUVauc) for each PET-positive 
lesion identified together with the maximum SUVauc value across all lesions within the spine 
PUBLIC COPY
dividua
PY 
dividua
nter
IC
nter
2.1.2)
PUB
2.1.2)
oved
P
oved
ocument cannot be used to support any marketing authorization 
ntegrated 
ny 
ntegrated 
Z or CZP 
use
Z or CZP 
inetics (P
be u
inetics (P
ection 2.1
nno
ection 2.1
ullets wer
can
ullets wer
ate the
nt c
ate the ef
c
ef
assess the
men
assess the
ange #
cum
ange #4
m
4
This do
Other E
doc
Other E
The 
s d
The 
application and any extensions or variations thereof.
d whole bl
iatio
d whole bl
on chang
ext
on chang
PK) and im
ny e
PK) and im
1.3)
and
1.3)
re added:
n a
re added:
ffect of B
tion
ffect of B
e pharmac
icat
e pharmac
a
ficacy V
ap
ficacy V


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 73 of 86
and sacroiliac joint (SIJ).  SUVauc will be derived from positron-emission tomography 
magnetic resonance imaging (PET MRI) or positron-emission tomography computed 
tomography (PET CT) scans at Baseline, Week 12, and Week 48
Change #5
Study design and conduct (Section 2.3)
The second paragraph was changed to:
It is planned that at least 60 subjects will be randomized to 1 of 2 treatment arms in a 2:1 
ratio and will receive either BKZ or CZP up to Week 44 (final dose of investigational 
medicinal product [IMP]).
Change #6
Determination of sample size (Section 2.4)
This section was rewritten to:
A sufficient number of subjects will be enrolled to ensure that at least 60 subjects are available in 
the main study at Week 12 to compare the change from Baseline in ASDAS between BKZ and 
CZP.  This will also provide at least 25 subjects enrolled in the PET-CT or PET-MRI substudy 
from multiple sites. Subjects will be randomized in a 2:1 ratio to receive BKZ or CZP 
respectively.
The sample size was calculated to provide at least 80% power to detect a difference between
treatment groups in the mean change from Baseline in ASDAS at Week 12 of 0.89 (group mean
change from Baseline for CZP and BKZ being -1.78 and -2.67 respectively) with a common 
standard deviation (SD) of 1.17 using frequentist methods for the comparison of the treatment 
group mean change from Baseline in ASDAS at Week 12 with Baseline ASDAS as a covariate 
(Overall and Starbuck, 1979).
The correlation between Baseline and Week 12 raw ASDAS was assumed to be 0.35. Note that 
the informative prior for the model intercept to be used in the Bayesian modelling of the primary 
efficacy variable, given by 𝛽𝐶𝑍𝑃~ Normal (-1.78, var=0.0605), contributes an effective sample 
size of approximately 20 CZP subjects. Prior data conflict will be investigated and a vague prior 
will be used for the model intercept coefficient if prior data conflict is evident.
Note that a clarification regarding the sample size for this study was provided in protocol 
amendment 3. As indicated above, the planned sample size of at least 60 subjects provides 
sufficient power to detect meaningful treatment differences in the primary efficacy variable 
whilst also providing at least 25 subjects for the PET-MRI or PET-CT substudy. However, due 
to complexities in the initiation of sites capable of performing PET-MRI or PET-CT scans, more 
than the planned 35 non-PET-MRI/CT substudy subjects were screened and randomized before it 
was possible to close enrolment at the sites not participating in the substudy. Owing to the 
novelty of the PET-MRI/CT outcomes within this disease area, it is considered important to 
ensure at least 25 evaluable subjects are included in the assessment of this exploratory objective 
to maximize the possibility of identifying the salient factors or variables that might differ 
between the treatment groups and, therefore, the total sample size is increased to at least 72 
subjects. This sample size increase will not negatively impact the power to detect a difference in 
the primary efficacy variable at Week 12 (ie, it will remain >80%), but will ensure that the target 
PUBLIC COPY
m B
Y
m B
olled in
PY 
olled in
in a 2:1
OPY
in a 2:1
e at least
C C
e at least
rom Bas
LIC
rom Bas
BKZ
BL
BKZ bei
BL
bei
using fre
PUB
using fre
ine in A
PU
ine in A
t be used to support any marketing authorization 
a 2:1 
hor
a 2:1 
onal 
uth
onal 
ast
m
ast 60 su
ma
60 su
e in ASD
y m
e in ASD
he PET
any
he PET-
y
-C
y
C
ratio to re
t an
ratio to re
80% pow
ppo
80% pow
eline in AS
upp
eline in AS
ng
ng -
s
-1.78 a
sup
1.78 a
quentist m
to s
quentist m
ASDAS at
d to
ASDAS at
ne a
u
ne and We
us
nd We
model int
be u
model int
y 
t
y 𝛽
t b
𝛽𝐶𝑍𝑃
t b
𝐶𝑍𝑃
ment canno
~ N
e
~ N
20 CZP su
ot 
20 CZP su
model int
nno
model int
fication 
can
fication r
n
r
.
t
. As indic
t ca
As indic
power to 
ent 
power to 
also provi
me
also provi
This docu
omplexitie
um
omplexitie
han the pl
ocu
han the pl
was pos
doc
was pos
nove
s d
nove
en
s
en
ny extensions or variations thereof.
ubjects are
ons
ubjects are
DAS betw
atio
DAS betw
CT or PET
iat
CT or PET
eceive
aria
eceive BK
ri
BK
wer to dete
or
wer to dete
ASDAS at 
ns o
ASDAS at 
and 
o
and -
on
-2.67 
ons
2.67 
methods fo
sio
methods fo
t Week 12
ens
t Week 12
eek 12 ra
ex
eek 12 ra
tercept to
ny e
tercept to
lication and a
Normal (
any
Normal (
ubjects.
d a
ubjects. P
a
P
tercept
and
tercept co
d
co
regarding 
n a
regarding 
icated abo
tion
icated abo
detect m
atio
detect m
iding at le
lica
iding at le
app
ies in the 
plic
ies in the 
lanned 35
app
lanned 35
ble to c
ap
ble to c


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 74 of 86
number of subjects are included in the exploratory analysis of changes in bone formation at 
Week 12 and Week 48. Since the analyses of PET-MRI/CT data are exploratory and treatment 
effect sizes are unknown, formal power calculations were not performed. Clinical expertise does, 
however, indicate that a sample size of at least 25 subjects in the substudy will characterize 
broad differences between treatment groups.
Change #7
Determination of sample size (Section 2.4)
The following paragraph was added at the end:
Note that a clarification regarding the sample size for this study was provided in protocol 
amendment 3. As indicated above, the planned sample size of at least 60 subjects provides 
sufficient power to detect meaningful treatment differences in the primary efficacy variable 
whilst also providing at least 25 subjects for the PET-MRI or PET-CT substudy. However, due 
to complexities in the initiation of sites capable of performing PET-MRI or PET-CT scans, more 
than the planned 35 non-PET-MRI/CT substudy subjects were screened and randomized before it 
was possible to close enrolment at the sites not participating in the substudy. Owing to the 
novelty of the PET-MRI/CT outcomes within this disease area, it is considered important to 
ensure at least 25 evaluable subjects are included in the assessment of this exploratory objective 
to maximize the possibility of identifying the salient factors or variables that might differ 
between the treatment groups and, therefore, the total sample size is increased to at least 72 
subjects. This sample size increase will not negatively impact the power to detect a difference in 
the primary efficacy variable at Week 12 (ie, it will remain >80%), but will ensure that the target 
number of subjects are included in the exploratory analysis of changes in bone formation at 
Week 12 and Week 48. Since the analyses of PET-MRI/CT data are exploratory and treatment 
effect sizes are unknown, formal power calculations were not performed. Clinical expertise does, 
however, indicate that a sample size of at least 25 subjects in the substudy will characterize 
broad differences between treatment groups.
Change #8
General presentation of summaries and analyses (Section 3.1)
The following paragraph was extended to:
Data listings containing all documented data and all derived data will be generated.  Subjects 
enrolled in the PET-MRI/PET-CT substudy will be flagged in the data listings.
Change #9
The following section was added:
PET Per-Protocol Set (Section 3.5.8)
The PET Per-Protocol Set (PET-PPS) will consist of all randomized subjects who receive at least 
1 dose of the IMP and have evaluable PET-MRI or PET-CT scan data at Baseline and at least 1 
of the post-Baseline assessments.
Change #10
Subject Disposition (Section 5.1)
PUBLIC COPY
ease
Y
ease
n the ass
PY 
n the ass
lient fac
OP
lient fac
the total
CO
the total
ot negati
C C
ot negati
12 (ie, it 
LIC
12 (ie, it 
he explo
BLI
he explo
analyse
UB
analyse
al powe
PU
al powe
size
P
size
This document cannot be used to support any marketing authorization 
otocol
aut
otocol
s provide
g a
s provide
ficacy var
ting
ficacy var
study. Ho
ketin
study. Ho
I or PET
rke
I or PET
ned and ra
mark
ned and ra
e substudy
ma
e substudy
, it is cons
y m
, it is cons
essment o
any
essment o
ors or var
rt a
ors or var
sample si
ort 
sample si
vely impac
ppo
vely impac
will remai
upp
will remai
ratory ana
sup
ratory ana
 of PET
to s
 of PET-M
r calculati
d to
r calculati
of at leas
ed 
of at leas
ent grou
use
ent group
e
p
f summar
ot b
f summar
raph was e
nno
raph was e
taining al
can
taining al
PET
t ca
PET-
c
-MR
ca
MR
9
e
9
ollowing 
ume
ollowing 
ET Per
ocu
ET Per-P
The PE
do
The PE
1 do
s d
1 do
s
application and any extensions or variations thereof.
es
e
es
riable 
ereo
riable 
owe
he
owever, d
her
ver, d
CT
th
CT scan
th
scan
randomize
ns t
randomize
dy. Owing
ions
dy. Owing
nsidered im
atio
nsidered im
of this exp
riat
of this exp
riables tha
var
riables tha
ize is incr
r va
ize is incr
ct the pow
or 
ct the pow
ain >80%)
ns o
ain >80%)
alysis of c
ons
alysis of c
MRI/CT
sio
MRI/CT
ions were
ens
ions were
st 25 subj
xten
st 25 subj
ps.
e
ps.
ries and a
d an
ries and a
extended
nd 
extended
ll docume
n a
ll docume
RI/PET
on 
RI/PET-C
section w
plic
section w
Protocol 
app
Protocol 
er
a
er-Pr
a
Pr


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 75 of 86
The opening paragraph was changed to:
The number and percentage of subjects who were randomized into the study (and into the PET-
MRI/PET-CT substudy), subjects who completed or prematurely discontinued the study, as well 
as the primary reason for discontinuation will be presented by treatment group and for all 
subjects, based on the RS. A subject who completed the study is defined as a subject who 
completed all visits up to the last scheduled study visit, ie, Visit 18 (Week 64). An additional 
summary of subject disposition in the PET-MRI/PET-CT substudy will also be presented 
separately by treatment group and for all subjects, based on the RS.
Change #11
Subject Disposition (Section 5.1)
The second bullet of the seventh paragraph was changed to:
•
for subjects participating in the respective pharmacogenomics, pharmacogenetic and PET 
MRI/CT substudies: date of respective informed consent
Change #12
Classification of age categories (Section 6.1.2)
The opening paragraph was changed to:
Age will be classified into categories based on requirements for European Union Drug 
Regulating Authorities Clinical Trials (EudraCT) and clinicaltrials.gov reporting.
Change #13
Demographics (Section 6.2)
The second paragraph was changed to:
All Baseline demographic characteristics (with the exception of year of birth) will be 
summarized by treatment group and for all subjects based on the SS. The summary of age will 
include descriptive statistics and categorical summaries, the latter based on requirements for 
EudraCT and clinicaltrials.gov reporting. This summary will be repeated for subjects in the SS 
who were randomized in the PET-MRI/CT substudy. Childbearing potential will be listed for the 
SS.
Change #14
Other Baseline characteristics (Section 6.3)
The section was changed to:
The following Baseline disease characteristics will be presented in a by-subject listing for the SS:
•
Duration of disease (as calculated in Section 6.1.3), including confirmation of sacroiliac joint 
X-ray and the date on which the sacroiliac joint X-ray was performed
•
hs-CRP
•
BASDAI score
•
PGADA
PUBLIC COPY 
on requi
CO
on requi
udraCT) 
C C
udraCT) 
nged t
PU
nged t
ment cannot be used to support any marketing authorization 
macogenet
ket
macogenet
ements fo
port
ements fo
and clinic
ppo
and clinic
o:
e
o:
teristics (w
use
teristics (w
p and for 
e us
p and for 
s and cate
be 
s and cate
ls.gov rep
ot b
ls.gov rep
in the PE
not
in the PE
This docum
eline 
nt
eline cha
t 
cha
ction was
me
ction was
he followi
cum
he followi
•
d
•
Dur
oc
Dur
X
tion and any extensions or variations thereof.
tic and PE
the
tic and PE
or Europe
or v
or Europe
caltrials.g
or
caltrials.g
with the e
exte
with the e
r all subjec
y ex
r all subjec
egorical su
any 
egorical su
porting.
d an
porting. T
n
T
ET
nd
ET-
d
-
applicat
MRI/C
nd a
MRI/C
aracterist
atio
aracterist
s s changed
lica
changed
ing Basel
ppl
ing Basel
on of d
ap
on of d


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 76 of 86
•
ASDAS
•
ASDAS disease activity states (ASDAS-ID, ASDAS-Moderate Disease activity 
[ASDAS-MD], ASDAS-High Disease activity [ASDAS-HD] and ASDAS-Very High 
Disease activity [ASDAS-vHD])
•
BASFI score
•
Total and nocturnal spinal pain NRS
•
PhGADA
•
Total HADS-A and HADS-D scores
The calculation of Baseline ASDAS and the classification of the ASDAS disease activity states 
will be based on the Baseline BASDAI, PGADA and hs-CRP values. The Baseline for each of 
the variables listed above is defined in Table 3‒1.
Baseline disease characteristics will be summarized using descriptive statistics by treatment 
group and for all subjects based on the SS.  This summary will be repeated for subjects in the SS 
who were randomized in the PET-MRI/PET-CT substudy and will also include summary 
statistics for SUVauc in the spine and in the SIJ at Baseline derived from the PET-MRI/PET-CT 
scans performed at Screening. SUVauc will be summarized in each SIJ quadrant and in each 
anatomical location of the spine together with the maximum SUVauc value in the SIJ and spine 
for each subject.
In addition, the above Baseline disease characteristics will be listed for the SS including SUVauc
and the maximum of the SUVauc values in the SIJ and spine.
Subject lifestyle details (alcohol use, smoking history and caffeine use) will be listed, based on 
the SS.
Change #15
Medical History (Section 6.4)
The opening paragraph was changed to:
Medical history will be listed for the RS and summarized for the SS by treatment group and for 
all subjects, MedDRA® system organ class (SOC) and preferred term (PT). The reported term 
will be included in the listing. The summary will include the number and percentage of subjects 
and will be sorted alphabetically by SOC and by descending incidence of PT within each SOC, 
based on the ‘All Subjects’ column. This summary will be repeated for subjects in the RS who 
were randomized in the PET-MRI/CT substudy. A glossary of all medical history conditions will 
be presented for the RS including the SOC, PT and reported term.
Change #16
Ankylosing spondylitis history (Section 6.5)
This section was shortened to:
Date of initial diagnosis of AS and the date that AS symptoms first started will be listed.
Change #17
PUBLIC COPY
ud
Y
ud
aseline 
PY 
aseline 
mmarize
OPY
mmarize
the max
COP
the max
characte
LIC
characte
ues in th
BLI
ues in th
use, sm
PUB
use, sm
This document cannot be used to support any marketing authorization 
se activity
g a
se activity
seline for
ting
seline for
statistics 
ark
statistics 
repeated f
ma
repeated f
will also in
y m
will also in
erived from
ny 
erived from
d in each S
t any
d in each S
mum SUV
ort a
mum SUV
ristics wil
upp
ristics wil
e SIJ and 
sup
e SIJ and 
oking hist
to 
oking hist
4)
be
4)
as change
t be
as change
be listed f
not
be listed f
DRA
an
DRA®
nn
® syst
nn
syst
d in the lis
can
d in the lis
orted alph
nt c
orted alph
the ‘All S
ent
the ‘All S
andomize
me
andomize
presented 
cum
presented 
Change 
doc
Change 
Anky
s d
Anky
T
s
T
application and any extensions or variations thereof.
y states 
eof
y states 
r each of 
ereo
r each of 
 by treatm
s th
 by treatm
for subjec
ons
for subjec
nclude su
tion
nclude su
m the PE
iati
m the PE
SIJ quadr
aria
SIJ quadr
UV
UVauc
va
auc valu
va
valu
ll be liste
ns o
ll be liste
spine.
ons
spine.
tory and c
nsio
tory and c
ed 
a
ed to:
an
to:
for the RS
nd 
for the RS
tem organ
an
tem organ
sting. The
on a
sting. The
habeticall
tion
habeticall
Subjects’ 
catio
Subjects’ 
d in the P
lica
d in the P
for the R
ppli
for the R
#16
a
16


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 77 of 86
Prior and concomitant medications (Section 6.6)
The opening paragraph was changed to:
Prior and concomitant medications (Section 6.6.1 and Section 6.6.2) will be listed for the RS by 
treatment group and subject, and summarized for the SS by WHODD Anatomical Main Group 
(Level 1), Pharmacological Subgroup (Level 3) and PT. The reported term will be included in 
the listing, together with flags to identify AS, rescue and prohibited medications, respectively. 
The flags for prohibited, AS and rescue medications will be confirmed and documented at the 
final DEM.
Change #18
Prior and concomitant medications (Section 6.6)
The second bullet of the fourth paragraph was changed to:
•
Rescue medication during study
Change #19
Prior and concomitant medications (Section 6.6)
The following paragraph was added:
These summaries will be repeated for subjects in the SS who were randomized in the PET-
MRI/PET-CT substudy.
Change #20
This section was removed:
Positron-emission tomography-magnetic resonance imaging/positron-emission tomography 
computed tomography
Change #21
Other efficacy variables (Section 8.3)
This sentence at the start was removed:
Results of the other efficacy variables will be listed and summarized by treatment group and visit
for the FAS.
Change #22
The phrase “for the FAS” was added for various requested outputs in the following sections:
•
Presentation of Assessment in SpondyloArthritis International Society Response (Section 
8.3.2)
•
Presentation of components of Assessment in SpondyloArthritis International Society 
(Section 8.3.3)
•
Physician’s Global Assessment of Disease Activity (Section 8.3.4)
•
Hospital Anxiety and Depression Scale (Section 8.3.5)
Change #23
PUBLIC COPY 
 in the S
COP
 in the S
hy
P
hy-
P
-magn
PU
magn
This document cannot be used to support any marketing authorization 
he
or
he
S who we
ort a
S who we
etic reson
d to
etic reson
ection 8.3
be 
ection 8.3
was rem
ot b
was rem
efficacy v
nno
efficacy v
ase “for th
men
ase “for th
Presentati
um
Presentati
8.3.2)
ocu
8.3.2)
•
d
•
Pre
o
Pre
application and any extensions or variations thereof.
ere random
va
ere random
nance im
ens
nance im
.3)
n
.3)
moved:
d an
moved:
variables 
and
variables 
he FAS” w
cat
he FAS” w
ion of Ass
plic
ion of Ass
ation
a
ation


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 78 of 86
Change in Bone Formation (PET-MRI/PET-CT Substudy) (Section 8.3.6)
The entire section was added (see above).
Change #24
Extent of Exposure (Section 11.1)
The final paragraph was extended to:
The number of injections received and duration of exposure will be listed for each subject and 
summarized by treatment group for the Treatment Period and Treatment Extension Period 
separately using descriptive statistics.  This summary will be repeated for subjects in the SS who 
were randomized in the PET-MRI/CT substudy.
Change #25
Adverse Events (Section 11.2)
The fourth and fifth paragraphs were changed to:
An overview of the number and percentage of subjects who experience TEAEs will be presented 
by treatment group, based on the SS. This tabulation will include the number and percentage of 
subjects with any TEAEs, serious TEAEs, related TEAEs, discontinuation due to TEAEs, severe 
TEAEs, AEs leading to death and TEAEs leading to death; event counts will also be included.  
This summary will be repeated for subjects in the SS who were randomized in the PET-
MRI/PET-CT substudy.
In addition, the following summaries will be presented by treatment group, SOC, high level term 
(HLT) and PT, based on the SS:
•
Incidence of TEAEs[a]
•
Incidence of TEAEs, stratified by overall ADA status (positive/negative) as defined in 
Section 10
•
Incidence of serious TEAEs[a]
•
Incidence of non-serious TEAEs
•
Incidence of TEAEs by relationship
•
Incidence of TEAEs by maximum relationship
•
Incidence of TEAEs by maximum intensity
•
Incidence of fatal TEAEs by relationship
•
Incidence of non-serious TEAEs by relationship
•
Incidence of serious TEAEs by relationship
•
Incidence of non-serious TEAEs above threshold of 5% of subjects
•
Incidence of non-serious TEAEs above threshold of 5% of subjects by relationship
•
Incidence of TEAEs by SOC and PT (including the number and percentage of subjects and 
individual subject numbers for each PT stratified by intensity, relationship and seriousness) 
PUBLIC COPY 
will i
Y
will i
TEAEs,
OPY
TEAEs,
ng to de
COP
ng to de
n the SS
CO
n the SS
will be p
BLIC
will be p
t be used to support any marketing authorization 
and 
or
and 
od 
th
od 
the SS w
auth
the SS w
rience TE
ma
rience TE
ude the nu
ny m
ude the nu
discontinu
any
discontinu
th; event 
rt a
th; event 
who were
ort
who were
resented b
sup
resented b
by overal
sed
by overal
ument cannot
AEs
be
AEs[a]
be
[a]
rious TEA
ot 
rious TEA
EAEs by r
ann
EAEs by r
of TEAEs
t ca
of TEAEs
nce of TE
ent 
nce of TE
cidence o
me
cidence o
This docu
Inciden
cu
Inciden
•
d
•
Inc
o
Inc
•
s
•
nd any extensions or variations thereof.
wh
f
EAEs will
tion
EAEs will
umber and
atio
umber and
nuatio
aria
nuation du
ria
n du
counts w
var
counts w
e random
r v
e random
by treatm
ons 
by treatm
ll ADA st
exte
ll ADA st
pplication a
AEs
d
AEs
relationsh
and
relationsh
s by maxi
on 
s by maxi
EAEs by m
atio
EAEs by m
f 
l
f fatal TE
plica
fatal TE
app
nce of non
pp
nce of non
ce of
a
ce of


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 79 of 86
[a] These summaries will be repeated for subjects in the SS who were randomized in the PET-
MRI/PET-CT substudy.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 80 of 86
15.2
Amendment 3
15.2.1
Rationale for the amendment
Updates to the description of the exploratory analysis of the PET-MRI/PET-CT imaging data 
were required based on a further understanding of the data expected for this study.  Other 
clarifications have also been incorporated into this amendment.
15.2.2
List of changes
Change #1
List of Abbreviations
The SUVmax definition has been removed.
Change #2
Protocol deviations (Section 5.2)
The third paragraph in this section has been changed to:
The number and percentage of subjects with IPDs will be summarized by treatment group 
and for all subjects for each deviation type, based on the RS. This summary will be 
repeated for the FAS (if this analysis set is different to the RS).
Change #3
Other baseline characteristics (Section 6.2)
The third and fourth paragraphs in this section have been changed to:
Baseline disease characteristics will be summarized using descriptive statistics by treatment 
group and for all subjects based on the SS.  This summary will be repeated for subjects in 
the SS who were randomized in the PET-MRI/PET-CT substudy and will also include 
summary statistics for SUVauc in the SIJ and spine at Baseline derived from the 
PET-MRI/PET-CT scans performed at Screening. SUVauc values for each of the PET-
positive lesions identified in the SIJ and spine will be pooled across subjects and across the 
SIJ and anatomical locations in the spine for the purpose of this summary.  In addition, the 
maximum SUVauc value across the SIJ and spine for each subject at Baseline will be 
summarized.
The above Baseline disease characteristics will be listed for the SS.
Change #4
Medical history and concomitant diseases (Section 6.4)
This section was amended as follows:
Medical history (except for AS) will be listed for the RS and summarized for the SS by 
treatment group and for all subjects, MedDRA® system organ class (SOC) and preferred 
term (PT). The reported term will be included in the listing. The summary will include the 
number and percentage of subjects and will be sorted alphabetically by SOC and by 
descending incidence of PT within each SOC, based on the ‘All Subjects’ column. This 
summary will be repeated for subjects in the SS who were randomized in the PET-MRI/CT
PUBLIC COPY
wi
Y
wi
d on th
PY 
d on th
ferent to
OPY
ferent to
I
6.2
C
6.2)
C C
)
his sectio
BLI
his sectio
s will be
PUB
s will be
sed on
PU
sed on
P
ot be used to support any marketing authorization 
ummarize
y m
ummarize
RS. This 
ny 
RS. This 
the RS).
t an
the RS).
n have be
sup
n have be
summari
to 
summari
the SS.
d t
the SS. T
he PET
sed
he PET-
d
-M
in the SIJ
use
in the SIJ
erformed
be u
erformed
in the SI
t be
in the SI
cations in
ot b
cations in
This document cann
alue acro
nno
alue acro
aseline di
t ca
aseline di
4
e
4
ical histor
ume
ical histor
h
o
his sectio
ocu
is sectio
Med
do
Medic
o
ic
trea
s d
trea
t
s
t
d any extensions or variations thereof.
ed by tre
tion
ed by tre
s summar
riat
s summar
een chang
ons
een chang
rized usin
nsio
rized usin
This sum
tens
This sum
MRI/PET
xte
MRI/PET
IJ and sp
ex
IJ and sp
d at Scree
ny e
d at Scree
IJ and sp
any
IJ and sp
n the spin
d a
n the spin
application an
oss the SI
nd 
oss the SI
isease ch
on 
isease ch
ory and co
plic
ory and co
on was am
app
on was am
stor
a
stor


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 81 of 86
substudy. A glossary of all medical history conditions will be presented for the RS 
including the SOC, PT and reported term.
Procedure history will be listed separately for the RS by treatment group for previous 
procedures relating to AS and previous procedures not relating to AS.  Concomitant 
medical procedures performed during the study will be listed for the RS.
Change #5
Efficacy assessment (Section 8.3.6.2)
The section was amended as follows:
SIJ and spine PET-CT and PET-MRI scans will be independently assessed at each time 
point (Baseline, Week 12 and Week 48) in a blinded fashion by two reviewers, with an 
additional adjudication read by a third reviewer, if applicable.  Independent reviewers will 
assess PET-MRI/PET-CT examinations quantitatively using VU University Medical Center 
(VUMC)’s in-house software (ACCURATE).
Initially, two primary readers will independently assess the images visually to identify 
PET-positive lesions in the SIJ and spine.  The readers will dichotomously score the 
presence or absence (1 versus 0) of PET-positive lesions in each side of the SIJ (Left and 
Right) and at each of the 24 spinal levels and 4 spinal regional levels [C2-C7 (Cervical), T1-
T12 (Thoracic), L1-L5 (Lumbar), Sacrum] in each of the following 8 spinal locations:
•
Process spinosus
•
Costo-vertebral (right)
•
Costo-vertebral (left)
•
Facet joint (right)
•
Facet joint (left)
•
Anterior vertebra
•
Posterior vertebra
•
Vertebra (other)
For each subject, PET-positive lesions may be identified in one or both sides of the SIJ and 
in one or more of the 192 possible anatomical locations (spinal location/level combinations).  
It is expected that only one lesion for a subject may be separated/identified in each side of 
the SIJ or individual anatomical location in the spine, therefore, there is a direct mapping 
of a subject’s lesion to a SIJ side or spinal location/level.
If there is a discrepancy between the two primary readers in the presence of PET-positive 
lesion assessment (Yes versus No for lesions in any side of the SIJ and 1 versus 0 for lesions 
in any spinal location), a consensus adjudication will take place with a third reader who 
will also be blinded to the clinical data. This reader will make an independent assessment 
and the results of the adjudication will be considered as the final assessment of the presence 
of PET-positive lesions.
PUBLIC COPY
ders
Y
ders
 lesions
PY 
 lesions
4 spinal
OPY
4 spinal
 in each
CO
 in each
This document cannot be used to support any marketing authorization 
t each tim
au
t each tim
ers, with
ng a
ers, with
ndent rev
ting
ndent rev
versity M
keti
versity M
mages visu
ma
mages visu
dichotom
y m
dichotom
in each si
any
in each si
regional 
t an
regional 
of the fol
ort 
of the fol
r)
n
r)
ct, PET
can
ct, PET-
ore of the
nt c
ore of the
cted that 
ent
cted that 
J or indiv
me
J or indiv
subject’
cum
subject’
If there i
doc
If there i
lesion
s do
lesion
in a
s 
in a
application and any extensions or variations thereof.
me
of
me
h an
reo
h an
viewers w
here
viewers w
Medical C
the
Medical C
ually to id
ions
ually to id
mously sc
atio
mously sc
ide of the
riat
ide of the
levels [C
vari
levels [C
llowing 8
r va
llowing 8
positive l
n a
positive l
e 192 pos
tion
e 192 pos
t only one
atio
t only one
vidual an
lica
vidual an
’s lesion t
pplic
’s lesion t
s a discr
app
a discr
ssm
a
ssm


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 82 of 86
Another reader who has not been involved in the visual identification of the PET-positive 
lesions, either as a primary reader or an adjudicator, will then draw volumes of interest 
(VOIs) on the pre-identified PET-positive lesions. In the case that no PET-positive lesions 
have been identified for a subject, then the final review step to draw VOIs will not occur. 
Efficacy PET-MRI/PET-CT review will occur provided that an acceptable PET-CT or 
PET-MRI scan is available and that PET-positive lesions were identified on the previous 
scan (for the Week 12 and Week 48 visits). During the PET-positive lesion VOI review, the 
independent reviewer will perform a quantitative assessment in ACCURATE and record 
the standard uptake values of 18F-fluoride in VOIs, corrected for both body weight and 
individual integrated whole blood activity concentration (SUVauc) for each PET-positive 
lesion identified during the PET-positive lesion identification review.
Data from the visual identification of PET-positive lesions and the results of the 
quantitative VOI review (i.e. SUVauc) will be listed, for each independent reader and 
adjudicator (if applicable), for each anatomical location in the spine, and for each side of 
the SIJ, by treatment group and visit for subjects in the SS who were enrolled into the 
PET-MRI/PET-CT substudy. 
No formal statistical modelling of the PET-MRI/PET-CT imaging data will be performed 
for this substudy; only summaries will be presented together with 95% CIs for mean 
values, as applicable. 
The summaries described below based on the visual identification of PET-positive lesions 
will include the final assessment data, ie, if adjudication was performed, then the 
adjudicated data will be summarized, otherwise data from one of the primary reviewers 
will be summarized.
All summaries will be presented for the PET-PPS.
Since the attenuation correction and quantification is variable in PET-MRI scans, PET-
MRI imaging data will be listed but will not be aggregated with the PET-CT imaging data 
in the summaries.
Due to the predicted sparseness of the number of PET-positive lesions in each of the 
individual anatomical locations of the spine, data will be pooled as follows for the purpose 
of some of the summaries:
•
In the SIJ and spine overall (across the SIJ and all anatomical locations in the 
spine);
•
In the SIJ overall (across both sides), and split by Left and Right side;
•
In the spine overall (across all anatomical locations in the spine), and split by 
spinal regional level (Cervical, Thoracic, Lumbar, Sacrum), and, depending on 
the distribution of lesions across the spine, further by spinal levels and spinal 
locations in which at least 1 PET-positive lesion is identified.
An overview of the total number of PET-positive lesions identified in the spine across all 
subjects in each of the individual anatomical locations will be presented by visit.
The presence of PET-positive lesions identified in the SIJ and spine will be summarized by 
visit.  The summary will include the number and percentage of subjects at each visit with 
PUBLIC COPY 
ET
Y
ET-
Y
-C
Y
C
nted tog
OPY
nted tog
n the vis
C CO
n the vis
ie, if ad
IC 
ie, if ad
ed, oth
BLIC
ed, othe
C
e
ted for 
PU
ted for 
annot be used to support any marketing authorization 
he 
iz
he 
ord
ori
ord
and
tho
and
positive
uth
positive
of the
ing
of the
nt reader
eting
nt reader
, and for 
ket
, and for 
were enro
ark
were enro
maging d
ny m
maging d
ether wit
any
ether wit
ual identi
por
ual identi
udication
pp
udication
wise data
sup
wise data
the PET
d to
the PET P
and quan
sed
and quan
d but wil
us
d but wil
arseness 
ot b
arseness 
al location
not 
al location
maries:
nno
maries:
This document c
he SIJ an
ca
he SIJ an
pine);
nt c
pine);
•
m
•
In th
men
In th
•
u
•
I
m
I
n and any extensions or variations thereof.
r and
here
r and
r each sid
the
r each sid
olled into
ns t
olled into
data will 
atio
data will 
a
h 95% C
ria
h 95% C
ification 
or v
ification 
n was per
s o
n was per
a from on
ons 
a from on
PPS.
ns
PPS.
ntification
xte
ntification
ill not be 
ex
ill not be 
of the nu
d an
of the nu
ns of the 
nd a
ns of the 
plication
nd spine 
on a
nd spine 
he SIJ ove
lica
he SIJ ove
app
In the sp
ppl
In the sp
spinal 
app
spinal 
the
a
the


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 83 of 86
any PET-positive lesions in the spine or the SIJ, in both the spine and the SIJ, in the SIJ 
overall (and split by Left and Right side) and in the spine overall [and split by spinal 
regional level (Cervical, Thoracic, Lumbar and Sacrum) and level/location, as applicable].  
This summary will also include a total count of PET-positive lesions across subjects for 
each of the pooled locations described above.  In the spine, the incidence and the total 
number of lesions will only be presented for the anatomical locations in which at least 1 
PET-positive lesion is identified.
The number of PET-positive lesions per subject in the SIJ and spine (overall and in pooled 
locations, as described above) will be calculated and summarized by visit using frequency 
counts and percentages, and/or descriptive statistics, as applicable.  In addition, in the 
spine and SIJ overall, in the spine overall and in each spinal regional level, the changes in 
the number of PET-positive lesions per subject from Baseline to Week 12 and Week 48, 
and the changes from Week 12 to Week 48 will be summarized using descriptive statistics.
Bar charts summarizing the total number of PET-positive lesions identified in the SIJ and 
in the spine will be presented by treatment group and visit for each of the pooled locations 
described above. 
Observed SUVauc values for each lesion will be pooled across subjects and summarized by 
visit for each of the pooled locations, as described above.  In the spine, the observed SUVauc
values will only be summarized for the anatomical locations in which at least 1 PET-
positive lesion is identified. Descriptive statistics will be presented including 95% CIs for 
the mean observed SUVauc values.  In addition, changes and percentage changes in SUVauc
values between visits will be calculated for each subject’s PET-positive lesion in the SIJ and 
spine, i.e. Week 12 - Baseline, Week 48 - Baseline and Week 48 - Week 12.  These changes 
in SUVauc values will be pooled across subjects and summarized by visit for each of the 
pooled locations described above. Descriptive statistics will be presented including 95% CIs 
for mean changes and percentage changes in SUVauc values between visits. 
Spaghetti plots of observed SUVauc values for lesions in the SIJ and spine will be presented 
over time for the SIJ overall, the spine overall, and for each spinal regional level (Cervical, 
Thoracic, Lumbar, Sacrum) by treatment group.
In addition, percentage changes in SUVauc values for lesions in the SIJ and spine will be 
summarized using waterfall plots.  These plots will identify subjects’ lesions by treatment 
group and will be presented by pooled location (as described above, as applicable) and for 
each visit comparison (Week 12 – Baseline, Week 48 – Baseline and Week 48 – Week 12).
The maximum of a subject’s observed SUVauc values will be calculated across the pooled 
locations described above. This maximum SUVauc value per subject will be summarized at 
each visit together with changes and percentage changes from Baseline between visits. 
Descriptive statistics will be presented including 95% CIs for the mean and the mean 
changes/percentage changes in the maximum SUVauc values.
The mean and 95% CI for the maximum SUVauc values per subject in the SIJ and spine 
over scheduled time will also be presented by treatment group.  The same plot will be 
repeated for the changes and percentage changes in the maximum SUVauc value per subject 
with treatment group overlaid on the same plot.
PUBLIC COPY
ooled a
PY 
ooled a
bed abov
OPY
bed abov
omical l
COP
omical l
tatistics 
C CO
tatistics 
addition
IC C
addition
ated for 
BLIC
ated for 
eek 48
UBL
eek 48
d across
PUB
d across
ove. D
PU
ove. D
e used to support any marketing authorization 
pooled
hori
pooled
equency
tho
equency
, in the
aut
, in the
he chang
g au
he chang
and Wee
ng 
and Wee
escriptive
eting
escriptive
dentified 
rke
dentified 
ach of the
mark
ach of the
oss subje
ny 
oss subje
e.  In the
t any
e.  In the
ocations i
ort a
ocations i
will be pr
por
will be pr
, changes
ppo
, changes
ach subj
sup
ach subj
Baseline 
o su
Baseline 
su
d t
subjects 
d to 
bjects 
escriptiv
ed t
escriptiv
e changes
sed
e changes
UV
e u
UVauc
e u
auc va
us
va
ent cannot be
all, the sp
be 
all, the sp
rum) by 
ot b
rum) by 
tage chan
nno
tage chan
ng waterf
ann
ng waterf
l be prese
ca
l be prese
ompariso
nt c
ompariso
This docume
aximum o
men
aximum o
ions desc
um
ions desc
ach visit t
cu
ach visit t
Descript
doc
Descript
chang
s do
chang
T
s
T
y extensions or variations thereof.
ges in
of
ges in
ek 48,
reo
ek 48,
ve statistic
here
ve statistic
d in the SI
s th
d in the SI
e pooled 
ns 
e pooled 
ects and s
iati
ects and s
e spine,
aria
e spine, th
a
th
in which
va
in which
resented 
or v
resented 
s an
s o
s and per
s o
d per
ject’s PET
ns 
ject’s PET
and Wee
ion
and Wee
and sum
nsio
and sum
ve statisti
tens
ve statisti
s in SUV
xte
s in SUV
lues
y e
lues
ation and any
for l
y e
for l
pine over
any 
pine over
treatmen
d an
treatmen
nges in SU
nd
nges in SU
fall plots.
an
fall plots.
sented by
on a
sented by
on (Week
tion
on (Week
applic
of a subje
icat
of a subje
cribed ab
plic
cribed ab
together w
app
together w
ve stati
ap
ve stati
rce
a


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 84 of 86
In addition, percentage changes in the maximum of SUVauc values per subject in the SIJ 
and spine will be summarized using waterfall plots.  These plots will identify subjects by 
treatment group and will be presented for each visit comparison (Week 12 – Baseline, 
Week 48 – Baseline and Week 48 – Week 12).
Additional exploratory analyses may include examining the relationship between changes 
from Baseline in bone formation and changes from Baseline in ASDAS at Week 12 
(primary efficacy variable) and Week 48, and also whether there are any differences in 
bone formation in clinical responders according to ASAS20 versus clinical non-responders 
at Weeks 12 and 48. Statistical modelling which accounts for multiple PET-positive lesions 
per subject may be used in these analyses.
Change #6
Adverse events (Section 11.2)
The first paragraph was changed to:
Adverse events with start date prior to the first dose of IMP are defined as pre-treatment 
AEs. Adverse events with a start date prior to the first dose of IMP will be defined as 
pre-treatment AEs. A treatment-emergent AE (TEAE) is defined as any AE with a start 
date/time at the time of or after the first dose of IMP up until 140 days after the last dose of 
IMP. Any AE with onset later than 140 days after the last dose of IMP will not be 
considered as treatment-emergent and therefore will not be included in the tabulations of 
TEAEs. Selected summaries will be presented separately for TEAEs during the Treatment
Period (any AE with a start date/time at the time or after the first dose of IMP up until the 
Week 12 Visit) and TEAEs during the study (as per the definition of TEAEs given above).
The fourth and fifth paragraphs were changed to:
An overview of the number and percentage of subjects who experience TEAEs will be 
presented by treatment group, based on the SS. Separate tabulations will be presented for 
TEAEs during the Treatment Period and TEAEs during the study and will include the 
number and percentage of subjects with any TEAEs, serious TEAEs, related TEAEs, 
discontinuation due to TEAEs, severe TEAEs, AEs leading to death and TEAEs leading to 
death; event counts will also be included.  The summary of TEAEs during the study will be 
repeated for subjects in the SS who were randomized in the PET-MRI/PET-CT substudy.
In addition, the following summaries will be presented by treatment group, SOC, high level 
term (HLT) and PT, based on the SS:
•
Incidence of TEAEs[a] [b]
•
Incidence of TEAEs, stratified by overall ADA status (positive/negative) as defined in 
Section 10
•
Incidence of serious TEAEs[a] [b]
•
Incidence of non-serious TEAEs[b]
•
Incidence of TEAEs by relationship
•
Incidence of TEAEs by maximum relationship
PUBLIC COPY
EAE) 
PY 
EAE) 
f IMP u
OPY
f IMP u
s after t
COP
s after t
herefore
C CO
herefore
esented
IC C
esented
me at th
BLIC
me at th
ng the st
UBL
ng the st
s were c
PU
s were c
d
P
d
This document cannot be used to support any marketing authorization 
onders
hori
onders
ve lesions
tho
ve lesions
e defined 
mar
e defined 
of IMP w
y m
of IMP w
defined a
ny 
defined a
p until 14
any
p until 14
he last dos
rt a
he last dos
will not b
port
will not b
separatel
ppo
separatel
time or a
supp
time or a
udy (as pe
o su
udy (as pe
hanged to:
d to
hanged to:
percentag
sed
percentag
based on
use
based on
nt Period
be u
nt Period
of s
t b
of subject
be
ubject
TEAEs, 
ot b
TEAEs, 
will also 
nno
will also 
jects in t
ann
jects in th
the follow
t ca
the follow
T) and PT
ent 
T) and PT
idence o
me
idence o
Inciden
cum
Inciden
Secti
oc
Secti
•
s d
•
I
application and any extensions or variations thereof.
d as pre
ons
d as pre-
s
-t
will be def
tion
will be def
as any AE
iati
as any AE
40 days a
aria
40 days a
ose of IMP
va
ose of IMP
be includ
or v
be includ
ly for TE
s or
ly for TE
after the 
ns 
after the 
er the de
ion
er the de
e
ge of subj
xte
ge of subj
n the SS. 
ex
n the SS. 
d and TE
ny e
d and TE
ts with an
any
ts with an
, severe T
d a
, severe T
o be inclu
nd 
o be inclu
he SS wh
an
he SS wh
wing sum
ion 
wing sum
T, based 
atio
T, based 
f TEAEs
lica
f TEAEs
nce of TE
pp
nce of TE
on
a
n 10
ap
10


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 85 of 86
•
Incidence of TEAEs by maximum intensity
•
Incidence of fatal TEAEs by relationship
•
Incidence of non-serious TEAEs by relationship
•
Incidence of serious TEAEs by relationship
•
Incidence of non-serious TEAEs above threshold of 5% of subjects
•
Incidence of non-serious TEAEs above threshold of 5% of subjects by relationship
•
Incidence of TEAEs by SOC and PT (including the number and percentage of subjects 
and individual subject numbers for each PT stratified by intensity, relationship and 
seriousness) 
[a] These summaries will be presented separately for TEAEs during the Treatment Period 
and TEAEs during the study.
[b] These summaries will be repeated for subjects in the SS who were randomized in the 
PET-MRI/PET-CT substudy and will be based on TEAEs during the study
PUBLIC COPY 
ing authorization 
ip
h
ip
of subject
uth
of subject
nship and
au
nship and
marketi
Treatme
eting
Treatme
were rand
ark
were rand
This document cannot be used to support any m
ring the s
ma
ring the s
reof.
d
of
d
application and any extensions or variations the
ent Perio
here
ent Perio
domized 
ns 
domized 
study
ion
study


UCB
19 June 2020
Statistical Analysis Plan Amendment 3
Bimekizumab
AS0013
Confidential
Page 86 of 86
STATISTICAL ANALYSIS PLAN SIGNATURE PAGE
This document has been reviewed and approved per the Review and Approval of Clinical 
Documents Standard Operating Procedures. Signatures indicate that the final version of the 
Statistical Analysis Plan (SAP) or amended SAP is released for execution.
PUBLIC COPY 
This document cannot be used to support any marketing authorization 
application and any extensions or variations thereof.